carvedilol has been researched along with Heart Failure in 823 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol demonstrated therapeutic benefits in patients with heart failure and reduced ejection fraction (HFrEF)." | 9.69 | Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study. ( Choi, DJ; Hong, SJ; Hong, SK; Jeon, ES; Kang, SM; Kim, EJ; Kim, JJ; Kim, MA; Kim, SY; Lee, HY; Park, CS; Park, DG; Park, JJ; Shin, JH; Yoo, BS, 2023) |
| "This paper aims to investigate the curative effect of carvedilol combined with conventional therapy in treatment of chronic heart failure." | 9.30 | The curative effect of carvedilol combined with conventional therapy in treatment of chronic heart failure. ( Li, X; Qu, W; Yu, Z, 2019) |
| "The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF)." | 9.30 | Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial. ( Kinugawa, S; Komuro, I; Masuyama, T; Momomura, SI; Murohara, T; Saito, Y; Tsutsui, H, 2019) |
| "Our data suggested that anemia was associated with a blunted response to carvedilol in HFrEF patients." | 9.27 | Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol - Insights From Japanese Chronic Heart Failure (J-CHF) Study. ( Hori, M; Kitabatake, A; Nagatomo, Y; Okamoto, H; Yoshikawa, T, 2018) |
| "Carvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment for patients with heart failure and reduced ejection fraction (HFrEF)." | 9.27 | Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial. ( Choi, DJ; Hong, SJ; Hong, SK; Jeon, ES; Kang, SM; Kim, EJ; Kim, JJ; Kim, MA; Kim, SY; Lee, HY; Park, CS; Park, DG; Park, JJ; Shin, JH; Yoo, BS, 2018) |
| "Carvedilol attenuated the development and promoted a partial reversal of cachexia in patients with severe chronic heart failure, supporting a role for prolonged sympathetic activation in the genesis of weight loss." | 9.24 | Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. ( Anker, SD; Clark, AL; Coats, AJS; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Salekin, D; Schultz, MK, 2017) |
| "It is unclear whether carvedilol and nebivolol produce different effects on short-term left ventricle (LV) systolic function in heart failure (HF)." | 9.20 | Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure. ( Doğan, A; Erdoğan, D; Karabacak, M; Özaydın, M; Tayyar, Ş, 2015) |
| " We attempted to determine the significance of β1-AAb in chronic heart failure (CHF) patients who received carvedilol in a substudy of the Japanese Chronic Heart Failure study." | 9.20 | Presence of autoantibody directed against β1-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol: Japanese Chronic Heart Failure (J-CHF) Study. ( Hori, M; Kitabatake, A; Nagatomo, Y; Okamoto, H; Yoshikawa, T, 2015) |
| "To observe the changes of serum heart-type fatty acid-binding protein (h-FABP) and brain natriuretic peptide (BNP) in children with chronic heart failure (CHF) and evaluate the effects of carvedilol." | 9.20 | Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure. ( Li, DH; Ma, SC; Qiao, LY; Shan, RB; Sun, YP; Wei, CP; Zhang, YF, 2015) |
| "Four thousand sixteen patients with stable systolic chronic heart failure who were using either carvedilol or metoprolol succinate were identified in the Norwegian Heart Failure Registry and The Heart Failure Registry of the University of Heidelberg, Germany." | 9.20 | Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. ( Agewall, S; Atar, D; Cebola, R; Frankenstein, L; Fröhlich, H; Grundtvig, M; Hole, T; Katus, HA; Schellberg, D; Täger, T; Zhao, J, 2015) |
| "Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF)." | 9.19 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud ( Hori, M; Izumi, T; Matsuzaki, M; Nagai, R, 2014) |
| "It is unclear whether carvedilol and nebivolol will produce different effects on platelet function and prothrombotic state in heart failure (HF)." | 9.19 | Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure. ( Aksoy, F; Dogan, A; Erdogan, D; Karabacak, M; Karabacak, P; Ozaydin, M, 2014) |
| "The aim of our study was to examine regional differences in the demographics, etiology, risk factors, comorbidities and treatment of female patients with heart failure (HF) in the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD) clinical trial." | 9.19 | Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD). ( Apostolovic, S; Djordjevic-Radojkovic, D; Düngen, HD; Gelbrich, G; Inkrot, S; Jankovic-Tomasevic, R; Lainscak, M; Musial-Bright, L; Pavlovic, M; Putnikovic, B; Radovanovic, S; Salinger-Martinovic, S; Stanojevic, D; Tahirovic, E; Tomasevic, M; Waagstein, F, 2014) |
| "Ivabradine (IVA), a selective If current inhibitor decreasing the heart rate (HR) in patients with sinus rhythm, has been added to the most recent European Guidelines on heart failure." | 9.17 | Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. ( Benvenuto, A; Buta, F; De Viti, D; Masciocco, L; Massari, F; Meliota, G; Riccioni, G; Saracino, P; Speziale, G, 2013) |
| "This study aimed to evaluate the clinical efficacy and safety of carvedilol for pediatric patients with chronic heart failure caused by dilated cardiomyopathy." | 9.17 | The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: a prospective, randomized-controlled study. ( Chen, S; Huang, M; Liu, F; Sun, J; Sun, Y; Xiao, Y; Zhang, X, 2013) |
| "The aim of the present study was to assess the safety and tolerability of the controlled-release (CR) formulation of the β-blocker carvedilol in Japanese patients with chronic heart failure (HF)." | 9.16 | Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure. ( Ando, H; Kitakaze, M; Nakajima, H; Sakamoto, T; Sarai, N, 2012) |
| " carvedilol in 883 elderly heart failure patients with reduced or preserved left ventricular ejection fraction in 41 European centres." | 9.15 | Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. ( Anker, SD; Apostolovic, S; Dietz, R; Doehner, W; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Herrmann-Lingen, C; Inkrot, S; Krotin, M; Lainscak, M; Mehrhof, F; Neskovic, AN; Prettin, C; Putnikovic, B; Rau, T; Sakac, D; Tahirovic, E; Töpper, A; Waagstein, F; Wachter, R, 2011) |
| "Carvedilol has been shown to be superior to metoprolol tartrate to improve clinical outcomes in patients with heart failure (HF), yet the mechanisms responsible for these differences remain unclear." | 9.15 | Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study. ( Christiansen, B; Dominguez, H; Falskov, B; Hermann, TS; Køber, L; Major-Pedersen, A; Rask-Madsen, C; Raunsø, J; Torp-Pedersen, C, 2011) |
| "Carvedilol and bisoprolol reduce QT dispersion (QTD) in chronic heart failure (CHF)." | 9.14 | The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. ( Aygul, MU; Aygul, N; Duzenli, MA; Ozdemir, K, 2009) |
| "Background Carvedilol may reduce the severity of central sleep apnea (CSA) in patients with chronic heart failure (CHF)." | 9.14 | Carvedilol reduces the severity of central sleep apnea in chronic heart failure. ( Kadota, J; Kawano, Y; Tamura, A, 2009) |
| "We investigated the clinical response of chronic heart failure patients with beta(2)-adrenergic receptor Gln(27)-->Glu polymorphism treated for 6 months with carvedilol, a alpha/beta-antagonist with antioxidant properties." | 9.14 | Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. ( Bravo, R; Castro, PF; Chiong, M; del Campo, A; Díaz-Araya, G; Greig, D; Lavandero, S; Mellado, R; Moraga, F; Rodriguez, A; Roldán, J; Sanhueza, C; Troncoso, R; Valenzuela, R; Vukasovic, JL, 2009) |
| "To determine whether metoprolol succinate (a beta(1)-selective beta-blocker) remains beta(1)-selective compared with carvedilol (a nonselective beta-blocker) during upward titration of doses in patients with American College of Cardiology (ACC) stage C heart failure." | 9.14 | Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. ( Gilbert, EM; Lombardi, WL; Macgregor, J; Munger, M; Stoddard, GP; Zebrack, JS, 2009) |
| "Twenty-nine patients (63+/-12 years old) with New York Heart Association class II-III heart failure underwent serial measurements of left ventricular volumes using 3-dimensional echocardiography and blood pressures by sphygmomanometry at baseline, 2 weeks, 2, 6, and 12 months after initiation of carvedilol." | 9.14 | Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure. ( Burkhoff, D; El-Khoury Rumbarger, L; King, DL; Maurer, MS; Sackner-Bernstein, JD; Yushak, M, 2009) |
| "Carvedilol is a beta-adrenoceptor antagonist used for treating chronic heart failure (CHF)." | 9.14 | Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. ( Hanada, K; Kaneko, M; Kawana, J; Mihara, K; Nagayama, M; Ogata, H; Ohno, T; Saito, M; Shiomi, M; Sumiyoshi, T, 2010) |
| "To investigate the effects of carvedilol and metoprolol on the expression of autoantibodies against cardiac β(1), β(2) and α(1) adrenergic receptors in aged patients with chronic heart failure (CHF) and ventricular arrhythmia (VA)." | 9.14 | [Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia]. ( Li, XD; Wang, JC; Ye, L; Zhao, Y; Zhou, NN; Zhu, X, 2010) |
| "Body weight increased significantly in the carvedilol group (mean change + 2." | 9.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| " * Up to now, for carvedilol in paediatric patients with congestive heart failure (CHF) the dose has been linearly extrapolated from adults, but the results with this dosing strategy are ambiguous." | 9.13 | Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. ( Albers, S; Läer, S; Meibohm, B; Mir, TS, 2008) |
| " with NYHA II or III heart failure were double-blind randomized and uptitrated to either carvedilol 25 mg bid (n=131) or betaxolol 20 mg od (n=124)." | 9.12 | Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). ( Chochola, J; Figulla, HR; Fridl, P; Kalmbach, C; Krzeminska-Pakula, M; Wrabec, K, 2006) |
| "To evaluate whether carvedilol influences exercise hyperventilation and the ventilatory response to hypoxia in heart failure (HF)." | 9.12 | Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. ( Agostoni, P; Andreini, D; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Magini, A; Palermo, P; Veglia, F, 2006) |
| "Because of potential side effects and logistical difficulty of titrating medications, outpatients with congestive heart failure rarely receive appropriate doses of carvedilol or other beta-blockers." | 9.12 | Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits. ( Gerstenblith, G; Gottlieb, SH; Hefter, G; Kasper, EK; Kern, L; Najjar, SS; Palmer, JG; Spaeder, J, 2006) |
| " The present study evaluated the effect of gender on the influence of carvedilol on serum digoxin levels in patients with heart failure." | 9.12 | Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ( Baris, N; Bozdemir, V; Güneri, S; Guven, H; Kalkan, S, 2006) |
| "To assess the effects on LV function of nebivolol compared with carvedilol in patients with chronic heart failure and reduced LV systolic function." | 9.12 | Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. ( Abrignani, MG; Braschi, A; De Castro, S; Lombardo, RM; Reina, C; Rizzo, PA, 2006) |
| "The aim of this study was investigate the effects of carvedilol therapy on ventricular repolarization characteristics as assessed by QT dispersion (QTd) and heart rate variability (HRV) in patients with heart failure." | 9.12 | Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure. ( Akdeniz, B; Aslan, O; Badak, O; Baris, N; Göldeli, O; Guneri, S; Kirimli, O; Savas, IZ, 2006) |
| "We compared the pharmacokinetic (PK) profiles of repeated dosing with the currently available immediate-release (IR) carvedilol (given twice daily) and a newly developed controlled-release (CR) formulation (given once daily) in patients with left ventricular dysfunction (LVD)." | 9.12 | Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. ( Baidoo, CA; Greenberg, BH; Lukas, MA; Packer, M; Tenero, DM, 2006) |
| "We aimed to compare the effects of carvedilol and metoprolol succinate on left atrial (LA) function in patients with chronic heart failure." | 9.12 | Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol. ( Acikel, M; Arslan, S; Atesal, S; Bozkurt, E; Erol, MK; Gundogdu, F; Senocak, H, 2007) |
| "To study the development of new onset diabetes in a large cohort of patients with heart failure treated with either metoprolol or carvedilol." | 9.12 | Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). ( Charlesworth, A; Cleland, JG; Di Lenarda, A; Lukas, MA; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 9.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Carvedilol, a beta1 and beta2 as well as an alpha1 adrenoreceptor antagonist with multiple hemodynamic, anti-ischemic and anti-oxidant properties, is widely accepted for the treatment of hypertension and congestive heart failure (CHF)." | 9.12 | The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. ( Abinader, EG; Goldhammer, E; Lanir, A; Maor, I; Shnitzer, S, 2007) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 9.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "To compare the effects of carvedilol and bisoprolol on lung function in patients with chronic heart failure (CHF)." | 9.12 | Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? ( Agostoni, P; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Fiorentini, C; Palermo, P; Sciomer, S, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 9.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "In the COMET study, carvedilol improved survival compared to metoprolol tartrate in 3029 patients with NYHA II-IV heart failure and EF <35%, followed for an average of 58 months." | 9.12 | Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Erhardt, L; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, P; Remme, WJ; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "To detect the serum autoantibodies against the cardiac beta(1)-adrenergic receptor and observe the clinical characteristics and response to carvedilol use in patients with chronic heart failure (CHF)." | 9.12 | [Serum autoantibodies against the cardiac beta(1)-adrenergic receptor in patients with chronic heart failure: clinical characteristics and response to carvedilol]. ( Chen, J; Liu, XL; Wang, SY; Wu, YF; Yang, XC; Zhang, L; Zhu, JG, 2007) |
| "This study aimed at describing usual conditions of carvedilol use in heart failure (HF) patients." | 9.12 | [Treating heart failure with carvedilol in private practice (initiating treatment and follow-up at one year. The KEOPS study]. ( Amouyel, P; Bergougnoux, L; Cohen-Solal, A; de Groote, P; Jaillon, P; Johnson, N; Komajda, M; Laperche, T, 2007) |
| "We sought to evaluate the influence of pretreatment systolic blood pressure (SBP) on the efficacy and safety of carvedilol in patients with chronic heart failure (CHF)." | 9.11 | Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. ( Castaigne, A; Coats, AJ; Fowler, MB; Holcslaw, TL; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Roecker, EB; Rouleau, JL; Scherhag, A; Tendera, M, 2004) |
| "In a parallel-group, 3-arm study of 18 months duration, 572 mild heart failure patients were randomly assigned to carvedilol (N = 191), enalapril (N = 190) or their combination (N = 191)." | 9.11 | The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). ( Bobbio, M; Hildebrandt, P; Jaarsma, W; Komajda, M; Lutiger, B; Remme, WJ; Riegger, G; Rydén, L; Scherhag, A; Soler-Soler, J, 2004) |
| "The Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial was an investigator-initiated study to evaluate if predischarge carvedilol initiation in stabilized patients hospitalized for heart failure (HF) increased the number of patients treated with beta-blockade at 60 days after randomization without increasing side effects or length of hospital stay." | 9.11 | Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. ( Gallup, DS; Gattis, WA; Gheorghiade, M; Hasselblad, V; O'Connor, CM, 2004) |
| "The impact of carvedilol on the survival of patients with severe heart failure was examined in the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial." | 9.11 | Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure. ( Fowler, MB, 2004) |
| "The purpose of this study was to investigate the effects of carvedilol on diastolic function (DF) in heart failure patients with preserved left ventricular (LV) systolic function and abnormal DF." | 9.11 | Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). ( Andersson, B; Bergström, A; Dahlström, U; Edner, M; Nylander, E; Persson, H, 2004) |
| "To assess the effects of carvedilol treatment on the renin-angiotensin system in patients with chronic heart failure (CHF)." | 9.11 | Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. ( Beauvais, F; Berdeaux, A; Cohen Solal, A; Jondeau, G, 2004) |
| "Although the benefits of carvedilol in patients with heart failure and depressed ejection fraction (EF) have been elucidated, those in patients with preserved EF are not understood." | 9.11 | Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. ( Fukutomi, T; Itoh, M; Kondo, H; Ogata, M; Shigeyama, J; Sugiura, M; Suzuki, S; Takeda, Y; Yamamoto, K, 2004) |
| "Although ACEI and carvedilol produce benefits in heart failure, whether the order of initiation of therapy determines the impact on left ventricular (LV) function and New York Heart Association functional class (NYHA FC) has not been determined." | 9.11 | Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. ( Candy, G; Essop, R; Kachope, J; Kone, N; Libhaber, C; Norton, GR; Sareli, P; Sliwa, K; Woodiwiss, AJ, 2004) |
| "Carvedilol is an antioxidant and adrenergic antagonist with demonstrated benefits in terms of mortality from heart failure (HF)." | 9.11 | [Effects of carvedilol on functional capacity, left ventricular function, catecholamines and oxidative stress in patients with chronic heart failure]. ( Castro, P; Chiong, M; Corbalán, R; Díaz-Araya, G; Greig, D; Lavandero, S; Moraga, F; Padilla, I; Pérez, O; Troncoso, R; Vukasovic, JL, 2004) |
| "Carvedilol has been shown to improve survival and morbidity in patients with heart failure." | 9.11 | Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. ( Bristow, MR; Gill, EA; Holcslaw, TL; Pittenger, B, 2004) |
| "The long-term effects of carvedilol on muscle sympathetic nerve activity (MSNA) and muscle blood flow at rest and exercise in patients with chronic heart failure (CHF) remain unknown." | 9.11 | Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. ( Barretto, AC; Brum, PC; De Matos, LD; Gardenghi, G; Middlekauff, HR; Negrão, CE; Rondon, MU; Soufen, HN; Tirone, AP, 2004) |
| "In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily." | 9.11 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005) |
| "Fifty-five patients with New York Heart Association (NYHA) classes II-III congestive heart failure and LVEF < or =35% entered the study with intention to assess LVEF, NYHA class, plasma brain natriuretic peptide (BNP), N-terminal atrial natriuretic peptide (NANP), big-endothelin, endothelin-1, norepinephrine, and angiotensin II at baseline and at 6 and 12 months after initiation of carvedilol." | 9.11 | Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. ( Backes, RJ; Bailey, KR; Burnett, JC; Frantz, RP; Grill, D; Hanna, RD; Heublein, D; Mookadam, F; Moualla, SK; Nelson, SM; Nobrega, TP; Olson, LJ, 2005) |
| "Carvedilol treatment in chronic heart failure (CHF) patients has been demonstrated to reduce mortality by improving cardiac systolic function and reducing left ventricular adverse remodeling." | 9.11 | Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure. ( Calabria, P; Gennari, L; Martini, G; Nuti, R; Palazzuoli, A; Quatrini, I; Vecchiato, L, 2005) |
| "Radionuclide isotopic ventriculography with phase analysis was performed in 30 patients with stable heart failure (HF), determining left ventricular (LV) and interventricular contraction synchrony at baseline and after 6 months of treatment with maximal tolerated doses of carvedilol." | 9.11 | Effects of carvedilol upon intra- and interventricular synchrony in patients with chronic heart failure. ( Alcaino, H; Bittner, A; Castro, PF; Chiong, M; Copaja, M; Corbalan, R; Díaz-Araya, G; Greig, D; Lavandero, S; Mc-Nab, P; Quintana, JC; Troncoso, R; Vergara, I; Vukasovic, JL, 2005) |
| "The Carvedilol or Metoprolol European Trial (COMET) compared the effects of a comprehensive adrenergic antagonist, carvedilol (target dosage 25 mg twice daily), with a beta-1-selective agent, metoprolol tartrate (target dosage 50 mg twice daily), in 3029 patients with chronic heart failure caused by left ventricular systolic dysfunction." | 9.11 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. ( Cleland, JG, 2004) |
| "Carvedilol treatment in chronic heart failure (CHF) demonstrated to reduce mortality and rehospitalisation, and improvement of cardiac systolic function with reduction of left ventricular volumes and remodelling." | 9.11 | Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure. ( De Paola, V; Iovine, F; Martini, G; Nuti, R; Palazzuoli, A; Quatrini, I; Scali, C; Vecchiato, L, 2005) |
| "Carvedilol is a beta-blocking agent with antioxidant properties that has been shown to improve survival in chronic heart failure (CHF)." | 9.11 | Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. ( Abergel, E; Berdeaux, A; Cohen-Solal, A; Le Guludec, D; Merlet, P; Rouzet, F; Syrota, A, 2005) |
| "It is still uncertain whether or not there is a difference between metoprolol and carvedilol for the treatment of congestive heart failure." | 9.11 | Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. ( Anzai, T; Kohno, T; Nakamura, I; Ogawa, S; Satoh, T; Yoshikawa, T; Yoshizawa, A, 2005) |
| "To investigate the effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure (CHF)." | 9.11 | [Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure]. ( Gao, LJ; Lin, XY; Xiao, LZ; Zhang, HF, 2005) |
| "Additional treatment with carvedilol is neutral with regard to influence the insulin sensitivity in patients with mild to moderate CHF." | 9.10 | Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. ( Andreasen, F; Gøtzsche, O; Refsgaard, J; Thomsen, C, 2002) |
| "Carvedilol is a medication with both beta-receptor and alpha-receptor blocking properties that has been approved for the treatment of heart failure in adults." | 9.10 | The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design. ( Boucek, MM; Burch, GH; Burr, J; Curtin, EL; Hsu, DT; LaSalle, B; Mahony, L; Pahl, E; Schlencker-Herceg, R; Shaddy, RE; Sower, B; Tani, LY, 2002) |
| "We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF)." | 9.10 | Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. ( Bristow, MR; D'Aloia, A; Dei Cas, L; Metra, M; Muneretto, C; Nodari, S; Robertson, AD, 2002) |
| "We randomly assigned 2289 patients with symptoms of heart failure at rest or on minimal exertion and with an ejection fraction <25% (but not volume-overloaded) to double-blind treatment with either placebo (n=1133) or carvedilol (n=1156) for an average of 10." | 9.10 | Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. ( Amann-Zalan, I; Coats, AJ; DeMets, DL; Fowler, MB; Holcslaw, TL; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Roecker, EB; Rouleau, JL; Staiger, C; Tendera, M, 2002) |
| "Recent studies have shown that carvedilol therapy in patients with heart failure improves clinical outcome and survival, however, the effects of such treatment on left cardiac morphology and function in elderly patients with severe heart failure has not been widely studied." | 9.10 | Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. ( Angori, P; Auteri, A; Bruni, F; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L, 2002) |
| "While receiving placebo (2 months) and a full dosage of carvedilol (4 months), 15 chronic heart failure patients were evaluated by quality-of-life questionnaire, pulmonary function tests, cardiopulmonary exercise tests with constant workload, and a ramp protocol." | 9.10 | Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients. ( Agostoni, P; Bussotti, M; De Vita, S; Guazzi, M; Palermo, P, 2002) |
| " We hypothesized that the nonselective beta-antagonist carvedilol, through its alpha1-adrenergic blocking properties, may modulate vascular reactivity to Ang II in patients with chronic heart failure (CHF)." | 9.10 | Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. ( Jorde, UP; Katz, SD; Lang, CC; Mancini, DM; Packer, M; Vittorio, TJ, 2003) |
| "To evaluate the early effects of the beta-blocker carvedilol in patients with severe heart failure." | 9.10 | Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. ( Coats, AJ; Fowler, MB; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Roecker, EB; Rouleau, JL; Tendera, M, 2003) |
| "Patients with congestive heart failure on a non-selective beta adrenoreceptor blocker or beta1 selective blocker responded differently to the inotropic drug dobutamine: the beta1 blockade caused by metoprolol could be counteracted by dobutamine, whereas with carvedilol a low dose of dobutamine increased cardiac output, and a higher dose of dobutamine caused a pressor effect." | 9.10 | Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. ( Andersson, B; Bollano, E; Hjalmarson, A; Täng, MS; Waagstein, F, 2003) |
| "In a multicentre, double-blind, and randomised parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily)." | 9.10 | Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lubsen, J; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2003) |
| "We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due to ischaemic left-ventricular systolic dysfunction." | 9.10 | Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. ( Cleland, JG; Coats, AJ; Lahiri, A; Macfarlane, PW; Mule, JD; Murray, GD; Pennell, DJ; Ray, SG; Vered, Z, 2003) |
| "Acute administration of carvedilol attenuates the vasoconstriction response to adrenergic stimuli when compared with placebo and metoprolol in normal subjects, whereas chronic administration of carvedilol does not attenuate the vasoconstrictor response to adrenergic stimuli when compared with metoprolol in heart failure subjects." | 9.10 | Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "We studied effects of beta-adrenoblocker carvedilol vs placebo in 60 patients with chronic cardiac failure (CCF) of functional classes III-IV in a 6-month open randomized trial." | 9.10 | [Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol]. ( Shliakhto, EV; Sitnikova, MIu, 2003) |
| " Thirty-three patients with CHF, with exercise limited by dyspnea and left ventricular ejection fraction of 26 +/- 4%, were randomized to receive metoprolol or carvedilol for 6 months." | 9.10 | Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). ( Blanchet, M; Ducharme, A; Fortier, A; Juneau, M; Larivée, L; Marquis, J; Nigam, A; Racine, N; Rouleau, JL; Tardif, JC; White, M, 2003) |
| "To examine the influence of carvedilol dose and concentration in serum on plasma brain natriuretic peptide (BNP), a measure of heart failure progression." | 9.10 | Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study. ( Konishi, H; Minouchi, T; Nishio, S; Tsutamoto, T; Yamaji, A, 2003) |
| "In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality and morbidity in patients with chronic heart failure." | 9.10 | Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; J Remme, W; Komajda, M; Metra, M; Poole-Wilson, PA; Swedberg, K; Torp-Pedersen, C, 2002) |
| "In a randomized (2:1), double-blinded design study, we studied 25 patients with congestive heart failure (66 +/- 9 years, ejection fraction 30 +/- 7%) before and after 23-week treatment with the beta blocker carvedilol 25 mg twice daily (n = 17) or placebo (n = 8) in addition to standard therapy." | 9.10 | Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. ( Andreasen, F; Bøttcher, M; Gøtzsche, O; Nielsen, TT; Refsgaard, J, 2002) |
| "Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo." | 9.09 | Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; Ikram, H; Macmahon, S; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 1999) |
| "We and others have previously shown that carvedilol improves left ventricular (LV) function and symptoms in chronic heart failure." | 9.09 | Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. ( Abraham, WT; Bristow, MR; Gilbert, EM; Gill, EA; Larrain, JR; Lowes, BD; Robertson, AD, 1999) |
| "Twenty-one patients with New York Heart Association class II to III heart failure were randomly assigned (2 to 1) to carvedilol (25 mg twice daily, n = 14) or placebo (n = 7) for 6 months." | 9.09 | Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. ( Agostoni, P; Guazzi, M; Guazzi, MD; Matturri, M; Pontone, G, 1999) |
| "This study was performed to compare the long-term clinical efficacy of treatment with metoprolol versus carvedilol in patients with chronic heart failure." | 9.09 | Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. ( Chan, KW; Chan, SK; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yip, G, 1999) |
| "Carvedilol reduces mortality and improves symptoms and ejection fraction in ischemic heart failure, but its mode of action is not well defined and not all patients respond to treatment." | 9.09 | The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. ( Atkinson, P; Burgess, M; Cleland, JG; Davies, G; Pennell, DJ; Ray, SG; Slomka, P; Webster, J, 2000) |
| "In patients with chronic heart failure, the use of carvedilol therapy induces clinical and hemodynamic improvement." | 9.09 | Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. ( Capomolla, S; Caporotondi, A; Cobelli, F; Febo, O; Gnemmi, M; Mortara, A; Opasich, C; Pinna, GD; Riccardi, G, 2000) |
| "Carvedilol improved LV regional WMSI in patients with heart failure caused by ischemic heart disease." | 9.09 | Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( Doughty, RN; Gamble, G; MacMahon, S; Sharpe, N; Whalley, GA, 2000) |
| "Both metoprolol and carvedilol produce hemodynamic and clinical benefits in patients with chronic heart failure; carvedilol exerts greater antiadrenergic effects than metoprolol, but it is unknown whether this pharmacological difference results in hemodynamic and clinical differences between the 2 drugs." | 9.09 | Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. ( Boldi, E; Dei Cas, L; Giubbini, R; Metra, M; Modena, MG; Nodari, S, 2000) |
| " The objective of this study was to determine if these antioxidant effects are detectable in patients with heart failure and to compare carvedilol with the selective beta-blocker metoprolol." | 9.09 | Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. ( Arumanayagam, M; Chan, S; Sanderson, JE; Tong, S, 2001) |
| "To verify and compare the effects respectively exercised in chronic heart failure patients by transdermal, slow release scopolamine patch and by the beta and alfa adrenoreceptor blocker carvedilol upon the main indexes derived from maximal cardiopulmonary stress test, as well as from analysis of heart rate variability." | 9.09 | Different impact of carvedilol and transdermal scopolamine on cardiovascular performance of mild-moderate chronic heart failure patients: evidence of useful effects of scopolamine on tolerance to work load. ( De Vecchis, R; Nocerino, L; Pucciarelli, G; Setaro, A, 2000) |
| "The objective of this study was to examine the pharmacokinetic and pharmacodynamic consequences of concomitant administration of fluoxetine and carvedilol in heart failure patients." | 9.09 | Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ( Adams, KF; Carson, SW; Cascio, WE; Graff, DW; Patterson, JH; Pieper, JA; Williamson, KM, 2001) |
| "Carvedilol has been shown to decrease the progression of heart failure and improve left ventricular function and survival in patients with a left ventricular ejection fraction (LVEF) less than 35%." | 9.09 | Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. ( Abraham, WT; Bristow, MR; Ferguson, D; Lindenfeld, JA; Lowes, BD; Schleman, KA; Wolfel, EE; Zisman, LS, 2001) |
| "A programme of four phase III clinical trials carried out in the USA on 1094 patients showed that Carvedilol, associated with the usual bitherapy and eventually with digitalis, reduced the mortality and number of hospital admissions of patients with cardiac failure." | 9.09 | [Economic study of carvedilol in heart failure. A cost effectiveness study in France]. ( Cohen-Solal, A; Dubois-Randé, JL; Lévy, E; Lévy, P, 2001) |
| "The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure." | 9.09 | Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Lukas, MA; Packer, M; Yancy, CW; Young, ST, 2001) |
| "Carvedilol treatment in patients with heart failure results in a 57% decrease in myocardial FFA use without a significant change in glucose use." | 9.09 | Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. ( DeGrado, TR; Nickles, RJ; Russell, DC; Stanko, P; Stone, CK; Taylor, M; Wallhaus, TR, 2001) |
| "The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial." | 9.09 | Effect of carvedilol on survival in severe chronic heart failure. ( Castaigne, A; Coats, AJ; DeMets, DL; Fowler, MB; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Roecker, EB; Rouleau, JL; Schultz, MK; Tendera, M, 2001) |
| "Although neurohormonal status has known prognostic significance in heart failure, the predictive power of either N-BNP or adrenomedullin in chronic ischemic LV dysfunction has not been previously reported." | 9.09 | Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; MacMahon, S; Murphy, J; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 2001) |
| "Fourteen digitalised patients diagnosed with heart failure (NYHA Functional class II) with idiopathic dilated cardiomyopathy in chronic established atrial fibrillation were administered carvedilol in addition to their anti-heart failure medications in an attempt to improve their heart rate control." | 9.09 | Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. ( Agarwal, AK; Venugopalan, P, 2001) |
| "Carvedilol has been shown to improve morbidity and mortality in patients with congestive heart failure (CHF)." | 9.09 | Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. ( Antonio, C; Choudhary, G; Heaney, L; Jain, A; Just, V; Kumar, A; Papp, MA, 2001) |
| "This study evaluated the independent and combined effects of captopril and carvedilol on left ventricular remodeling in chronic heart failure." | 9.09 | Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol. ( Khattar, RS; Lahiri, A; Senior, R; Soman, P; van der Does, R, 2001) |
| "This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF)." | 9.09 | Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. ( Böhm, M; Crivaro, M; Elter, T; LaRosee, K; Maack, C; Nickenig, G; Stäblein, A; Wuttke, H, 2001) |
| "The purpose of this study was to determine whether carvedilol's alpha(1)-adrenoceptor antagonism persists during long-term therapy of patients with congestive heart failure (CHF)." | 9.09 | Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. ( Azevedo, ER; Floras, JS; Kubo, T; Newton, GE; Parker, JD, 2001) |
| "A number of studies showed the improvement in left ventricular (LV) function and clinical outcome that carvedilol produces in patients with severe congestive heart failure (CHF)." | 9.09 | [Tolerability and clinical effects of carvedilol in patients over 70 years of age with chronic heart failure due to left ventricular dysfunction]. ( Cioffi, G; Stefenelli, C, 2001) |
| "This study investigated the effects of carvedilol, a beta-blocker with alpha 1-blocking properties, on left ventricular size and function, maximal and submaximal exercise performance, and symptoms in 415 patients with stable heart failure of ischemic etiology (ejection fraction < 45%)." | 9.08 | Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( , 1995) |
| "We enrolled 56 patients with severe chronic heart failure into a double-blind, placebo-controlled study of the vasodilating beta-blocker carvedilol." | 9.08 | Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. ( Goldsmith, RL; Horn, E; Katz, SD; Krum, H; Kukin, ML; Medina, N; Penn, J; Sackner-Bernstein, JD; Schwartz, B; Yushak, M, 1995) |
| "This study assessed the safety and efficacy of carvedilol in patients with heart failure caused by idiopathic or ischemic cardiomyopathy." | 9.08 | Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. ( Bristow, MR; Gilbert, EM; Olsen, SL; Renlund, DG; Taylor, DO; Yanowitz, FD, 1995) |
| "Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor." | 9.08 | The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Packer, M; Shusterman, NH, 1996) |
| "415 patients with chronic stable heart failure were randomly assigned treatment with carvedilol (207) or matching placebo (208)." | 9.08 | Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. ( , 1997) |
| "The aim of this study, a substudy of the Australia-New Zealand trial of carvedilol in patients with heart failure due to ischemic heart disease, was to determine the effects of this treatment on left ventricular size and function with the use of quantitative two-dimensional (2D) echocardiography." | 9.08 | Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( Doughty, RN; Gamble, G; MacMahon, S; Sharpe, N; Whalley, GA, 1997) |
| "One hundred thirty-one patients with severe congestive heart failure were enrolled into a double-blind, placebo-controlled study of the vasodilating beta-blocker carvedilol." | 9.08 | Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Holcslaw, TL; Kinhal, V; Krueger, SK; Lejemtel, T; Lukas, MA; Narahara, KA; Packer, M; Young, ST, 1997) |
| "This study was aimed at investigating in chronic heart failure (CHF) the effects that beta-blockade with carvedilol may have on lung function, and their relationship with left ventricular (LV) performance and peak exercise oxygen uptake (VO2p)." | 9.08 | [A failed improvement in pulmonary function and exercise capacity with carvedilol in congestive heart failure despite an excellent effect on left ventricular function]. ( Agostoni, P; Guazzi, M; Lomanto, M; Matturri, M; Pontone, G; Trevisi, N, 1998) |
| "This study investigated the effects of carvedilol on right ventricular (RV) volume and systolic function in chronic heart failure patients." | 9.08 | Effects of carvedilol on right ventricular function in chronic heart failure. ( Bristow, MR; Christian, PE; Datz, FL; Gilbert, EM; Quaife, RA; Volkman, K, 1998) |
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 9.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "We retrospectively analyzed the Australia/New Zealand Carvedilol Heart Failure Research Collaborative Group study of 415 patients with mild to moderate ischemic heart failure where amiodarone was administered as part of the treatment therapy (in 52 patients)." | 9.08 | Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group. ( Krum, H; MacMahon, S; Sharpe, N; Shusterman, N, 1998) |
| "Carvedilol is a nonselective beta-blocker with alpha-mediated vasodilating properties that has been shown to be effective in systemic hypertension, stable angina, and congestive heart failure (CHF)." | 9.07 | Effects of carvedilol on ventricular arrhythmias. ( DasGupta, P; Lahiri, A; Müller-Beckmann, B; Senior, R; van der Does, R, 1992) |
| "Long-term treatment with appropriate doses of carvedilol or metoprolol is currently recommended for patients with heart failure with reduced ejection fraction (HFrEF) to decrease the risk of death, hospitalizations, and patients' symptoms." | 8.91 | Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure. ( Afonso, L; Briasoulis, A; Palla, M, 2015) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 8.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "The third generation beta-blocker (carvedilol) is effective in reduction of hypertension, and of mortality and morbidity as a supplement to conventional drugs of heart failure therapies (diuretics, ACE inhibitors), based on randomized controlled trials and retrospective analysis." | 8.83 | [The effectiveness of carvedilol in heart failure]. ( Brodszky, V; Farsang, C; Gulácsi, L; Jermendy, G; Kárpáti, K; Vándorfi, G; Zámolyi, K, 2006) |
| "The safety, tolerability, and hemodynamic effects of carvedilol in patients with heart failure were first studied in the mid 1990s." | 8.82 | Landmark studies: the Australia/New Zealand Heart Failure Collaborative Group (ANZ) Trial and the US Carvedilol Trials Program. ( Gilbert, EM, 2004) |
| "Both metoprolol and carvedilol improve cardiac function and prolong survival in patients with heart failure." | 8.81 | Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. ( Antonopoulos, GV; Berlin, JA; Chittams, J; Konstam, MA; Packer, M; Udelson, JE, 2001) |
| "Carvedilol and vesnarinone are drugs attracting recent interest in the treatment of chronic heart failure." | 8.81 | Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy. ( Cheng, JH; Kamiya, K; Kodama, I, 2001) |
| "Carvedilol, a beta-adrenoceptor blocking agent with additional alpha(1)-adrenoceptor blocking properties, has been shown to improve left ventricular function in chronic heart failure (CHF)." | 8.80 | Assuming the worst may not be bad at all. Carvedilol in heart failure treatment. ( Janson, CP; Schmidt, BM; Wehling, M, 1998) |
| "Carvedilol is a novel, multiple-action cardiovascular drug that is currently approved in many countries for the treatment of hypertension." | 8.79 | Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1997) |
| "Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF)." | 8.02 | Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. ( Andersson, C; Gislason, GH; Kristensen, SL; Køber, L; Madelaire, C; Pierce, C; Schou, M; Schwartz, B; Torp-Pedersen, C, 2021) |
| "The Beta-Blocker Evaluation Survival Trial showed no survival benefit for bucindolol in New York Heart Association (NYHA) class III/IV heart failure (HF) with reduced ejection fraction, but subanalyses suggested survival benefits for non-Black subjects and Arg389 homozygotes." | 8.02 | Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. ( Abraham, I; Alkhatib, N; Erstad, B; Gharaibeh, M; Karnes, J; Klimecki, W; Lee, CS; Ramos, K; Slack, M; Sweitzer, NK, 2021) |
| "Although prior literature suggests that metoprolol may worsen glucose control compared to carvedilol, whether this has clinical relevance among older adults with diabetes and heart failure (HF) remains an open question." | 8.02 | Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes. ( Dave, CV; Dejanovic, I; Gerhard, T; Horton, DB; Kobylarz, FA; Nyandege, A; Setoguchi, S; Strom, BL; Tseng, CL, 2021) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 7.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "This study sought to assess the safety of carvedilol therapy among heart failure (HF) patients with a cocaine-use disorder (CUD)." | 7.91 | Carvedilol Among Patients With Heart Failure With a Cocaine-Use Disorder. ( Afshar, M; Alvi, RM; Awadalla, M; Banerji, D; Groarke, JD; Hassan, MO; Mulligan, CP; Neilan, TG; Rokicki, A; Tariq, N; Zhang, L, 2019) |
| "Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction." | 7.91 | Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. ( Branka, JZ; Davor, M; Domagoj, M; Duska, G; Jelena, M, 2019) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 7.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "To compare the effects carvedilol and nebivolol on oxidative stress status in non-ischaemic heart failure (HF) patients." | 7.81 | The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure. ( Bas, HA; Dogan, A; Karabacak, M; Tayyar, S, 2015) |
| " The objective of this study was to develop PBPK models that incorporate the haemodynamic changes in hepatic and renal blood flows occurring in chronic heart failure (CHF) and to evaluate these changes in adults and children, using carvedilol as a model drug." | 7.81 | A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. ( Khalil, F; Läer, S; Rasool, MF, 2015) |
| "Carvedilol is the standard of care for heart failure (HF) patients." | 7.80 | Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure. ( Arcavi, L; Bar-Haim, A; Berkovitch, M; Caspi, A; Goland, S; Harary, I; Nulman, I; Shihmanter, R, 2014) |
| "The β-blockers carvedilol and metoprolol succinate both reduce mortality in patients with heart failure (HF), but the comparative clinical effectiveness of these drugs is unknown." | 7.80 | Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. ( Hviid, A; Melbye, M; Pasternak, B; Svanström, H, 2014) |
| "Data were retrospectively collected from 23 patients with HF [age 57±18 years, left ventricular ejection fraction (LVEF) 33±15%] who could not increase the dosage of carvedilol because of dizziness or hypotension, defined as systolic blood pressure<90 mmHg." | 7.79 | Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. ( Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013) |
| "The aim of this study was to derive population pharmacokinetic (PK) model for clearance (CL) of carvedilol in adult patients with chronic heart failure (CHF)." | 7.79 | Population pharmacokinetics of carvedilol in patients with congestive heart failure. ( Apostolović, S; Djuric, J; Jankovic, SM; Jevtovic-Stoimenov, T; Markovic, V; Milovanovic, JR; Nikolic, VN; Pesic, S; Stanojevic, D; Stefanovic, N; Velickovic-Radovanović, R; Zivanovic, S, 2013) |
| "In 49 consecutive patients with chronic heart failure (HF), LVEF ≤35%, NYHA functional class II-IV, on angiotensin-converting enzyme inhibitors but not on ß-blockers, LV contractile performance and remodeling were assessed by comprehensive echocardiography at baseline and after 3 and 6 months of treatment with carvedilol." | 7.78 | New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. ( Ather, S; Bolos, M; Bozkurt, B; Carabello, B; Chan, W; Deswal, A; Mann, DL, 2012) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 7.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "The aim of the present study was to determine whether carvedilol-treated chronic heart failure patients have a different prognosis when stratified for a specific combination of a gain-of-function genotype of the adrenergic β-1 receptor gene (ADRB1) (Arg389-homozygous), two gain-of-function genotypes of the angiotensinogen gene (AGT) (Thr174-homozygous and Thr235-homozygous), and a downregulated genotype of the adrenergic β-2 receptor gene (ADRB2) (Gln27-carrier)." | 7.78 | Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial. ( Afzal, S; Andersen, JT; Broedbaek, K; Børglum, AD; Jimenez-Solem, E; Køber, L; Nyegaard, M; Petersen, M; Poulsen, HE; Stender, S; Torp-Pedersen, C, 2012) |
| "Relative effectiveness of carvedilol and metoprolol succinate has never been compared in patients with heart failure (HF)." | 7.78 | Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis. ( Aggarwal, V; Shore, S; Zolty, R, 2012) |
| "The effect of carvedilol on heart failure (HF) in patients with a functionally univentricular heart (UVH) remains unclear." | 7.77 | Effect of carvedilol on heart failure in patients with a functionally univentricular heart. ( Ando, M; Doi, S; Ishibashi, N; Mimori, S; Mizutani, S; Mori, K; Murakami, Y; Nakanishi, T; Park, IS; Takahashi, Y; Waragai, T; Yoshikawa, T, 2011) |
| " We present a case where carvedilol was replaced with bisoprolol resulting in acute urinary retention." | 7.77 | Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( Lindenfeld, J; Page, RL; Rohrer, CK; Shakar, SF, 2011) |
| "To evaluate the heart rate dynamic in heart failure patients with different sensibilities of the Carvedilol therapy during an exercise test." | 7.76 | Heart rate dynamic during an exercise test in heart failure patients with different sensibilities of the carvedilol therapy: heart rate dynamic during exercise test. ( Bocchi, EA; Carvalho, VO; Guimarães, GV; Rodrigues Alves, RX, 2010) |
| "In COMET (Carvedilol or Metoprolol European Trial), carvedilol reduced mortality compared with metoprolol in patients with chronic heart failure." | 7.76 | Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy. ( Boman, K; Cleland, JG; Jansson, JH; Nilsson, T; Poole-Wilson, P; Swedberg, K, 2010) |
| "Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects." | 7.76 | Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. ( Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M, 2010) |
| "Large clinical trials using the betablockers carvedilol, metoprolol, bisoprolol and nebivolol have demonstrated improvement of survival and symptoms in patients with heart failure." | 7.76 | Replacement of carvedilol for propranolol in patients with heart failure. ( Castro, RB; Gallo, L; Maciel, BC; Marques, F; Nobre, F; Pintya, AO; Simões, MV, 2010) |
| "Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure." | 7.76 | A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. ( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010) |
| "To study beta1-adrenoceptor gene (ADRB1) polymorphism on the development and course of chronic heart failure (CHF) and on the efficiency of its treatment with the beta-adrenoblocker carvedilol in patients with coronary heart failure." | 7.76 | [Impact of Gly389Arg beta1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol]. ( Berezikova, EN; Efremov, AV; Karpov, RS; Maianskaia, SD; Popova, AA; Safronov, ID; Shilov, SN; Tepliakov, AT; Torim, IuIu; Voronina, EN, 2010) |
| "In the UK, the licence for carvedilol was extended in 1998 to include symptomatic heart failure (New York Heart Association [NYHA] class II and III heart failure) with the recommendation that initiation and up-titration should be under the supervision of a hospital physician." | 7.75 | Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. ( Aurich-Barrera, B; Shakir, SA; Wilton, LV, 2009) |
| "To study the effects of carvedilol combined with perindopril on Ca(2+) pump activity and the density of Ca(2+)-release channel ryanodine receptor (RyR2) in the myocardial sarcoplasmic reticulum (SR) in rats with chronic heart failure caused by myocardial infarction." | 7.75 | [Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction]. ( Cui, B; Geng, ZH; Li, LG; Liu, CY; Peng, YH; Yu, SY; Zhao, XH, 2009) |
| "To examine serum B-type natriuretic peptide (BNP) levels and BNP expression of protein and mRNA in the right ventricular myocardium in juvenile rats with right heart failure (RHF) and the effects of beta-adrenergic receptor blocker carvedilol on serum and myocardial BNP levels in order to investigate the role of BNP in the diagnosis and treatment of RHF." | 7.75 | [B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure]. ( An, JD; Feng, S; Liang, F, 2009) |
| "The effect of the dose of carvedilol on cardiac sympathetic nerve activity (CSA) and mortality remain uncertain in patients with chronic heart failure (CHF)." | 7.75 | Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine. ( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2009) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 7.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "A Holter ECG recording was obtained before and 1 and 3 months after titrated addition of carvedilol therapy in 10 patients with advanced congestive heart failure." | 7.74 | Carvedilol can restore the multifractal properties of heart beat dynamics in patients with advanced congestive heart failure. ( Chan, HL; Chiu, KM; Chu, SH; Lin, TY, 2007) |
| "The IMPACT-HF trial demonstrated that carvedilol use at the time of heart failure (HF) hospital discharge significantly increased 90-day postdischarge treatment rates." | 7.74 | Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). ( Abraham, WT; Albert, NM; Fonarow, GC; Gheorghiade, M; Greenberg, BH; O'Connor, CM; Stough, WG; Sun, JL; Yancy, C; Young, JB, 2007) |
| "Carvedilol therapy resulted in a marked decrease in plasma NT-proBNP levels and increase left ventricular ejection fraction in patients with congestive heart failure." | 7.74 | The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure. ( Arslan, S; Bozkurt, E; Gundogdu, F; Gurlertop, Y; Karakelleoglu, S; Kiziltunc, A; Senocak, H; Sevimli, S, 2007) |
| "To study the effects of carvedilol on the transmural heterogeneity of ventricular repolarization in rabbits with congestive heart failure (CHF)." | 7.74 | Low-dose carvedilol reduces transmural heterogeneity of ventricular repolarization in congestive heart failure. ( Chen, XP; Chen, YF; Li, WJ; Yao, Z; Yun, ML; Zhong, JH, 2007) |
| "To characterize prescribing of carvedilol and controlled-release (CR) metoprolol for veterans with heart failure who were predominantly elderly (aged > or = 65) and to compare the time to first hospitalization or death." | 7.74 | Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. ( Anand, IS; Ensrud, KE; Nelson, DB; Rector, TS, 2008) |
| "Although most patients in Europe with systolic heart failure (SHF) are treated with I(2)-blocking agents at doses significantly lower than the recommended dose, there is limited information available regarding the hemodynamic effects of dobutamine in this patient population." | 7.74 | Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol. ( Dalampiras, P; Kelepeshis, G; Sitafidis, G; Skoularigis, J; Triposkiadis, F, 2008) |
| "The purpose of this study was to evaluate the pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure." | 7.74 | Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. ( Fujii, N; Hashimoto, Y; Honda, M; Horiuchi, I; Inoue, H; Nozawa, T; Shimizu, T; Taguchi, M, 2008) |
| "This is an interim report of a prospective observational cohort study to monitor the safety and tolerability of carvedilol in clinical practice when prescribed for heart failure in England." | 7.73 | Observational cohort study to monitor the use and safety of carvedilol in the treatment of heart failure in clinical practice in England--1st interim report. ( Acharya, NV; Shakir, SA; Wilton, LV, 2005) |
| "Using data from a large United States health-insurance claims database, we conducted a retrospective study to compare the risks of death and hospitalization and the cost of inpatient care in heart failure patients receiving carvedilol vs." | 7.73 | Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. ( Delea, TE; Edelsberg, JS; Hagiwara, M; Oster, G; Stanford, R, 2005) |
| "The aim of this study was to determine the effects of carvedilol on the costs related to the treatment of severe chronic heart failure (CHF)." | 7.73 | Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. ( Coats, AJ; Hebborn, A; McMurray, JJ; Packer, M; Stewart, S, 2005) |
| "To observe the changes of serum PDCD5 antibody in chronic ischemic heart failure patients and the effect of carvedilol treatment." | 7.73 | [The effect of carvedilol on apoptosis gene PDCD5 expression in chronic heart failure patients]. ( Hu, DY; Lu, PN; Luo, L; Nie, XY; Wu, Y; Zhang, GQ, 2005) |
| "To study the condition of the sympathico-adrenal system (SAS), synthesis of cAMP dependent on beta2-adrenoreceptors and parameters of free radical oxidation in patients with primary pulmonary hypertension (PPH); to examine efficacy of non-selective beta- and alpha1-adrenoblocker carvedilol in PPH patients." | 7.73 | [Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy]. ( Aref'eva, TI; Ataullakhanova, DM; Chazova, IE; Irodova, NL; Konovalova, GG; Krasnikova, TL; Lankin, VZ; Lazutkina, VK; Masenko, VP; Orlova, IaA; Sokolov, SF, 2005) |
| "Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) studied whether a standardized protocol for the initiation and titration of the beta-blocker carvedilol in a multicenter, open-label program would optimize beta-blocker use in heart failure (HF) patients." | 7.73 | Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. ( Diaz, A; Doval, H; Ferrante, D; Grancelli, H; Nul, D; Soifer, S; Varini, S; Zambrano, C, 2005) |
| "Our previous studies suggest that the increase in heart rate from rest to peak exercise is reduced in patients with chronic heart failure (CHF) and this is associated with increased oxidative stress, as determined by malondialdehyde (MDA) plasma levels." | 7.73 | Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. ( Alcaino, H; Castro, P; Chiong, M; Copaja, M; Corbalan, R; Díaz-Araya, G; Greig, D; Lavandero, S; Pérez, O; Valenzuela, R; Vukasovic, JL, 2005) |
| " In this study, the metabolic effect of carvedilol in nondiabetic patients with chronic heart failure (CHF) was evaluated." | 7.73 | Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? ( Bobbio, M; Catalano, E; Ferrua, S; Grassi, G; Massobrio, N; Pinach, S; Rossi, C; Trevi, GP; Veglio, M, 2005) |
| " Objectives of the present study were to evaluate the feasibility, tolerability and safety of carvedilol therapy in a cohort of patients > 70 years of age with CHF and left ventricular ejection fraction < 40% with chronic atrial fibrillation." | 7.73 | Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol? ( Cioffi, G; De Feo, S; Del Sindaco, D; Opasich, C; Pulignano, G; Stefenelli, C; Tarantini, L, 2006) |
| "In this retrospective study, 27 patients with symptomatic congestive heart failure were given carvedilol upon admission." | 7.73 | Significance of combined angiotensin II receptor blocker and carvedilol therapy in patients with congestive heart failure and arginine variant. ( Iwata, A; Kawamura, A; Kumagai, K; Matsuo, K; Matsuo, Y; Miura, S; Nishikawa, H; Sako, H; Saku, K, 2006) |
| "Carvedilol was well tolerated by Japanese patients with chronic heart failure." | 7.73 | [Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure]. ( Endo, Y; Kasanuki, H; Kawashiro, N; Matsuda, N; Uchida, Y, 2006) |
| "Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin." | 7.73 | Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. ( Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA, 2006) |
| "Our previous study showed that static handgrip caused increases in the plasma adrenomedullin (ADM) both in patients with heart failure (HF) and healthy subjects." | 7.73 | Effect of adrenergic blockade on plasma adrenomedullin concentration during static handgrip in patients with heart failure. ( Cybulski, G; Krzemiński, K; Mikulski, T; Nazar, K, 2006) |
| "To retrospectively investigate the effect of carvedilol and spironolactone plus furosemide, administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) to patients with chronic heart failure (CHF)." | 7.73 | Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. ( Hirooka, K; Nakayama, D; Saito, M; Takada, M; Yasumura, Y, 2006) |
| "We hypothesized that abnormal oxidative stress in chronic heart failure (CHF) could be related to endothelial damage and platelet activation, and that the vasodilating beta-blocker carvedilol would have beneficial effects on these processes compared with a selective non-vasodilating cardioselective beta-blocker, bisoprolol." | 7.72 | Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection. ( Blann, AD; Chin, BS; Gibbs, CR; Lip, GY, 2003) |
| "To assess the efficacy and tolerability of carvedilol administration in patients with heart failure and concomitant diabetes." | 7.72 | Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. ( Dei Cas, A; Dei Cas, L; Metra, M; Nodari, S, 2003) |
| "Carvedilol and metoprolol are beta(1)-adrenoceptor antagonists that decrease mortality in heart failure." | 7.72 | Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure? ( Doggrell, SA, 2004) |
| "To investigate the effects of carvedilol administration on neurohormonal activation and left ventricular function, carvedilol was added to standard treatment for heart failure in 9 patients with dilated cardiomyopathy due to heart muscle disease." | 7.72 | Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol. ( Bonvicini, M; Bronzetti, G; Donti, A; Formigari, R; Giardini, A; Picchio, FM; Prandstraller, D, 2003) |
| "Peak oxygen consumption (VO2) is traditionally used for risk stratification in chronic heart failure (CHF); however, its predictive value is unknown with carvedilol treatment." | 7.72 | Limited predictive value of cardiopulmonary exercise indices in patients with moderate chronic heart failure treated with carvedilol. ( Bosimini, E; Corrà, U; Eleuteri, E; Giannuzzi, P; Mezzani, A; Scapellato, F; Temporelli, PL, 2004) |
| "The long-term beta-blockade strategy with carvedilol, metoprolol succinate or bisoprolol is now strongly recommended to reduce the rates of mortality and morbidity in patients with chronic heart failure (CHF)." | 7.72 | Long-term oral carvedilol in chronic heart failure. ( Di Lenarda, A; Moretti, M; Sabbadini, G; Sinagra, G, 2004) |
| "We investigated the contribution of the sympathetic nervous system (SNS) in maintaining the blood pressure and in regulating the cardiac function during and after carvedilol administration in rats with heart failure (group F)." | 7.72 | Hemodynamic effects of carvedilol infusion and the contribution of the sympathetic nervous system in rats with heart failure. ( Abe, Y; Aizawa, Y; Kakemi, M; Kamal, FA; Kashimura, T; Kodama, M; Ma, M; Miyazaki, M; Nagai, Y; Narasimman, G; Sato, S; Suresh, P; Tachikawa, H; Takahashi, T; Tanabe, N; Wahed, MI; Watanabe, K; Wen, J; Yamaguchi, K, 2004) |
| "Patients with CHF and COPD tolerated carvedilol well with no significant reversible airflow limitation, but patients with CHF and asthma tolerated carvedilol poorly." | 7.71 | Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. ( Arnold, RH; Glanville, AR; Keogh, AM; Kotlyar, E; Macdonald, PS; McCaffrey, DJ, 2002) |
| "The objective was to determine the dosing, efficacy, and side effects of the nonselective beta-blocker carvedilol for the management of heart failure in children." | 7.71 | Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. ( Addonizio, LJ; Blume, ED; Bruns, LA; Canter, CE; Chrisant, MK; Hallowell, S; Lamour, JM; Pahl, E; Shaddy, RE, 2001) |
| "Carvedilol reduces disease progression in heart failure, but to our knowledge, its effects on hospitalizations and costs have not been evaluated." | 7.71 | Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Lacey, MJ; Lukas, MA; Oster, G; Packer, M; Richner, R; Vera-Llonch, M; Young, ST, 2001) |
| "To evaluate prospectively the impact of carvedilol on a short-term physical training program in stable patients with moderate chronic heart failure (CHF), and to analyze parameters predictive of improvement after training." | 7.71 | Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure. ( Bertrand, P; Charbonnier, B; Forissier, JF; Monpère, C; Vernochet, P, 2001) |
| "This study considers the cost-effectiveness of bisoprolol in heart failure patients as an adjunctive therapy to usual treatment." | 7.71 | A cost-effectiveness analysis of bisoprolol for heart failure. ( Varney, S, 2001) |
| "The purpose of this study was to estimate the cost-effectiveness of beta-blocker therapy with either metoprolol or carvedilol in addition to conventional therapy for patients with heart failure (HF) in Canada." | 7.71 | Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. ( Briggs, AH; Demers, C; Levy, AR; O'Brien, BJ, 2001) |
| "Carvedilol therapy reduces mortality from sudden cardiac death and progressive pump failure in congestive heart failure (CHF)." | 7.71 | The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. ( Oto, A; Sade, E; Tokgozoglu, L; Yildirir, A, 2001) |
| "Milrinone and dobutamine are used to manage decompensated heart failure, but their efficacy in patients on beta-blocker therapy was unknown." | 7.71 | Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. ( Bristow, MR; Eichhorn, EJ; Gilbert, EM; Lowes, BD; Tsvetkova, T, 2001) |
| "Our purpose was to evaluate the clinical effect of carvedilol among pediatric patients with congestive heart failure (CHF) who did not respond to standard therapy and to assess the pharmacokinetics of carvedilol among these children." | 7.71 | Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. ( Behn, F; Eiselt, M; Läer, S; Meibohm, B; Mir, TS; Scholz, H; Venzke, A; Weil, J, 2002) |
| "Carvedilol, a nonselective beta-adrenergic blocking drug with alpha-adrenergic blocking and antioxidant properties, has been shown to improve left ventricular function and clinical outcome in patients with mild to moderate chronic heart failure." | 7.70 | Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. ( Aboyoun, CL; Amor, R; Keogh, AM; Lund, M; Macdonald, PS; McCaffrey, DJ, 1999) |
| "In this study, we examine the cost effectiveness of carvedilol for the treatment of chronic heart failure (CHF)." | 7.70 | Cost effectiveness of carvedilol for heart failure. ( Delea, TE; Fowler, MB; Oster, G; Richner, RE; Vera-Llonch, M, 1999) |
| "Despite less than target doses in most patients, a favorable effect of carvedilol on functional class in patients with severe congestive heart failure (CHF) referred for transplant was observed." | 7.70 | Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation. ( Amin, H; Aminbakhsh, A; D'yachkova, Y; Ignaszweski, AP; Mortimer, S; Pamboukian, SV; Thompson, CR, 1999) |
| "To assess the safety and efficacy of carvedilol when administered to heart failure patients already receiving amiodarone." | 7.70 | Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure. ( Aboyoun, C; Amor, R; Keogh, AM; Lund, M; Macdonald, PS; McCaffrey, D, 1999) |
| "A 54-year-old white man with severe heart failure was placed on carvedilol 3." | 7.70 | Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. ( Bristow, MR; Lindenfeld, J; Lowes, BD, 1999) |
| "Carvedilol and at least in some studies, amiodarone have been shown to improve symptoms and prognosis of patients with heart failure." | 7.70 | Combination therapy with carvedilol and amiodarone in patients with severe heart failure. ( Bohlmann, M; Eck, U; Nägele, H; Petersen, B; Rödiger, W, 2000) |
| "Carvedilol is a relatively new drug with beta- and alpha 1-receptor blocking activity and antioxidant effects recently approved for the treatment of congestive heart failure (CHF)." | 7.70 | Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. ( Boike, S; Boyle, D; Brozena, S; Fesniak, HF; Ilson, B; Jorkasky, D; Tenero, D, 2000) |
| "Carvedilol has been shown to be beneficial for patients with heart failure, but it is not clear how it should be initiated in routine clinical practice, particularly in the elderly." | 7.70 | Experience of commencing Carvedilol in elderly patients with heart failure in a routine outpatient clinic. ( Owen, A, 2000) |
| "The Coreg (brand of carvedilol; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) Heart Failure Registry (COHERE) is intended to collect data on outcomes and other clinical variables in a typical HF population and to observe experience with carvedilol in the hands of community practitioners." | 7.70 | Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians. ( Abraham, WT; Chen, T; Fowler, M; Franciosa, JA; Gilbert, EM; Greenberg, B; Lukas, MA; Massie, BM; Nelson, JJ, 2000) |
| "We retrospectively performed stepwise logistic regression analysis on 1,509 patients with chronic heart failure in 4 multicenter United States studies and 1 Australia-New Zealand study to examine the effect of digoxin in patients randomized to carvedilol or placebo." | 7.70 | Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure. ( Eichhorn, EJ; Lukas, MA; Shusterman, N; Wu, B, 2000) |
| "Retrospective analysis of tolerance to carvedilol in patients with chronic heart failure." | 7.70 | Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. ( Krum, H; MacDonald, P; Ninio, D, 2000) |
| "In this study we observed that carvedilol administration to patients with heart failure improves hemodynamic function, baroreflex sensitivity, and heart rate variability." | 7.70 | Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure. ( Cacciafesta, M; Celli, V; Lionetti, M; Luparini, RL; Marigliano, V; Moisè, A; Piccirillo, G, 2000) |
| "To determine the effect of beta blockade on parasympathetic nervous system activity, we assessed RR variability during 24-hour Holter monitoring in 10 patients with congestive heart failure before and after 3 to 4 months of treatment with the beta blocker carvedilol." | 7.69 | Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. ( Bigger, JT; Bloomfield, DM; Goldsmith, RL; Krum, H; Packer, M; Sackner-Bernstein, J; Steinman, RC, 1997) |
| " In the CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-Scale Randomized Controlled Trial), patients with STEMI with successful percutaneous coronary intervention with an LVEF of ≥40% were randomly assigned to carvedilol or no β-blocker therapy." | 7.30 | Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction. ( Akao, M; Amano, M; Bingyuan, B; Furukawa, Y; Inada, T; Inuzuka, Y; Izumi, C; Kadota, K; Kaji, S; Kimura, T; Minamimoto, Y; Miyake, M; Morimoto, T; Nakagawa, Y; Ozasa, N; Suwa, S; Suzuki, T; Tamura, T; Watanabe, H, 2023) |
| " Randomized clinical trials and meta-analyses have clearly demonstrated that the long-term use of β-Blockers improves the outcome of patients with HF." | 6.82 | Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. ( Park, K; Park, TH, 2016) |
| "During the mean 3-year follow-up, resting heart rate (HR) and BNP were significantly reduced with dose-response relations in the early period but without dose-response relations in the late period." | 6.78 | Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. ( Azuma, J; Fujio, Y; Hori, M; Izumi, T; Kitabatake, A; Matsuzaki, M; Nagai, R; Nonen, S; Ohashi, Y; Okamoto, H; Tsutsui, H; Yamazaki, T; Yoshikawa, T, 2013) |
| "Bisoprolol was started at 1." | 6.76 | Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. ( Arisi, G; Caminiti, G; Iellamo, F; Madonna, M; Marazzi, G; Massaro, R; Righi, D; Rosano, GM; Volterrani, M, 2011) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 6.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "Beta-blockers are mainstay of current treatment of heart failure (HF)." | 6.75 | Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. ( Bettari, L; Bugatti, S; Covolo, L; Dei Cas, L; Donato, F; Gelatti, U; Giubbini, R; Lombardi, C; Metra, M; Pezzali, N; Romeo, A; Zacà, V, 2010) |
| "Carvedilol was initiated at a dose of 0." | 6.74 | Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease. ( Ando, M; Hatai, Y; Mori, K; Murakami, Y; Nishiyama, M; Park, IS; Takahashi, Y; Yoshikawa, T, 2009) |
| " By simplifying the medical regimen, once-daily dosing can potentially improve compliance." | 6.74 | Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart F ( Hauptman, PJ; Lukas, MA; Massaro, J; Ordronneau, P; Pressler, SJ; Sackner-Bernstein, J; Udelson, JE, 2009) |
| "Heart failure is one of the leading death reasons in the world." | 6.73 | Carvedilol therapy is associated with an improvement in left atrial appendage function in patients with congestive heart failure. ( Acikel, M; Arslan, S; Bozkurt, E; Erol, MK; Gundogdu, F; Gurlertop, Y; Senocak, H; Sevimli, S; Yilmaz, M, 2007) |
| "Carvedilol was associated with conventional optimised treatment in 64% of diabetics and 65% of non-diabetics (P = NS)." | 6.73 | Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. ( Cioffi, G; De Feo, S; Del Sindaco, D; Di Lenarda, A; Giovannini, E; Leggio, F; Minardi, G; Opasich, C; Pulignano, G; Tarantini, L, 2007) |
| " Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol." | 6.73 | Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. ( Ahuja, K; Hirsh, DS; Jorde, UP; Kasper, ME; Khandwalla, RM; Tseng, CH; Vittorio, TJ; Zolty, R, 2008) |
| "Carvedilol therapy was then initiated." | 6.71 | Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly? ( de Albuquerque, DC; Filho, FM; Gerk, AR; Gouvea, EP; Perin, EC; Rocha, RM; Santos, VM; Silva, GV, 2003) |
| "The use of beta-blockers for the treatment of heart failure in the United States is inadequate, despite available data and current guidelines that support their use." | 6.71 | Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. ( Gattis, WA; O'Connor, CM, 2004) |
| "10, NYHA III-IV 29%) to treatment with either bisoprolol or carvedilol, in order to assess and compare the maximally achievable number of patients on treatment with these BB and the maximally achieved dosage during a minimum of 2 months attendance at our out patient heart failure clinic." | 6.71 | Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison. ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR, 2004) |
| "Treatment with carvedilol was associated with significant increases in total frequency power, very low frequency power, high frequency power, SDNN, the root-mean square of difference of successive RRs, and pNN50." | 6.71 | Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. ( Alharethi, R; Bristow, MR; Bullinga, JR; Gilbert, EM; Schram, MS, 2005) |
| " The trial data will determine if in-hospital initiation of beta-blocker therapy is effective at improving the long-term use of pharmacologic agents proven to reduce morbidity and mortality." | 6.70 | The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. ( Gattis, WA; Gheorghiade, M; O'Connor, CM, 2002) |
| "Carvedilol was well tolerated both during dose titration and during maintenance therapy." | 6.70 | [Long term use of a non-selective beta-blocker with vasodilating properties carvedilol in patients with severe heart failure]. ( Gruzdev, AK; Iosava, IK; Sidorenko, BA; Vasechkin, SS; Zaikin, SY, 2002) |
| "2%) and 4 others who were subsequently unable to withstand the progressive stepping up of drug dosage (8." | 6.69 | [Tolerance and efficacy of carvedilol prescription in patients with mild to moderated chronic heart failure]. ( Barnay, P; Gelisse, R; Levy, S; Maixent, JM; Paganelli, F; Saadjian, A; Sbragia, P, 2000) |
| "Peak reactive hyperemia (mL." | 6.68 | Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. ( Bijou, R; Demopoulos, L; Gentilucci, M; Jones, M; Katz, SD; LeJemtel, TH; Mancini, D; Testa, M; Yeh, M, 1997) |
| "Carvedilol is a new drug which possesses a balanced combination of vasodilatation and beta-blockade." | 6.67 | The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. ( Broadhurst, P; DasGupta, P; Lahiri, A, 1991) |
| "Carvedilol use has been adapted into pediatric heart failure practice although data supporting its efficacy in infants and children are scarce." | 6.43 | The use of carvedilol in pediatric heart failure. ( Benson, LN; Greenway, SC, 2006) |
| " Based on this evidence, it is now recommended to add beta-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis." | 6.43 | The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. ( De Freitas, O; Fornoni, A; Lenz, O; Materson, BJ, 2006) |
| "Carvedilol was generally well tolerated in patients with CHF." | 6.42 | Carvedilol: a review of its use in chronic heart failure. ( Jarvis, B; Keating, GM, 2003) |
| " These include the choice of dose and dosage regimen of immediate-release metoprolol tartrate, a dosage form that has never been shown to reduce mortality in patients with heart failure." | 6.42 | Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial. ( Bauman, JL; Talbert, RL, 2004) |
| "Carvedilol is a beta-blocker with ancillary properties." | 6.41 | Carvedilol versus other beta-blockers in heart failure. ( Doggrell, SA, 2001) |
| "Carvedilol is a novel multiple-action neurohormonal antagonist that has been shown to be effective in the management of congestive heart failure." | 6.40 | Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1998) |
| "We conclude that the amplitude of benefit of the beta-blockers carvedilol, metoprolol and bisoprolol on mortality and morbidity is similar, regardless of the severity of chronic heart failure." | 6.20 | Beta-blocker benefit according to severity of heart failure. ( Bouzamondo, A; Hulot, JS; Lechat, P; Sanchez, P, 2003) |
| "Carvedilol demonstrated therapeutic benefits in patients with heart failure and reduced ejection fraction (HFrEF)." | 5.69 | Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study. ( Choi, DJ; Hong, SJ; Hong, SK; Jeon, ES; Kang, SM; Kim, EJ; Kim, JJ; Kim, MA; Kim, SY; Lee, HY; Park, CS; Park, DG; Park, JJ; Shin, JH; Yoo, BS, 2023) |
| "Treatment with carvedilol directly improved the systolic function of the right and left ventricles." | 5.48 | Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot. ( Hirata, Y; Inaba, T; Ishikawa, Y; Komuro, I; Saito, A; Soma, K; Yao, A, 2018) |
| "The long-term use of β-blockers has been shown to improve clinical outcomes among patients with heart failure (HF)." | 5.46 | Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. ( Bouvier, M; de Denus, S; Deblois, D; Dorais, M; Dubé, MP; Haibe-Kains, B; Jenna, S; Leduc, R; Perreault, S; Rouleau, JL; Tardif, JC; White, M; White-Guay, B, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 5.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| " For such a drug, the pathophysiological changes occurring in CHF can have a profound impact on PK, and thus the resulting pharmacodynamic response, of both enantiomers." | 5.43 | Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach. ( Khalil, F; Läer, S; Rasool, MF, 2016) |
| " Carvedilol maintenance dosage was lower in patients with preserved EF (7." | 5.39 | Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol. ( Hiramatsu, K; Kobayashi, F; Mori, Y; Nishikawa, Y, 2013) |
| "Carvedilol is a novel third generation non-selective β-blocker." | 5.38 | Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function. ( Afonso, L; Ali Kizilbash, M; Badheka, AO; Bharadwaj, A; Rathod, A; Tuliani, TA, 2012) |
| "The heart failure was modeled in rats by ligation of the coronary artery." | 5.37 | [Effects of carvedilol and proxodolol on nitric oxide (NO) metabolism in various organs in a congestive heart failure model]. ( Medvedev, OS; Shashurin, DA; Timoshin, AA; Vanin, AF, 2011) |
| "The animal model of congestive heart failure was established by coarctation of abdominal aorta." | 5.37 | [Effect of carvedilol and Radix astragali on ryanodine receptor in heart failure in mice]. ( Li, R; Yi, QJ; Zhang, Q, 2011) |
| " We evaluated relation in HF patients among cytokines and asymmetric dimethylarginine (ADMA) and left ventricular ejection fraction (LVEF) at baseline and after long-term administration of carvedilol." | 5.35 | Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. ( Alfieri, AB; Arioli, F; Bassanelli, G; Briceno, L; Cuko, A; Fragasso, G; Margonato, A; Montano, C; Palloshi, A; Ruotolo, G; Spoladore, R, 2008) |
| "Treatment with carvedilol in the shunt group reversed the heart weight and ventricular dimension to the baseline values." | 5.33 | Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. ( Chang, H; Kuan, P; Lu, MJ; Shyu, KG; Sun, HY; Wang, BW, 2005) |
| "Heart failure is characterized by limited exercise tolerance and by a skeletal muscle myopathy with atrophy and shift toward fast fibres." | 5.33 | Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. ( Angelini, A; Dalla Libera, L; Danieli Betto, D; Germinario, E; Gobbo, V; Ravara, B; Vescovo, G, 2005) |
| "Carvedilol is a combined alpha(1)- and beta-adrenoceptor antagonist." | 5.33 | Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure. ( Bøkenes, J; Osnes, JB; Qvigstad, E; Schiander, I; Sejersted, OM; Sjaastad, I; Skomedal, T; Solberg, L, 2005) |
| " Therefore we analyzed 24-h ECG Holter recordings from a study which compared the long-term clinical efficacy of metoprolol tartrate to carvedilol in chronic heart failure patients using the same dosing regimen as in COMET." | 5.33 | Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure? ( Chan, SK; Fung, JW; Leung, LY; Sanderson, JE; Yip, GW; Yu, CM, 2005) |
| "Carvedilol was administered through direct gastric gavage." | 5.33 | [Effect of carvedilol on ryanodine receptor in heart failure]. ( Li, R; Liu, XY; Qian, YR; Yi, QJ, 2005) |
| "Carvedilol was then commenced and up titrated over the next 6-8 weeks and all samples were again obtained." | 5.33 | Carvedilol reduces aldosterone release in systolic heart failure. ( Aggarwal, A; Campbell, DJ; Wong, J, 2006) |
| " The pharmacokinetic (PK)/pharmacodynamic (PD) relation between S(-)-carvedilol concentration-the enantiomer with beta-blocking activity-and change in exercise-induced heart rate was defined in healthy subjects and was best described using a direct effect inhibitory E(max) model (with E(max) being the maximum effect)." | 5.33 | Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. ( Baidoo, CA; Boyle, D; Campanile, AM; Henderson, LS; Tenero, DM, 2006) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 5.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carvedilol treatment for CHF patients is a highly cost-effective method of therapy in the Japanese medical environment." | 5.32 | Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. ( Inomata, T; Izumi, T; Kobayashi, M, 2004) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | 5.32 | Remote titration of carvedilol for heart failure patients by advanced practice nurses. ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| "35 +/- 1 months, the daily dosage of carvedilol was 49." | 5.32 | Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure. ( Boffa, GM; Iliceto, S; Orlando, S; Razzolini, R; Tarantini, G, 2004) |
| "Congestive heart failure is associated with impaired endothelial function in the peripheral systemic vasculature and with systemic release of inflammatory cytokines." | 5.31 | Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. ( Dimmeler, S; Freyssinet, JM; Haendeler, J; Hugel, B; Mallat, Z; Rössig, L; Tedgui, A; Zeiher, AM, 2000) |
| "Patients with congestive heart failure (CHF) have alterations in the traditional and nonlinear indices of heart rate (HR) dynamics, which have been associated with an increased risk of mortality." | 5.31 | Effects of carvedilol on heart rate dynamics in patients with congestive heart failure. ( Castellanos, A; Chakko, S; de Marchena, E; Huikuri, HV; Lopera, G; Mäkikallio, TH; Myerburg, RJ; Pastor, J; Ridha, M, 2002) |
| "This paper aims to investigate the curative effect of carvedilol combined with conventional therapy in treatment of chronic heart failure." | 5.30 | The curative effect of carvedilol combined with conventional therapy in treatment of chronic heart failure. ( Li, X; Qu, W; Yu, Z, 2019) |
| "The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF)." | 5.30 | Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial. ( Kinugawa, S; Komuro, I; Masuyama, T; Momomura, SI; Murohara, T; Saito, Y; Tsutsui, H, 2019) |
| "Carvedilol was well tolerated by 16 (76%) patients." | 5.30 | [Effects of carvedilol (beta 1, beta 2, alpha 1 bloker) on refractory congestive heart failure]. ( Bacal, F; Bellotti, G; Bocchi, EA; Carrara, D; Ramires, JA, 1998) |
| " Exercise testing, radionuclide ventriculography, and right-sided cardiac catheterization were performed and intraarterial blood pressure measured before and after 8 weeks of carvedilol therapy in a dosage of 12." | 5.28 | Value of carvedilol in congestive heart failure secondary to coronary artery disease. ( Broadhurst, P; Das Gupta, P; Lahiri, A; Raftery, EB, 1990) |
| "Our data suggested that anemia was associated with a blunted response to carvedilol in HFrEF patients." | 5.27 | Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol - Insights From Japanese Chronic Heart Failure (J-CHF) Study. ( Hori, M; Kitabatake, A; Nagatomo, Y; Okamoto, H; Yoshikawa, T, 2018) |
| "To compare the hazard of all-cause, chronic obstructive pulmonary disease (COPD) and heart failure (HF) hospitalization in carvedilol vs." | 5.27 | Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. ( Andersen, MP; Capuano, A; Enghusen-Poulsen, H; Gislason, G; Mascolo, A; Mortensen, RN; Rosano, GMC; Rossi, F; Sessa, M; Torp-Pedersen, C, 2018) |
| "Carvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment for patients with heart failure and reduced ejection fraction (HFrEF)." | 5.27 | Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial. ( Choi, DJ; Hong, SJ; Hong, SK; Jeon, ES; Kang, SM; Kim, EJ; Kim, JJ; Kim, MA; Kim, SY; Lee, HY; Park, CS; Park, DG; Park, JJ; Shin, JH; Yoo, BS, 2018) |
| "Carvedilol attenuated the development and promoted a partial reversal of cachexia in patients with severe chronic heart failure, supporting a role for prolonged sympathetic activation in the genesis of weight loss." | 5.24 | Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. ( Anker, SD; Clark, AL; Coats, AJS; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Salekin, D; Schultz, MK, 2017) |
| "Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients." | 5.22 | Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. ( Borley, A; Broom, A; Collins, G; Guppy, A; Hall, P; Henriksen, PA; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Radford, J; Rowntree, C; Scott, F, 2022) |
| "It is unclear whether carvedilol and nebivolol produce different effects on short-term left ventricle (LV) systolic function in heart failure (HF)." | 5.20 | Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure. ( Doğan, A; Erdoğan, D; Karabacak, M; Özaydın, M; Tayyar, Ş, 2015) |
| " We attempted to determine the significance of β1-AAb in chronic heart failure (CHF) patients who received carvedilol in a substudy of the Japanese Chronic Heart Failure study." | 5.20 | Presence of autoantibody directed against β1-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol: Japanese Chronic Heart Failure (J-CHF) Study. ( Hori, M; Kitabatake, A; Nagatomo, Y; Okamoto, H; Yoshikawa, T, 2015) |
| "To observe the changes of serum heart-type fatty acid-binding protein (h-FABP) and brain natriuretic peptide (BNP) in children with chronic heart failure (CHF) and evaluate the effects of carvedilol." | 5.20 | Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure. ( Li, DH; Ma, SC; Qiao, LY; Shan, RB; Sun, YP; Wei, CP; Zhang, YF, 2015) |
| "Four thousand sixteen patients with stable systolic chronic heart failure who were using either carvedilol or metoprolol succinate were identified in the Norwegian Heart Failure Registry and The Heart Failure Registry of the University of Heidelberg, Germany." | 5.20 | Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. ( Agewall, S; Atar, D; Cebola, R; Frankenstein, L; Fröhlich, H; Grundtvig, M; Hole, T; Katus, HA; Schellberg, D; Täger, T; Zhao, J, 2015) |
| "Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF)." | 5.19 | Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud ( Hori, M; Izumi, T; Matsuzaki, M; Nagai, R, 2014) |
| "It is unclear whether carvedilol and nebivolol will produce different effects on platelet function and prothrombotic state in heart failure (HF)." | 5.19 | Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure. ( Aksoy, F; Dogan, A; Erdogan, D; Karabacak, M; Karabacak, P; Ozaydin, M, 2014) |
| "The aim of our study was to examine regional differences in the demographics, etiology, risk factors, comorbidities and treatment of female patients with heart failure (HF) in the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD) clinical trial." | 5.19 | Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD). ( Apostolovic, S; Djordjevic-Radojkovic, D; Düngen, HD; Gelbrich, G; Inkrot, S; Jankovic-Tomasevic, R; Lainscak, M; Musial-Bright, L; Pavlovic, M; Putnikovic, B; Radovanovic, S; Salinger-Martinovic, S; Stanojevic, D; Tahirovic, E; Tomasevic, M; Waagstein, F, 2014) |
| "The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet been investigated." | 5.17 | Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). ( Abu-Zeitone, A; Jons, C; Kutyifa, V; McNitt, S; Moss, AJ; Ruwald, AC; Ruwald, MH; Zareba, W, 2013) |
| "Carvedilol, a nonselective β-blocker, may be more effective than the selective β-blocker metoprolol in reducing the risk of thromboembolic events in heart failure." | 5.17 | Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure. ( Bakx, A; de Peuter, OR; Kamphuisen, PW; Kok, WE; Meijers, JC; Nieuwland, R; Schaap, MC; Somsen, GA; van den Bogaard, B; Verberne, HJ, 2013) |
| "Ivabradine (IVA), a selective If current inhibitor decreasing the heart rate (HR) in patients with sinus rhythm, has been added to the most recent European Guidelines on heart failure." | 5.17 | Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study. ( Benvenuto, A; Buta, F; De Viti, D; Masciocco, L; Massari, F; Meliota, G; Riccioni, G; Saracino, P; Speziale, G, 2013) |
| "This study aimed to evaluate the clinical efficacy and safety of carvedilol for pediatric patients with chronic heart failure caused by dilated cardiomyopathy." | 5.17 | The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: a prospective, randomized-controlled study. ( Chen, S; Huang, M; Liu, F; Sun, J; Sun, Y; Xiao, Y; Zhang, X, 2013) |
| " carvedilol is influenced by clinical and psychosocial factors in elderly patients with heart failure." | 5.17 | Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). ( Apostolović, S; Düngen, HD; Edelmann, F; Haverkamp, W; Herrmann-Lingen, C; Inkrot, S; Lashki, DJ; Loncar, G; Neskovic, A; Scherer, M; Tahirović, E; Wachter, R, 2013) |
| "The aim of the present study was to assess the safety and tolerability of the controlled-release (CR) formulation of the β-blocker carvedilol in Japanese patients with chronic heart failure (HF)." | 5.16 | Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure. ( Ando, H; Kitakaze, M; Nakajima, H; Sakamoto, T; Sarai, N, 2012) |
| "This pharmacogenetic substudy of the prospective, double-blind, randomized CIBIS-ELD trial determined the impact of the β1-adrenoceptor Arg189Gly polymorphism on heart-rate responses to bisoprolol or carvedilol in elderly patients with heart failure (421 with sinus rhythm, 107 with atrial fibrillation)." | 5.16 | Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. ( Apostolović, S; Dimković, S; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Haverkamp, W; Lainščak, M; Nešković, AN; Rau, T; Waagstein, F, 2012) |
| " carvedilol in 883 elderly heart failure patients with reduced or preserved left ventricular ejection fraction in 41 European centres." | 5.15 | Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. ( Anker, SD; Apostolovic, S; Dietz, R; Doehner, W; Düngen, HD; Edelmann, F; Eschenhagen, T; Gelbrich, G; Herrmann-Lingen, C; Inkrot, S; Krotin, M; Lainscak, M; Mehrhof, F; Neskovic, AN; Prettin, C; Putnikovic, B; Rau, T; Sakac, D; Tahirovic, E; Töpper, A; Waagstein, F; Wachter, R, 2011) |
| "Carvedilol is an effective treatment in hypertension and chronic heart failure." | 5.15 | Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. ( Brockmöller, J; Gültepe, S; Meineke, I; Sehrt, D; Tzvetkov, M, 2011) |
| "Carvedilol has been shown to be superior to metoprolol tartrate to improve clinical outcomes in patients with heart failure (HF), yet the mechanisms responsible for these differences remain unclear." | 5.15 | Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study. ( Christiansen, B; Dominguez, H; Falskov, B; Hermann, TS; Køber, L; Major-Pedersen, A; Rask-Madsen, C; Raunsø, J; Torp-Pedersen, C, 2011) |
| "Carvedilol and bisoprolol reduce QT dispersion (QTD) in chronic heart failure (CHF)." | 5.14 | The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. ( Aygul, MU; Aygul, N; Duzenli, MA; Ozdemir, K, 2009) |
| "Background Carvedilol may reduce the severity of central sleep apnea (CSA) in patients with chronic heart failure (CHF)." | 5.14 | Carvedilol reduces the severity of central sleep apnea in chronic heart failure. ( Kadota, J; Kawano, Y; Tamura, A, 2009) |
| "We investigated the clinical response of chronic heart failure patients with beta(2)-adrenergic receptor Gln(27)-->Glu polymorphism treated for 6 months with carvedilol, a alpha/beta-antagonist with antioxidant properties." | 5.14 | Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. ( Bravo, R; Castro, PF; Chiong, M; del Campo, A; Díaz-Araya, G; Greig, D; Lavandero, S; Mellado, R; Moraga, F; Rodriguez, A; Roldán, J; Sanhueza, C; Troncoso, R; Valenzuela, R; Vukasovic, JL, 2009) |
| "To determine whether metoprolol succinate (a beta(1)-selective beta-blocker) remains beta(1)-selective compared with carvedilol (a nonselective beta-blocker) during upward titration of doses in patients with American College of Cardiology (ACC) stage C heart failure." | 5.14 | Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. ( Gilbert, EM; Lombardi, WL; Macgregor, J; Munger, M; Stoddard, GP; Zebrack, JS, 2009) |
| "Twenty-nine patients (63+/-12 years old) with New York Heart Association class II-III heart failure underwent serial measurements of left ventricular volumes using 3-dimensional echocardiography and blood pressures by sphygmomanometry at baseline, 2 weeks, 2, 6, and 12 months after initiation of carvedilol." | 5.14 | Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure. ( Burkhoff, D; El-Khoury Rumbarger, L; King, DL; Maurer, MS; Sackner-Bernstein, JD; Yushak, M, 2009) |
| "Carvedilol is a beta-adrenoceptor antagonist used for treating chronic heart failure (CHF)." | 5.14 | Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure. ( Hanada, K; Kaneko, M; Kawana, J; Mihara, K; Nagayama, M; Ogata, H; Ohno, T; Saito, M; Shiomi, M; Sumiyoshi, T, 2010) |
| "To investigate the effects of carvedilol and metoprolol on the expression of autoantibodies against cardiac β(1), β(2) and α(1) adrenergic receptors in aged patients with chronic heart failure (CHF) and ventricular arrhythmia (VA)." | 5.14 | [Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia]. ( Li, XD; Wang, JC; Ye, L; Zhao, Y; Zhou, NN; Zhu, X, 2010) |
| "Body weight increased significantly in the carvedilol group (mean change + 2." | 5.13 | Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. ( Gobec, L; Kovacić, D; Lainscak, M; Marinsek, M; Podbregar, M, 2008) |
| " * Up to now, for carvedilol in paediatric patients with congestive heart failure (CHF) the dose has been linearly extrapolated from adults, but the results with this dosing strategy are ambiguous." | 5.13 | Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. ( Albers, S; Läer, S; Meibohm, B; Mir, TS, 2008) |
| " with NYHA II or III heart failure were double-blind randomized and uptitrated to either carvedilol 25 mg bid (n=131) or betaxolol 20 mg od (n=124)." | 5.12 | Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). ( Chochola, J; Figulla, HR; Fridl, P; Kalmbach, C; Krzeminska-Pakula, M; Wrabec, K, 2006) |
| "beta-adrenergic receptor antagonism with drugs like carvedilol slows the progression of heart failure by an undefined mechanism." | 5.12 | The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure. ( Bocchi, EA; Chizzola, PR; Gonçalves de Freitas, HF; Mansur, JA; Marinho, NV; Meneghetti, JC, 2006) |
| "To evaluate whether carvedilol influences exercise hyperventilation and the ventilatory response to hypoxia in heart failure (HF)." | 5.12 | Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. ( Agostoni, P; Andreini, D; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Magini, A; Palermo, P; Veglia, F, 2006) |
| "Because of potential side effects and logistical difficulty of titrating medications, outpatients with congestive heart failure rarely receive appropriate doses of carvedilol or other beta-blockers." | 5.12 | Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits. ( Gerstenblith, G; Gottlieb, SH; Hefter, G; Kasper, EK; Kern, L; Najjar, SS; Palmer, JG; Spaeder, J, 2006) |
| " The present study evaluated the effect of gender on the influence of carvedilol on serum digoxin levels in patients with heart failure." | 5.12 | Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ( Baris, N; Bozdemir, V; Güneri, S; Guven, H; Kalkan, S, 2006) |
| "To assess the effects on LV function of nebivolol compared with carvedilol in patients with chronic heart failure and reduced LV systolic function." | 5.12 | Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. ( Abrignani, MG; Braschi, A; De Castro, S; Lombardo, RM; Reina, C; Rizzo, PA, 2006) |
| "The aim of this study was investigate the effects of carvedilol therapy on ventricular repolarization characteristics as assessed by QT dispersion (QTd) and heart rate variability (HRV) in patients with heart failure." | 5.12 | Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure. ( Akdeniz, B; Aslan, O; Badak, O; Baris, N; Göldeli, O; Guneri, S; Kirimli, O; Savas, IZ, 2006) |
| "We compared the pharmacokinetic (PK) profiles of repeated dosing with the currently available immediate-release (IR) carvedilol (given twice daily) and a newly developed controlled-release (CR) formulation (given once daily) in patients with left ventricular dysfunction (LVD)." | 5.12 | Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. ( Baidoo, CA; Greenberg, BH; Lukas, MA; Packer, M; Tenero, DM, 2006) |
| "We aimed to compare the effects of carvedilol and metoprolol succinate on left atrial (LA) function in patients with chronic heart failure." | 5.12 | Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol. ( Acikel, M; Arslan, S; Atesal, S; Bozkurt, E; Erol, MK; Gundogdu, F; Senocak, H, 2007) |
| "The COLA (Carvedilol Open Label Assessment) II Study prospectively evaluated the tolerability of carvedilol in 1030 patients >70 years of age with chronic heart failure (CHF)." | 5.12 | The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA (Carvedilol Open Label Assessment) II Study. ( Hill, J; Krum, H; Macdonald, PS, 2006) |
| "To study the development of new onset diabetes in a large cohort of patients with heart failure treated with either metoprolol or carvedilol." | 5.12 | Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). ( Charlesworth, A; Cleland, JG; Di Lenarda, A; Lukas, MA; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 5.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Carvedilol, a beta1 and beta2 as well as an alpha1 adrenoreceptor antagonist with multiple hemodynamic, anti-ischemic and anti-oxidant properties, is widely accepted for the treatment of hypertension and congestive heart failure (CHF)." | 5.12 | The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. ( Abinader, EG; Goldhammer, E; Lanir, A; Maor, I; Shnitzer, S, 2007) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 5.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "To compare the effects of carvedilol and bisoprolol on lung function in patients with chronic heart failure (CHF)." | 5.12 | Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? ( Agostoni, P; Apostolo, A; Bussotti, M; Cattadori, G; Contini, M; Fiorentini, C; Palermo, P; Sciomer, S, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 5.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "The purpose of the study was to evaluate the influence of metoprolol succinate and carvedilol on the physical ability (FA) of patients with chronic heart failure (CHF) of different etiologies." | 5.12 | [The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin]. ( Andreev, DA; Kalashnikov, VIu; Poltavskaia, MG; Sarkisova, EA; Svet, AV; Syrkin, AL, 2007) |
| "In the COMET study, carvedilol improved survival compared to metoprolol tartrate in 3029 patients with NYHA II-IV heart failure and EF <35%, followed for an average of 58 months." | 5.12 | Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Erhardt, L; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, P; Remme, WJ; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Forty-four patients with chronic congestive heart failure were enrolled in the study to randomly receive carvedilol or bisoprolol in addition to background therapy." | 5.12 | Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker? ( Hua, C; Hua, L; Huang, J; Huang, Y; Jiang, W; Li, F; Li, N; Li, Y; Wang, F; Wu, Y; Xu, Z, 2007) |
| "To detect the serum autoantibodies against the cardiac beta(1)-adrenergic receptor and observe the clinical characteristics and response to carvedilol use in patients with chronic heart failure (CHF)." | 5.12 | [Serum autoantibodies against the cardiac beta(1)-adrenergic receptor in patients with chronic heart failure: clinical characteristics and response to carvedilol]. ( Chen, J; Liu, XL; Wang, SY; Wu, YF; Yang, XC; Zhang, L; Zhu, JG, 2007) |
| "This study aimed at describing usual conditions of carvedilol use in heart failure (HF) patients." | 5.12 | [Treating heart failure with carvedilol in private practice (initiating treatment and follow-up at one year. The KEOPS study]. ( Amouyel, P; Bergougnoux, L; Cohen-Solal, A; de Groote, P; Jaillon, P; Johnson, N; Komajda, M; Laperche, T, 2007) |
| "Carvedilol therapy reduces mortality in patients with chronic heart failure." | 5.11 | Heart failure in a district general hospital: are target doses of beta-blockers realistic? ( Dubrey, SW; Grocott-Mason, R; McDonagh, S; Mehta, PA; Poole-Wilson, PA, 2004) |
| "Neither profiles nor prognostic value of cardiac N-terminal proBNP (NT-proBNP) have been prospectively evaluated in a sufficient number of patients with severe chronic heart failure (CHF) treated with carvedilol or placebo." | 5.11 | NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. ( Amann-Zalan, I; Castaigne, A; Coats, AJ; Fowler, MB; Hartmann, F; Hoersch, S; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Rouleau, JL; Tendera, M; Trawinski, J, 2004) |
| "We sought to evaluate the influence of pretreatment systolic blood pressure (SBP) on the efficacy and safety of carvedilol in patients with chronic heart failure (CHF)." | 5.11 | Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. ( Castaigne, A; Coats, AJ; Fowler, MB; Holcslaw, TL; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Roecker, EB; Rouleau, JL; Scherhag, A; Tendera, M, 2004) |
| "In a parallel-group, 3-arm study of 18 months duration, 572 mild heart failure patients were randomly assigned to carvedilol (N = 191), enalapril (N = 190) or their combination (N = 191)." | 5.11 | The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). ( Bobbio, M; Hildebrandt, P; Jaarsma, W; Komajda, M; Lutiger, B; Remme, WJ; Riegger, G; Rydén, L; Scherhag, A; Soler-Soler, J, 2004) |
| "The Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial was an investigator-initiated study to evaluate if predischarge carvedilol initiation in stabilized patients hospitalized for heart failure (HF) increased the number of patients treated with beta-blockade at 60 days after randomization without increasing side effects or length of hospital stay." | 5.11 | Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. ( Gallup, DS; Gattis, WA; Gheorghiade, M; Hasselblad, V; O'Connor, CM, 2004) |
| "The impact of carvedilol on the survival of patients with severe heart failure was examined in the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial." | 5.11 | Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure. ( Fowler, MB, 2004) |
| "The COMET trial was a prospective, double-blind, randomised trial comparing carvedilol, a comprehensive adrenergic receptor antagonist, with metoprolol, a beta-1-selective agent in patients with heart failure and left ventricular systolic dysfunction." | 5.11 | A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). ( Charlesworth, A; Cleland, JG; Di Lenarda, A; Erhardt, L; Goode, K; Hanrath, P; Komajda, M; Metra, M; Poole-Wilson, PA; Remme, WJ; Swedberg, K; Torp-Pedersen, C, 2004) |
| "The purpose of this study was to investigate the effects of carvedilol on diastolic function (DF) in heart failure patients with preserved left ventricular (LV) systolic function and abnormal DF." | 5.11 | Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). ( Andersson, B; Bergström, A; Dahlström, U; Edner, M; Nylander, E; Persson, H, 2004) |
| "To assess the effects of carvedilol treatment on the renin-angiotensin system in patients with chronic heart failure (CHF)." | 5.11 | Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. ( Beauvais, F; Berdeaux, A; Cohen Solal, A; Jondeau, G, 2004) |
| "Although the benefits of carvedilol in patients with heart failure and depressed ejection fraction (EF) have been elucidated, those in patients with preserved EF are not understood." | 5.11 | Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. ( Fukutomi, T; Itoh, M; Kondo, H; Ogata, M; Shigeyama, J; Sugiura, M; Suzuki, S; Takeda, Y; Yamamoto, K, 2004) |
| "Although ACEI and carvedilol produce benefits in heart failure, whether the order of initiation of therapy determines the impact on left ventricular (LV) function and New York Heart Association functional class (NYHA FC) has not been determined." | 5.11 | Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. ( Candy, G; Essop, R; Kachope, J; Kone, N; Libhaber, C; Norton, GR; Sareli, P; Sliwa, K; Woodiwiss, AJ, 2004) |
| "Carvedilol is an antioxidant and adrenergic antagonist with demonstrated benefits in terms of mortality from heart failure (HF)." | 5.11 | [Effects of carvedilol on functional capacity, left ventricular function, catecholamines and oxidative stress in patients with chronic heart failure]. ( Castro, P; Chiong, M; Corbalán, R; Díaz-Araya, G; Greig, D; Lavandero, S; Moraga, F; Padilla, I; Pérez, O; Troncoso, R; Vukasovic, JL, 2004) |
| "Carvedilol has been shown to improve survival and morbidity in patients with heart failure." | 5.11 | Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. ( Bristow, MR; Gill, EA; Holcslaw, TL; Pittenger, B, 2004) |
| "The long-term effects of carvedilol on muscle sympathetic nerve activity (MSNA) and muscle blood flow at rest and exercise in patients with chronic heart failure (CHF) remain unknown." | 5.11 | Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. ( Barretto, AC; Brum, PC; De Matos, LD; Gardenghi, G; Middlekauff, HR; Negrão, CE; Rondon, MU; Soufen, HN; Tirone, AP, 2004) |
| "Bisoprolol, carvedilol, enalapril are widely used for the treatment of patients with chronic heart failure." | 5.11 | [Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure]. ( Belousov, IuB; Khanina, NIu; Upnitskiĭ, AA, 2005) |
| "In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily." | 5.11 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005) |
| "Fifty-five patients with New York Heart Association (NYHA) classes II-III congestive heart failure and LVEF < or =35% entered the study with intention to assess LVEF, NYHA class, plasma brain natriuretic peptide (BNP), N-terminal atrial natriuretic peptide (NANP), big-endothelin, endothelin-1, norepinephrine, and angiotensin II at baseline and at 6 and 12 months after initiation of carvedilol." | 5.11 | Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. ( Backes, RJ; Bailey, KR; Burnett, JC; Frantz, RP; Grill, D; Hanna, RD; Heublein, D; Mookadam, F; Moualla, SK; Nelson, SM; Nobrega, TP; Olson, LJ, 2005) |
| "Carvedilol treatment in chronic heart failure (CHF) patients has been demonstrated to reduce mortality by improving cardiac systolic function and reducing left ventricular adverse remodeling." | 5.11 | Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure. ( Calabria, P; Gennari, L; Martini, G; Nuti, R; Palazzuoli, A; Quatrini, I; Vecchiato, L, 2005) |
| "Radionuclide isotopic ventriculography with phase analysis was performed in 30 patients with stable heart failure (HF), determining left ventricular (LV) and interventricular contraction synchrony at baseline and after 6 months of treatment with maximal tolerated doses of carvedilol." | 5.11 | Effects of carvedilol upon intra- and interventricular synchrony in patients with chronic heart failure. ( Alcaino, H; Bittner, A; Castro, PF; Chiong, M; Copaja, M; Corbalan, R; Díaz-Araya, G; Greig, D; Lavandero, S; Mc-Nab, P; Quintana, JC; Troncoso, R; Vergara, I; Vukasovic, JL, 2005) |
| "The Carvedilol or Metoprolol European Trial (COMET) compared the effects of a comprehensive adrenergic antagonist, carvedilol (target dosage 25 mg twice daily), with a beta-1-selective agent, metoprolol tartrate (target dosage 50 mg twice daily), in 3029 patients with chronic heart failure caused by left ventricular systolic dysfunction." | 5.11 | Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. ( Cleland, JG, 2004) |
| "To evaluate the effect of carvedilol on the cardiac function and autoantibodies against the cardiac beta(1), beta(2) and alpha(1)-adrenergic receptors in patients with chronic heart failure (CHF)." | 5.11 | [The effect of carvedilol on cardiac function and autoantibodies against the cardiac receptors]. ( Chen, J; Hu, DY; Li, J; Liu, XL; Wu, YF; Zhang, L, 2005) |
| "Carvedilol treatment in chronic heart failure (CHF) demonstrated to reduce mortality and rehospitalisation, and improvement of cardiac systolic function with reduction of left ventricular volumes and remodelling." | 5.11 | Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure. ( De Paola, V; Iovine, F; Martini, G; Nuti, R; Palazzuoli, A; Quatrini, I; Scali, C; Vecchiato, L, 2005) |
| "Carvedilol is a beta-blocking agent with antioxidant properties that has been shown to improve survival in chronic heart failure (CHF)." | 5.11 | Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. ( Abergel, E; Berdeaux, A; Cohen-Solal, A; Le Guludec, D; Merlet, P; Rouzet, F; Syrota, A, 2005) |
| "It is still uncertain whether or not there is a difference between metoprolol and carvedilol for the treatment of congestive heart failure." | 5.11 | Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. ( Anzai, T; Kohno, T; Nakamura, I; Ogawa, S; Satoh, T; Yoshikawa, T; Yoshizawa, A, 2005) |
| "To investigate the effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure (CHF)." | 5.11 | [Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure]. ( Gao, LJ; Lin, XY; Xiao, LZ; Zhang, HF, 2005) |
| "Additional treatment with carvedilol is neutral with regard to influence the insulin sensitivity in patients with mild to moderate CHF." | 5.10 | Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. ( Andreasen, F; Gøtzsche, O; Refsgaard, J; Thomsen, C, 2002) |
| "Patients with chronic heart failure were randomized to treatment (double blind) with metoprolol 50 mg twice daily or carvedilol 25 mg twice daily in addition to standard therapy." | 5.10 | Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. ( Chan, SK; Fung, JW; Sanderson, JE; Yeung, LY, 2002) |
| "Carvedilol is a medication with both beta-receptor and alpha-receptor blocking properties that has been approved for the treatment of heart failure in adults." | 5.10 | The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design. ( Boucek, MM; Burch, GH; Burr, J; Curtin, EL; Hsu, DT; LaSalle, B; Mahony, L; Pahl, E; Schlencker-Herceg, R; Shaddy, RE; Sower, B; Tani, LY, 2002) |
| "We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF)." | 5.10 | Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. ( Bristow, MR; D'Aloia, A; Dei Cas, L; Metra, M; Muneretto, C; Nodari, S; Robertson, AD, 2002) |
| "We randomly assigned 2289 patients with symptoms of heart failure at rest or on minimal exertion and with an ejection fraction <25% (but not volume-overloaded) to double-blind treatment with either placebo (n=1133) or carvedilol (n=1156) for an average of 10." | 5.10 | Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. ( Amann-Zalan, I; Coats, AJ; DeMets, DL; Fowler, MB; Holcslaw, TL; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Roecker, EB; Rouleau, JL; Staiger, C; Tendera, M, 2002) |
| "Recent studies have shown that carvedilol therapy in patients with heart failure improves clinical outcome and survival, however, the effects of such treatment on left cardiac morphology and function in elderly patients with severe heart failure has not been widely studied." | 5.10 | Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. ( Angori, P; Auteri, A; Bruni, F; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L, 2002) |
| "We performed a prospective, randomized, double-blind, placebo-controlled study of carvedilol effects in children with severe, chronic heart failure (HF), despite the use of conventional therapy." | 5.10 | Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. ( Alcides Bocchi, E; Azeka, E; Franchini Ramires, JA; Valler, C, 2002) |
| "While receiving placebo (2 months) and a full dosage of carvedilol (4 months), 15 chronic heart failure patients were evaluated by quality-of-life questionnaire, pulmonary function tests, cardiopulmonary exercise tests with constant workload, and a ramp protocol." | 5.10 | Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients. ( Agostoni, P; Bussotti, M; De Vita, S; Guazzi, M; Palermo, P, 2002) |
| " We hypothesized that the nonselective beta-antagonist carvedilol, through its alpha1-adrenergic blocking properties, may modulate vascular reactivity to Ang II in patients with chronic heart failure (CHF)." | 5.10 | Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers. ( Jorde, UP; Katz, SD; Lang, CC; Mancini, DM; Packer, M; Vittorio, TJ, 2003) |
| "To evaluate the early effects of the beta-blocker carvedilol in patients with severe heart failure." | 5.10 | Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. ( Coats, AJ; Fowler, MB; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Roecker, EB; Rouleau, JL; Tendera, M, 2003) |
| "Patients with congestive heart failure on a non-selective beta adrenoreceptor blocker or beta1 selective blocker responded differently to the inotropic drug dobutamine: the beta1 blockade caused by metoprolol could be counteracted by dobutamine, whereas with carvedilol a low dose of dobutamine increased cardiac output, and a higher dose of dobutamine caused a pressor effect." | 5.10 | Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. ( Andersson, B; Bollano, E; Hjalmarson, A; Täng, MS; Waagstein, F, 2003) |
| "In a multicentre, double-blind, and randomised parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily)." | 5.10 | Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lubsen, J; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2003) |
| "We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due to ischaemic left-ventricular systolic dysfunction." | 5.10 | Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. ( Cleland, JG; Coats, AJ; Lahiri, A; Macfarlane, PW; Mule, JD; Murray, GD; Pennell, DJ; Ray, SG; Vered, Z, 2003) |
| "Acute administration of carvedilol attenuates the vasoconstriction response to adrenergic stimuli when compared with placebo and metoprolol in normal subjects, whereas chronic administration of carvedilol does not attenuate the vasoconstrictor response to adrenergic stimuli when compared with metoprolol in heart failure subjects." | 5.10 | Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "We studied effects of beta-adrenoblocker carvedilol vs placebo in 60 patients with chronic cardiac failure (CCF) of functional classes III-IV in a 6-month open randomized trial." | 5.10 | [Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol]. ( Shliakhto, EV; Sitnikova, MIu, 2003) |
| " Thirty-three patients with CHF, with exercise limited by dyspnea and left ventricular ejection fraction of 26 +/- 4%, were randomized to receive metoprolol or carvedilol for 6 months." | 5.10 | Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). ( Blanchet, M; Ducharme, A; Fortier, A; Juneau, M; Larivée, L; Marquis, J; Nigam, A; Racine, N; Rouleau, JL; Tardif, JC; White, M, 2003) |
| "To examine the influence of carvedilol dose and concentration in serum on plasma brain natriuretic peptide (BNP), a measure of heart failure progression." | 5.10 | Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study. ( Konishi, H; Minouchi, T; Nishio, S; Tsutamoto, T; Yamaji, A, 2003) |
| "In large clinical trials both carvedilol and metoprolol have been shown to reduce mortality and morbidity in patients with chronic heart failure." | 5.10 | Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; J Remme, W; Komajda, M; Metra, M; Poole-Wilson, PA; Swedberg, K; Torp-Pedersen, C, 2002) |
| "In a randomized (2:1), double-blinded design study, we studied 25 patients with congestive heart failure (66 +/- 9 years, ejection fraction 30 +/- 7%) before and after 23-week treatment with the beta blocker carvedilol 25 mg twice daily (n = 17) or placebo (n = 8) in addition to standard therapy." | 5.10 | Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. ( Andreasen, F; Bøttcher, M; Gøtzsche, O; Nielsen, TT; Refsgaard, J, 2002) |
| "Plasma neurohormones were analyzed for prediction of adverse outcomes and response to treatment in 415 patients with ischemic left ventricular dysfunction randomly assigned to receive carvedilol or placebo." | 5.09 | Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; Ikram, H; Macmahon, S; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 1999) |
| "We and others have previously shown that carvedilol improves left ventricular (LV) function and symptoms in chronic heart failure." | 5.09 | Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. ( Abraham, WT; Bristow, MR; Gilbert, EM; Gill, EA; Larrain, JR; Lowes, BD; Robertson, AD, 1999) |
| "Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure." | 5.09 | Carvedilol. ( , 1999) |
| "Twenty-one patients with New York Heart Association class II to III heart failure were randomly assigned (2 to 1) to carvedilol (25 mg twice daily, n = 14) or placebo (n = 7) for 6 months." | 5.09 | Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. ( Agostoni, P; Guazzi, M; Guazzi, MD; Matturri, M; Pontone, G, 1999) |
| "This study was performed to compare the long-term clinical efficacy of treatment with metoprolol versus carvedilol in patients with chronic heart failure." | 5.09 | Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. ( Chan, KW; Chan, SK; Raymond, K; Sanderson, JE; Woo, KS; Yeung, LY; Yip, G, 1999) |
| "Carvedilol reduces mortality and improves symptoms and ejection fraction in ischemic heart failure, but its mode of action is not well defined and not all patients respond to treatment." | 5.09 | The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure. ( Atkinson, P; Burgess, M; Cleland, JG; Davies, G; Pennell, DJ; Ray, SG; Slomka, P; Webster, J, 2000) |
| "In patients with chronic heart failure, the use of carvedilol therapy induces clinical and hemodynamic improvement." | 5.09 | Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. ( Capomolla, S; Caporotondi, A; Cobelli, F; Febo, O; Gnemmi, M; Mortara, A; Opasich, C; Pinna, GD; Riccardi, G, 2000) |
| "Carvedilol improved LV regional WMSI in patients with heart failure caused by ischemic heart disease." | 5.09 | Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( Doughty, RN; Gamble, G; MacMahon, S; Sharpe, N; Whalley, GA, 2000) |
| "Both metoprolol and carvedilol produce hemodynamic and clinical benefits in patients with chronic heart failure; carvedilol exerts greater antiadrenergic effects than metoprolol, but it is unknown whether this pharmacological difference results in hemodynamic and clinical differences between the 2 drugs." | 5.09 | Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. ( Boldi, E; Dei Cas, L; Giubbini, R; Metra, M; Modena, MG; Nodari, S, 2000) |
| "Carvedilol improves left ventricular (LV) function when heart failure is due to LV systolic dysfunction, but the magnitude of the response is heterogeneous among patients with coronary disease, possibly reflecting the presence or volume of hibernating myocardium." | 5.09 | The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators. ( Cleland, JG; Coats, A; Cowley, A; Lahiri, A; MacFarlane, P; Murray, G; Pennel, D; Ray, S, 1999) |
| " The objective of this study was to determine if these antioxidant effects are detectable in patients with heart failure and to compare carvedilol with the selective beta-blocker metoprolol." | 5.09 | Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. ( Arumanayagam, M; Chan, S; Sanderson, JE; Tong, S, 2001) |
| "To verify and compare the effects respectively exercised in chronic heart failure patients by transdermal, slow release scopolamine patch and by the beta and alfa adrenoreceptor blocker carvedilol upon the main indexes derived from maximal cardiopulmonary stress test, as well as from analysis of heart rate variability." | 5.09 | Different impact of carvedilol and transdermal scopolamine on cardiovascular performance of mild-moderate chronic heart failure patients: evidence of useful effects of scopolamine on tolerance to work load. ( De Vecchis, R; Nocerino, L; Pucciarelli, G; Setaro, A, 2000) |
| "The aim of this study was to investigate in dialysis patients with symptomatic heart failure New York Heart Association (NYHA) functional class II or III whether the addition of carvedilol to conventional therapy is associated with beneficial effects on cardiac architecture, function and clinical status." | 5.09 | Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Marinelli, G; Pavese, F; Russo, PE, 2001) |
| "The objective of this study was to examine the pharmacokinetic and pharmacodynamic consequences of concomitant administration of fluoxetine and carvedilol in heart failure patients." | 5.09 | Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ( Adams, KF; Carson, SW; Cascio, WE; Graff, DW; Patterson, JH; Pieper, JA; Williamson, KM, 2001) |
| "To assess clinical response to carvedilol in long-term treatment of cardiac failure (CF)." | 5.09 | [Clinical efficacy of carvedilol in patients with severe cardiac insufficiency]. ( Bol'shakova, OO; Brodskaia, IS; Kozlova, SN; Krutikov, AN; Shliakhto, EV; Sitnikova, MIu, 2001) |
| "Carvedilol has been shown to decrease the progression of heart failure and improve left ventricular function and survival in patients with a left ventricular ejection fraction (LVEF) less than 35%." | 5.09 | Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. ( Abraham, WT; Bristow, MR; Ferguson, D; Lindenfeld, JA; Lowes, BD; Schleman, KA; Wolfel, EE; Zisman, LS, 2001) |
| "A programme of four phase III clinical trials carried out in the USA on 1094 patients showed that Carvedilol, associated with the usual bitherapy and eventually with digitalis, reduced the mortality and number of hospital admissions of patients with cardiac failure." | 5.09 | [Economic study of carvedilol in heart failure. A cost effectiveness study in France]. ( Cohen-Solal, A; Dubois-Randé, JL; Lévy, E; Lévy, P, 2001) |
| "The benefits of angiotensin-converting-enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure." | 5.09 | Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Lukas, MA; Packer, M; Yancy, CW; Young, ST, 2001) |
| "Carvedilol treatment in patients with heart failure results in a 57% decrease in myocardial FFA use without a significant change in glucose use." | 5.09 | Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. ( DeGrado, TR; Nickles, RJ; Russell, DC; Stanko, P; Stone, CK; Taylor, M; Wallhaus, TR, 2001) |
| "The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial." | 5.09 | Effect of carvedilol on survival in severe chronic heart failure. ( Castaigne, A; Coats, AJ; DeMets, DL; Fowler, MB; Katus, HA; Krum, H; Mohacsi, P; Packer, M; Roecker, EB; Rouleau, JL; Schultz, MK; Tendera, M, 2001) |
| "Although neurohormonal status has known prognostic significance in heart failure, the predictive power of either N-BNP or adrenomedullin in chronic ischemic LV dysfunction has not been previously reported." | 5.09 | Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. ( Doughty, R; Espiner, EA; Frampton, C; MacMahon, S; Murphy, J; Nicholls, MG; Richards, AM; Sharpe, N; Yandle, TG, 2001) |
| "Fourteen digitalised patients diagnosed with heart failure (NYHA Functional class II) with idiopathic dilated cardiomyopathy in chronic established atrial fibrillation were administered carvedilol in addition to their anti-heart failure medications in an attempt to improve their heart rate control." | 5.09 | Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. ( Agarwal, AK; Venugopalan, P, 2001) |
| "Carvedilol has been shown to improve morbidity and mortality in patients with congestive heart failure (CHF)." | 5.09 | Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. ( Antonio, C; Choudhary, G; Heaney, L; Jain, A; Just, V; Kumar, A; Papp, MA, 2001) |
| "This study evaluated the independent and combined effects of captopril and carvedilol on left ventricular remodeling in chronic heart failure." | 5.09 | Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol. ( Khattar, RS; Lahiri, A; Senior, R; Soman, P; van der Does, R, 2001) |
| "This study investigates the effects of a change of beta-adrenergic blocking agent treatment from metoprolol to carvedilol and vice versa in patients with heart failure (HF)." | 5.09 | Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. ( Böhm, M; Crivaro, M; Elter, T; LaRosee, K; Maack, C; Nickenig, G; Stäblein, A; Wuttke, H, 2001) |
| "Thirty-six patients with chronic heart failure were randomized to the nonselective beta-blocker carvedilol or the selective beta-blocker metoprolol (double-blind)." | 5.09 | Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. ( Al-Hesayen, A; Allan, R; Azevedo, ER; Floras, JS; Kelly, S; Kubo, T; Mak, S; Newton, GE; Parker, JD; Schofield, A, 2001) |
| "The purpose of this study was to determine whether carvedilol's alpha(1)-adrenoceptor antagonism persists during long-term therapy of patients with congestive heart failure (CHF)." | 5.09 | Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. ( Azevedo, ER; Floras, JS; Kubo, T; Newton, GE; Parker, JD, 2001) |
| "We retrospectively evaluated patients entered into the Multicenter Oral Carvedilol Heart failure Assessment (MOCHA) trial, a 6-month, double-blind, randomized, placebo-controlled, multicenter, dose-response evaluation of carvedilol in patients with chronic stable symptomatic heart failure." | 5.09 | Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. ( Bristow, MR; Lindenfeld, J; Lowes, BD; Robertson, AD, 2001) |
| "A number of studies showed the improvement in left ventricular (LV) function and clinical outcome that carvedilol produces in patients with severe congestive heart failure (CHF)." | 5.09 | [Tolerability and clinical effects of carvedilol in patients over 70 years of age with chronic heart failure due to left ventricular dysfunction]. ( Cioffi, G; Stefenelli, C, 2001) |
| "This study investigated the effects of carvedilol, a beta-blocker with alpha 1-blocking properties, on left ventricular size and function, maximal and submaximal exercise performance, and symptoms in 415 patients with stable heart failure of ischemic etiology (ejection fraction < 45%)." | 5.08 | Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( , 1995) |
| "We enrolled 56 patients with severe chronic heart failure into a double-blind, placebo-controlled study of the vasodilating beta-blocker carvedilol." | 5.08 | Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. ( Goldsmith, RL; Horn, E; Katz, SD; Krum, H; Kukin, ML; Medina, N; Penn, J; Sackner-Bernstein, JD; Schwartz, B; Yushak, M, 1995) |
| "This study assessed the safety and efficacy of carvedilol in patients with heart failure caused by idiopathic or ischemic cardiomyopathy." | 5.08 | Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. ( Bristow, MR; Gilbert, EM; Olsen, SL; Renlund, DG; Taylor, DO; Yanowitz, FD, 1995) |
| "Carvedilol is a non-selective beta-adrenoceptor antagonist with vasodilating properties which has been shown to be effective in the management both of hypertension and of stable angina pectoris." | 5.08 | Vasodilating beta-blockers in heart failure. ( Raftery, EB, 1995) |
| "Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor." | 5.08 | The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Packer, M; Shusterman, NH, 1996) |
| "415 patients with chronic stable heart failure were randomly assigned treatment with carvedilol (207) or matching placebo (208)." | 5.08 | Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. ( , 1997) |
| "The aim of this study, a substudy of the Australia-New Zealand trial of carvedilol in patients with heart failure due to ischemic heart disease, was to determine the effects of this treatment on left ventricular size and function with the use of quantitative two-dimensional (2D) echocardiography." | 5.08 | Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. ( Doughty, RN; Gamble, G; MacMahon, S; Sharpe, N; Whalley, GA, 1997) |
| "One hundred thirty-one patients with severe congestive heart failure were enrolled into a double-blind, placebo-controlled study of the vasodilating beta-blocker carvedilol." | 5.08 | Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Holcslaw, TL; Kinhal, V; Krueger, SK; Lejemtel, T; Lukas, MA; Narahara, KA; Packer, M; Young, ST, 1997) |
| "This study was aimed at investigating in chronic heart failure (CHF) the effects that beta-blockade with carvedilol may have on lung function, and their relationship with left ventricular (LV) performance and peak exercise oxygen uptake (VO2p)." | 5.08 | [A failed improvement in pulmonary function and exercise capacity with carvedilol in congestive heart failure despite an excellent effect on left ventricular function]. ( Agostoni, P; Guazzi, M; Lomanto, M; Matturri, M; Pontone, G; Trevisi, N, 1998) |
| "This study investigated the effects of carvedilol on right ventricular (RV) volume and systolic function in chronic heart failure patients." | 5.08 | Effects of carvedilol on right ventricular function in chronic heart failure. ( Bristow, MR; Christian, PE; Datz, FL; Gilbert, EM; Quaife, RA; Volkman, K, 1998) |
| "This study was designed to evaluate the effect of carvedilol on nitrate tolerance in patients with chronic heart failure." | 5.08 | Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "We retrospectively analyzed the Australia/New Zealand Carvedilol Heart Failure Research Collaborative Group study of 415 patients with mild to moderate ischemic heart failure where amiodarone was administered as part of the treatment therapy (in 52 patients)." | 5.08 | Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group. ( Krum, H; MacMahon, S; Sharpe, N; Shusterman, N, 1998) |
| "Carvedilol is a nonselective beta-blocker with alpha-mediated vasodilating properties that has been shown to be effective in systemic hypertension, stable angina, and congestive heart failure (CHF)." | 5.07 | Effects of carvedilol on ventricular arrhythmias. ( DasGupta, P; Lahiri, A; Müller-Beckmann, B; Senior, R; van der Does, R, 1992) |
| "Beta-blockers such as metoprolol, carvedilol, and bisoprolol are indicated for the treatment of patients with reduced ejection fraction heart failure." | 5.05 | Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure. ( Ingram, A; Valente, M, 2020) |
| "This first update of our review found very low-quality evidence for the effects of either carvedilol or rosuvastatin, compared with placebo, for treating heart failure in people with Chagas disease." | 4.93 | Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. ( Kwong, JS; Martí-Carvajal, AJ, 2016) |
| " Studies investigating any of three beta blockers (carvedilol, bisoprolol, and extended release metoprolol succinate) which are known to be effective in adult patients with heart failure were included." | 4.91 | Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies. ( Cho, MJ; Jung Kwak, M; Kim, HY; Kim, YM; Lee, HD; Lim, RK; Park, KH, 2015) |
| "Long-term treatment with appropriate doses of carvedilol or metoprolol is currently recommended for patients with heart failure with reduced ejection fraction (HFrEF) to decrease the risk of death, hospitalizations, and patients' symptoms." | 4.91 | Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure. ( Afonso, L; Briasoulis, A; Palla, M, 2015) |
| " Odds ratio for chronic heart failure related mortality/heart transplantation secondary to carvedilol was 0." | 4.90 | Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis. ( Bjelakovic, B; Buchhorn, R; Kosutic, J; Prijic, A; Prijic, S; Vukomanovic, V; Zdravkovic, M, 2014) |
| "This Cochrane review has found a lack of evidence on the effects of carvedilol for treating heart failure in patients with Chagas disease." | 4.88 | Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy. ( Hidalgo, R; Kwong, JS; Martí-Carvajal, AJ; Nicola, S; Simancas-Racines, D, 2012) |
| "Carvedilol is a beta-adrenergic antagonist with vasodilatory properties (alpha1-antagonism), which has been extensively evaluated in the treatment of patients with heart failure." | 4.84 | Carvedilol: use in chronic heart failure. ( Doughty, RN; White, HD, 2007) |
| "The historical choice of angiotensin-converting enzyme (ACE) inhibition as first-line therapy in heart failure is challenged by early activation of the sympathetic system and multiple ways beta blockade (in particular, unselective agents such as carvedilol) may affect cardiac remodeling, its underlying mechanisms, and, hence, progression of heart failure, compared with ACE inhibition." | 4.84 | Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first? ( Remme, WJ, 2007) |
| "The third generation beta-blocker (carvedilol) is effective in reduction of hypertension, and of mortality and morbidity as a supplement to conventional drugs of heart failure therapies (diuretics, ACE inhibitors), based on randomized controlled trials and retrospective analysis." | 4.83 | [The effectiveness of carvedilol in heart failure]. ( Brodszky, V; Farsang, C; Gulácsi, L; Jermendy, G; Kárpáti, K; Vándorfi, G; Zámolyi, K, 2006) |
| " The remodeling effect of beta-blockade with carvedilol has been studied in patients with left ventricular dysfunction after myocardial infarction and in patients with chronic heart failure of ischemic etiology." | 4.82 | Cardiac remodeling in coronary artery disease. ( Sharpe, N, 2004) |
| "The safety, tolerability, and hemodynamic effects of carvedilol in patients with heart failure were first studied in the mid 1990s." | 4.82 | Landmark studies: the Australia/New Zealand Heart Failure Collaborative Group (ANZ) Trial and the US Carvedilol Trials Program. ( Gilbert, EM, 2004) |
| "Carvedilol is an adrenergic antagonist with nonselective beta- and a1-receptor blocking properties that has demonstrated significant clinical benefit in the management of patients with heart failure and in the post-myocardial infarction setting." | 4.82 | Carvedilol: beta-blockade and beyond. ( Gheorghiade, M; Stroe, AF, 2004) |
| "In the United States, carvedilol and metoprolol (tartrate or succinate) are the most commonly employed beta-adrenoreceptor antagonists for the treatment of heart failure." | 4.82 | Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET. ( McBride, BF; White, CM, 2005) |
| "There is overwhelming evidence that beta blocker therapy in the form of metoprolol, bisoprolol, and carvedilol can have positive outcomes on morbidity, mortality, and quality of life in patients who have been diagnosed with mild to severe heart failure." | 4.82 | Emerging trends in the management of heart failure: Beta blocker therapy. ( Rone, T; Sauls, JL, 2005) |
| "The Carvedilol or Metoprolol European Trial (COMET) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol." | 4.82 | [Beta-adrenolytics in heart failure--are they all really equal?]. ( Filipiak, KJ; Opolski, G, 2005) |
| "Several recently completed survival trials, including Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), and the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial have examined the effects of ss-blockers on survival and the need for hospitalization." | 4.81 | Consistency of ss-blocker effect across various subgroups with heart failure: insights from the MERIT-HF trial. ( Ghali, JK; Goldstein, S; Wikstrand, J, 2002) |
| "Both metoprolol and carvedilol improve cardiac function and prolong survival in patients with heart failure." | 4.81 | Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. ( Antonopoulos, GV; Berlin, JA; Chittams, J; Konstam, MA; Packer, M; Udelson, JE, 2001) |
| "All patients with New York Heart Association class II and III heart failure should receive beta-blocker therapy with bisoprolol, carvedilol, or metoprolol." | 4.81 | Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. ( Lee, S; Spencer, A, 2001) |
| "n 1987 the results of the Consensus study were published, and showed that enalapril, an angiotensin convertor enzyme inhibitor (ACEI), was able to modify the clinical course of the heart failure syndrome thereby reducing mortality." | 4.81 | [Clinical trials on heart failure]. ( Cosín Aguilar, J; Hernándiz Martínez, A, 2001) |
| "Carvedilol and vesnarinone are drugs attracting recent interest in the treatment of chronic heart failure." | 4.81 | Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy. ( Cheng, JH; Kamiya, K; Kodama, I, 2001) |
| "Patients with chronic heart failure due to left ventricular systolic dysfunction of ischemic or nonischemic etiology have shown improvement in morbidity and mortality with carvedilol therapy." | 4.81 | Carvedilol in the failing heart. ( Gilbert, EM; Lombardi, WL, 2001) |
| "Carvedilol is a third-generation vasodilating beta-blocker initially approved for the treatment of hypertension." | 4.80 | Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure. ( Feuerstein, GZ; Ohlstein, EH; Ruffolo, RR, 1998) |
| "Carvedilol, a beta-adrenoceptor blocking agent with additional alpha(1)-adrenoceptor blocking properties, has been shown to improve left ventricular function in chronic heart failure (CHF)." | 4.80 | Assuming the worst may not be bad at all. Carvedilol in heart failure treatment. ( Janson, CP; Schmidt, BM; Wehling, M, 1998) |
| "Carvedilol is a vasodilating beta-blocker currently marketed for the treatment of mild to moderate hypertension and application is being filed to the FDA for treatment of congestive heart failure." | 4.79 | Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. ( Feuerstein, GZ; Ruffolo, RR, 1996) |
| "Carvedilol is a novel, multiple-action cardiovascular drug that is currently approved in many countries for the treatment of hypertension." | 4.79 | Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1997) |
| " Carvedilol, which is a nonselective beta-blocking and alpha 1-blocking drug, with additional Ca(2+)-antagonistic properties, is being developed as an antihypertensive, antianginal drug and as an adjunct therapy in congestive heart failure." | 4.78 | Development of a multiaction beta blocker. Scientific challenges and regulatory needs. ( Lessem, JN; Lukas, MA, 1993) |
| "Carvedilol, a β-blocker prescribed for chronic heart failure, suffers from poor bioavailability and rapid first pass metabolism when administered orally." | 4.31 | Tip loaded cyclodextrin-carvedilol complexes microarray patches. ( Anjani, QK; Donnelly, RF; Hamid, KA; Li, H; Moreno-Castellanos, N; Sabri, AHB, 2023) |
| "Background Carvedilol may have favorable glycemic properties compared with metoprolol, but it is unknown if carvedilol has mortality benefit over metoprolol in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF)." | 4.02 | Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. ( Andersson, C; Gislason, GH; Kristensen, SL; Køber, L; Madelaire, C; Pierce, C; Schou, M; Schwartz, B; Torp-Pedersen, C, 2021) |
| "The Beta-Blocker Evaluation Survival Trial showed no survival benefit for bucindolol in New York Heart Association (NYHA) class III/IV heart failure (HF) with reduced ejection fraction, but subanalyses suggested survival benefits for non-Black subjects and Arg389 homozygotes." | 4.02 | Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. ( Abraham, I; Alkhatib, N; Erstad, B; Gharaibeh, M; Karnes, J; Klimecki, W; Lee, CS; Ramos, K; Slack, M; Sweitzer, NK, 2021) |
| "Although prior literature suggests that metoprolol may worsen glucose control compared to carvedilol, whether this has clinical relevance among older adults with diabetes and heart failure (HF) remains an open question." | 4.02 | Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes. ( Dave, CV; Dejanovic, I; Gerhard, T; Horton, DB; Kobylarz, FA; Nyandege, A; Setoguchi, S; Strom, BL; Tseng, CL, 2021) |
| "This study compared the survival and the risk of heart failure (HF), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), hypoglycemia, and renal failure (RF) hospitalizations in geriatric patients exposed to carvedilol or metoprolol." | 3.96 | Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure. ( Andersen, M; Jensen, MT; Kragholm, K; Rasmussen, DB; Sessa, M; Torp-Pedersen, C, 2020) |
| "Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol." | 3.91 | Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. ( Andersen, M; Capuano, A; Jensen, MT; Kragholm, K; Mascolo, A; Pagliaro, C; Rafaniello, C; Rasmussen, DB; Rossi, F; Sessa, M; Sportiello, L; Tari, GM, 2019) |
| "This study sought to assess the safety of carvedilol therapy among heart failure (HF) patients with a cocaine-use disorder (CUD)." | 3.91 | Carvedilol Among Patients With Heart Failure With a Cocaine-Use Disorder. ( Afshar, M; Alvi, RM; Awadalla, M; Banerji, D; Groarke, JD; Hassan, MO; Mulligan, CP; Neilan, TG; Rokicki, A; Tariq, N; Zhang, L, 2019) |
| "Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction." | 3.91 | Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. ( Branka, JZ; Davor, M; Domagoj, M; Duska, G; Jelena, M, 2019) |
| "The evidence-based beta-blockers carvedilol, bisoprolol, and metoprolol succinate reduce mortality and hospitalizations among patients with heart failure with reduced ejection fraction (HFrEF)." | 3.91 | Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction. ( Brown, TM; Chen, L; Durant, RW; Kilgore, ML; Levitan, EB; Loop, MS; Safford, MM; van Dyke, MK, 2019) |
| "The effects of carvedilol and metoprolol succinate on appropriate and inappropriate implantable cardioverter defibrillator (ICD) therapy in patients with heart failure with reduced ejection fraction (HFrEF) are not fully understood." | 3.91 | A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators. ( Alqam, B; Ayan, M; Cross, M; Gheith, Z; Habash, F; Paydak, H; Vallurupalli, S, 2019) |
| "Clinical efficacy and adverse effects of the β-blocking agents, carvedilol, bisoprolol, and metoprolol were analyzed theoretically, and then compared quantitatively, for the purpose of determining their proper use for chronic heart failure." | 3.85 | Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure. ( Fujito, K; Kimura, K; Takayanagi, R; Yamada, Y, 2017) |
| "The left ventricular reverse remodeling (LVRR) in idiopathic dilated cardiomyopathy (DCM) and the treatment with carvedilol in infants with severe heart failure remain poorly understood." | 3.83 | Left ventricular reverse remodeling with infantile dilated cardiomyopathy and pitfalls of carvedilol therapy. ( Abe, T; Iwasa, T; Negishi, J; Noritake, K; Tsuda, E, 2016) |
| "Heart failure is a highly prevalent cardiovascular complication among patients receiving long-term hemodialysis, but the benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release on the outcomes of these patients remain unclear." | 3.83 | Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort. ( Chen, TH; Hong, CY; Sue, YM; Tang, CH; Wang, CC, 2016) |
| "To compare the effects carvedilol and nebivolol on oxidative stress status in non-ischaemic heart failure (HF) patients." | 3.81 | The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure. ( Bas, HA; Dogan, A; Karabacak, M; Tayyar, S, 2015) |
| "The influence of beta-blocker therapy (bisoprolol or carvedilol) (bB) on the prognosis of heart failure (HF) patients with diabetes mellitus (DM) is uncertain." | 3.81 | Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. ( Andrey, JL; Aranda, RM; Garcia-Egido, A; Gomez, F; López-Sáez, JB; Pedrosa, MJ; Puerto, JL; Rosety, M, 2015) |
| " The objective of this study was to develop PBPK models that incorporate the haemodynamic changes in hepatic and renal blood flows occurring in chronic heart failure (CHF) and to evaluate these changes in adults and children, using carvedilol as a model drug." | 3.81 | A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. ( Khalil, F; Läer, S; Rasool, MF, 2015) |
| "To determine if metoprolol succinate or carvedilol is more effective in delaying the time to first cardiovascular disease hospital admission in systolic heart failure patients." | 3.81 | Comparison of metoprolol succinate versus carvedilol in time to cardiovascular admission in a Veterans Affairs healthcare system: An observational study. ( Baker, E; Brennan, MT; Church, KM; Henalt, R; Joseph, J; Smith, GL, 2015) |
| "The β-blockers carvedilol and metoprolol provide important therapeutic strategies for heart failure treatment." | 3.80 | Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium. ( Berk, E; Christ, T; Engel, A; Galindo-Tovar, A; Gillette, KT; Kaumann, AJ; Molenaar, P; Ravens, U, 2014) |
| "Carvedilol is the standard of care for heart failure (HF) patients." | 3.80 | Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure. ( Arcavi, L; Bar-Haim, A; Berkovitch, M; Caspi, A; Goland, S; Harary, I; Nulman, I; Shihmanter, R, 2014) |
| "The β-blockers carvedilol and metoprolol succinate both reduce mortality in patients with heart failure (HF), but the comparative clinical effectiveness of these drugs is unknown." | 3.80 | Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. ( Hviid, A; Melbye, M; Pasternak, B; Svanström, H, 2014) |
| "Data were retrospectively collected from 23 patients with HF [age 57±18 years, left ventricular ejection fraction (LVEF) 33±15%] who could not increase the dosage of carvedilol because of dizziness or hypotension, defined as systolic blood pressure<90 mmHg." | 3.79 | Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. ( Asano, Y; Ichibori, Y; Kanzaki, M; Komuro, I; Minamiguchi, H; Mizote, I; Ohtani, T; Sakata, Y; Taniguchi, T, 2013) |
| "The aim of this study was to derive population pharmacokinetic (PK) model for clearance (CL) of carvedilol in adult patients with chronic heart failure (CHF)." | 3.79 | Population pharmacokinetics of carvedilol in patients with congestive heart failure. ( Apostolović, S; Djuric, J; Jankovic, SM; Jevtovic-Stoimenov, T; Markovic, V; Milovanovic, JR; Nikolic, VN; Pesic, S; Stanojevic, D; Stefanovic, N; Velickovic-Radovanović, R; Zivanovic, S, 2013) |
| "In 49 consecutive patients with chronic heart failure (HF), LVEF ≤35%, NYHA functional class II-IV, on angiotensin-converting enzyme inhibitors but not on ß-blockers, LV contractile performance and remodeling were assessed by comprehensive echocardiography at baseline and after 3 and 6 months of treatment with carvedilol." | 3.78 | New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. ( Ather, S; Bolos, M; Bozkurt, B; Carabello, B; Chan, W; Deswal, A; Mann, DL, 2012) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 3.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "The aim of the present study was to determine whether carvedilol-treated chronic heart failure patients have a different prognosis when stratified for a specific combination of a gain-of-function genotype of the adrenergic β-1 receptor gene (ADRB1) (Arg389-homozygous), two gain-of-function genotypes of the angiotensinogen gene (AGT) (Thr174-homozygous and Thr235-homozygous), and a downregulated genotype of the adrenergic β-2 receptor gene (ADRB2) (Gln27-carrier)." | 3.78 | Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial. ( Afzal, S; Andersen, JT; Broedbaek, K; Børglum, AD; Jimenez-Solem, E; Køber, L; Nyegaard, M; Petersen, M; Poulsen, HE; Stender, S; Torp-Pedersen, C, 2012) |
| "Relative effectiveness of carvedilol and metoprolol succinate has never been compared in patients with heart failure (HF)." | 3.78 | Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis. ( Aggarwal, V; Shore, S; Zolty, R, 2012) |
| "Beta-adrenoceptor blockers nebivolol and carvedilol do not affect diuresis and renal sodium excretion in intact rats, but significantly increase urinary excretion of sodium in animals with a model of heart failure caused by excessive physical exercise and injection of phenylephrine." | 3.78 | [Effect of the third generation beta-blockers on ion-regulating renal function in rats with heart failure model]. ( Buchneva, NV; Kuz'min, OB, 2012) |
| " We investigated whether a predefined combination of the Arg389Gly polymorphism in the adrenergic β(1) -receptor gene (ADRB1) and the Gln27Glu polymorphism in the adrenergic β(2) -receptor gene (ADRB2) could predict survival in carvedilol- and metoprolol-treated chronic heart failure (HF) patients." | 3.77 | Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. ( Afzal, S; Andersen, JT; Broedbaek, K; Børglum, AD; Hjelvang, BR; Køber, L; Nyegaard, M; Petersen, M; Poulsen, HE; Stender, S; Torp-Pedersen, C, 2011) |
| "The effect of carvedilol on heart failure (HF) in patients with a functionally univentricular heart (UVH) remains unclear." | 3.77 | Effect of carvedilol on heart failure in patients with a functionally univentricular heart. ( Ando, M; Doi, S; Ishibashi, N; Mimori, S; Mizutani, S; Mori, K; Murakami, Y; Nakanishi, T; Park, IS; Takahashi, Y; Waragai, T; Yoshikawa, T, 2011) |
| " We present a case where carvedilol was replaced with bisoprolol resulting in acute urinary retention." | 3.77 | Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure? ( Lindenfeld, J; Page, RL; Rohrer, CK; Shakar, SF, 2011) |
| "To evaluate the heart rate dynamic in heart failure patients with different sensibilities of the Carvedilol therapy during an exercise test." | 3.76 | Heart rate dynamic during an exercise test in heart failure patients with different sensibilities of the carvedilol therapy: heart rate dynamic during exercise test. ( Bocchi, EA; Carvalho, VO; Guimarães, GV; Rodrigues Alves, RX, 2010) |
| "In COMET (Carvedilol or Metoprolol European Trial), carvedilol reduced mortality compared with metoprolol in patients with chronic heart failure." | 3.76 | Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy. ( Boman, K; Cleland, JG; Jansson, JH; Nilsson, T; Poole-Wilson, P; Swedberg, K, 2010) |
| "Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects." | 3.76 | Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. ( Hachiya, H; Haraguchi, G; Hirao, K; Inagaki, H; Isobe, M; Kawabata, M; Kimura, S; Konishi, M, 2010) |
| " Carvedilol is an anti-heart failure agent that is used to induce cardiac reverse remodeling, and its effect is reportedly dose-dependent." | 3.76 | High-dose carvedilol therapy for mechanical circulatory assisted patients. ( Kyo, S; Nishimura, T, 2010) |
| "Large clinical trials using the betablockers carvedilol, metoprolol, bisoprolol and nebivolol have demonstrated improvement of survival and symptoms in patients with heart failure." | 3.76 | Replacement of carvedilol for propranolol in patients with heart failure. ( Castro, RB; Gallo, L; Maciel, BC; Marques, F; Nobre, F; Pintya, AO; Simões, MV, 2010) |
| "Histamine has a positive inotropic effect on ventricular myocardium and stimulation of histamine H₂ receptors increases the intracellular cAMP level via Gs protein, as dose stimulation of β-adrenergic receptors, and worsens heart failure." | 3.76 | A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade. ( Asakura, M; Asanuma, H; Fujita, M; Kim, J; Kitakaze, M; Komamura, K; Minamino, T; Sanada, S; Sasaki, H; Sugimachi, M; Takahama, H; Takashima, S; Wakeno, M, 2010) |
| "To study beta1-adrenoceptor gene (ADRB1) polymorphism on the development and course of chronic heart failure (CHF) and on the efficiency of its treatment with the beta-adrenoblocker carvedilol in patients with coronary heart failure." | 3.76 | [Impact of Gly389Arg beta1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol]. ( Berezikova, EN; Efremov, AV; Karpov, RS; Maianskaia, SD; Popova, AA; Safronov, ID; Shilov, SN; Tepliakov, AT; Torim, IuIu; Voronina, EN, 2010) |
| "In the UK, the licence for carvedilol was extended in 1998 to include symptomatic heart failure (New York Heart Association [NYHA] class II and III heart failure) with the recommendation that initiation and up-titration should be under the supervision of a hospital physician." | 3.75 | Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. ( Aurich-Barrera, B; Shakir, SA; Wilton, LV, 2009) |
| "To study the effects of carvedilol combined with perindopril on Ca(2+) pump activity and the density of Ca(2+)-release channel ryanodine receptor (RyR2) in the myocardial sarcoplasmic reticulum (SR) in rats with chronic heart failure caused by myocardial infarction." | 3.75 | [Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction]. ( Cui, B; Geng, ZH; Li, LG; Liu, CY; Peng, YH; Yu, SY; Zhao, XH, 2009) |
| "To examine serum B-type natriuretic peptide (BNP) levels and BNP expression of protein and mRNA in the right ventricular myocardium in juvenile rats with right heart failure (RHF) and the effects of beta-adrenergic receptor blocker carvedilol on serum and myocardial BNP levels in order to investigate the role of BNP in the diagnosis and treatment of RHF." | 3.75 | [B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure]. ( An, JD; Feng, S; Liang, F, 2009) |
| "This retrospective cohort study using administrative claims data included veterans 65 years and older receiving bisoprolol, carvedilol, or metoprolol succinate for which prescribing physicians indicated treatment was for heart failure." | 3.75 | The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study. ( Barratt, JD; Gilbert, AL; Killer, G; Peck, R; Pratt, N; Ramsay, E; Roughead, EE; Ryan, P, 2009) |
| "The effect of the dose of carvedilol on cardiac sympathetic nerve activity (CSA) and mortality remain uncertain in patients with chronic heart failure (CHF)." | 3.75 | Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine. ( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2009) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 3.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "A Holter ECG recording was obtained before and 1 and 3 months after titrated addition of carvedilol therapy in 10 patients with advanced congestive heart failure." | 3.74 | Carvedilol can restore the multifractal properties of heart beat dynamics in patients with advanced congestive heart failure. ( Chan, HL; Chiu, KM; Chu, SH; Lin, TY, 2007) |
| "The IMPACT-HF trial demonstrated that carvedilol use at the time of heart failure (HF) hospital discharge significantly increased 90-day postdischarge treatment rates." | 3.74 | Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). ( Abraham, WT; Albert, NM; Fonarow, GC; Gheorghiade, M; Greenberg, BH; O'Connor, CM; Stough, WG; Sun, JL; Yancy, C; Young, JB, 2007) |
| "Carvedilol therapy resulted in a marked decrease in plasma NT-proBNP levels and increase left ventricular ejection fraction in patients with congestive heart failure." | 3.74 | The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure. ( Arslan, S; Bozkurt, E; Gundogdu, F; Gurlertop, Y; Karakelleoglu, S; Kiziltunc, A; Senocak, H; Sevimli, S, 2007) |
| " Here, we investigate whether long-term treatment with carvedilol or metoprolol may functionally alter myofibrillar function in end-stage human heart failure." | 3.74 | Chronic treatment with carvedilol improves Ca(2+)-dependent ATP consumption in triton X-skinned fiber preparations of human myocardium. ( Bloch, W; Boelck, B; Brixius, K; Grafweg, S; Hoyer, F; Lu, R; Mehlhorn, U; Pott, C; Schwinger, RH, 2007) |
| " Carvedilol is more effective than Metoprolol for improving the hemodynamics and in attenuating ventricular remodeling after heart failure." | 3.74 | Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. ( Chen, GW; Jiang, ZF; Lin, Y; Wang, LX; Wu, TG; Zhao, Q, 2007) |
| "To study the effects of carvedilol on the transmural heterogeneity of ventricular repolarization in rabbits with congestive heart failure (CHF)." | 3.74 | Low-dose carvedilol reduces transmural heterogeneity of ventricular repolarization in congestive heart failure. ( Chen, XP; Chen, YF; Li, WJ; Yao, Z; Yun, ML; Zhong, JH, 2007) |
| "To characterize prescribing of carvedilol and controlled-release (CR) metoprolol for veterans with heart failure who were predominantly elderly (aged > or = 65) and to compare the time to first hospitalization or death." | 3.74 | Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. ( Anand, IS; Ensrud, KE; Nelson, DB; Rector, TS, 2008) |
| "Although most patients in Europe with systolic heart failure (SHF) are treated with I(2)-blocking agents at doses significantly lower than the recommended dose, there is limited information available regarding the hemodynamic effects of dobutamine in this patient population." | 3.74 | Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol. ( Dalampiras, P; Kelepeshis, G; Sitafidis, G; Skoularigis, J; Triposkiadis, F, 2008) |
| "The purpose of this study was to evaluate the pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure." | 3.74 | Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. ( Fujii, N; Hashimoto, Y; Honda, M; Horiuchi, I; Inoue, H; Nozawa, T; Shimizu, T; Taguchi, M, 2008) |
| "This is an interim report of a prospective observational cohort study to monitor the safety and tolerability of carvedilol in clinical practice when prescribed for heart failure in England." | 3.73 | Observational cohort study to monitor the use and safety of carvedilol in the treatment of heart failure in clinical practice in England--1st interim report. ( Acharya, NV; Shakir, SA; Wilton, LV, 2005) |
| "Using data from a large United States health-insurance claims database, we conducted a retrospective study to compare the risks of death and hospitalization and the cost of inpatient care in heart failure patients receiving carvedilol vs." | 3.73 | Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. ( Delea, TE; Edelsberg, JS; Hagiwara, M; Oster, G; Stanford, R, 2005) |
| "The aim of this study was to determine the effects of carvedilol on the costs related to the treatment of severe chronic heart failure (CHF)." | 3.73 | Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. ( Coats, AJ; Hebborn, A; McMurray, JJ; Packer, M; Stewart, S, 2005) |
| "To evaluate the hemodynamic effects of orally administered carvedilol in healthy dogs with doses that might be used to initiate treatment in dogs with congestive heart failure." | 3.73 | Hemodynamic effects of orally administered carvedilol in healthy conscious dogs. ( Abbott, JA; Broadstone, RV; Pyle, RL; Ward, DL, 2005) |
| "To observe the changes of serum PDCD5 antibody in chronic ischemic heart failure patients and the effect of carvedilol treatment." | 3.73 | [The effect of carvedilol on apoptosis gene PDCD5 expression in chronic heart failure patients]. ( Hu, DY; Lu, PN; Luo, L; Nie, XY; Wu, Y; Zhang, GQ, 2005) |
| "To study the condition of the sympathico-adrenal system (SAS), synthesis of cAMP dependent on beta2-adrenoreceptors and parameters of free radical oxidation in patients with primary pulmonary hypertension (PPH); to examine efficacy of non-selective beta- and alpha1-adrenoblocker carvedilol in PPH patients." | 3.73 | [Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy]. ( Aref'eva, TI; Ataullakhanova, DM; Chazova, IE; Irodova, NL; Konovalova, GG; Krasnikova, TL; Lankin, VZ; Lazutkina, VK; Masenko, VP; Orlova, IaA; Sokolov, SF, 2005) |
| "Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) studied whether a standardized protocol for the initiation and titration of the beta-blocker carvedilol in a multicenter, open-label program would optimize beta-blocker use in heart failure (HF) patients." | 3.73 | Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. ( Diaz, A; Doval, H; Ferrante, D; Grancelli, H; Nul, D; Soifer, S; Varini, S; Zambrano, C, 2005) |
| "We investigated the change of LV remodeling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 mg/kg/d) or metoprolol (60 mg/kg/d) treatment for 6 weeks (n = 9 in the MI plus carvedilol group, and n = 8 in every other group)." | 3.73 | Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. ( Hu, SJ; Hu, Y; Sun, YL; Wang, LH; Zhou, JY, 2005) |
| "To understand the basis of the effectiveness of carvedilol in heart failure by determining its specific properties at human heart beta1- and beta2-adrenoceptors." | 3.73 | Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart. ( Christ, T; Kaumann, A; Molenaar, P; Ravens, U, 2006) |
| "Our previous studies suggest that the increase in heart rate from rest to peak exercise is reduced in patients with chronic heart failure (CHF) and this is associated with increased oxidative stress, as determined by malondialdehyde (MDA) plasma levels." | 3.73 | Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. ( Alcaino, H; Castro, P; Chiong, M; Copaja, M; Corbalan, R; Díaz-Araya, G; Greig, D; Lavandero, S; Pérez, O; Valenzuela, R; Vukasovic, JL, 2005) |
| " In this study, the metabolic effect of carvedilol in nondiabetic patients with chronic heart failure (CHF) was evaluated." | 3.73 | Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? ( Bobbio, M; Catalano, E; Ferrua, S; Grassi, G; Massobrio, N; Pinach, S; Rossi, C; Trevi, GP; Veglio, M, 2005) |
| " Objectives of the present study were to evaluate the feasibility, tolerability and safety of carvedilol therapy in a cohort of patients > 70 years of age with CHF and left ventricular ejection fraction < 40% with chronic atrial fibrillation." | 3.73 | Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol? ( Cioffi, G; De Feo, S; Del Sindaco, D; Opasich, C; Pulignano, G; Stefenelli, C; Tarantini, L, 2006) |
| "In this retrospective study, 27 patients with symptomatic congestive heart failure were given carvedilol upon admission." | 3.73 | Significance of combined angiotensin II receptor blocker and carvedilol therapy in patients with congestive heart failure and arginine variant. ( Iwata, A; Kawamura, A; Kumagai, K; Matsuo, K; Matsuo, Y; Miura, S; Nishikawa, H; Sako, H; Saku, K, 2006) |
| "The COMET study suggested the better effect of carvedilol to metoprolol in treating heart failure." | 3.73 | Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. ( Fukagawa, Y; Harada, N; Kametani, R; Kawamura, S; Matsuzaki, M; Miura, T; Shibuya, M; Tan, H; Wang, R, 2006) |
| " Two strategies were evaluated: (1) conventional therapy (conventional)-the risks for death and hospitalization were derived from the angiotensin-converting enzyme inhibitor arm of the SOLVD treatment trial; and (2) pacemaker insertion with atrial pacing and carvedilol therapy (pacemaker-carvedilol)-risk reductions for death and CHF-related hospitalizations for carvedilol compared with conventional therapy were derived from the US Carvedilol Heart Failure Study." | 3.73 | Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia. ( Aaronson, KD; Fendrick, AM; Knight, BP; Stecker, EC, 2006) |
| "Carvedilol was well tolerated by Japanese patients with chronic heart failure." | 3.73 | [Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure]. ( Endo, Y; Kasanuki, H; Kawashiro, N; Matsuda, N; Uchida, Y, 2006) |
| "Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin." | 3.73 | Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. ( Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA, 2006) |
| "To demonstrate the alterations of Protein Kinase C epsilon (PKC epsilon) and components of its signaling complexes after treatment with fosinopril and carvedilol and analyze potential molecular mechanisms of the two drugs for cardiac hypertrophy and heart failure." | 3.73 | Fosinopril and carvedilol reverse hypertrophy and change the levels of protein kinase C epsilon and components of its signaling complex. ( Gao, J; He, H; Ma, L; Wang, P; Wang, W; Wu, H; Zhang, H, 2006) |
| "Our previous study showed that static handgrip caused increases in the plasma adrenomedullin (ADM) both in patients with heart failure (HF) and healthy subjects." | 3.73 | Effect of adrenergic blockade on plasma adrenomedullin concentration during static handgrip in patients with heart failure. ( Cybulski, G; Krzemiński, K; Mikulski, T; Nazar, K, 2006) |
| "To retrospectively investigate the effect of carvedilol and spironolactone plus furosemide, administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) to patients with chronic heart failure (CHF)." | 3.73 | Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. ( Hirooka, K; Nakayama, D; Saito, M; Takada, M; Yasumura, Y, 2006) |
| "We hypothesized that abnormal oxidative stress in chronic heart failure (CHF) could be related to endothelial damage and platelet activation, and that the vasodilating beta-blocker carvedilol would have beneficial effects on these processes compared with a selective non-vasodilating cardioselective beta-blocker, bisoprolol." | 3.72 | Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection. ( Blann, AD; Chin, BS; Gibbs, CR; Lip, GY, 2003) |
| "To assess the efficacy and tolerability of carvedilol administration in patients with heart failure and concomitant diabetes." | 3.72 | Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. ( Dei Cas, A; Dei Cas, L; Metra, M; Nodari, S, 2003) |
| "Carvedilol and metoprolol are beta(1)-adrenoceptor antagonists that decrease mortality in heart failure." | 3.72 | Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure? ( Doggrell, SA, 2004) |
| "The Carvedilol or Metoprolol European Trial (COMET; Lancet 2003; 362:7-13) found that in patients with heart failure, survival appears to be better with carvedilol than with immediate-release metoprolol tartrate." | 3.72 | In heart failure, all beta-blockers are not necessarily equal. ( Francis, GS; Militello, M; Tang, WH, 2003) |
| "To investigate the effects of carvedilol administration on neurohormonal activation and left ventricular function, carvedilol was added to standard treatment for heart failure in 9 patients with dilated cardiomyopathy due to heart muscle disease." | 3.72 | Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol. ( Bonvicini, M; Bronzetti, G; Donti, A; Formigari, R; Giardini, A; Picchio, FM; Prandstraller, D, 2003) |
| "Body weight and plasma norepinephrine, leptin, and insulin levels were measured in 27 subjects with CHF before and after 6 months of beta-adrenergic receptor blockade with carvedilol or long-acting metoprolol." | 3.72 | Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. ( Androne, AS; Hryniewicz, K; Hudaihed, A; Katz, SD, 2003) |
| "Peak oxygen consumption (VO2) is traditionally used for risk stratification in chronic heart failure (CHF); however, its predictive value is unknown with carvedilol treatment." | 3.72 | Limited predictive value of cardiopulmonary exercise indices in patients with moderate chronic heart failure treated with carvedilol. ( Bosimini, E; Corrà, U; Eleuteri, E; Giannuzzi, P; Mezzani, A; Scapellato, F; Temporelli, PL, 2004) |
| "In a population of previously hospitalised patients with low previous uptake of b-blockers and no uptake of N-LEI, optimal combined uptake of interventions through specialist heart failure services can potentially help prevent or postpone approximately four times as many readmissions and a minimum of twice as many deaths compared with simply optimising uptake of spironolactone (not necessarily requiring specialist services)." | 3.72 | Assessing the impact of heart failure specialist services on patient populations. ( Cook, GA; Edwards, R; Havely, D; Heller, RF; Lyratzopoulos, G; McElduff, P, 2004) |
| "The long-term beta-blockade strategy with carvedilol, metoprolol succinate or bisoprolol is now strongly recommended to reduce the rates of mortality and morbidity in patients with chronic heart failure (CHF)." | 3.72 | Long-term oral carvedilol in chronic heart failure. ( Di Lenarda, A; Moretti, M; Sabbadini, G; Sinagra, G, 2004) |
| " The normalization was predicted by the nonischemic etiology of CHF, arterial hypertension, absence of diabetes mellitus, carvedilol therapy, and the dose of carvedilol." | 3.72 | Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. ( Cioffi, G; Opasich, C; Stefenelli, C; Tarantini, L, 2004) |
| "We prospectively assessed the feasibility, safety, tolerability, and 1-year outcome of the in-hospital initiation of carvedilol in elderly patients admitted for worsening heart failure." | 3.72 | Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure. ( Catania, G; Cioffi, G; De Feo, S; Del Sindaco, D; Di Lenarda, A; Opasich, C; Pulignano, G; Russo, P; Stefenelli, C; Tarantini, L, 2004) |
| "We investigated the contribution of the sympathetic nervous system (SNS) in maintaining the blood pressure and in regulating the cardiac function during and after carvedilol administration in rats with heart failure (group F)." | 3.72 | Hemodynamic effects of carvedilol infusion and the contribution of the sympathetic nervous system in rats with heart failure. ( Abe, Y; Aizawa, Y; Kakemi, M; Kamal, FA; Kashimura, T; Kodama, M; Ma, M; Miyazaki, M; Nagai, Y; Narasimman, G; Sato, S; Suresh, P; Tachikawa, H; Takahashi, T; Tanabe, N; Wahed, MI; Watanabe, K; Wen, J; Yamaguchi, K, 2004) |
| " In this report, we describe 5 cases of severe chronic heart failure due to ACM effectively treated with the beta-blocker, carvedilol." | 3.72 | Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. ( Iwato, K; Kaseda, S; Kyo, T; Mukai, N; Mukai, Y; Nakaike, R; Yoshida, T, 2004) |
| " For all these reasons, the CAPRICORN trial of carvedilol in post-MI left ventricular dysfunction was an important and eagerly awaited trial, which could show that carvedilol treatment post-MI on top of the so-called modern post-MI therapy reduces mortality." | 3.71 | [Beta blockers in post-infarction state]. ( Schultheiss, HP; Tschöpe, C, 2002) |
| "Patients with CHF and COPD tolerated carvedilol well with no significant reversible airflow limitation, but patients with CHF and asthma tolerated carvedilol poorly." | 3.71 | Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. ( Arnold, RH; Glanville, AR; Keogh, AM; Kotlyar, E; Macdonald, PS; McCaffrey, DJ, 2002) |
| "The objective was to determine the dosing, efficacy, and side effects of the nonselective beta-blocker carvedilol for the management of heart failure in children." | 3.71 | Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. ( Addonizio, LJ; Blume, ED; Bruns, LA; Canter, CE; Chrisant, MK; Hallowell, S; Lamour, JM; Pahl, E; Shaddy, RE, 2001) |
| "Carvedilol reduces disease progression in heart failure, but to our knowledge, its effects on hospitalizations and costs have not been evaluated." | 3.71 | Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. ( Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Lacey, MJ; Lukas, MA; Oster, G; Packer, M; Richner, R; Vera-Llonch, M; Young, ST, 2001) |
| "To evaluate prospectively the impact of carvedilol on a short-term physical training program in stable patients with moderate chronic heart failure (CHF), and to analyze parameters predictive of improvement after training." | 3.71 | Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure. ( Bertrand, P; Charbonnier, B; Forissier, JF; Monpère, C; Vernochet, P, 2001) |
| "This study considers the cost-effectiveness of bisoprolol in heart failure patients as an adjunctive therapy to usual treatment." | 3.71 | A cost-effectiveness analysis of bisoprolol for heart failure. ( Varney, S, 2001) |
| "The ANZ trial, a carvedilol study in heart failure, is characterized by a considerable number of early withdrawals in the carvedilol group." | 3.71 | Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial. ( Sharpe, N; Sponer, G; Tillmann, HC; Wehling, M, 2001) |
| "The purpose of this study was to estimate the cost-effectiveness of beta-blocker therapy with either metoprolol or carvedilol in addition to conventional therapy for patients with heart failure (HF) in Canada." | 3.71 | Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. ( Briggs, AH; Demers, C; Levy, AR; O'Brien, BJ, 2001) |
| "Carvedilol therapy reduces mortality from sudden cardiac death and progressive pump failure in congestive heart failure (CHF)." | 3.71 | The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. ( Oto, A; Sade, E; Tokgozoglu, L; Yildirir, A, 2001) |
| "Milrinone and dobutamine are used to manage decompensated heart failure, but their efficacy in patients on beta-blocker therapy was unknown." | 3.71 | Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. ( Bristow, MR; Eichhorn, EJ; Gilbert, EM; Lowes, BD; Tsvetkova, T, 2001) |
| "To examine the ability of myocardial contractile reserve (MCR) assessment to predict the improvement of left ventricular ejection fraction with treatment by carvedilol, a prospective study was undertaken in 85 patients with chronic heart failure and left ventricular ejection fraction < 45%." | 3.71 | Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. ( Bellorini, M; Desnos, M; Fulla, Y; Funck, F; Guillard, N; Hagege, A; Jourdain, P; Loiret, J; Thebault, B, 2002) |
| "Our purpose was to evaluate the clinical effect of carvedilol among pediatric patients with congestive heart failure (CHF) who did not respond to standard therapy and to assess the pharmacokinetics of carvedilol among these children." | 3.71 | Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. ( Behn, F; Eiselt, M; Läer, S; Meibohm, B; Mir, TS; Scholz, H; Venzke, A; Weil, J, 2002) |
| "As experience with beta-blocker use in patients with congestive heart failure is increasing, enthusiasm for carvedilol use in these patients is also increasing." | 3.70 | Possible adverse skin reaction to carvedilol. ( Gutierrez, R; Lo, A; Simpson, SH; Teo, KK; Tsuyuki, RT, 1998) |
| "Carvedilol (Coreg), a beta- and alpha-blocker and an antioxidant drug, was evaluated for moderate to severe heart failure patients in a program containing four United States and one Australia/New Zealand study." | 3.70 | Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. ( Fisher, LD, 1999) |
| "Clinical studies conducted with carvedilol suggest that beta-adrenoceptor antagonism is an effective therapeutic approach to the treatment of heart failure." | 3.70 | In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. ( Aiyar, N; Disa, J; Mitchell, MP; Naselsky, DP; Ohlstein, EH; Ruffolo, RR; Stadel, JM; Storer, BL; Willette, RN; Yue, TL, 1999) |
| "Carvedilol, a nonselective beta-adrenergic blocking drug with alpha-adrenergic blocking and antioxidant properties, has been shown to improve left ventricular function and clinical outcome in patients with mild to moderate chronic heart failure." | 3.70 | Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. ( Aboyoun, CL; Amor, R; Keogh, AM; Lund, M; Macdonald, PS; McCaffrey, DJ, 1999) |
| "In this study, we examine the cost effectiveness of carvedilol for the treatment of chronic heart failure (CHF)." | 3.70 | Cost effectiveness of carvedilol for heart failure. ( Delea, TE; Fowler, MB; Oster, G; Richner, RE; Vera-Llonch, M, 1999) |
| "Despite less than target doses in most patients, a favorable effect of carvedilol on functional class in patients with severe congestive heart failure (CHF) referred for transplant was observed." | 3.70 | Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation. ( Amin, H; Aminbakhsh, A; D'yachkova, Y; Ignaszweski, AP; Mortimer, S; Pamboukian, SV; Thompson, CR, 1999) |
| "To assess the safety and efficacy of carvedilol when administered to heart failure patients already receiving amiodarone." | 3.70 | Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure. ( Aboyoun, C; Amor, R; Keogh, AM; Lund, M; Macdonald, PS; McCaffrey, D, 1999) |
| "The aim of the present study was to assess the effects of carvedilol therapy in addition to conventional heart failure therapy on heart rate variability (HRV) and on left ventricular function in 14 patients with mild to moderate heart failure due to idiopathic dilated cardiomyopathy (IDC)." | 3.70 | [Prospective evaluation of effect of carvedilol therapy on heart rate variability in patients with dilated cardiomyopathy]. ( Grimm, W; Hoffmann, J; Hufnagel, G; Maisch, B; Menz, V, 1999) |
| "A 54-year-old white man with severe heart failure was placed on carvedilol 3." | 3.70 | Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. ( Bristow, MR; Lindenfeld, J; Lowes, BD, 1999) |
| "Carvedilol and at least in some studies, amiodarone have been shown to improve symptoms and prognosis of patients with heart failure." | 3.70 | Combination therapy with carvedilol and amiodarone in patients with severe heart failure. ( Bohlmann, M; Eck, U; Nägele, H; Petersen, B; Rödiger, W, 2000) |
| "Carvedilol is a relatively new drug with beta- and alpha 1-receptor blocking activity and antioxidant effects recently approved for the treatment of congestive heart failure (CHF)." | 3.70 | Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. ( Boike, S; Boyle, D; Brozena, S; Fesniak, HF; Ilson, B; Jorkasky, D; Tenero, D, 2000) |
| "Carvedilol has been shown to be beneficial for patients with heart failure, but it is not clear how it should be initiated in routine clinical practice, particularly in the elderly." | 3.70 | Experience of commencing Carvedilol in elderly patients with heart failure in a routine outpatient clinic. ( Owen, A, 2000) |
| "The Coreg (brand of carvedilol; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) Heart Failure Registry (COHERE) is intended to collect data on outcomes and other clinical variables in a typical HF population and to observe experience with carvedilol in the hands of community practitioners." | 3.70 | Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians. ( Abraham, WT; Chen, T; Fowler, M; Franciosa, JA; Gilbert, EM; Greenberg, B; Lukas, MA; Massie, BM; Nelson, JJ, 2000) |
| " Recently completed mortality studies with beta-blockers (BB) in chronic heart failure CIBIS II and MERIT HF confirmed the conclusions of pilot studies with carvedilol that in stabilized chronic heart failure BB reduces the mortality rate as well as the need of hospital admission on account of deteriorating heart failure." | 3.70 | [Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice]. ( Spinar, J; Vítovec, J, 2000) |
| "We retrospectively performed stepwise logistic regression analysis on 1,509 patients with chronic heart failure in 4 multicenter United States studies and 1 Australia-New Zealand study to examine the effect of digoxin in patients randomized to carvedilol or placebo." | 3.70 | Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure. ( Eichhorn, EJ; Lukas, MA; Shusterman, N; Wu, B, 2000) |
| "Retrospective analysis of tolerance to carvedilol in patients with chronic heart failure." | 3.70 | Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. ( Krum, H; MacDonald, P; Ninio, D, 2000) |
| "In this study we observed that carvedilol administration to patients with heart failure improves hemodynamic function, baroreflex sensitivity, and heart rate variability." | 3.70 | Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure. ( Cacciafesta, M; Celli, V; Lionetti, M; Luparini, RL; Marigliano, V; Moisè, A; Piccirillo, G, 2000) |
| "To determine the effect of beta blockade on parasympathetic nervous system activity, we assessed RR variability during 24-hour Holter monitoring in 10 patients with congestive heart failure before and after 3 to 4 months of treatment with the beta blocker carvedilol." | 3.69 | Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. ( Bigger, JT; Bloomfield, DM; Goldsmith, RL; Krum, H; Packer, M; Sackner-Bernstein, J; Steinman, RC, 1997) |
| " In the CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-Scale Randomized Controlled Trial), patients with STEMI with successful percutaneous coronary intervention with an LVEF of ≥40% were randomly assigned to carvedilol or no β-blocker therapy." | 3.30 | Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction. ( Akao, M; Amano, M; Bingyuan, B; Furukawa, Y; Inada, T; Inuzuka, Y; Izumi, C; Kadota, K; Kaji, S; Kimura, T; Minamimoto, Y; Miyake, M; Morimoto, T; Nakagawa, Y; Ozasa, N; Suwa, S; Suzuki, T; Tamura, T; Watanabe, H, 2023) |
| " The present study aimed to investigate in a large database of HFrEF patients (MECKI score database) the association of β-blocker treatment with a composite outcome of cardiovascular death, urgent heart transplantation or left ventricular assist device implantation, addressing the role of β-selectivity and dosage regimens." | 2.84 | Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. ( Agostoni, P; Apostolo, A; Badagliacca, R; Battaia, E; Belardinelli, R; Binno, S; Bonomi, A; Bussotti, M; Caravita, S; Carubelli, V; Cattadori, G; Cicoira, M; Clemenza, F; Contini, M; Corrà, U; Correale, M; Di Lenarda, A; Emdin, M; Frigerio, M; Gentile, P; Guazzi, M; Iorio, A; Lagioia, R; Limongelli, G; Lombardi, C; Magrì, D; Mapelli, M; Marchese, G; Metra, M; Mezzani, A; Minà, C; Oliva, F; Pacileo, G; Palermo, P; Paolillo, S; Parati, G; Passantino, A; Passino, C; Pastormerlo, L; Perrone Filardi, P; Piepoli, M; Raimondo, R; Re, F; Ricci, R; Salvioni, E; Scardovi, AB; Sciomer, S; Scrutino, D; Sinagra, G; Spadafora, E; Veglia, F; Zambon, E, 2017) |
| " Randomized clinical trials and meta-analyses have clearly demonstrated that the long-term use of β-Blockers improves the outcome of patients with HF." | 2.82 | Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial. ( Park, K; Park, TH, 2016) |
| "Treatment with carvedilol was associated with a significantly decreased risk of hospitalization for HF or death when compared with metoprolol (hazard ratio [HR]: 0." | 2.78 | Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). ( Alexis, J; Jons, C; McNitt, S; Moss, AJ; Ruwald, AC; Ruwald, MH; Zareba, W, 2013) |
| "During the mean 3-year follow-up, resting heart rate (HR) and BNP were significantly reduced with dose-response relations in the early period but without dose-response relations in the late period." | 2.78 | Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. ( Azuma, J; Fujio, Y; Hori, M; Izumi, T; Kitabatake, A; Matsuzaki, M; Nagai, R; Nonen, S; Ohashi, Y; Okamoto, H; Tsutsui, H; Yamazaki, T; Yoshikawa, T, 2013) |
| "Bisoprolol was started at 1." | 2.76 | Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. ( Arisi, G; Caminiti, G; Iellamo, F; Madonna, M; Marazzi, G; Massaro, R; Righi, D; Rosano, GM; Volterrani, M, 2011) |
| "Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and underdosing." | 2.76 | Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. ( Kovacic, D; Lainscak, M; Podbregar, M; Rozman, J; von Haehling, S, 2011) |
| "Cardiac resynchronization therapy (CRT), combined with optimal medical therapy (OMT), is an established treatment for patients with advanced chronic heart failure (ACHF)." | 2.76 | CArdiac resynchronization in combination with beta blocker treatment in advanced chronic heart failure (CARIBE-HF): the results of the CARIBE-HF study. ( Bisetti, S; Cantù, F; De Luca, A; De Santo, T; Gavazzi, A; Gori, M; Grosu, A; Iacovoni, A; Senni, M, 2011) |
| "Beta-blockers are mainstay of current treatment of heart failure (HF)." | 2.75 | Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. ( Bettari, L; Bugatti, S; Covolo, L; Dei Cas, L; Donato, F; Gelatti, U; Giubbini, R; Lombardi, C; Metra, M; Pezzali, N; Romeo, A; Zacà, V, 2010) |
| "In subjects with COPD, forced expiratory volume in 1 s was lowest with carvedilol and highest with bisoprolol (carvedilol 1." | 2.75 | Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. ( Coleman, CF; Elsik, M; Hayward, CS; Jabbour, A; Keogh, AM; Kotlyar, E; Krum, H; Macdonald, PS; Mellemkjaer, S, 2010) |
| "Heart failure is one of the most serious complications in Duchenne muscular dystrophy (DMD)." | 2.75 | Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. ( Kawai, M; Kikuchi, Y; Kuru, S; Matsumura, T; Tamura, T, 2010) |
| "metoprolol were 10." | 2.74 | Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. ( Cleland, JG; Kenyon, KW; Komajda, M; Levy, WC; Linker, DT; Metra, M; Mozaffarian, D; Poole-Wilson, PA; Remme, WJ; Torp-Pedersen, C, 2009) |
| "Carvedilol was initiated at a dose of 0." | 2.74 | Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease. ( Ando, M; Hatai, Y; Mori, K; Murakami, Y; Nishiyama, M; Park, IS; Takahashi, Y; Yoshikawa, T, 2009) |
| " By simplifying the medical regimen, once-daily dosing can potentially improve compliance." | 2.74 | Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart F ( Hauptman, PJ; Lukas, MA; Massaro, J; Ordronneau, P; Pressler, SJ; Sackner-Bernstein, J; Udelson, JE, 2009) |
| "Beta-blocker treatment of stable heart failure in primary care." | 2.74 | Beta-blocker treatment of stable heart failure in primary care. ( Barroso, A; Bernáldez, MJ; Domingo, M; Domíngueza, M; Pie, M; Sancho, F; Simó, M; Verdú Rotellar, JM, 2009) |
| " The purpose of this study was to evaluate the effects of the polymorphism on pharmacokinetics of carvedilol by population pharmacokinetic analysis." | 2.73 | Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. ( Kitabatake, A; Kiyokawa, M; Okamoto, H; Sugawara, M; Takekuma, Y; Takenaka, T; Tsutsui, H; Yamazaki, K, 2007) |
| "4% for those with a reduced dosage (n." | 2.73 | Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. ( Cleland, JG; Dei Cas, L; Di Lenarda, A; Komajda, M; Metra, M; Poole-Wilson, PA; Remme, WJ; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Heart failure is one of the leading death reasons in the world." | 2.73 | Carvedilol therapy is associated with an improvement in left atrial appendage function in patients with congestive heart failure. ( Acikel, M; Arslan, S; Bozkurt, E; Erol, MK; Gundogdu, F; Gurlertop, Y; Senocak, H; Sevimli, S; Yilmaz, M, 2007) |
| "Carvedilol was associated with conventional optimised treatment in 64% of diabetics and 65% of non-diabetics (P = NS)." | 2.73 | Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. ( Cioffi, G; De Feo, S; Del Sindaco, D; Di Lenarda, A; Giovannini, E; Leggio, F; Minardi, G; Opasich, C; Pulignano, G; Tarantini, L, 2007) |
| " Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol." | 2.73 | Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. ( Ahuja, K; Hirsh, DS; Jorde, UP; Kasper, ME; Khandwalla, RM; Tseng, CH; Vittorio, TJ; Zolty, R, 2008) |
| "Carvedilol therapy was then initiated." | 2.71 | Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly? ( de Albuquerque, DC; Filho, FM; Gerk, AR; Gouvea, EP; Perin, EC; Rocha, RM; Santos, VM; Silva, GV, 2003) |
| "The use of beta-blockers for the treatment of heart failure in the United States is inadequate, despite available data and current guidelines that support their use." | 2.71 | Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. ( Gattis, WA; O'Connor, CM, 2004) |
| "Beta-blockers substantially improve survival in patients with chronic heart failure (HF) with left ventricular systolic dysfunction, but concerns about cardiovascular adverse effects may deter physicians from prescribing this therapy." | 2.71 | Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. ( Coffey, CS; Curtis, JP; Foody, JM; Hebert, PR; Ko, DT; Krumholz, HM; Sedrakyan, A, 2004) |
| "10, NYHA III-IV 29%) to treatment with either bisoprolol or carvedilol, in order to assess and compare the maximally achievable number of patients on treatment with these BB and the maximally achieved dosage during a minimum of 2 months attendance at our out patient heart failure clinic." | 2.71 | Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison. ( Atar, D; Galatius, S; Gustafsson, F; Hildebrandt, PR, 2004) |
| "Treatment with carvedilol compared with metoprolol offers additional benefits among patients with atrial fibrillation." | 2.71 | Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. ( Charlesworth, A; Cleland, J; Hanrath, P; Komajda, M; Metra, M; Olsson, LG; Poole-Wilson, P; Swedberg, K; Torp-Pedersen, C, 2005) |
| "Fatigue, but not breathlessness, remained a significant predictor for developing worsening heart failure (RR 1." | 2.71 | Symptoms in patients with heart failure are prognostic predictors: insights from COMET. ( Charlesworth, A; Cleland, JG; Ekman, I; Metra, M; Poole-Wilson, PA; Swedberg, K, 2005) |
| "Carvedilol treatment caused a significant reduction in CANESP while metoprolol had a neutral effect (-95+/-27 vs." | 2.71 | Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. ( Al-Hesayen, A; Azevedo, ER; Floras, JS; Hollingshead, S; Lopaschuk, GD; Parker, JD, 2005) |
| " The dosage of beta-blockers were increased gradually to target or the tolerant dosages (bisoprolol 10 mg qd, carvedilol 25 mg bid) during 3 months in 36 patients." | 2.71 | [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure]. ( Bian, WY; Duan, B; Jia, X; Li, W; Li, YS; Wang, F; Wang, L; Xu, ZM, 2005) |
| "Treatment with carvedilol was associated with significant increases in total frequency power, very low frequency power, high frequency power, SDNN, the root-mean square of difference of successive RRs, and pNN50." | 2.71 | Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. ( Alharethi, R; Bristow, MR; Bullinga, JR; Gilbert, EM; Schram, MS, 2005) |
| " The trial data will determine if in-hospital initiation of beta-blocker therapy is effective at improving the long-term use of pharmacologic agents proven to reduce morbidity and mortality." | 2.70 | The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. ( Gattis, WA; Gheorghiade, M; O'Connor, CM, 2002) |
| "Carvedilol was well tolerated both during dose titration and during maintenance therapy." | 2.70 | [Long term use of a non-selective beta-blocker with vasodilating properties carvedilol in patients with severe heart failure]. ( Gruzdev, AK; Iosava, IK; Sidorenko, BA; Vasechkin, SS; Zaikin, SY, 2002) |
| "Metoprolol is a beta(1)-selective beta-adrenergic antagonist while carvedilol is a non-selective beta-blocker with additional blockades of alpha(1)-adrenoceptors." | 2.70 | Differing beta-blocking effects of carvedilol and metoprolol. ( Fruhwald, FM; Klein, W; Koshucharova, G; Maier, R; Stoschitzky, K; Watzinger, N; Zweiker, R, 2001) |
| "Previous studies in patients with congestive heart failure (CHF) have revealed abnormalities of cellular volume that might have an impact on the dysregulation of peripheral vascular resistance." | 2.70 | Impact of pharmacotherapy on lymphocyte volumes and activity of the Na+/H+ exchanger in patients with congestive heart failure. ( Bertsch, T; Feuring, M; Jester, I; Kugler, I; Schmidt, BM; Tillmann, HC; Wehling, M, 2001) |
| "2%) and 4 others who were subsequently unable to withstand the progressive stepping up of drug dosage (8." | 2.69 | [Tolerance and efficacy of carvedilol prescription in patients with mild to moderated chronic heart failure]. ( Barnay, P; Gelisse, R; Levy, S; Maixent, JM; Paganelli, F; Saadjian, A; Sbragia, P, 2000) |
| "Peak reactive hyperemia (mL." | 2.68 | Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. ( Bijou, R; Demopoulos, L; Gentilucci, M; Jones, M; Katz, SD; LeJemtel, TH; Mancini, D; Testa, M; Yeh, M, 1997) |
| "Carvedilol is a new drug which possesses a balanced combination of vasodilatation and beta-blockade." | 2.67 | The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. ( Broadhurst, P; DasGupta, P; Lahiri, A, 1991) |
| "There is not enough evidence to support or discourage the use of beta-blockers in children with congestive heart failure, or to propose a paediatric dosing scheme." | 2.66 | Beta-blockers for congestive heart failure in children. ( Al Dakhoul, S; Alabed, S; Bdaiwi, Y; Sabouni, A, 2020) |
| "There is not enough evidence to support or discourage the use of beta-blockers in children with congestive heart failure, or to propose a paediatric dosing scheme." | 2.53 | Beta-blockers for congestive heart failure in children. ( Al Dakhoul, S; Alabed, S; Bdaiwi, Y; Frobel-Mercier, AK; Sabouni, A, 2016) |
| "β-blockers are an important treatment of heart failure (HF) and are useful in reducing the progression of the syndrome." | 2.48 | β-blockers in stage B: a precursor of heart failure. ( Francis, GS; Sarraf, M, 2012) |
| "Metoprolol was significantly superior to carvedilol (P = 0." | 2.48 | β-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients. ( Cheng, XJ; He, YM; Li, X; Qian, YX; Xu, HF; Yang, XJ; Zhao, X, 2012) |
| "Carvedilol is a beta(1)- and beta(2)-adrenergic receptor antagonist with additional vasodilatory alpha(1)-blocking properties." | 2.45 | Role of carvedilol controlled-release in cardiovascular disease. ( Fonarow, GC, 2009) |
| "Carvedilol use has been adapted into pediatric heart failure practice although data supporting its efficacy in infants and children are scarce." | 2.43 | The use of carvedilol in pediatric heart failure. ( Benson, LN; Greenway, SC, 2006) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| " Based on this evidence, it is now recommended to add beta-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis." | 2.43 | The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. ( De Freitas, O; Fornoni, A; Lenz, O; Materson, BJ, 2006) |
| "Carvedilol was generally well tolerated in patients with CHF." | 2.42 | Carvedilol: a review of its use in chronic heart failure. ( Jarvis, B; Keating, GM, 2003) |
| "Heart failure is associated with increased sympathetic nervous stimulation that results in down-regulation of myocardial beta-1 receptors." | 2.42 | Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. ( Ahmed, A, 2003) |
| " We analyze the problems with the trial design of COMET from the standpoint of comparing 2 therapeutic agents at different positions on a common dose-response curve, and discuss the theoretical reasons why postjunctional adrenergic receptor blockade that is in addition to beta1-receptor antagonism will likely produce only minimal or no incremental benefit in chronic heart failure." | 2.42 | Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? ( Adams, KF; Bristow, MR; Feldman, AM; Goldstein, S, 2003) |
| " Pharmacokinetic and pharmacodynamic analyses, however, indicate that the dosing regimen of metoprolol selected for use in the COMET trial produces a magnitude and time course of beta(1)-blockade during a 24-hour period that is similar to the dose of carvedilol targeted for use in the trial." | 2.42 | Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. ( Packer, M, 2003) |
| " These include the choice of dose and dosage regimen of immediate-release metoprolol tartrate, a dosage form that has never been shown to reduce mortality in patients with heart failure." | 2.42 | Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial. ( Bauman, JL; Talbert, RL, 2004) |
| "Patients with chronic obstructive pulmonary disease (COPD) have airflow obstruction that leads to dynamic lung hyperinflation and reduced ventilatory response to exercise." | 2.42 | Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. ( Jelic, S; Le Jemtel, TH; Sirak, TE, 2004) |
| " Results from the recently published trials are summarized to emphasize the proper selection and dosage of beta blocker therapy to optimize the care of this high risk population." | 2.42 | The effects of beta blockers on morbidity and mortality in heart failure. ( Jafri, SM, 2004) |
| "Carvedilol is an inherently long-acting beta-blocker while the duration of beta blockade for metoprolol is dependent on the salt and formulation, which is used." | 2.42 | Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. ( Talbert, RL, 2004) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | 2.41 | [Prevention and treatment of congestive heart failure in diabetic patients]. ( Anguita Sánchez, M, 2002) |
| "Conversely, in individuals with chronic congestive heart failure, the sustained, heightened activation of adrenergic nervous system, as manifested by increases in circulating catecholamines, results in down- regulation and desensitization of myocardial beta-ARs, and potentially, significant myocardial damage." | 2.41 | Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure. ( Gilbert, EM; Port, JD, 2000) |
| "Carvedilol is a beta-blocker with ancillary properties." | 2.41 | Carvedilol versus other beta-blockers in heart failure. ( Doggrell, SA, 2001) |
| "Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential." | 2.41 | Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. ( Cheng, J; Kamiya, K; Kodama, I, 2001) |
| " To date, controlled clinical trials performed in more than 13,000 patients with chronic heart failure have consistently shown that the long term administration of beta-blockers is associated with significant improvement in left ventricular function, clinical symptoms, and survival." | 2.41 | [Role of beta-blockers in the treatment of chronic heart heart failure]. ( Czuriga, I; Edes, I, 2001) |
| "Congestive heart failure is a major public health problem in Western countries." | 2.40 | Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results. ( Doughty, RN; Sharpe, N, 1997) |
| "This ability to decrease the risk of disease progression led to the recent approval of carvedilol for the treatment of chronic heart failure by the US Food and Drug Administration." | 2.40 | Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. ( Packer, M, 1997) |
| "Carvedilol is a novel multiple-action neurohormonal antagonist that has been shown to be effective in the management of congestive heart failure." | 2.40 | Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1998) |
| "Today congestive heart failure due to underlying coronary heart disease is by far more common than the hypertension-induced variety." | 2.40 | Hypertension-induced congestive heart failure. ( Hansson, L, 1998) |
| "Carvedilol, which has beta-blocking, alpha-blocking, and antioxidant properties, is associated with a reduction in hospitalizations and symptoms and improvements in ejection fraction it also appears to reduce mortality, although confirmatory studies are needed." | 2.40 | Catecholamines and their blockade in congestive heart failure. ( White, CM, 1998) |
| "Carvedilol is a multiple-action neurohormonal antagonist that is effective in slowing the progression of CHF." | 2.40 | Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. ( Feuerstein, GZ; Ruffolo, RR, 1998) |
| "Carvedilol is a non-selective beta-adrenergic blocking drug with vasodilatory properties that has been recently approved by the U." | 2.40 | Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life? ( Fowler, MB, 1998) |
| "Patients with hypertension are at increased risk of developing heart failure (HF), but the mechanisms by which hypertension leads to HF have not been clarified [although left ventricular hypertrophy (LVH) is clearly a predictor of an increased risk of HF]." | 2.40 | Progression from hypertension to heart failure. Mechanisms and management. ( Cleland, JG, 1999) |
| "Furthermore, beta-blockers delay disease progression in CHF by reversing the pathological myocardial remodelling process that accompanies the disease." | 2.40 | Sympathetic activation and the role of beta-blockers in chronic heart failure. ( Krum, H, 1999) |
| "Carvedilol is a beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade." | 2.38 | Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. ( Campoli-Richards, D; McTavish, D; Sorkin, EM, 1993) |
| "Carvedilol is a dual-acting drug designed to produce two complementary effects: beta-blockade and vasodilation." | 2.38 | Vasodilatory action of carvedilol. ( Bartsch, W; Müller-Beckmann, B; Sponer, G; Strein, K, 1992) |
| " The dose-response relationship between the administered beta blockers and respiratory rates was examined using multivariable regression models." | 1.91 | Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study. ( Nagamine, T; Takayama, A; Yoshioka, T, 2023) |
| "Carvedilol vs metoprolol was also associated with a 16% reduction in the risk of fast VA." | 1.91 | Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients. ( Aktaş, MK; Chen, AY; Diamond, A; Goldenberg, I; Kutyifa, V; McNitt, S; Polonsky, B; Sampath, R; Steinberg, JS; Younis, A; Zareba, W, 2023) |
| "Although liver cirrhosis complicated with chylothorax is rare, several case reports have shown all patients with chylothorax caused by liver cirrhosis were transudative." | 1.72 | [Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report]. ( Higashizawa, T; Hisatake, Y; Kitagawa, K; Kondo, M; Noda, M; Okamura, Y; Sekine, C; Sunaga, S; Teramoto, K, 2022) |
| "Carvedilol was prescribed in 7 331 patients treated for HF (9." | 1.62 | Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic. ( Aiglova, R; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M, 2021) |
| "Metoprolol treatment did not significantly decrease the mRNA expression of myocardial SERCA2a in the unloaded heart after 2 weeks." | 1.62 | Effects of carvedilol and metoprolol on the myocardium during mechanical unloading in a rat heterotopic heart transplantation model. ( Kil, HR; Kim, G; Lee, SS; Quan, C, 2021) |
| "The treatment of heart failure has changed with the use of angiotensin-converting enzyme inhibitors (ACEIs) and beta-blockers since the middle of the 1990s." | 1.51 | Improvement of the outcome in patients with infantile dilated cardiomyopathy over three decades - The usefulness of long-term gradually medical supportive care. ( Kitano, M; Tsuda, E; Yamada, O, 2019) |
| "Treatment with carvedilol directly improved the systolic function of the right and left ventricles." | 1.48 | Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot. ( Hirata, Y; Inaba, T; Ishikawa, Y; Komuro, I; Saito, A; Soma, K; Yao, A, 2018) |
| "Carvedilol is an effective additional therapy for the patients with chronic heart failure already receiving Amiodarone." | 1.46 | THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS. ( Khintibidze, I; Tsetskhladze, E, 2017) |
| "Bisoprolol was found to reduce mortality and CHF exacerbation compared to carvedilol and metoprolol." | 1.46 | The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study. ( Chen, CY; Huang, YB; Kuo, CC; Liao, KM; Lin, TY, 2017) |
| "The long-term use of β-blockers has been shown to improve clinical outcomes among patients with heart failure (HF)." | 1.46 | Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. ( Bouvier, M; de Denus, S; Deblois, D; Dorais, M; Dubé, MP; Haibe-Kains, B; Jenna, S; Leduc, R; Perreault, S; Rouleau, JL; Tardif, JC; White, M; White-Guay, B, 2017) |
| " After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR) = 0." | 1.43 | Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease. ( Chang, YS; Chen, TJ; Chou, KT; Hu, YW; Hung, MH; Lee, FY; Liu, CJ; Ou, SM; Perng, DW; Su, VY; Yang, KY, 2016) |
| " For such a drug, the pathophysiological changes occurring in CHF can have a profound impact on PK, and thus the resulting pharmacodynamic response, of both enantiomers." | 1.43 | Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach. ( Khalil, F; Läer, S; Rasool, MF, 2016) |
| "Echocardiography showed 73% dilated cardiomyopathy; 83% showed moderate to severe LV systolic dysfunction (mean EF 36." | 1.43 | Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti. ( Malebranche, R; Morisset, PH; Raphael, NA; Tabou Moyo, C; Wilentz, JR, 2016) |
| "Chronic obstructive pulmonary disease (COPD) is present in approximately one-third of all congestive heart failure (CHF) patients, and is a key cause of underprescription and underdosing of β-blockers, largely owing to concerns about precipitating respiratory deterioration." | 1.42 | Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. ( Asai, K; Furuse, E; Kubota, Y; Murai, K; Nakamura, S; Shimizu, W; Tsukada, YT, 2015) |
| "We here report a HF patient with left bundle branch block due to nonischemic cardiomyopathy who did not respond to 20 mg/day of carvedilol in terms of LVRR." | 1.42 | Reverse Remodeling Achieved by Combination Therapy With High-Dose Beta Blocker and Cardiac Resynchronization. ( Imamura, T; Kinugawa, K; Muraoka, H, 2015) |
| " Carvedilol maintenance dosage was lower in patients with preserved EF (7." | 1.39 | Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol. ( Hiramatsu, K; Kobayashi, F; Mori, Y; Nishikawa, Y, 2013) |
| "Carvedilol is a novel third generation non-selective β-blocker." | 1.38 | Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function. ( Afonso, L; Ali Kizilbash, M; Badheka, AO; Bharadwaj, A; Rathod, A; Tuliani, TA, 2012) |
| "The heart failure was modeled in rats by ligation of the coronary artery." | 1.37 | [Effects of carvedilol and proxodolol on nitric oxide (NO) metabolism in various organs in a congestive heart failure model]. ( Medvedev, OS; Shashurin, DA; Timoshin, AA; Vanin, AF, 2011) |
| "Carvedilol is a non-selective β- and α-blocker enantiomer with antioxidant effects that are attributed to its carbazole moiety." | 1.37 | Novel design and synthesis of modified structure of carvedilol. ( Hashemzadeh, M; Hill, DN; Movahed, MR; Russu, WA; Soroush, L, 2011) |
| "The animal model of congestive heart failure was established by coarctation of abdominal aorta." | 1.37 | [Effect of carvedilol and Radix astragali on ryanodine receptor in heart failure in mice]. ( Li, R; Yi, QJ; Zhang, Q, 2011) |
| " We evaluated relation in HF patients among cytokines and asymmetric dimethylarginine (ADMA) and left ventricular ejection fraction (LVEF) at baseline and after long-term administration of carvedilol." | 1.35 | Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. ( Alfieri, AB; Arioli, F; Bassanelli, G; Briceno, L; Cuko, A; Fragasso, G; Margonato, A; Montano, C; Palloshi, A; Ruotolo, G; Spoladore, R, 2008) |
| " In the first 60 to 90 days after hospital discharge, little up-titration in beta-blocker dosing occurs." | 1.35 | Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). ( Abraham, WT; Albert, NM; Fonarow, GC; Gheorghiade, M; Greenberg, BH; O'Connor, CM; Stough, WG; Sun, JL; Yancy, CW; Young, JB, 2008) |
| "Insulin resistance is prevalent in heart failure (HF) patients, and beta2 adrenergic receptors (beta2-AR) are involved in glucose homeostasis." | 1.35 | The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker. ( Detry, MA; Johnson, MR; Moran, JJ; Sweitzer, NK; Vardeny, O, 2008) |
| "The prevalence of COPD was 39." | 1.35 | Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. ( Azevedo, A; Bettencourt, P; Lopes, R; Lourenço, P; Mascarenhas, J, 2008) |
| "Beta-blocker dosing in community HF appears lower than in randomized clinical trials, especially when prescribed by noncardiologists." | 1.34 | Beta-blocker dosing in community-based treatment of heart failure. ( Abraham, WT; Fowler, MB; Franciosa, JA; Gilbert, EM; Greenberg, B; Lottes, SR; Lukas, MA; Massie, BM; Nelson, JJ, 2007) |
| "Treatment with carvedilol in the shunt group reversed the heart weight and ventricular dimension to the baseline values." | 1.33 | Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure. ( Chang, H; Kuan, P; Lu, MJ; Shyu, KG; Sun, HY; Wang, BW, 2005) |
| "Heart failure is characterized by limited exercise tolerance and by a skeletal muscle myopathy with atrophy and shift toward fast fibres." | 1.33 | Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol. ( Angelini, A; Dalla Libera, L; Danieli Betto, D; Germinario, E; Gobbo, V; Ravara, B; Vescovo, G, 2005) |
| "Carvedilol is a combined alpha(1)- and beta-adrenoceptor antagonist." | 1.33 | Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure. ( Bøkenes, J; Osnes, JB; Qvigstad, E; Schiander, I; Sejersted, OM; Sjaastad, I; Skomedal, T; Solberg, L, 2005) |
| " The relationship between these two phenomena and the suitable dosage of carvedilol remains unclear." | 1.33 | Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart. ( Hu, SJ; Hu, Y; Sun, YL; Wang, LH; Zhou, JY, 2005) |
| " Therefore we analyzed 24-h ECG Holter recordings from a study which compared the long-term clinical efficacy of metoprolol tartrate to carvedilol in chronic heart failure patients using the same dosing regimen as in COMET." | 1.33 | Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure? ( Chan, SK; Fung, JW; Leung, LY; Sanderson, JE; Yip, GW; Yu, CM, 2005) |
| "Carvedilol was administered through direct gastric gavage." | 1.33 | [Effect of carvedilol on ryanodine receptor in heart failure]. ( Li, R; Liu, XY; Qian, YR; Yi, QJ, 2005) |
| "Mean carvedilol dose achieved was 31." | 1.33 | Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. ( Abraham, G; Fruhwald, F; Hill, J; Kragten, JA; Krum, H; Poy, C; Sharpe, C; Zhu, JR, 2006) |
| "Heart failure is correlated with attenuation of parasympathetic nervous function and enhanced sympathetic activity." | 1.33 | Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. ( Kang, XQ; Li, M; Lu, J; Xu, XL; Yu, XJ; Zang, WJ, 2006) |
| "Carvedilol was then commenced and up titrated over the next 6-8 weeks and all samples were again obtained." | 1.33 | Carvedilol reduces aldosterone release in systolic heart failure. ( Aggarwal, A; Campbell, DJ; Wong, J, 2006) |
| "Treatment with carvedilol in the shunt group reversed the increase in heart weight and ventricular dimension to the baseline values." | 1.33 | Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. ( Chang, H; Lu, MJ; Shyu, KG; Sun, HY; Wang, BW, 2006) |
| " The pharmacokinetic (PK)/pharmacodynamic (PD) relation between S(-)-carvedilol concentration-the enantiomer with beta-blocking activity-and change in exercise-induced heart rate was defined in healthy subjects and was best described using a direct effect inhibitory E(max) model (with E(max) being the maximum effect)." | 1.33 | Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. ( Baidoo, CA; Boyle, D; Campanile, AM; Henderson, LS; Tenero, DM, 2006) |
| "Carvedilol is a non-selective beta-blocker with alpha-receptor blockade and antioxidant properties." | 1.32 | Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure. ( Doye, AA; Gwathmey, JK; Hajjar, RJ; Jabbour, G; Laste, N; Lebeche, D; Lee, MX; Okafor, CC; Perreault-Micale, C; Skiroman, K, 2003) |
| "Carvedilol treatment for CHF patients is a highly cost-effective method of therapy in the Japanese medical environment." | 1.32 | Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan. ( Inomata, T; Izumi, T; Kobayashi, M, 2004) |
| "beta-blockers (BB) in the treatment of heart failure (HF) are frequently underprescribed and underdosed, perhaps because of recommendations for office visits at each dose change." | 1.32 | Remote titration of carvedilol for heart failure patients by advanced practice nurses. ( Mischke, L; Moyer-Knox, D; Mueller, TM; Vuckovic, K; Williams, RE, 2004) |
| "Carvedilol was shown to be well tolerated and effective in elderly heart failure patients in the observational COLA II study." | 1.32 | Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. ( Clark, AL; Cleland, JG; Coletta, AP; Freemantle, N, 2004) |
| "35 +/- 1 months, the daily dosage of carvedilol was 49." | 1.32 | Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure. ( Boffa, GM; Iliceto, S; Orlando, S; Razzolini, R; Tarantini, G, 2004) |
| "Management of heart failure is estimated to consume 1% to 2% of total healthcare resources and recent data from the UK suggests this may be as high as 4% with hospital admissions accounting for approximately 70% of this expenditure." | 1.31 | Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland. ( Barry, M, 2002) |
| "Carvedilol treatment was even cost-effective in severe disease." | 1.31 | [Beta blockers in heart failure therapy with special reference to the COPERNICUS Study]. ( Hartmann, F; Katus, HA, 2002) |
| "Carvedilol is a nonselective beta-adrenoceptor antagonist with additional alpha 1-receptor-blocking properties." | 1.31 | [Hormonal hyperactivity in heart failure. Differences in beta blockers]. ( Beuckelmann, DJ, 2002) |
| "Metoprolol was 35-fold beta(1)-selective and lacked guanine nucleotide modulatable binding." | 1.31 | Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. ( Böhm, M; Cremers, B; Flesch, M; Höper, A; Maack, C; Südkamp, M, 2000) |
| "Congestive heart failure is associated with impaired endothelial function in the peripheral systemic vasculature and with systemic release of inflammatory cytokines." | 1.31 | Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. ( Dimmeler, S; Freyssinet, JM; Haendeler, J; Hugel, B; Mallat, Z; Rössig, L; Tedgui, A; Zeiher, AM, 2000) |
| "Patients with Becker muscular dystrophy-related cardiomyopathy typically survive into their 30s, when they succumb to complications of cardiomyopathy or receive heart transplants." | 1.31 | Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy. ( Doing, AH; Renlund, DG; Smith, RA, 2002) |
| " We report the use of a short-acting intravenous beta blocker in combination with inotropic therapy as a means to bridge five patients with advanced heart failure to chronic oral beta blockade; two of these patients had been chronically managed with intravenous inotrope." | 1.31 | Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. ( Hauptman, PJ; Prirzker, MR; Woods, D, 2002) |
| "Patients with congestive heart failure (CHF) have alterations in the traditional and nonlinear indices of heart rate (HR) dynamics, which have been associated with an increased risk of mortality." | 1.31 | Effects of carvedilol on heart rate dynamics in patients with congestive heart failure. ( Castellanos, A; Chakko, S; de Marchena, E; Huikuri, HV; Lopera, G; Mäkikallio, TH; Myerburg, RJ; Pastor, J; Ridha, M, 2002) |
| "Carvedilol was recently approved for the treatment of congestive heart failure, and bucindolol is currently in large clinical trials for this indication." | 1.30 | Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. ( Lukas, MA; Mitchell, MP; Ohlstein, EH; Ruffolo, RR; Willette, RN, 1998) |
| "Carvedilol was well tolerated by 16 (76%) patients." | 1.30 | [Effects of carvedilol (beta 1, beta 2, alpha 1 bloker) on refractory congestive heart failure]. ( Bacal, F; Bellotti, G; Bocchi, EA; Carrara, D; Ramires, JA, 1998) |
| "This drug was developed for congestive heart failure in a series of trials, four in the United States and one in Australia and New Zealand, briefly summarized in this document." | 1.30 | Carvedilol and the Food and Drug Administration approval process: an introduction. ( Fisher, LD; Moyé, LA, 1999) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| " Exercise testing, radionuclide ventriculography, and right-sided cardiac catheterization were performed and intraarterial blood pressure measured before and after 8 weeks of carvedilol therapy in a dosage of 12." | 1.28 | Value of carvedilol in congestive heart failure secondary to coronary artery disease. ( Broadhurst, P; Das Gupta, P; Lahiri, A; Raftery, EB, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 118 (14.34) | 18.2507 |
| 2000's | 499 (60.63) | 29.6817 |
| 2010's | 178 (21.63) | 24.3611 |
| 2020's | 28 (3.40) | 2.80 |
| Authors | Studies |
|---|---|
| Onohuean, H | 1 |
| Al-Kuraishy, HM | 1 |
| Al-Gareeb, AI | 1 |
| Qusti, S | 1 |
| Alshammari, EM | 1 |
| Batiha, GE | 1 |
| Schwartz, B | 2 |
| Pierce, C | 1 |
| Madelaire, C | 1 |
| Schou, M | 1 |
| Kristensen, SL | 1 |
| Gislason, GH | 2 |
| Køber, L | 5 |
| Torp-Pedersen, C | 23 |
| Andersson, C | 1 |
| Park, CS | 2 |
| Park, JJ | 3 |
| Lee, HY | 4 |
| Kang, SM | 4 |
| Yoo, BS | 4 |
| Jeon, ES | 4 |
| Hong, SK | 2 |
| Shin, JH | 2 |
| Kim, MA | 2 |
| Park, DG | 2 |
| Kim, EJ | 2 |
| Hong, SJ | 2 |
| Kim, SY | 2 |
| Kim, JJ | 4 |
| Choi, DJ | 4 |
| Rovai, S | 1 |
| Contini, M | 8 |
| Sciomer, S | 7 |
| Vignati, C | 3 |
| Agostoni, P | 11 |
| Sunaga, S | 1 |
| Okamura, Y | 1 |
| Kondo, M | 1 |
| Kitagawa, K | 1 |
| Noda, M | 1 |
| Hisatake, Y | 1 |
| Teramoto, K | 1 |
| Higashizawa, T | 1 |
| Sekine, C | 1 |
| Henriksen, PA | 1 |
| Hall, P | 1 |
| Oikonomidou, O | 1 |
| MacPherson, IR | 1 |
| Maclean, M | 1 |
| Lewis, S | 1 |
| McVicars, H | 1 |
| Broom, A | 1 |
| Scott, F | 1 |
| McKay, P | 1 |
| Borley, A | 1 |
| Rowntree, C | 1 |
| Lord, S | 1 |
| Collins, G | 1 |
| Radford, J | 1 |
| Guppy, A | 1 |
| Payne, JR | 1 |
| Newby, DE | 1 |
| Mills, NL | 1 |
| Lang, NN | 1 |
| Dunlay, SM | 1 |
| Killian, JM | 1 |
| Roger, VL | 1 |
| Schulte, PJ | 1 |
| Blecker, SB | 1 |
| Savitz, ST | 1 |
| Redfield, MM | 1 |
| Takayama, A | 1 |
| Yoshioka, T | 1 |
| Nagamine, T | 1 |
| Amano, M | 1 |
| Izumi, C | 1 |
| Watanabe, H | 2 |
| Ozasa, N | 1 |
| Morimoto, T | 1 |
| Bingyuan, B | 1 |
| Suwa, S | 1 |
| Miyake, M | 1 |
| Tamura, T | 2 |
| Nakagawa, Y | 2 |
| Kadota, K | 1 |
| Inuzuka, Y | 1 |
| Minamimoto, Y | 1 |
| Furukawa, Y | 1 |
| Kaji, S | 1 |
| Suzuki, T | 1 |
| Akao, M | 1 |
| Inada, T | 1 |
| Kimura, T | 1 |
| Diamond, A | 1 |
| Goldenberg, I | 2 |
| Younis, A | 1 |
| Sampath, R | 1 |
| Kutyifa, V | 2 |
| Chen, AY | 1 |
| McNitt, S | 3 |
| Polonsky, B | 1 |
| Steinberg, JS | 1 |
| Zareba, W | 3 |
| Aktaş, MK | 1 |
| Anjani, QK | 1 |
| Sabri, AHB | 1 |
| Hamid, KA | 1 |
| Moreno-Castellanos, N | 1 |
| Li, H | 1 |
| Donnelly, RF | 1 |
| Rahm, AK | 1 |
| Hackbarth, J | 1 |
| Müller, ME | 1 |
| Pfeiffer, J | 1 |
| Gampp, H | 1 |
| Petersenn, F | 1 |
| Rivinius, R | 1 |
| Frey, N | 1 |
| Lugenbiel, P | 1 |
| Thomas, D | 1 |
| Sessa, M | 3 |
| Mascolo, A | 2 |
| Rasmussen, DB | 2 |
| Kragholm, K | 2 |
| Jensen, MT | 2 |
| Sportiello, L | 1 |
| Rafaniello, C | 1 |
| Tari, GM | 1 |
| Pagliaro, C | 1 |
| Andersen, M | 2 |
| Rossi, F | 2 |
| Capuano, A | 2 |
| Toyoda, S | 1 |
| Haruyama, A | 1 |
| Inami, S | 1 |
| Arikawa, T | 1 |
| Saito, F | 1 |
| Watanabe, R | 1 |
| Sakuma, M | 1 |
| Abe, S | 1 |
| Nakajima, T | 1 |
| Tanaka, A | 1 |
| Node, K | 1 |
| Inoue, T | 1 |
| Page, RL | 2 |
| Allen, LA | 1 |
| Banerji, D | 1 |
| Alvi, RM | 1 |
| Afshar, M | 1 |
| Tariq, N | 1 |
| Rokicki, A | 1 |
| Mulligan, CP | 1 |
| Zhang, L | 4 |
| Hassan, MO | 1 |
| Awadalla, M | 1 |
| Groarke, JD | 1 |
| Neilan, TG | 1 |
| Qu, W | 1 |
| Li, X | 2 |
| Yu, Z | 1 |
| Sun, J | 2 |
| Shang, H | 1 |
| Yang, X | 1 |
| Xing, Y | 1 |
| Nagara, K | 1 |
| Suzuki, A | 1 |
| Shiga, T | 2 |
| Hagiwara, N | 1 |
| Syed, MP | 1 |
| Doshi, A | 1 |
| Pandey, D | 1 |
| Kate, Y | 1 |
| Harizi, R | 1 |
| Alabed, S | 2 |
| Sabouni, A | 2 |
| Al Dakhoul, S | 2 |
| Bdaiwi, Y | 2 |
| Alkhatib, N | 1 |
| Sweitzer, NK | 2 |
| Lee, CS | 1 |
| Erstad, B | 1 |
| Slack, M | 1 |
| Gharaibeh, M | 1 |
| Karnes, J | 1 |
| Klimecki, W | 1 |
| Ramos, K | 1 |
| Abraham, I | 1 |
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 1 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Tanaka, S | 1 |
| Imamura, T | 3 |
| Ueno, H | 1 |
| Kinugawa, K | 3 |
| Taborsky, M | 2 |
| Aiglova, R | 1 |
| Lazarova, M | 1 |
| Pavlu, L | 1 |
| Danek, J | 1 |
| Precek, J | 1 |
| Schee, A | 1 |
| Gloger, V | 1 |
| Vicha, M | 1 |
| Skala, T | 1 |
| Butts, R | 1 |
| Atz, AM | 1 |
| BaezHernandez, N | 1 |
| Sutcliffe, D | 1 |
| Reisch, J | 1 |
| Mahony, L | 3 |
| Kim, G | 1 |
| Kil, HR | 1 |
| Quan, C | 1 |
| Lee, SS | 1 |
| McGranaghan, P | 1 |
| Saxena, A | 1 |
| Düngen, HD | 11 |
| Rubens, M | 1 |
| Appunni, S | 1 |
| Salami, J | 1 |
| Veledar, E | 1 |
| Lacour, P | 1 |
| Blaschke, F | 1 |
| Obradovic, D | 2 |
| Loncar, G | 4 |
| Tahirovic, E | 9 |
| Edelmann, F | 8 |
| Pieske, B | 3 |
| Trippel, TD | 3 |
| Dave, CV | 1 |
| Strom, BL | 1 |
| Kobylarz, FA | 1 |
| Horton, DB | 1 |
| Gerhard, T | 1 |
| Tseng, CL | 1 |
| Dejanovic, I | 1 |
| Nyandege, A | 1 |
| Setoguchi, S | 1 |
| Koraćević, G | 1 |
| Stojanović, M | 1 |
| Kostić, T | 1 |
| Lović, D | 1 |
| Zdravković, M | 3 |
| Koraćević, M | 1 |
| Pavlović, D | 1 |
| Mićić, S | 1 |
| Aonuma, T | 1 |
| Moukette, B | 1 |
| Kawaguchi, S | 1 |
| Barupala, NP | 1 |
| Sepúlveda, MN | 1 |
| Corr, C | 1 |
| Tang, Y | 1 |
| Liangpunsakul, S | 1 |
| Payne, RM | 1 |
| Willis, MS | 1 |
| Kim, IM | 1 |
| Chavanon, ML | 1 |
| Inkrot, S | 7 |
| Zelenak, C | 1 |
| Stanojevic, D | 3 |
| Apostolovic, S | 9 |
| Sljivic, A | 1 |
| Ristic, AD | 1 |
| Matic, D | 1 |
| Veskovic, J | 1 |
| Lainscak, M | 9 |
| Herrmann-Lingen, C | 3 |
| Jhorawat, R | 1 |
| Kumari, S | 1 |
| Varma, SC | 1 |
| Rohit, MK | 1 |
| Narula, N | 1 |
| Suri, V | 1 |
| Malhotra, P | 1 |
| Jain, S | 1 |
| Fröhlich, H | 2 |
| Torres, L | 1 |
| Täger, T | 2 |
| Schellberg, D | 2 |
| Corletto, A | 1 |
| Kazmi, S | 1 |
| Goode, K | 2 |
| Grundtvig, M | 2 |
| Hole, T | 2 |
| Katus, HA | 11 |
| Cleland, JGF | 1 |
| Atar, D | 3 |
| Clark, AL | 9 |
| Agewall, S | 2 |
| Frankenstein, L | 2 |
| Moser-Bracher, A | 1 |
| Balmer, C | 1 |
| Cavigelli, A | 1 |
| Satir, A | 1 |
| Caduff Good, A | 1 |
| Klauwer, D | 1 |
| Takayanagi, R | 1 |
| Fujito, K | 1 |
| Kimura, K | 1 |
| Yamada, Y | 1 |
| Tyrrell, C | 1 |
| Toyooka, A | 1 |
| Khan, F | 1 |
| Thornburg, KL | 1 |
| Mudd, JO | 1 |
| Hasan, W | 1 |
| Tsetskhladze, E | 1 |
| Khintibidze, I | 1 |
| Nagatomo, Y | 5 |
| Yoshikawa, T | 13 |
| Okamoto, H | 6 |
| Kitabatake, A | 7 |
| Hori, M | 5 |
| Liao, KM | 1 |
| Lin, TY | 3 |
| Huang, YB | 2 |
| Kuo, CC | 1 |
| Chen, CY | 2 |
| Mortensen, RN | 1 |
| Andersen, MP | 1 |
| Rosano, GMC | 2 |
| Gislason, G | 1 |
| Enghusen-Poulsen, H | 1 |
| Yoshihisa, A | 1 |
| Gupta, A | 1 |
| Das, SR | 1 |
| Pandey, A | 1 |
| Domagoj, M | 1 |
| Branka, JZ | 1 |
| Jelena, M | 1 |
| Davor, M | 1 |
| Duska, G | 1 |
| Ruwald, AC | 3 |
| Vinther, M | 1 |
| Johansen, JB | 1 |
| Nielsen, JC | 1 |
| Philbert, BT | 1 |
| Riahi, S | 1 |
| Jøns, C | 1 |
| Ajam, T | 2 |
| Ajam, S | 2 |
| Devaraj, S | 2 |
| Mohammed, K | 1 |
| Sawada, S | 1 |
| Kamalesh, M | 2 |
| Ingram, A | 1 |
| Valente, M | 1 |
| Franken, PR | 1 |
| Woltersdorf, R | 1 |
| Fudim, M | 1 |
| Williams, MR | 1 |
| Parker, BM | 1 |
| Rogers, SL | 1 |
| Lymperopoulos, A | 1 |
| Soma, K | 1 |
| Yao, A | 2 |
| Saito, A | 1 |
| Inaba, T | 2 |
| Ishikawa, Y | 2 |
| Hirata, Y | 1 |
| Komuro, I | 4 |
| Choi, KH | 1 |
| Lee, GY | 1 |
| Choi, JO | 1 |
| Lee, SE | 1 |
| Chae, SC | 2 |
| Baek, SH | 2 |
| Kim, KH | 2 |
| Cho, MC | 2 |
| Park, HY | 1 |
| Oh, BH | 2 |
| Loop, MS | 1 |
| van Dyke, MK | 1 |
| Chen, L | 1 |
| Safford, MM | 1 |
| Kilgore, ML | 1 |
| Brown, TM | 1 |
| Durant, RW | 1 |
| Levitan, EB | 1 |
| Parikh, KS | 1 |
| Fiuzat, M | 1 |
| Davis, G | 1 |
| Neely, M | 1 |
| Blain-Nelson, P | 1 |
| Whellan, DJ | 1 |
| Abraham, WT | 12 |
| Adams, KF | 6 |
| Felker, GM | 2 |
| Liggett, SB | 2 |
| O'Connor, CM | 7 |
| Bristow, MR | 19 |
| Ayan, M | 1 |
| Habash, F | 1 |
| Alqam, B | 1 |
| Gheith, Z | 1 |
| Cross, M | 1 |
| Vallurupalli, S | 1 |
| Paydak, H | 1 |
| Nemoto, S | 1 |
| Kasahara, Y | 1 |
| Izawa, KP | 1 |
| Watanabe, S | 1 |
| Yoshizawa, K | 1 |
| Takeichi, N | 1 |
| Kamiya, K | 3 |
| Suzuki, N | 1 |
| Omiya, K | 1 |
| Matsunaga, A | 1 |
| Akashi, YJ | 2 |
| Park, HA | 1 |
| Cho, HJ | 1 |
| Mueller, DN | 1 |
| Wilck, N | 1 |
| Riemekasten, G | 1 |
| Dragun, D | 1 |
| Busjahn, A | 1 |
| Heidecke, H | 1 |
| Junker, J | 1 |
| Dechend, R | 1 |
| Yamamoto, H | 1 |
| Kawada, T | 1 |
| Shimizu, S | 1 |
| Hayama, Y | 1 |
| Shishido, T | 1 |
| Iwanaga, Y | 1 |
| Fukuda, K | 1 |
| Miyazaki, S | 1 |
| Sugimachi, M | 2 |
| Tsuda, E | 4 |
| Yamada, O | 1 |
| Kitano, M | 1 |
| Tsutsui, H | 5 |
| Momomura, SI | 1 |
| Masuyama, T | 1 |
| Saito, Y | 1 |
| Murohara, T | 1 |
| Kinugawa, S | 1 |
| Volterrani, M | 4 |
| Cice, G | 3 |
| Caminiti, G | 4 |
| Vitale, C | 3 |
| D'Isa, S | 2 |
| Filardi, PP | 1 |
| Acquistapace, F | 2 |
| Marazzi, G | 4 |
| Fini, M | 2 |
| Grandinetti, V | 1 |
| Carlos, FP | 1 |
| Antonio, EL | 1 |
| de Oliveira, HA | 1 |
| Dos Santos, LFN | 1 |
| Yoshizaki, A | 1 |
| Mansano, BSDM | 1 |
| Silva, FA | 1 |
| Porte, LA | 1 |
| Albuquerque-Pontes, GM | 1 |
| de Carvalho, PTC | 1 |
| Manchini, MT | 1 |
| Leal-Junior, EC | 1 |
| Tucci, PJF | 1 |
| Serra, AJ | 1 |
| Kida, K | 1 |
| Yoneyama, K | 1 |
| Kobayashi, Y | 1 |
| Takano, M | 1 |
| Miyake, F | 1 |
| Mori, Y | 1 |
| Nishikawa, Y | 1 |
| Kobayashi, F | 1 |
| Hiramatsu, K | 1 |
| Ruwald, MH | 2 |
| Jons, C | 2 |
| Alexis, J | 1 |
| Moss, AJ | 2 |
| Apostolo, A | 7 |
| Cattadori, G | 7 |
| Paolillo, S | 2 |
| Iorio, A | 2 |
| Bertella, E | 1 |
| Salvioni, E | 5 |
| Alimento, M | 2 |
| Farina, S | 3 |
| Palermo, P | 8 |
| Loguercio, M | 1 |
| Mantegazza, V | 1 |
| Karsten, M | 2 |
| Magrì, D | 4 |
| Fiorentini, C | 4 |
| Taniguchi, T | 1 |
| Ohtani, T | 1 |
| Mizote, I | 1 |
| Kanzaki, M | 1 |
| Ichibori, Y | 1 |
| Minamiguchi, H | 1 |
| Asano, Y | 1 |
| Sakata, Y | 1 |
| Nessler, J | 4 |
| Nessler, B | 3 |
| Golebiowska-Wiatrak, R | 1 |
| Palka, I | 1 |
| Gackowski, A | 2 |
| Kitlinski, M | 3 |
| Melander, O | 1 |
| Fedorowski, A | 1 |
| Nagai, R | 3 |
| Izumi, T | 3 |
| Matsuzaki, M | 4 |
| Fonarow, G | 2 |
| Cannon, C | 1 |
| Epstein, A | 1 |
| Díez-Manglano, J | 1 |
| Vanzelli, AS | 4 |
| Medeiros, A | 4 |
| Rolim, N | 1 |
| Bartholomeu, JB | 2 |
| Cunha, TF | 1 |
| Bechara, LR | 2 |
| Bechara, LG | 1 |
| Gomes, ER | 1 |
| Mattos, KC | 2 |
| Sirvente, R | 1 |
| Salemi, VM | 2 |
| Salemi, V | 1 |
| Mady, C | 2 |
| Negrao, CE | 3 |
| Guatimosim, S | 2 |
| Brum, PC | 5 |
| Littmann, L | 1 |
| Narveson, SY | 1 |
| Fesel, NM | 1 |
| Marconi, SL | 1 |
| Karabacak, M | 4 |
| Dogan, A | 4 |
| Aksoy, F | 1 |
| Ozaydin, M | 3 |
| Erdogan, D | 3 |
| Karabacak, P | 1 |
| De Pauw, M | 1 |
| Van Heuverswyn, F | 1 |
| Duytschaever, M | 1 |
| De Buyzere, M | 1 |
| Brignardello-Petersen, R | 1 |
| Guyatt, GH | 1 |
| Nikolic, VN | 1 |
| Jankovic, SM | 1 |
| Velickovic-Radovanović, R | 1 |
| Zivanovic, S | 1 |
| Stefanovic, N | 1 |
| Pesic, S | 1 |
| Jevtovic-Stoimenov, T | 1 |
| Djuric, J | 1 |
| Markovic, V | 1 |
| Milovanovic, JR | 1 |
| Raitt, MH | 1 |
| Abu-Zeitone, A | 1 |
| Tayyar, S | 3 |
| de Peuter, OR | 1 |
| Verberne, HJ | 1 |
| Kok, WE | 1 |
| van den Bogaard, B | 1 |
| Schaap, MC | 1 |
| Nieuwland, R | 1 |
| Meijers, JC | 1 |
| Somsen, GA | 1 |
| Bakx, A | 1 |
| Kamphuisen, PW | 1 |
| Gelbrich, G | 7 |
| Jankovic-Tomasevic, R | 1 |
| Pavlovic, M | 2 |
| Djordjevic-Radojkovic, D | 1 |
| Salinger-Martinovic, S | 1 |
| Putnikovic, B | 3 |
| Radovanovic, S | 1 |
| Waagstein, F | 8 |
| Tomasevic, M | 1 |
| Musial-Bright, L | 2 |
| Yanagihara, K | 1 |
| Kinugasa, Y | 1 |
| Sugihara, S | 1 |
| Hirai, M | 1 |
| Yamada, K | 1 |
| Ishida, K | 1 |
| Kato, M | 1 |
| Yamamoto, K | 2 |
| Öcal, L | 1 |
| Çakir, H | 1 |
| Tellice, M | 1 |
| İzci, S | 1 |
| Alizade, E | 1 |
| Esen, AM | 1 |
| Riccioni, G | 1 |
| Masciocco, L | 1 |
| Benvenuto, A | 1 |
| Saracino, P | 1 |
| De Viti, D | 1 |
| Massari, F | 1 |
| Meliota, G | 1 |
| Buta, F | 1 |
| Speziale, G | 1 |
| Constantinescu, AA | 1 |
| Caliskan, K | 1 |
| Manintveld, OC | 1 |
| van Domburg, R | 1 |
| Jewbali, L | 1 |
| Balk, AH | 1 |
| Molenaar, P | 2 |
| Christ, T | 2 |
| Berk, E | 1 |
| Engel, A | 1 |
| Gillette, KT | 1 |
| Galindo-Tovar, A | 1 |
| Ravens, U | 2 |
| Kaumann, AJ | 1 |
| Shihmanter, R | 1 |
| Nulman, I | 1 |
| Goland, S | 1 |
| Caspi, A | 1 |
| Bar-Haim, A | 1 |
| Harary, I | 1 |
| Berkovitch, M | 1 |
| Arcavi, L | 1 |
| Sekularac, N | 1 |
| Störk, S | 1 |
| Tscholl, V | 1 |
| Krackhardt, F | 2 |
| Pasternak, B | 1 |
| Svanström, H | 1 |
| Melbye, M | 1 |
| Hviid, A | 1 |
| Prijic, S | 1 |
| Buchhorn, R | 1 |
| Kosutic, J | 1 |
| Vukomanovic, V | 1 |
| Prijic, A | 1 |
| Bjelakovic, B | 1 |
| Cho, MJ | 1 |
| Lim, RK | 1 |
| Jung Kwak, M | 1 |
| Park, KH | 1 |
| Kim, HY | 1 |
| Kim, YM | 1 |
| Lee, HD | 1 |
| Bas, HA | 1 |
| Miranda, SM | 1 |
| Moscavitch, SD | 1 |
| Pereira, SB | 1 |
| de Azevedo, JC | 1 |
| Messias, LR | 1 |
| Rodrigues, RC | 1 |
| Mesquita, ET | 1 |
| Ribeiro, GS | 1 |
| Mesquita, CT | 1 |
| Palmisano, P | 1 |
| Ammendola, E | 1 |
| D'Onofrio, A | 1 |
| Accogli, M | 1 |
| Calò, L | 1 |
| Ruocco, A | 1 |
| Rapacciuolo, A | 1 |
| Del Giorno, G | 1 |
| Bianchi, V | 1 |
| Malacrida, M | 1 |
| Valsecchi, S | 1 |
| Gronda, E | 2 |
| Yu, H | 1 |
| Wei, F | 1 |
| Qian, G | 1 |
| Li, L | 1 |
| Zhang, C | 1 |
| Cheng, Z | 1 |
| Khand, AU | 2 |
| Chew, PG | 1 |
| Douglas, H | 1 |
| Jones, J | 1 |
| Jan, A | 1 |
| Cleland, JG | 34 |
| Ikeda, Y | 2 |
| Inomata, T | 3 |
| Iida, Y | 2 |
| Iwamoto-Ishida, M | 2 |
| Nabeta, T | 2 |
| Ishii, S | 2 |
| Sato, T | 1 |
| Yanagisawa, T | 1 |
| Mizutani, T | 2 |
| Naruke, T | 2 |
| Koitabashi, T | 2 |
| Takeuchi, I | 2 |
| Nishii, M | 1 |
| Ako, J | 2 |
| Garcia-Egido, A | 1 |
| Andrey, JL | 1 |
| Puerto, JL | 1 |
| Aranda, RM | 1 |
| Pedrosa, MJ | 1 |
| López-Sáez, JB | 1 |
| Rosety, M | 1 |
| Gomez, F | 1 |
| Briasoulis, A | 1 |
| Palla, M | 1 |
| Afonso, L | 2 |
| Rasool, MF | 2 |
| Khalil, F | 2 |
| Läer, S | 4 |
| Kubota, Y | 1 |
| Asai, K | 1 |
| Furuse, E | 1 |
| Nakamura, S | 1 |
| Murai, K | 1 |
| Tsukada, YT | 1 |
| Shimizu, W | 1 |
| Sun, YP | 1 |
| Wei, CP | 1 |
| Ma, SC | 1 |
| Zhang, YF | 1 |
| Qiao, LY | 1 |
| Li, DH | 1 |
| Shan, RB | 1 |
| Souza, FC | 1 |
| Neri, JS | 1 |
| Marques, EB | 1 |
| Barros, RB | 1 |
| Scaramello, CB | 1 |
| Muraoka, H | 2 |
| Zhao, J | 1 |
| Cebola, R | 1 |
| Shinagawa, H | 1 |
| Negishi, J | 1 |
| Noritake, K | 2 |
| Iwasa, T | 1 |
| Abe, T | 1 |
| Church, KM | 1 |
| Henalt, R | 1 |
| Baker, E | 1 |
| Smith, GL | 1 |
| Brennan, MT | 1 |
| Joseph, J | 1 |
| Tang, CH | 1 |
| Wang, CC | 1 |
| Chen, TH | 1 |
| Hong, CY | 1 |
| Sue, YM | 1 |
| Frobel-Mercier, AK | 1 |
| Su, VY | 1 |
| Chang, YS | 1 |
| Hu, YW | 1 |
| Hung, MH | 1 |
| Ou, SM | 1 |
| Lee, FY | 1 |
| Chou, KT | 1 |
| Yang, KY | 1 |
| Perng, DW | 1 |
| Chen, TJ | 1 |
| Liu, CJ | 1 |
| Sallam, M | 1 |
| Al-Saadi, T | 1 |
| Alshekaili, L | 1 |
| Al-Zakwani, I | 1 |
| Fi, Z | 1 |
| Szentes, V | 1 |
| Carr, R | 1 |
| Schilling, J | 1 |
| Song, J | 2 |
| Carter, RL | 1 |
| Du, Y | 1 |
| Yoo, SM | 1 |
| Traynham, CJ | 1 |
| Koch, WJ | 1 |
| Cheung, JY | 1 |
| Tilley, DG | 1 |
| Benovic, JL | 1 |
| Miró, Ò | 1 |
| Müller, C | 1 |
| Martín-Sánchez, FJ | 1 |
| Bueno, H | 1 |
| Mebazaa, A | 1 |
| Herrero, P | 1 |
| Jacob, J | 1 |
| Gil, V | 1 |
| Escoda, R | 1 |
| Llorens, P | 1 |
| Martí-Carvajal, AJ | 2 |
| Kwong, JS | 2 |
| Malebranche, R | 1 |
| Tabou Moyo, C | 1 |
| Morisset, PH | 1 |
| Raphael, NA | 1 |
| Wilentz, JR | 1 |
| Armenian, SH | 1 |
| Hudson, MM | 1 |
| Chen, MH | 1 |
| Colan, SD | 1 |
| Lindenfeld, L | 1 |
| Mills, G | 1 |
| Siyahian, A | 1 |
| Gelehrter, S | 1 |
| Dang, H | 1 |
| Hein, W | 1 |
| Green, DM | 1 |
| Robison, LL | 1 |
| Wong, FL | 1 |
| Douglas, PS | 1 |
| Bhatia, S | 1 |
| Park, K | 1 |
| Park, TH | 1 |
| Wang, Q | 1 |
| Liu, Y | 1 |
| Fu, Q | 1 |
| Xu, B | 1 |
| Zhang, Y | 1 |
| Kim, S | 1 |
| Tan, R | 1 |
| Barbagallo, F | 1 |
| West, T | 1 |
| Anderson, E | 1 |
| Wei, W | 1 |
| Abel, ED | 1 |
| Xiang, YK | 1 |
| Nakamura, T | 2 |
| Fujita, T | 1 |
| Kishimura, M | 1 |
| Suita, K | 1 |
| Hidaka, Y | 1 |
| Cai, W | 1 |
| Umemura, M | 1 |
| Yokoyama, U | 1 |
| Uechi, M | 1 |
| Perreault, S | 1 |
| de Denus, S | 2 |
| White, M | 4 |
| White-Guay, B | 1 |
| Bouvier, M | 1 |
| Dorais, M | 1 |
| Dubé, MP | 1 |
| Rouleau, JL | 9 |
| Tardif, JC | 2 |
| Jenna, S | 1 |
| Haibe-Kains, B | 1 |
| Leduc, R | 1 |
| Deblois, D | 1 |
| Luzum, JA | 1 |
| Sweet, KM | 1 |
| Binkley, PF | 1 |
| Schmidlen, TJ | 1 |
| Jarvis, JP | 1 |
| Christman, MF | 1 |
| Sadee, W | 1 |
| Kitzmiller, JP | 1 |
| Mapelli, M | 1 |
| Bonomi, A | 1 |
| Corrà, U | 3 |
| Piepoli, M | 1 |
| Veglia, F | 3 |
| Gentile, P | 1 |
| Lagioia, R | 1 |
| Metra, M | 23 |
| Limongelli, G | 1 |
| Sinagra, G | 5 |
| Scardovi, AB | 1 |
| Carubelli, V | 1 |
| Scrutino, D | 1 |
| Badagliacca, R | 1 |
| Raimondo, R | 1 |
| Emdin, M | 1 |
| Correale, M | 1 |
| Parati, G | 1 |
| Caravita, S | 1 |
| Spadafora, E | 1 |
| Re, F | 1 |
| Cicoira, M | 1 |
| Frigerio, M | 1 |
| Bussotti, M | 7 |
| Minà, C | 1 |
| Oliva, F | 1 |
| Battaia, E | 1 |
| Belardinelli, R | 1 |
| Mezzani, A | 4 |
| Pastormerlo, L | 1 |
| Di Lenarda, A | 17 |
| Passino, C | 1 |
| Zambon, E | 1 |
| Guazzi, M | 4 |
| Pacileo, G | 1 |
| Ricci, R | 1 |
| Clemenza, F | 1 |
| Marchese, G | 1 |
| Binno, S | 1 |
| Lombardi, C | 2 |
| Passantino, A | 1 |
| Perrone Filardi, P | 2 |
| Coats, AJS | 1 |
| Krum, H | 21 |
| Mohacsi, P | 8 |
| Salekin, D | 1 |
| Schultz, MK | 2 |
| Packer, M | 21 |
| Anker, SD | 6 |
| Hanada, K | 3 |
| Asari, K | 1 |
| Saito, M | 4 |
| Kawana, J | 3 |
| Mita, M | 1 |
| Ogata, H | 3 |
| Wachter, R | 3 |
| Eschenhagen, T | 3 |
| Follath, F | 1 |
| Rauchhaus, M | 1 |
| Haverkamp, W | 3 |
| Osterziel, KJ | 1 |
| Dietz, R | 4 |
| Alfieri, AB | 1 |
| Briceno, L | 1 |
| Fragasso, G | 2 |
| Spoladore, R | 2 |
| Palloshi, A | 1 |
| Bassanelli, G | 1 |
| Montano, C | 1 |
| Arioli, F | 1 |
| Cuko, A | 1 |
| Ruotolo, G | 1 |
| Margonato, A | 2 |
| Rolim, NP | 1 |
| Ferreira, JC | 1 |
| Tanaka, LY | 1 |
| Rosa, KT | 2 |
| Alves, MM | 1 |
| Coelho, MA | 1 |
| Irigoyen, MC | 2 |
| Krieger, EM | 1 |
| Krieger, JE | 1 |
| Ramires, PR | 1 |
| Aygul, N | 1 |
| Ozdemir, K | 1 |
| Duzenli, MA | 1 |
| Aygul, MU | 1 |
| Van Tassell, BW | 1 |
| Rondina, MT | 1 |
| Huggins, F | 1 |
| Gilbert, EM | 22 |
| Munger, MA | 1 |
| Remme, WJ | 20 |
| Carter, NJ | 1 |
| Keating, GM | 2 |
| Sehnert, AJ | 1 |
| Daniels, SE | 1 |
| Elashoff, M | 1 |
| Wingrove, JA | 1 |
| Burrow, CR | 1 |
| Horne, B | 1 |
| Muhlestein, JB | 1 |
| Donahue, M | 1 |
| Anderson, JL | 1 |
| Kraus, WE | 1 |
| Carvalho, VO | 5 |
| Guimarães, GV | 6 |
| Ciolac, EG | 1 |
| Bocchi, EA | 8 |
| Duygu, H | 1 |
| Turk, U | 1 |
| Ozdogan, O | 1 |
| Akyuz, S | 1 |
| Kirilmaz, B | 1 |
| Alioglu, E | 1 |
| Gunduz, R | 1 |
| Bozkaya, YT | 1 |
| Turkoglu, C | 1 |
| Payzin, S | 1 |
| Fonarow, GC | 5 |
| Albert, NM | 2 |
| Stough, WG | 2 |
| Gheorghiade, M | 7 |
| Greenberg, BH | 4 |
| Sun, JL | 2 |
| Yancy, CW | 3 |
| Young, JB | 4 |
| Vardeny, O | 1 |
| Detry, MA | 1 |
| Moran, JJ | 1 |
| Johnson, MR | 1 |
| Tamura, A | 2 |
| Kawano, Y | 2 |
| Kadota, J | 2 |
| Aurich-Barrera, B | 1 |
| Wilton, LV | 2 |
| Shakir, SA | 2 |
| Rodrigues Alves, RX | 1 |
| Levy, WC | 1 |
| Mozaffarian, D | 1 |
| Linker, DT | 1 |
| Kenyon, KW | 1 |
| Komajda, M | 16 |
| Poole-Wilson, PA | 14 |
| Kohno, T | 5 |
| Yoshizawa, A | 5 |
| Baba, A | 3 |
| Anzai, T | 6 |
| Meguro, T | 3 |
| Satoh, T | 5 |
| Ogawa, S | 7 |
| Lobo-Vielma, L | 1 |
| Colmenarez-Mendoza, H | 1 |
| Donis, JH | 1 |
| Sanchez, F | 1 |
| Perez, A | 1 |
| Villarroel, V | 1 |
| Dávila, DF | 1 |
| Frishman, WH | 2 |
| Henderson, LS | 2 |
| Lukas, MA | 20 |
| Yamaji, M | 2 |
| Tsutamoto, T | 3 |
| Tanaka, T | 1 |
| Kawahara, C | 2 |
| Nishiyama, K | 2 |
| Yamamoto, T | 2 |
| Fujii, M | 2 |
| Horie, M | 2 |
| Giordano, A | 1 |
| Bosimini, E | 3 |
| Giannuzzi, P | 3 |
| Troncoso, R | 3 |
| Moraga, F | 2 |
| Chiong, M | 4 |
| Roldán, J | 1 |
| Bravo, R | 1 |
| Valenzuela, R | 2 |
| Díaz-Araya, G | 4 |
| del Campo, A | 1 |
| Sanhueza, C | 1 |
| Rodriguez, A | 2 |
| Vukasovic, JL | 4 |
| Mellado, R | 1 |
| Greig, D | 4 |
| Castro, PF | 2 |
| Lavandero, S | 4 |
| Pascoalino, LN | 1 |
| Ferreira, SA | 1 |
| Nishiyama, M | 1 |
| Park, IS | 2 |
| Hatai, Y | 1 |
| Ando, M | 2 |
| Takahashi, Y | 2 |
| Mori, K | 2 |
| Murakami, Y | 2 |
| Udelson, JE | 5 |
| Pressler, SJ | 2 |
| Sackner-Bernstein, J | 4 |
| Massaro, J | 1 |
| Ordronneau, P | 3 |
| Hauptman, PJ | 3 |
| Minami, N | 1 |
| Kobayashi, J | 1 |
| Fukaya, T | 1 |
| Nozaki, H | 1 |
| Echigo, S | 1 |
| Jolobe, OM | 1 |
| Wu, XY | 1 |
| Song, HM | 1 |
| Wei, M | 1 |
| Cohen-Solal, A | 6 |
| Beauvais, F | 2 |
| Tan, LB | 1 |
| Manrique, C | 1 |
| Giles, TD | 2 |
| Ferdinand, KC | 1 |
| Sowers, JR | 1 |
| Geng, ZH | 1 |
| Liu, CY | 1 |
| Peng, YH | 1 |
| Li, LG | 1 |
| Zhao, XH | 1 |
| Cui, B | 1 |
| Yu, SY | 1 |
| Zebrack, JS | 1 |
| Munger, M | 1 |
| Macgregor, J | 1 |
| Lombardi, WL | 2 |
| Stoddard, GP | 1 |
| An, JD | 1 |
| Liang, F | 1 |
| Feng, S | 1 |
| Wikstrand, J | 1 |
| Ghali, JK | 4 |
| Goldstein, S | 6 |
| Shaw, SM | 1 |
| Coppinger, T | 1 |
| Waywell, C | 1 |
| Dunne, L | 1 |
| Archer, LD | 1 |
| Critchley, WR | 1 |
| Yonan, N | 1 |
| Fildes, JE | 1 |
| Williams, SG | 1 |
| Boman, K | 2 |
| Jansson, JH | 1 |
| Nilsson, T | 1 |
| Swedberg, K | 19 |
| Poole-Wilson, P | 5 |
| Verdú Rotellar, JM | 1 |
| Barroso, A | 1 |
| Bernáldez, MJ | 1 |
| Domíngueza, M | 1 |
| Pie, M | 1 |
| Sancho, F | 1 |
| Simó, M | 1 |
| Domingo, M | 1 |
| Shimada, YJ | 1 |
| Sato, K | 2 |
| Hanon, S | 1 |
| Schweitzer, P | 1 |
| Maurer, MS | 1 |
| Sackner-Bernstein, JD | 2 |
| El-Khoury Rumbarger, L | 1 |
| Yushak, M | 3 |
| King, DL | 1 |
| Burkhoff, D | 1 |
| Roughead, EE | 1 |
| Barratt, JD | 1 |
| Ramsay, E | 1 |
| Pratt, N | 1 |
| Ryan, P | 1 |
| Peck, R | 1 |
| Killer, G | 1 |
| Gilbert, AL | 1 |
| Lou, YF | 1 |
| Shi, XP | 1 |
| Tong, H | 1 |
| Yu, GY | 1 |
| Yao, GD | 1 |
| Dong, K | 1 |
| Vitulano, N | 1 |
| Giubilato, G | 1 |
| Santangeli, P | 1 |
| Ierardi, C | 1 |
| Pieroni, M | 1 |
| Bellocci, F | 1 |
| Crea, F | 1 |
| Coletta, AP | 4 |
| Freemantle, N | 2 |
| Ahmed, D | 1 |
| Rubis, P | 1 |
| Cardinale, D | 1 |
| Colombo, A | 1 |
| Lamantia, G | 1 |
| Colombo, N | 1 |
| Civelli, M | 1 |
| De Giacomi, G | 1 |
| Rubino, M | 1 |
| Cipolla, CM | 1 |
| Matsuo, M | 1 |
| Sakaguchi, H | 1 |
| Hayashi, T | 1 |
| Hosoda, K | 2 |
| Miyazaki, A | 1 |
| Zakrzewski-Jakubiak, M | 1 |
| Leblanc, MH | 1 |
| Turgeon, J | 1 |
| Covolo, L | 1 |
| Pezzali, N | 1 |
| Zacà, V | 1 |
| Bugatti, S | 1 |
| Bettari, L | 1 |
| Romeo, A | 1 |
| Gelatti, U | 1 |
| Giubbini, R | 3 |
| Donato, F | 1 |
| Dei Cas, L | 8 |
| Konishi, M | 1 |
| Haraguchi, G | 1 |
| Kimura, S | 1 |
| Inagaki, H | 1 |
| Kawabata, M | 1 |
| Hachiya, H | 1 |
| Hirao, K | 1 |
| Isobe, M | 1 |
| Nishimura, T | 1 |
| Kyo, S | 1 |
| Jabbour, A | 1 |
| Macdonald, PS | 5 |
| Keogh, AM | 4 |
| Kotlyar, E | 2 |
| Mellemkjaer, S | 1 |
| Coleman, CF | 1 |
| Elsik, M | 1 |
| Hayward, CS | 1 |
| Zakirova, AN | 1 |
| Abdiukova, ER | 1 |
| Cauti, FM | 1 |
| Magini, A | 2 |
| Ito, H | 1 |
| Marques, F | 1 |
| Castro, RB | 1 |
| Nobre, F | 1 |
| Pintya, AO | 1 |
| Gallo, L | 1 |
| Maciel, BC | 1 |
| Simões, MV | 1 |
| Berna, G | 1 |
| Antonioli, L | 1 |
| Schina, M | 1 |
| Auerbach, SR | 1 |
| Richmond, ME | 1 |
| Lamour, JM | 2 |
| Blume, ED | 2 |
| Addonizio, LJ | 2 |
| Shaddy, RE | 4 |
| Pahl, E | 3 |
| Hsu, DT | 2 |
| Baudhuin, LM | 1 |
| Miller, WL | 1 |
| Train, L | 1 |
| Bryant, S | 1 |
| Hartman, KA | 1 |
| Phelps, M | 1 |
| Larock, M | 1 |
| Jaffe, AS | 1 |
| Matsumura, T | 1 |
| Kuru, S | 1 |
| Kikuchi, Y | 1 |
| Kawai, M | 1 |
| Sirvente, Rde A | 1 |
| Ohno, T | 2 |
| Kaneko, M | 2 |
| Mihara, K | 2 |
| Shiomi, M | 1 |
| Nagayama, M | 3 |
| Sumiyoshi, T | 4 |
| Takahama, H | 1 |
| Asanuma, H | 1 |
| Sanada, S | 1 |
| Fujita, M | 1 |
| Sasaki, H | 1 |
| Wakeno, M | 1 |
| Kim, J | 1 |
| Asakura, M | 1 |
| Takashima, S | 1 |
| Minamino, T | 1 |
| Komamura, K | 2 |
| Kitakaze, M | 3 |
| Talan, MI | 1 |
| Ahmet, I | 1 |
| Xiao, RP | 1 |
| Lakatta, EG | 1 |
| Tian, X | 1 |
| Hou, Y | 1 |
| Xu, W | 1 |
| Dong, Y | 1 |
| Liu, J | 1 |
| Liang, J | 1 |
| Li, XD | 1 |
| Wang, JC | 1 |
| Ye, L | 1 |
| Zhao, Y | 1 |
| Zhou, NN | 1 |
| Zhu, X | 1 |
| Lowenthal, A | 1 |
| Shah, A | 1 |
| Bernstein, HS | 1 |
| Iellamo, F | 1 |
| Madonna, M | 1 |
| Arisi, G | 1 |
| Massaro, R | 2 |
| Righi, D | 1 |
| Rosano, GM | 2 |
| Petersen, M | 2 |
| Andersen, JT | 2 |
| Hjelvang, BR | 1 |
| Broedbaek, K | 2 |
| Afzal, S | 2 |
| Nyegaard, M | 2 |
| Børglum, AD | 2 |
| Stender, S | 2 |
| Poulsen, HE | 2 |
| Töpper, A | 1 |
| Mehrhof, F | 1 |
| Prettin, C | 1 |
| Neskovic, AN | 3 |
| Krotin, M | 1 |
| Sakac, D | 1 |
| Rau, T | 2 |
| Doehner, W | 1 |
| Ishibashi, N | 1 |
| Waragai, T | 1 |
| Mimori, S | 1 |
| Doi, S | 1 |
| Mizutani, S | 1 |
| Nakanishi, T | 1 |
| Cefalù, C | 1 |
| Catai, AM | 1 |
| Shashurin, DA | 1 |
| Timoshin, AA | 1 |
| Medvedev, OS | 1 |
| Vanin, AF | 1 |
| Tepliakov, AT | 1 |
| Shilov, SN | 1 |
| Berezikova, EN | 1 |
| Torim, IuIu | 1 |
| Efremov, AV | 1 |
| Safronov, ID | 1 |
| Maianskaia, SD | 1 |
| Popova, AA | 1 |
| Voronina, EN | 1 |
| Karpov, RS | 1 |
| Kubo, T | 4 |
| Azevedo, ER | 5 |
| Newton, GE | 4 |
| Picton, P | 2 |
| Parker, JD | 6 |
| Floras, JS | 5 |
| Sehrt, D | 1 |
| Meineke, I | 1 |
| Tzvetkov, M | 1 |
| Gültepe, S | 1 |
| Brockmöller, J | 1 |
| Ozova, EM | 1 |
| Kiiakbaev, GK | 1 |
| Kobalava, ZhD | 1 |
| Moiseev, VS | 1 |
| Wada, Y | 1 |
| Kobayashi, D | 1 |
| Murakami, S | 1 |
| Oda, M | 1 |
| Hanawa, H | 1 |
| Kuroda, T | 1 |
| Nakano, M | 1 |
| Narita, I | 1 |
| Hashemzadeh, M | 1 |
| Movahed, MR | 1 |
| Russu, WA | 1 |
| Soroush, L | 1 |
| Hill, DN | 1 |
| Iaia, L | 1 |
| Sposato, B | 1 |
| Mercuro, G | 1 |
| Rosano, G | 1 |
| Giardini, A | 2 |
| Lovato, L | 1 |
| Donti, A | 2 |
| Formigari, R | 2 |
| Gargiulo, G | 1 |
| Picchio, FM | 2 |
| Fattori, R | 1 |
| Li, R | 2 |
| Zhang, Q | 1 |
| Yi, QJ | 2 |
| Rohrer, CK | 1 |
| Shakar, SF | 1 |
| Lindenfeld, J | 3 |
| Falskov, B | 1 |
| Hermann, TS | 1 |
| Raunsø, J | 1 |
| Christiansen, B | 2 |
| Rask-Madsen, C | 1 |
| Major-Pedersen, A | 1 |
| Dominguez, H | 1 |
| Podbregar, M | 3 |
| Kovacic, D | 2 |
| Rozman, J | 1 |
| von Haehling, S | 3 |
| Wehland, M | 1 |
| Grosse, J | 1 |
| Simonsen, U | 1 |
| Infanger, M | 1 |
| Bauer, J | 1 |
| Grimm, D | 1 |
| Grosu, A | 1 |
| Senni, M | 1 |
| Iacovoni, A | 1 |
| Gori, M | 1 |
| Cantù, F | 1 |
| Bisetti, S | 1 |
| De Santo, T | 1 |
| De Luca, A | 1 |
| Gavazzi, A | 2 |
| Vondráková, D | 1 |
| Málek, F | 1 |
| Dvorák, J | 1 |
| Sedivá, L | 1 |
| Kupec, J | 1 |
| Petrů, J | 1 |
| Neuzil, P | 1 |
| Loeffler, M | 1 |
| Sarai, N | 1 |
| Ando, H | 1 |
| Sakamoto, T | 1 |
| Nakajima, H | 1 |
| Perseghin, G | 1 |
| De Cobelli, F | 1 |
| Esposito, A | 1 |
| Maranta, F | 1 |
| Calori, G | 1 |
| Locatelli, M | 1 |
| Lattuada, G | 1 |
| Scifo, P | 1 |
| Del Maschio, A | 1 |
| Bozkurt, B | 1 |
| Bolos, M | 1 |
| Deswal, A | 1 |
| Ather, S | 1 |
| Chan, W | 1 |
| Mann, DL | 1 |
| Carabello, B | 1 |
| Kawaguchi, T | 1 |
| Takasugi, N | 1 |
| Kubota, T | 1 |
| Takasugi, M | 1 |
| Kanamori, H | 1 |
| Ushikoshi, H | 1 |
| Hattori, A | 1 |
| Aoyama, T | 1 |
| Kawasaki, M | 1 |
| Nishigaki, K | 1 |
| Takemura, G | 1 |
| Minatoguchi, S | 1 |
| Verrier, RL | 1 |
| Sarraf, M | 1 |
| Francis, GS | 2 |
| He, YM | 1 |
| Yang, XJ | 1 |
| Zhao, X | 1 |
| Cheng, XJ | 1 |
| Xu, HF | 1 |
| Qian, YX | 1 |
| Dimković, S | 1 |
| Stiefelhagen, P | 1 |
| Ahmad, T | 1 |
| Patel, CB | 1 |
| Milano, CA | 1 |
| Rogers, JG | 1 |
| Jimenez-Solem, E | 1 |
| Badheka, AO | 1 |
| Tuliani, TA | 1 |
| Rathod, A | 1 |
| Ali Kizilbash, M | 1 |
| Bharadwaj, A | 1 |
| Hirsh, BJ | 1 |
| Mignatti, A | 1 |
| Garan, AR | 1 |
| Uriel, N | 1 |
| Colombo, P | 1 |
| Sims, DB | 1 |
| Jorde, UP | 3 |
| Teeter, WA | 1 |
| Thibodeau, JT | 1 |
| Rao, K | 1 |
| Brickner, ME | 1 |
| Toto, KH | 1 |
| Nelson, LL | 1 |
| Mishkin, JD | 1 |
| Ayers, CR | 1 |
| Miller, JG | 1 |
| Mammen, PP | 1 |
| Patel, PC | 1 |
| Markham, DW | 1 |
| Drazner, MH | 1 |
| Huang, M | 2 |
| Zhang, X | 1 |
| Chen, S | 2 |
| Sun, Y | 1 |
| Xiao, Y | 1 |
| Liu, F | 1 |
| Dekleva, M | 1 |
| Incrot, S | 1 |
| Suzic Lazic, J | 1 |
| Pavlovic Kleut, M | 1 |
| Hidalgo, R | 1 |
| Simancas-Racines, D | 1 |
| Nicola, S | 1 |
| Shore, S | 1 |
| Aggarwal, V | 1 |
| Zolty, R | 2 |
| Yamazaki, T | 1 |
| Fujio, Y | 1 |
| Nonen, S | 1 |
| Azuma, J | 1 |
| Ohashi, Y | 1 |
| Kato, N | 1 |
| Minatsuki, S | 1 |
| Maki, H | 1 |
| Hatano, M | 1 |
| Buchneva, NV | 1 |
| Kuz'min, OB | 1 |
| Scherer, M | 1 |
| Lashki, DJ | 1 |
| Neskovic, A | 1 |
| Bobadilla, RV | 1 |
| Refsgaard, J | 2 |
| Thomsen, C | 1 |
| Andreasen, F | 2 |
| Gøtzsche, O | 2 |
| Fung, JW | 3 |
| Chan, SK | 3 |
| Yeung, LY | 2 |
| Sanderson, JE | 5 |
| Otterstad, JE | 1 |
| Ford, I | 1 |
| Barry, M | 2 |
| Perkan, A | 1 |
| Cherubini, A | 1 |
| Salvatore, L | 1 |
| Harada, T | 1 |
| Ohtaki, E | 2 |
| Kitahara, K | 2 |
| Hosoda, S | 3 |
| Deedwania, PC | 1 |
| Curtin, EL | 1 |
| Sower, B | 1 |
| Tani, LY | 1 |
| Burr, J | 1 |
| LaSalle, B | 1 |
| Boucek, MM | 1 |
| Burch, GH | 1 |
| Schlencker-Herceg, R | 1 |
| Schultheiss, HP | 1 |
| Tschöpe, C | 1 |
| Hartmann, F | 3 |
| Beuckelmann, DJ | 1 |
| Anguita Sánchez, M | 2 |
| Nodari, S | 5 |
| D'Aloia, A | 1 |
| Muneretto, C | 1 |
| Robertson, AD | 3 |
| Wollert, KC | 1 |
| Drexler, H | 1 |
| Fowler, MB | 18 |
| Roecker, EB | 5 |
| Coats, AJ | 11 |
| Tendera, M | 7 |
| Staiger, C | 1 |
| Holcslaw, TL | 4 |
| Amann-Zalan, I | 3 |
| DeMets, DL | 2 |
| Piccirillo, G | 2 |
| Quaglione, R | 1 |
| Nocco, M | 1 |
| Naso, C | 1 |
| Moisè, A | 2 |
| Lionetti, M | 2 |
| Di Carlo, S | 1 |
| Marigliano, V | 2 |
| Bruns, LA | 2 |
| Canter, CE | 2 |
| Cesario, DA | 1 |
| Gattis, WA | 4 |
| Palazzuoli, A | 3 |
| Bruni, F | 1 |
| Puccetti, L | 1 |
| Pastorelli, M | 1 |
| Angori, P | 1 |
| Pasqui, AL | 1 |
| Auteri, A | 1 |
| Turchetti, V | 1 |
| Bellini, MA | 1 |
| Boschi, L | 1 |
| Postorino, G | 1 |
| Pallassini, A | 1 |
| Richichi, MG | 1 |
| Trabalzini, L | 1 |
| Guerrini, M | 1 |
| Forconi, S | 1 |
| Azeka, E | 1 |
| Franchini Ramires, JA | 1 |
| Valler, C | 1 |
| Alcides Bocchi, E | 1 |
| De Vita, S | 1 |
| Arnold, RH | 1 |
| McCaffrey, DJ | 2 |
| Glanville, AR | 1 |
| Zaikin, SY | 1 |
| Iosava, IK | 1 |
| Vasechkin, SS | 1 |
| Gruzdev, AK | 1 |
| Sidorenko, BA | 1 |
| Isnard, R | 1 |
| Takeda, N | 1 |
| Misu, K | 1 |
| Asano, R | 1 |
| Tobaru, T | 1 |
| Umemura, J | 1 |
| Leimberger, JD | 1 |
| Voga, G | 1 |
| Vittorio, TJ | 2 |
| Lang, CC | 1 |
| Katz, SD | 5 |
| Mancini, DM | 1 |
| Logeart, D | 1 |
| Guiti, C | 1 |
| Bourgoin, P | 1 |
| Paganelli, F | 1 |
| Maixent, JM | 1 |
| Gelisse, R | 1 |
| Saadjian, A | 1 |
| Sbragia, P | 1 |
| Barnay, P | 1 |
| Levy, S | 1 |
| Parrinello, G | 1 |
| Manca, C | 1 |
| Somlói, M | 1 |
| Tomcsányi, J | 1 |
| Rostant, TM | 1 |
| Nasser, M | 1 |
| Starling, RC | 1 |
| Francis, D | 1 |
| Jourdain, P | 3 |
| Funck, F | 3 |
| Bellorini, M | 3 |
| Guillard, N | 3 |
| Loiret, J | 3 |
| Thebault, B | 3 |
| Desnos, M | 3 |
| Duboc, D | 1 |
| Chin, BS | 2 |
| Langford, NJ | 2 |
| Nuttall, SL | 2 |
| Gibbs, CR | 2 |
| Blann, AD | 2 |
| Lip, GY | 2 |
| Al-Nasser, F | 2 |
| Yousufuddin, M | 1 |
| Al-Nozha, F | 1 |
| Piepoli, MF | 1 |
| Ponikowski, PP | 1 |
| Bollano, E | 1 |
| Täng, MS | 1 |
| Hjalmarson, A | 2 |
| Andersson, B | 2 |
| Inoko, M | 1 |
| Nohara, R | 1 |
| Bouzamondo, A | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Lechat, P | 2 |
| Etheridge, SP | 1 |
| Kaye, DM | 2 |
| Smirk, B | 1 |
| Williams, C | 1 |
| Jennings, G | 1 |
| Esler, M | 1 |
| Holst, D | 1 |
| Sallach, JA | 1 |
| Dargie, HJ | 1 |
| Hanrath, P | 5 |
| Lubsen, J | 1 |
| Lutiger, B | 6 |
| Scherhag, A | 11 |
| Skene, A | 2 |
| Pennell, DJ | 2 |
| Ray, SG | 2 |
| Macfarlane, PW | 1 |
| Murray, GD | 1 |
| Mule, JD | 1 |
| Vered, Z | 1 |
| Lahiri, A | 8 |
| Rajput, FS | 1 |
| Gnanasekeram, H | 1 |
| Satwani, S | 1 |
| Davenport, JD | 1 |
| Gracely, EJ | 1 |
| Gopalan, R | 1 |
| Narula, J | 1 |
| Okafor, CC | 1 |
| Perreault-Micale, C | 1 |
| Hajjar, RJ | 1 |
| Lebeche, D | 1 |
| Skiroman, K | 1 |
| Jabbour, G | 1 |
| Doye, AA | 1 |
| Lee, MX | 1 |
| Laste, N | 1 |
| Gwathmey, JK | 1 |
| Song, JP | 1 |
| Shen, B | 1 |
| Liu, ZH | 1 |
| Jiang, WP | 1 |
| Jarvis, B | 1 |
| Hryniewicz, K | 2 |
| Androne, AS | 2 |
| Hudaihed, A | 2 |
| Vasil'ev, AP | 1 |
| Strel'tsova, NN | 1 |
| Gorbunova, TIu | 1 |
| Yu, CM | 2 |
| Yip, G | 2 |
| Chan, S | 2 |
| Yandle, TG | 3 |
| Richards, AM | 3 |
| Nicholls, MG | 3 |
| Seymour, AM | 1 |
| Sitnikova, MIu | 2 |
| Shliakhto, EV | 2 |
| Blanchet, M | 2 |
| Ducharme, A | 2 |
| Racine, N | 2 |
| Juneau, M | 2 |
| Marquis, J | 2 |
| Larivée, L | 1 |
| Nigam, A | 1 |
| Fortier, A | 1 |
| Rocha, RM | 1 |
| Silva, GV | 1 |
| Perin, EC | 1 |
| Gerk, AR | 1 |
| Gouvea, EP | 1 |
| Santos, VM | 1 |
| Filho, FM | 1 |
| de Albuquerque, DC | 1 |
| Boucher, JM | 1 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| Heinzl, S | 2 |
| Köszegi, Z | 1 |
| Balogh, E | 1 |
| Bolger, AP | 1 |
| Liebson, PR | 1 |
| Johnsson, G | 1 |
| Aberg, J | 1 |
| Kobayakawa, N | 1 |
| Sawaki, D | 1 |
| Otani, Y | 1 |
| Sekita, G | 1 |
| Fukushima, K | 1 |
| Takeuchi, H | 1 |
| Aoyagi, T | 1 |
| Ahmed, A | 2 |
| Dei Cas, A | 1 |
| Doggrell, SA | 2 |
| Tang, WH | 2 |
| Militello, M | 1 |
| Gupta, R | 1 |
| Konishi, H | 1 |
| Nishio, S | 1 |
| Minouchi, T | 1 |
| Yamaji, A | 1 |
| Bronzetti, G | 1 |
| Prandstraller, D | 1 |
| Bonvicini, M | 1 |
| Kobayashi, M | 1 |
| Voors, AA | 1 |
| van Gilst, WH | 1 |
| van Veldhuisen, DJ | 4 |
| Paul, S | 1 |
| Trupp, RJ | 1 |
| Ramaswamy, K | 1 |
| Alexander, JH | 1 |
| Patel, MR | 1 |
| Gattis, W | 1 |
| Sasayama, S | 1 |
| Toyo-oka, T | 1 |
| Handa, S | 2 |
| Yokoyama, M | 1 |
| Takeshita, A | 1 |
| Origasa, H | 1 |
| Matsui, K | 1 |
| Massie, BM | 6 |
| Feldman, AM | 1 |
| Cohn, JN | 7 |
| Shepherd, AM | 1 |
| Skrzypek, A | 1 |
| Mehta, PA | 1 |
| McDonagh, S | 1 |
| Grocott-Mason, R | 1 |
| Dubrey, SW | 1 |
| Castaigne, A | 4 |
| Trawinski, J | 1 |
| Hoersch, S | 2 |
| Scapellato, F | 1 |
| Temporelli, PL | 1 |
| Eleuteri, E | 1 |
| Ertl, G | 1 |
| Nitschmann, S | 1 |
| Friesewinkel, O | 1 |
| Furrer, M | 1 |
| Hänggi, G | 1 |
| Rutschmann, A | 1 |
| Giesler, G | 1 |
| Lenihan, DJ | 1 |
| Durand, JB | 1 |
| Riegger, G | 2 |
| Hildebrandt, P | 2 |
| Jaarsma, W | 2 |
| Bobbio, M | 3 |
| Soler-Soler, J | 3 |
| Rydén, L | 3 |
| Gallup, DS | 1 |
| Hasselblad, V | 1 |
| Sharpe, N | 10 |
| Lyratzopoulos, G | 1 |
| Cook, GA | 1 |
| McElduff, P | 1 |
| Havely, D | 1 |
| Edwards, R | 1 |
| Heller, RF | 1 |
| Erhardt, L | 3 |
| Charlesworth, A | 7 |
| Sabbadini, G | 2 |
| Moretti, M | 1 |
| Bergström, A | 1 |
| Edner, M | 1 |
| Nylander, E | 1 |
| Persson, H | 1 |
| Dahlström, U | 1 |
| Cohen Solal, A | 1 |
| Jondeau, G | 1 |
| Berdeaux, A | 2 |
| Madeira, H | 1 |
| Thygesen, K | 1 |
| Iyengar, S | 1 |
| Stroe, AF | 1 |
| Moyer-Knox, D | 1 |
| Mueller, TM | 1 |
| Vuckovic, K | 1 |
| Mischke, L | 1 |
| Williams, RE | 2 |
| Cioffi, G | 6 |
| Stefenelli, C | 4 |
| Tarantini, L | 5 |
| Opasich, C | 7 |
| Abdulla, J | 1 |
| Ko, DT | 1 |
| Hebert, PR | 1 |
| Coffey, CS | 1 |
| Curtis, JP | 1 |
| Foody, JM | 1 |
| Sedrakyan, A | 1 |
| Krumholz, HM | 1 |
| Smith, KM | 1 |
| Ruffolo, B | 1 |
| Bauman, JL | 1 |
| Talbert, RL | 2 |
| Nakamura, I | 3 |
| Moritani, K | 1 |
| Suzuki, M | 2 |
| Iwanaga, S | 1 |
| Mitamura, H | 2 |
| Dell'Italia, LJ | 1 |
| Pulignano, G | 4 |
| Del Sindaco, D | 4 |
| De Feo, S | 4 |
| Russo, P | 1 |
| Catania, G | 1 |
| Takeda, Y | 1 |
| Fukutomi, T | 1 |
| Suzuki, S | 1 |
| Ogata, M | 1 |
| Kondo, H | 1 |
| Sugiura, M | 1 |
| Shigeyama, J | 1 |
| Itoh, M | 1 |
| Galatius, S | 1 |
| Gustafsson, F | 1 |
| Hildebrandt, PR | 1 |
| Torp-Pedersen, CT | 1 |
| Sirak, TE | 1 |
| Jelic, S | 1 |
| Le Jemtel, TH | 1 |
| Brostrøm, S | 1 |
| Franciosa, JA | 5 |
| Nelson, JJ | 5 |
| Lottes, S | 1 |
| Fowler, M | 2 |
| Greenberg, B | 5 |
| Razzolini, R | 1 |
| Tarantini, G | 1 |
| Boffa, GM | 1 |
| Orlando, S | 1 |
| Iliceto, S | 1 |
| Jafri, SM | 1 |
| Anh, D | 1 |
| Marine, JE | 1 |
| Leier, CV | 1 |
| Sliwa, K | 1 |
| Norton, GR | 1 |
| Kone, N | 1 |
| Candy, G | 1 |
| Kachope, J | 1 |
| Woodiwiss, AJ | 1 |
| Libhaber, C | 1 |
| Sareli, P | 1 |
| Essop, R | 1 |
| Nordling, MK | 1 |
| Abe, Y | 1 |
| Watanabe, K | 1 |
| Sato, S | 1 |
| Nagai, Y | 1 |
| Kamal, FA | 1 |
| Wahed, MI | 1 |
| Wen, J | 1 |
| Narasimman, G | 1 |
| Ma, M | 1 |
| Suresh, P | 1 |
| Takahashi, T | 2 |
| Tachikawa, H | 1 |
| Kashimura, T | 1 |
| Tanabe, N | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Yamaguchi, K | 1 |
| Miyazaki, M | 1 |
| Kakemi, M | 1 |
| Castro, P | 2 |
| Pérez, O | 2 |
| Padilla, I | 1 |
| Corbalán, R | 3 |
| Ho, WJ | 1 |
| Tsay, PK | 1 |
| Chu, PH | 1 |
| Chang, CJ | 1 |
| Kuo, CT | 1 |
| Chen, WJ | 1 |
| Pittenger, B | 1 |
| Gill, EA | 2 |
| De Matos, LD | 1 |
| Gardenghi, G | 1 |
| Rondon, MU | 1 |
| Soufen, HN | 1 |
| Tirone, AP | 1 |
| Barretto, AC | 1 |
| Middlekauff, HR | 1 |
| McBride, BF | 1 |
| White, CM | 3 |
| Hery, E | 1 |
| El Hallak, A | 1 |
| Mukai, Y | 1 |
| Yoshida, T | 1 |
| Nakaike, R | 1 |
| Mukai, N | 1 |
| Iwato, K | 1 |
| Kyo, T | 1 |
| Kaseda, S | 1 |
| Meyers, DE | 1 |
| Maddicks-Law, J | 1 |
| Seaton, DM | 1 |
| Galbraith, AJ | 1 |
| Cuneo, RC | 1 |
| Acharya, NV | 1 |
| Delea, TE | 2 |
| Stanford, R | 1 |
| Hagiwara, M | 1 |
| Edelsberg, JS | 1 |
| Oster, G | 3 |
| Drapkina, OM | 1 |
| klimenkov, AV | 1 |
| Ivashkin, VT | 1 |
| Shyu, KG | 2 |
| Lu, MJ | 2 |
| Chang, H | 2 |
| Sun, HY | 2 |
| Wang, BW | 2 |
| Kuan, P | 1 |
| Sauls, JL | 1 |
| Rone, T | 1 |
| Olsson, LG | 2 |
| Cleland, J | 1 |
| Murakami, T | 1 |
| Belousov, IuB | 1 |
| Upnitskiĭ, AA | 1 |
| Khanina, NIu | 1 |
| Cinquegrana, G | 1 |
| D'Aniello, L | 1 |
| Landi, M | 1 |
| Spinelli, L | 1 |
| Grande, G | 1 |
| De Prisco, F | 1 |
| Petretta, M | 1 |
| Stewart, S | 1 |
| McMurray, JJ | 2 |
| Hebborn, A | 1 |
| Dalla Libera, L | 1 |
| Ravara, B | 1 |
| Gobbo, V | 1 |
| Danieli Betto, D | 1 |
| Germinario, E | 1 |
| Angelini, A | 1 |
| Vescovo, G | 1 |
| Díez Manglano, J | 1 |
| de Groote, P | 3 |
| Helbecque, N | 1 |
| Lamblin, N | 2 |
| Hermant, X | 1 |
| Mc Fadden, E | 1 |
| Foucher-Hossein, C | 2 |
| Amouyel, P | 2 |
| Dallongeville, J | 1 |
| Bauters, C | 2 |
| Frantz, RP | 2 |
| Olson, LJ | 2 |
| Grill, D | 1 |
| Moualla, SK | 1 |
| Nelson, SM | 1 |
| Nobrega, TP | 1 |
| Hanna, RD | 1 |
| Backes, RJ | 1 |
| Mookadam, F | 1 |
| Heublein, D | 1 |
| Bailey, KR | 1 |
| Burnett, JC | 1 |
| Ekman, I | 2 |
| Finsterer, S | 1 |
| Nentwich, Ch | 1 |
| Silber, S | 1 |
| Quatrini, I | 2 |
| Vecchiato, L | 2 |
| Calabria, P | 1 |
| Gennari, L | 1 |
| Martini, G | 2 |
| Nuti, R | 2 |
| Abbott, JA | 1 |
| Broadstone, RV | 1 |
| Ward, DL | 1 |
| Pyle, RL | 1 |
| Gualco, A | 1 |
| Patrignani, A | 1 |
| Qvigstad, E | 1 |
| Sjaastad, I | 1 |
| Bøkenes, J | 1 |
| Schiander, I | 1 |
| Solberg, L | 1 |
| Sejersted, OM | 1 |
| Osnes, JB | 1 |
| Skomedal, T | 1 |
| Al-Hesayen, A | 2 |
| Hollingshead, S | 1 |
| Lopaschuk, GD | 1 |
| Witte, KK | 2 |
| Thackray, S | 3 |
| Nikitin, NP | 2 |
| Wu, Y | 2 |
| Nie, XY | 1 |
| Hu, DY | 2 |
| Lu, PN | 1 |
| Zhang, GQ | 1 |
| Luo, L | 1 |
| Chazova, IE | 1 |
| Irodova, NL | 1 |
| Krasnikova, TL | 1 |
| Aref'eva, TI | 1 |
| Lazutkina, VK | 1 |
| Orlova, IaA | 1 |
| Sokolov, SF | 1 |
| Ataullakhanova, DM | 1 |
| Masenko, VP | 1 |
| Konovalova, GG | 1 |
| Lankin, VZ | 1 |
| Wolk, R | 1 |
| Johnson, BD | 1 |
| Somers, VK | 1 |
| Allison, TG | 1 |
| Squires, RW | 1 |
| Gau, GT | 1 |
| Reiffel, JA | 1 |
| Kowey, PR | 1 |
| Law, Y | 1 |
| Willenheimer, R | 1 |
| Ponikowski, P | 1 |
| Mc-Nab, P | 1 |
| Quintana, JC | 1 |
| Bittner, A | 1 |
| Vergara, I | 1 |
| Copaja, M | 2 |
| Alcaino, H | 2 |
| Nul, D | 1 |
| Zambrano, C | 1 |
| Diaz, A | 1 |
| Ferrante, D | 1 |
| Varini, S | 1 |
| Soifer, S | 1 |
| Grancelli, H | 1 |
| Doval, H | 1 |
| Sun, YL | 2 |
| Hu, SJ | 2 |
| Wang, LH | 2 |
| Hu, Y | 2 |
| Zhou, JY | 2 |
| Baruch, L | 1 |
| Kunamneni, P | 1 |
| Leung, LY | 1 |
| Yip, GW | 1 |
| Chen, J | 2 |
| Liu, XL | 2 |
| Wu, YF | 2 |
| Li, J | 1 |
| Wang, F | 2 |
| Xu, ZM | 1 |
| Wang, L | 1 |
| Bian, WY | 1 |
| Jia, X | 1 |
| Duan, B | 1 |
| Li, W | 1 |
| Li, YS | 1 |
| McMurray, J | 1 |
| Eichhorn, E | 1 |
| Hobbs, FD | 1 |
| Maggioni, A | 1 |
| McKelvie, RS | 1 |
| Piña, IL | 1 |
| Atchison, DJ | 1 |
| Andersson, G | 1 |
| Figulla, HR | 2 |
| Krzeminska-Pakula, M | 1 |
| Wrabec, K | 1 |
| Chochola, J | 1 |
| Kalmbach, C | 1 |
| Fridl, P | 1 |
| Scali, C | 1 |
| De Paola, V | 1 |
| Iovine, F | 1 |
| Qian, YR | 1 |
| Liu, XY | 1 |
| Hill, J | 2 |
| Fruhwald, F | 1 |
| Sharpe, C | 1 |
| Abraham, G | 1 |
| Zhu, JR | 1 |
| Poy, C | 1 |
| Kragten, JA | 1 |
| Kaumann, A | 1 |
| Ferrua, S | 1 |
| Catalano, E | 1 |
| Grassi, G | 1 |
| Massobrio, N | 1 |
| Pinach, S | 1 |
| Rossi, C | 1 |
| Veglio, M | 1 |
| Trevi, GP | 1 |
| Kaandorp, TA | 1 |
| Lamb, HJ | 1 |
| Bax, JJ | 1 |
| Boersma, E | 1 |
| Viergever, EP | 1 |
| van der Wall, EE | 1 |
| de Roos, A | 1 |
| Rouzet, F | 1 |
| Le Guludec, D | 1 |
| Abergel, E | 1 |
| Syrota, A | 1 |
| Merlet, P | 1 |
| Temple, R | 1 |
| Chizzola, PR | 2 |
| Gonçalves de Freitas, HF | 1 |
| Marinho, NV | 1 |
| Mansur, JA | 1 |
| Meneghetti, JC | 1 |
| Bullinga, JR | 1 |
| Alharethi, R | 1 |
| Schram, MS | 1 |
| Fukumoto, K | 1 |
| Kobayashi, T | 1 |
| Kamakura, S | 1 |
| Ueno, K | 1 |
| Iwata, A | 1 |
| Miura, S | 1 |
| Nishikawa, H | 1 |
| Kawamura, A | 1 |
| Matsuo, Y | 1 |
| Sako, H | 1 |
| Kumagai, K | 1 |
| Matsuo, K | 1 |
| Saku, K | 1 |
| Kametani, R | 1 |
| Miura, T | 1 |
| Harada, N | 1 |
| Shibuya, M | 1 |
| Wang, R | 1 |
| Tan, H | 1 |
| Fukagawa, Y | 1 |
| Kawamura, S | 1 |
| Urrutia, A | 1 |
| Lupón, J | 1 |
| Altimir, S | 1 |
| González, B | 1 |
| Herreros, J | 1 |
| Díez, C | 1 |
| Coll, R | 1 |
| Valle, V | 1 |
| Rey-Joly, C | 1 |
| Andreini, D | 1 |
| Lin, XY | 1 |
| Xiao, LZ | 1 |
| Gao, LJ | 1 |
| Zhang, HF | 1 |
| Stecker, EC | 1 |
| Fendrick, AM | 1 |
| Knight, BP | 1 |
| Aaronson, KD | 1 |
| Spaeder, J | 1 |
| Najjar, SS | 1 |
| Gerstenblith, G | 1 |
| Hefter, G | 1 |
| Kern, L | 1 |
| Palmer, JG | 1 |
| Gottlieb, SH | 1 |
| Kasper, EK | 1 |
| Song, G | 1 |
| Hennessy, M | 1 |
| Zhao, YL | 1 |
| Li, Q | 1 |
| Han, WD | 1 |
| Qi, Y | 1 |
| Zhao, WN | 1 |
| Silke, B | 1 |
| Doyle, R | 1 |
| Spiers, JP | 1 |
| Filipiak, KJ | 1 |
| Opolski, G | 1 |
| Paraskevaidis, IA | 1 |
| Tsiapras, D | 1 |
| Karavolias, G | 1 |
| Adamopoulos, S | 1 |
| Dodouras, T | 1 |
| Cokkinos, P | 1 |
| Kremastinos, DT | 1 |
| Greenway, SC | 1 |
| Benson, LN | 1 |
| Kawashiro, N | 1 |
| Matsuda, N | 1 |
| Endo, Y | 1 |
| Uchida, Y | 1 |
| Kasanuki, H | 1 |
| Baris, N | 2 |
| Kalkan, S | 1 |
| Güneri, S | 2 |
| Bozdemir, V | 1 |
| Guven, H | 1 |
| Sugita, R | 1 |
| Okada, N | 1 |
| Oosato, S | 1 |
| Xu, XL | 1 |
| Zang, WJ | 1 |
| Lu, J | 1 |
| Kang, XQ | 1 |
| Li, M | 1 |
| Yu, XJ | 1 |
| Krauser, DG | 1 |
| Devereux, RB | 1 |
| Berlowitz, DR | 1 |
| Miller, DR | 1 |
| Oliveria, SA | 1 |
| Cunningham, F | 1 |
| Gomez-Caminero, A | 1 |
| Rothendler, JA | 1 |
| Lombardo, RM | 1 |
| Reina, C | 1 |
| Abrignani, MG | 1 |
| Rizzo, PA | 1 |
| Braschi, A | 1 |
| De Castro, S | 1 |
| Aggarwal, A | 1 |
| Wong, J | 1 |
| Campbell, DJ | 1 |
| Akdeniz, B | 1 |
| Savas, IZ | 1 |
| Aslan, O | 1 |
| Badak, O | 1 |
| Kirimli, O | 1 |
| Göldeli, O | 1 |
| Mizuta, Y | 1 |
| Imaizumi, T | 1 |
| Tenero, DM | 2 |
| Campanile, AM | 1 |
| Baidoo, CA | 2 |
| Boyle, D | 2 |
| Mehra, M | 1 |
| Teerlink, JR | 1 |
| McCollum, D | 1 |
| He, H | 1 |
| Wang, W | 1 |
| Zhang, H | 1 |
| Ma, L | 1 |
| Wu, H | 1 |
| Wang, P | 1 |
| Gao, J | 1 |
| Krzemiński, K | 1 |
| Nazar, K | 1 |
| Cybulski, G | 1 |
| Mikulski, T | 1 |
| Singh, TP | 1 |
| Kárpáti, K | 1 |
| Brodszky, V | 1 |
| Farsang, C | 1 |
| Jermendy, G | 1 |
| Vándorfi, G | 1 |
| Zámolyi, K | 1 |
| Gulácsi, L | 1 |
| Lottes, SR | 3 |
| Chiu, KM | 1 |
| Chan, HL | 1 |
| Chu, SH | 1 |
| Drábiková, K | 1 |
| Jancinová, V | 1 |
| Nosál', R | 1 |
| Solík, P | 1 |
| Murín, J | 2 |
| Holománová, D | 1 |
| Arslan, S | 3 |
| Erol, MK | 2 |
| Bozkurt, E | 3 |
| Acikel, M | 2 |
| Gundogdu, F | 3 |
| Atesal, S | 1 |
| Senocak, H | 3 |
| Yancy, C | 1 |
| Nakayama, D | 1 |
| Takada, M | 1 |
| Hirooka, K | 1 |
| Yasumura, Y | 1 |
| Doughty, RN | 5 |
| White, HD | 1 |
| Naono, S | 1 |
| Kotoku, M | 1 |
| Spark, P | 5 |
| Kiziltunc, A | 1 |
| Sevimli, S | 2 |
| Gurlertop, Y | 2 |
| Karakelleoglu, S | 1 |
| De Freitas, O | 1 |
| Lenz, O | 1 |
| Fornoni, A | 1 |
| Materson, BJ | 1 |
| Takekuma, Y | 1 |
| Takenaka, T | 1 |
| Kiyokawa, M | 1 |
| Yamazaki, K | 1 |
| Sugawara, M | 1 |
| Moullet, C | 3 |
| Loh, H | 1 |
| Windram, J | 1 |
| Brixius, K | 1 |
| Lu, R | 1 |
| Boelck, B | 1 |
| Grafweg, S | 1 |
| Hoyer, F | 1 |
| Pott, C | 1 |
| Mehlhorn, U | 1 |
| Bloch, W | 1 |
| Schwinger, RH | 1 |
| Kojima, M | 1 |
| Kimura, G | 1 |
| Ueda, R | 1 |
| Dohi, Y | 1 |
| Zhao, Q | 1 |
| Wu, TG | 1 |
| Jiang, ZF | 1 |
| Chen, GW | 1 |
| Lin, Y | 1 |
| Wang, LX | 1 |
| Goldhammer, E | 1 |
| Maor, I | 1 |
| Shnitzer, S | 1 |
| Lanir, A | 1 |
| Abinader, EG | 1 |
| Aoyama, N | 1 |
| Shimamoto, K | 1 |
| Kawana, M | 1 |
| Cavallari, LH | 1 |
| Momary, KM | 1 |
| Groo, VL | 1 |
| Viana, MA | 1 |
| Camp, JR | 1 |
| Stamos, TD | 1 |
| Silva, CP | 1 |
| Bacal, F | 2 |
| Pires, PV | 1 |
| Mangini, S | 1 |
| Issa, VS | 1 |
| Moreira, SF | 1 |
| Souza, GE | 1 |
| Kawano, S | 1 |
| Kveiborg, B | 1 |
| Major-Petersen, A | 1 |
| Yilmaz, M | 1 |
| Remme, W | 1 |
| Nakanishi, M | 1 |
| Harada, M | 1 |
| Tadamura, E | 1 |
| Kotani, H | 1 |
| Kawakami, R | 1 |
| Kuwahara, K | 1 |
| Usami, S | 1 |
| Kinoshita, H | 1 |
| Fujiwara, M | 1 |
| Ueshima, K | 1 |
| Nakao, K | 1 |
| Zhong, JH | 1 |
| Chen, XP | 1 |
| Yun, ML | 1 |
| Li, WJ | 1 |
| Chen, YF | 1 |
| Yao, Z | 1 |
| Poltavskaia, MG | 1 |
| Syrkin, AL | 1 |
| Andreev, DA | 1 |
| Svet, AV | 1 |
| Sarkisova, EA | 1 |
| Kalashnikov, VIu | 1 |
| Spark, PA | 1 |
| Marinsek, M | 1 |
| Gobec, L | 1 |
| Go, AS | 1 |
| Yang, J | 1 |
| Gurwitz, JH | 1 |
| Hsu, J | 1 |
| Lane, K | 1 |
| Platt, R | 1 |
| Minardi, G | 1 |
| Giovannini, E | 1 |
| Leggio, F | 1 |
| Delour, P | 1 |
| Mouquet, F | 1 |
| Dagorn, J | 1 |
| Hennebert, O | 1 |
| Le Tourneau, T | 1 |
| Verkindère, C | 1 |
| Leschot, NJ | 1 |
| Wilde, AA | 1 |
| Li, N | 1 |
| Li, Y | 1 |
| Jiang, W | 1 |
| Huang, J | 1 |
| Xu, Z | 1 |
| Hua, L | 1 |
| Hua, C | 1 |
| Huang, Y | 1 |
| Li, F | 1 |
| Yang, XC | 1 |
| Wang, SY | 1 |
| Zhu, JG | 1 |
| Albers, S | 1 |
| Meibohm, B | 2 |
| Mir, TS | 2 |
| Johnson, N | 1 |
| Bergougnoux, L | 1 |
| Laperche, T | 1 |
| Jaillon, P | 1 |
| Libionka, A | 1 |
| Kubinyi, A | 1 |
| Konduracka, E | 1 |
| Piwowarska, W | 2 |
| Kasper, ME | 1 |
| Khandwalla, RM | 1 |
| Hirsh, DS | 1 |
| Tseng, CH | 1 |
| Ahuja, K | 1 |
| Mascarenhas, J | 1 |
| Lourenço, P | 1 |
| Lopes, R | 1 |
| Azevedo, A | 1 |
| Bettencourt, P | 1 |
| Kataoka, M | 1 |
| Stepniewski, M | 1 |
| Rector, TS | 2 |
| Anand, IS | 1 |
| Nelson, DB | 1 |
| Ensrud, KE | 1 |
| Triposkiadis, F | 1 |
| Dalampiras, P | 1 |
| Kelepeshis, G | 1 |
| Skoularigis, J | 1 |
| Sitafidis, G | 1 |
| O'Sullivan, JJ | 1 |
| Roche, SL | 1 |
| Crossland, DS | 1 |
| Chaudhari, MP | 1 |
| Kirk, RC | 1 |
| Asif, H | 1 |
| Horiuchi, I | 1 |
| Nozawa, T | 1 |
| Fujii, N | 1 |
| Inoue, H | 1 |
| Honda, M | 1 |
| Shimizu, T | 1 |
| Taguchi, M | 1 |
| Hashimoto, Y | 1 |
| Krantz, MJ | 1 |
| Havranek, EP | 1 |
| Haynes, DK | 1 |
| Smith, I | 1 |
| Bucher-Bartelson, B | 1 |
| Long, CS | 1 |
| Aronson, JK | 1 |
| Carbajal, EV | 1 |
| Lee, YC | 2 |
| Goldsmith, RL | 2 |
| Kukin, ML | 2 |
| Penn, J | 1 |
| Medina, N | 2 |
| Horn, E | 1 |
| McTavish, D | 1 |
| Campoli-Richards, D | 1 |
| Sorkin, EM | 1 |
| Olsen, SL | 1 |
| Renlund, DG | 2 |
| Taylor, DO | 1 |
| Yanowitz, FD | 1 |
| Taylor, SH | 1 |
| Storstein, L | 1 |
| Kelly, DT | 1 |
| Lessem, JN | 1 |
| Raftery, EB | 3 |
| Gu, A | 1 |
| Wilshire-Clement, M | 1 |
| Goldsmith, R | 1 |
| Miller, M | 1 |
| Colucci, WS | 4 |
| Shusterman, NH | 1 |
| Pfeffer, MA | 1 |
| Stevenson, LW | 1 |
| Dib, J | 1 |
| Klein, W | 2 |
| Feuerstein, GZ | 6 |
| Ruffolo, RR | 8 |
| Cosín Aguilar, J | 2 |
| Böhm, M | 5 |
| Erdmann, E | 2 |
| Moyé, LA | 3 |
| Abernethy, D | 1 |
| von Olshausen, K | 1 |
| Pop, T | 1 |
| Berger, J | 1 |
| Kwasniewski, R | 1 |
| Clem, J | 1 |
| Demopoulos, L | 1 |
| Yeh, M | 1 |
| Gentilucci, M | 1 |
| Testa, M | 1 |
| Bijou, R | 1 |
| Mancini, D | 1 |
| Jones, M | 1 |
| LeJemtel, TH | 1 |
| Whalley, GA | 2 |
| Gamble, G | 2 |
| MacMahon, S | 6 |
| Rodgers, A | 1 |
| Pickl, S | 1 |
| Antepohl, W | 1 |
| Herzig, S | 1 |
| Kukin, M | 1 |
| Feuerstein, G | 1 |
| Kinhal, V | 1 |
| Krueger, SK | 1 |
| Lejemtel, T | 1 |
| Narahara, KA | 1 |
| Young, ST | 3 |
| Bigger, JT | 1 |
| Bloomfield, DM | 1 |
| Steinman, RC | 1 |
| Gordon, A | 1 |
| Voipio-Pulkki, LM | 1 |
| Willette, RN | 2 |
| Mitchell, MP | 2 |
| Ohlstein, EH | 3 |
| Boccanelli, A | 1 |
| Camerini, F | 1 |
| Maggioni, AP | 1 |
| Rapezzi, C | 1 |
| Scherillo, M | 1 |
| Tavazzi, L | 1 |
| Neal, CP | 1 |
| Kendrach, MG | 1 |
| Hansson, L | 1 |
| Pontone, G | 2 |
| Trevisi, N | 1 |
| Lomanto, M | 1 |
| Matturri, M | 2 |
| Quaife, RA | 1 |
| Christian, PE | 1 |
| Datz, FL | 1 |
| Volkman, K | 1 |
| Schmidt, BM | 2 |
| Janson, CP | 1 |
| Wehling, M | 3 |
| Darlington, MR | 1 |
| Fazio, S | 1 |
| Palmieri, EA | 1 |
| Ferravante, B | 1 |
| Bonè, F | 1 |
| Biondi, B | 1 |
| Saccà, L | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| Bellotti, G | 1 |
| Carrara, D | 1 |
| Ramires, JA | 1 |
| Vanderhoff, BT | 1 |
| Ruppel, HM | 1 |
| Amsterdam, PB | 1 |
| Simpson, SH | 1 |
| Tsuyuki, RT | 1 |
| Gutierrez, R | 1 |
| Lo, A | 1 |
| Teo, KK | 1 |
| Roden, RL | 1 |
| Lowes, BD | 6 |
| Eichhorn, EJ | 5 |
| Andréjak, M | 1 |
| Slama, M | 1 |
| Pornin, M | 1 |
| Van Viet, H | 1 |
| Hamdan, MH | 1 |
| Shusterman, N | 2 |
| Doughty, R | 2 |
| Ikram, H | 1 |
| Espiner, EA | 2 |
| Frampton, C | 2 |
| Fisher, LD | 2 |
| Aiyar, N | 1 |
| Yue, TL | 1 |
| Disa, J | 1 |
| Storer, BL | 1 |
| Naselsky, DP | 1 |
| Stadel, JM | 1 |
| Aboyoun, CL | 1 |
| Lund, M | 2 |
| Amor, R | 2 |
| Phillips, L | 1 |
| Singer, RB | 1 |
| Vera-Llonch, M | 2 |
| Richner, RE | 1 |
| Conti, CR | 1 |
| Larrain, JR | 1 |
| Cohn, LJ | 1 |
| Böhler, S | 1 |
| Saubadu, S | 1 |
| Scheldewaert, R | 1 |
| Carson, PE | 1 |
| Guazzi, MD | 1 |
| Pamboukian, SV | 1 |
| Aminbakhsh, A | 1 |
| Thompson, CR | 1 |
| Amin, H | 1 |
| Mortimer, S | 1 |
| D'yachkova, Y | 1 |
| Ignaszweski, AP | 1 |
| Aboyoun, C | 1 |
| McCaffrey, D | 1 |
| Hoffmann, J | 1 |
| Grimm, W | 1 |
| Menz, V | 1 |
| Hufnagel, G | 1 |
| Maisch, B | 1 |
| vom Dahl, J | 1 |
| Schotten, U | 1 |
| Sasse, A | 1 |
| Chan, KW | 1 |
| Raymond, K | 1 |
| Woo, KS | 1 |
| Hoffman, I | 1 |
| Witkowska, M | 1 |
| McCormick, SA | 1 |
| Davies, G | 1 |
| Burgess, M | 1 |
| Webster, J | 1 |
| Slomka, P | 1 |
| Atkinson, P | 1 |
| Grayburn, PA | 1 |
| Capomolla, S | 3 |
| Febo, O | 2 |
| Gnemmi, M | 2 |
| Riccardi, G | 1 |
| Caporotondi, A | 2 |
| Mortara, A | 3 |
| Pinna, GD | 3 |
| Cobelli, F | 3 |
| Nägele, H | 2 |
| Bohlmann, M | 1 |
| Eck, U | 1 |
| Petersen, B | 2 |
| Rödiger, W | 2 |
| Garlichs, C | 1 |
| Daniel, WG | 1 |
| Reddy, P | 1 |
| Dunn, AB | 1 |
| Yokozuka, H | 1 |
| Okada, Y | 1 |
| Nagami, K | 1 |
| Maack, C | 2 |
| Cremers, B | 1 |
| Flesch, M | 1 |
| Höper, A | 1 |
| Südkamp, M | 1 |
| Gottlieb, SS | 1 |
| Boldi, E | 2 |
| Modena, MG | 1 |
| Dickerson, LM | 1 |
| Carek, PJ | 1 |
| Tenero, D | 1 |
| Boike, S | 1 |
| Ilson, B | 1 |
| Fesniak, HF | 1 |
| Brozena, S | 1 |
| Jorkasky, D | 1 |
| Pennel, D | 1 |
| Ray, S | 1 |
| Murray, G | 1 |
| MacFarlane, P | 1 |
| Cowley, A | 1 |
| Coats, A | 1 |
| Owen, A | 1 |
| Denbow, CE | 1 |
| Port, JD | 2 |
| Chen, T | 1 |
| Einecke, D | 1 |
| Ochiai, N | 1 |
| Furukawa, K | 1 |
| Ebizawa, T | 1 |
| Yagi, T | 1 |
| Akashi, K | 1 |
| Azuma, A | 1 |
| Sugihara, H | 1 |
| Whorlow, SL | 1 |
| Vítovec, J | 1 |
| Spinar, J | 1 |
| Wu, B | 1 |
| Berger, R | 1 |
| Strecker, K | 1 |
| Hülsmann, M | 1 |
| Frey, B | 1 |
| Pacher, R | 1 |
| Stanek, B | 1 |
| La Rovere, MT | 2 |
| Maestri, R | 2 |
| Ninio, D | 1 |
| MacDonald, P | 1 |
| Luparini, RL | 1 |
| Celli, V | 1 |
| Cacciafesta, M | 1 |
| Witte, K | 1 |
| Cooklin, M | 1 |
| Kendall, MJ | 1 |
| Rössig, L | 1 |
| Haendeler, J | 1 |
| Mallat, Z | 1 |
| Hugel, B | 1 |
| Freyssinet, JM | 1 |
| Tedgui, A | 1 |
| Dimmeler, S | 1 |
| Zeiher, AM | 1 |
| Movahed, A | 1 |
| Chavey, WE | 1 |
| Hart, SM | 1 |
| Arumanayagam, M | 1 |
| Tong, S | 1 |
| Kulbertus, H | 1 |
| De Vecchis, R | 1 |
| Pucciarelli, G | 1 |
| Setaro, A | 1 |
| Nocerino, L | 1 |
| Motta, J | 1 |
| Pichel, D | 1 |
| Nuñez, P | 1 |
| Arrocha, A | 1 |
| Calzada, N | 1 |
| Ferrara, L | 1 |
| Di Benedetto, A | 1 |
| Russo, PE | 1 |
| Marinelli, G | 1 |
| Pavese, F | 1 |
| Iacono, A | 1 |
| Graff, DW | 1 |
| Williamson, KM | 1 |
| Pieper, JA | 1 |
| Carson, SW | 1 |
| Cascio, WE | 1 |
| Patterson, JH | 1 |
| Bol'shakova, OO | 1 |
| Brodskaia, IS | 1 |
| Kozlova, SN | 1 |
| Krutikov, AN | 1 |
| Schleman, KA | 1 |
| Lindenfeld, JA | 1 |
| Ferguson, D | 1 |
| Wolfel, EE | 1 |
| Zisman, LS | 1 |
| Lévy, P | 1 |
| Dubois-Randé, JL | 1 |
| Lévy, E | 1 |
| Conraads, V | 1 |
| Brutsaert, D | 1 |
| Vrints, C | 1 |
| Spicer, RL | 1 |
| Chrisant, MK | 1 |
| Hallowell, S | 1 |
| Gregory, D | 1 |
| Konstam, MA | 2 |
| Wood, AJ | 1 |
| Moe, G | 1 |
| Lacey, MJ | 1 |
| Richner, R | 1 |
| Johnston, L | 1 |
| Vaddadi, G | 1 |
| Brunner-LaRocca, H | 1 |
| Jennings, GL | 1 |
| Esler, MD | 1 |
| Wallhaus, TR | 1 |
| Taylor, M | 1 |
| DeGrado, TR | 1 |
| Russell, DC | 1 |
| Stanko, P | 1 |
| Nickles, RJ | 1 |
| Stone, CK | 1 |
| Antonopoulos, GV | 1 |
| Berlin, JA | 1 |
| Chittams, J | 1 |
| de Boer, RA | 2 |
| Siebelink, HJ | 1 |
| Tio, RA | 1 |
| Boomsma, F | 1 |
| Forissier, JF | 1 |
| Vernochet, P | 1 |
| Bertrand, P | 1 |
| Charbonnier, B | 1 |
| Monpère, C | 1 |
| Stoschitzky, K | 2 |
| Koshucharova, G | 1 |
| Zweiker, R | 1 |
| Maier, R | 1 |
| Watzinger, N | 1 |
| Fruhwald, FM | 1 |
| Varney, S | 1 |
| Louis, A | 1 |
| Crabbe, S | 1 |
| Ford, S | 1 |
| Houghton, T | 1 |
| Clark, A | 1 |
| Tillmann, HC | 2 |
| Sponer, G | 3 |
| Braunwald, E | 1 |
| Murphy, J | 1 |
| Lee, S | 1 |
| Spencer, A | 1 |
| SoRelle, R | 1 |
| Coutinho, J | 1 |
| Correia, JM | 1 |
| Cheng, J | 1 |
| Kodama, I | 2 |
| Agarwal, AK | 1 |
| Venugopalan, P | 1 |
| Kumar, A | 1 |
| Choudhary, G | 1 |
| Antonio, C | 1 |
| Just, V | 1 |
| Jain, A | 1 |
| Heaney, L | 1 |
| Papp, MA | 1 |
| Levy, AR | 1 |
| Briggs, AH | 1 |
| Demers, C | 1 |
| O'Brien, BJ | 1 |
| Hernándiz Martínez, A | 1 |
| Negut, C | 1 |
| Sabio, JM | 1 |
| Jiménez-Alonso, J | 1 |
| Khattar, RS | 1 |
| Senior, R | 2 |
| Soman, P | 1 |
| van der Does, R | 3 |
| Czuriga, I | 1 |
| Edes, I | 1 |
| Elter, T | 1 |
| Nickenig, G | 1 |
| LaRosee, K | 1 |
| Crivaro, M | 1 |
| Stäblein, A | 1 |
| Wuttke, H | 1 |
| Mak, S | 1 |
| Schofield, A | 1 |
| Allan, R | 1 |
| Kelly, S | 1 |
| Guazzotti, G | 1 |
| Sleiman, OI | 1 |
| Ghanem, WM | 1 |
| Yildirir, A | 1 |
| Sade, E | 1 |
| Tokgozoglu, L | 1 |
| Oto, A | 1 |
| Cheng, JH | 1 |
| Tsvetkova, T | 1 |
| Feuring, M | 1 |
| Jester, I | 1 |
| Bertsch, T | 1 |
| Kugler, I | 1 |
| Doing, AH | 1 |
| Smith, RA | 1 |
| Richardt, G | 1 |
| Richardt, D | 1 |
| Adler, S | 1 |
| Kraatz, E | 1 |
| Nötzold, A | 1 |
| Kurz, T | 1 |
| Comin-Colet, J | 1 |
| Sánchez-Corral, MA | 1 |
| Manito, N | 1 |
| Gómez-Hospital, JA | 1 |
| Roca, J | 1 |
| Fernández-Nofrerias, E | 1 |
| Valdovinos, P | 1 |
| Esplugas, E | 1 |
| Taccetta-Chapnick, M | 1 |
| Kindermann, M | 1 |
| Heitmann, M | 1 |
| Davidsen, U | 1 |
| Stokholm, KH | 1 |
| Rasmussen, K | 1 |
| Burchardt, H | 1 |
| Petersen, EB | 1 |
| Schomburg, R | 1 |
| Woods, D | 1 |
| Prirzker, MR | 1 |
| Fulla, Y | 1 |
| Hagege, A | 1 |
| J Remme, W | 1 |
| Gardner, RS | 1 |
| McGowan, J | 1 |
| McDonagh, TA | 1 |
| Behn, F | 1 |
| Eiselt, M | 1 |
| Scholz, H | 1 |
| Venzke, A | 1 |
| Weil, J | 1 |
| Ridha, M | 1 |
| Mäkikallio, TH | 1 |
| Lopera, G | 1 |
| Pastor, J | 1 |
| de Marchena, E | 1 |
| Chakko, S | 1 |
| Huikuri, HV | 1 |
| Castellanos, A | 1 |
| Myerburg, RJ | 1 |
| Bøttcher, M | 1 |
| Nielsen, TT | 1 |
| Okay, T | 1 |
| Larrabee, P | 1 |
| Müller-Beckmann, B | 3 |
| Minobe, W | 1 |
| Roden, R | 1 |
| Skerl, L | 1 |
| Klein, J | 1 |
| Handwerger, D | 1 |
| DasGupta, P | 4 |
| Strein, K | 2 |
| Bartsch, W | 1 |
| Broadhurst, P | 2 |
| Buchwald, A | 1 |
| Unterberg, C | 1 |
| Wiegand, V | 1 |
| Das Gupta, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Carvedilol on Exercise Performance in Fontan Patients[NCT02946892] | Phase 4 | 26 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Assessment of Clinical Effect and Treatment Quality of Rapid Release Carvedilol Versus SLOW Release Carvedilol-SR in HEART FAILURE Patient (SLOW-HF): A Prospective Randomized, Open-label, Multicenter Study[NCT03209180] | Phase 4 | 320 participants (Anticipated) | Interventional | 2016-10-27 | Recruiting | ||
| Registry (Prospective Cohort) for Heart Failure in Korea (KorAHF)[NCT01389843] | 5,625 participants (Actual) | Observational | 2011-03-31 | Completed | |||
| Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy[NCT00180271] | 1,820 participants (Actual) | Interventional | 2004-12-31 | Completed | |||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
| Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial[NCT02717507] | Phase 2 | 196 participants (Actual) | Interventional | 2016-04-04 | Active, not recruiting | ||
| Comparative Effects of Nebivolol and Carvedilol on Diastolic Function of the Left Ventricle in the Elderly Heart Failure Patients With Preserved Ejection Fraction: Study Protocol for a Randomized Controlled Trial[NCT02619526] | 62 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | |||
| Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446] | 81 participants (Anticipated) | Observational [Patient Registry] | 2017-11-02 | Recruiting | |||
| The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment[NCT00585091] | 15 participants (Actual) | Interventional | 2003-10-31 | Completed | |||
| Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR vs Twice-Daily COREG Immediate Release(IR)on Measures of Compliance and Quality of Life in Patients With Heart Failure and Left Ventricular Systolic Dysfunction[NCT00272805] | Phase 3 | 400 participants | Interventional | 2005-10-31 | Completed | ||
| Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study.[NCT03392740] | Phase 4 | 200 participants (Anticipated) | Interventional | 2018-03-15 | Not yet recruiting | ||
| Early Detection of Late Anthracycline Induced Cardiotoxicity in Survivors of Childhood Malignancy[NCT04852965] | 208 participants (Anticipated) | Observational | 2021-10-20 | Recruiting | |||
| Identification of Biomarkers for Heart Failure in Children With Single Ventricle Physiology[NCT00571233] | 71 participants (Actual) | Observational | 2007-02-28 | Completed | |||
| Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function[NCT00517725] | Phase 4 | 60 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [NCT00497003] | Phase 4 | 50 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Study to Evaluate the Safety and Tolerability of SK&F-105517-D in Patients With Chronic Heart Failure- An Open-label Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SK&F-105517-D in Patients With Chronic Heart Fai[NCT00742508] | Phase 1 | 41 participants (Actual) | Interventional | 2008-08-28 | Completed | ||
| A Multicenter, Placebo-Controlled, 8-Month Study of the Effect of Twice Daily Carvedilol in Children With Congestive Heart Failure Due to Systemic Ventricular Systolic Dysfunction[NCT00052026] | Phase 3 | 161 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure[NCT01971944] | 50 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment[NCT03387605] | Phase 4 | 40 participants (Anticipated) | Interventional | 2018-03-15 | Recruiting | ||
| Efficacy of an m-Health Cardiac Rehabilitation Program in Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Controlled Trial[NCT05002075] | 80 participants (Anticipated) | Interventional | 2021-11-20 | Recruiting | |||
| Effects of Nebivolol Versus Metoprolol on Blood Flow Responses to Exercise and Angiotensin II in Hypertensive Patients[NCT01502787] | Phase 4 | 46 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Ivabradine Initiated at the Time of Discharge From the Observation Unit[NCT03168529] | Phase 4 | 132 participants (Anticipated) | Interventional | 2018-07-01 | Recruiting | ||
| A Mechanistic Study to Assess The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)[NCT02354573] | 121 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384] | 52 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)[NCT02398929] | Phase 4 | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Effects of a Mindfulness-Based Intervention on Symptoms and Signs, Well-Being and Health in Patients With Chronic Heart Failure[NCT04871178] | 50 participants (Actual) | Interventional | 2010-10-10 | Completed | |||
| The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612] | 7,057 participants (Actual) | Observational [Patient Registry] | 2009-05-31 | Completed | |||
| Wearable Remote Monitoring of Heart Rate and Respiratory Rate for Heart Failure[NCT04455828] | 0 participants (Actual) | Observational | 2021-03-01 | Withdrawn (stopped due to IRB Approval lapsed) | |||
| Remote Physiologic Monitoring to Detect Inflammatory Bowel Disease (IBD) Flares: A Feasibility Study[NCT04333810] | 8 participants (Actual) | Observational | 2020-10-01 | Completed | |||
| Remote Physiologic Monitoring of Resident Wellness and Burnout[NCT04304703] | 38 participants (Actual) | Observational | 2020-07-03 | Completed | |||
| Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects.[NCT00924833] | Phase 4 | 27 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037] | Phase 3 | 318 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients[NCT00344513] | Phase 4 | 50,000 participants | Interventional | 2002-12-16 | Completed | ||
| The Prevalence and Risk Factors of Sleep Disordered Breathing in a Heart Failure Program[NCT00679822] | 195 participants (Actual) | Observational | 2007-06-30 | Completed | |||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| Effects of Inpatient Initiation of Carvedilol and Nurse Management on Health Outcomes in Vulnerable Heart Failure Patients (ECHO Study): a Randomized Trial[NCT00381030] | Phase 4 | 100 participants | Interventional | 2002-10-31 | Completed | ||
| Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.[NCT01870310] | 50 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | |||
| Congestive Heart Failure Atrial Arrhythmia Monitoring and Pacing (CHAMP)[NCT00156728] | Phase 4 | 172 participants | Interventional | 2003-10-31 | Completed | ||
| A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart[NCT00326690] | 0 participants (Actual) | Interventional | 2005-11-30 | Withdrawn (stopped due to Unable to recruit and enroll patients) | |||
| Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442] | 18,240 participants (Anticipated) | Observational | 2008-08-31 | Enrolling by invitation | |||
| Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study[NCT04397302] | 652 participants (Actual) | Observational [Patient Registry] | 2019-01-13 | Completed | |||
| Lung Water By Ultra-Sound Guided Treatment To Prevent Death and Cardiovascular Complications in High Risk End Stage Renal Disease Patients With Cardiomyopathy (Lust Study)[NCT02310061] | 383 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Beta-blocker Uptitration in Heart Failure Patients Receiving Cardiac Resynchronization Therapy With Optivol Fluid Status Monitoring System[NCT00433043] | Phase 4 | 2 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to Insufficient enrollment) | ||
| Modified Ross Score for Evaluation of Heart Failure in Children With Lower Respiratory Tract[NCT03885050] | 100 participants (Anticipated) | Observational | 2019-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
during exercise test on week 12 and week 30 (NCT02946892)
Timeframe: on week 12 and week 30 of the study
| Intervention | ml/kg/min (Mean) |
|---|---|
| Carvedilol | -1.02 |
| Placebo | -1.78 |
during exercise test on week 12 and week 30 (NCT02946892)
Timeframe: on week 12 and week 30 of the study
| Intervention | beats per minute (Mean) |
|---|---|
| Carvedilol | -32.3 |
| Placebo | 1.9 |
during exercise test on week 12 and week 30 (NCT02946892)
Timeframe: on week 12 and week 30 of the study
| Intervention | ml/kg/min (Mean) |
|---|---|
| Carvedilol | -2.01 |
| Placebo | -1.01 |
"MADIT-CRT was an event-driven trial in which patients were monitored for all-cause mortality and HF events. An HF event was defined as either hospitalization for symptoms and/or signs consistent with congestive HF and:~administration of intravenous decongestive therapy that does not involve formal in-patient hospital admission, regardless of the setting (i.e. in an emergency room setting, in the physician's office, etc.), or~administration of an augmented HF regimen with oral or intravenous medications during an in-hospital stay." (NCT00180271)
Timeframe: Outcome measured at average follow-up duration of 2.4 years.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Patients who are Event Free | Patients with Death or Heart Failure Event | Patients with Heart Failure Event Alone | Patients with Death at Any Time | |
| Cardiac Resynchronization Therapy + Defibrillator | 901 | 188 | 152 | 74 |
| Implantable Cardioverter Defibrillator Alone | 543 | 188 | 170 | 53 |
The number of pills taken out of the total prescribed in a 3-month period, averaged across all study time points. The proportion of participants with average adherence rate >90% is computed by arm and corresponding 95% confidence intervals are reported. (NCT02717507)
Timeframe: Average adherence across 6 months, 12 months, 18 months, 24 months after treatment initiation are calculated.
| Intervention | proportion of participants (Number) |
|---|---|
| Arm I (Carvedilol) | 0.483 |
| Arm II (Placebo) | 0.517 |
Patients with toxicities reported via CTEP-AERS and all Grade ≥ 2 adverse events (AEs) that can be attributed probably or definitely to the study drug are considered to have AEs. The proportion of patients with AEs are reported by arm with corresponding 95% confidence intervals. (NCT02717507)
Timeframe: From baseline to month 24 since baseline
| Intervention | Proportion of patients with AE (Number) |
|---|---|
| Arm I (Carvedilol) | 0.0267 |
| Arm II (Placebo) | 0 |
"In a questionnaire, patients responded Yes/No to certain symptoms. If answered Yes, they selected slightly, moderately, quite a bit, or extremely regarding how bothersome the symptom was. The proportion of participants responding with any of these three categories was calculated by arm, and corresponding 95% confidence intervals are reported." (NCT02717507)
Timeframe: responses at days 14 to 730 were combined
| Intervention | Proportion of patients (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | Skin rash | Itchy skin | Dry Mouth | Easy bruising | Nosebleeds | Sunburn easily | Weight gain | Fluid retention | Swollen feet | Increased sweating | Feeling weak in parts of your body | Shortness of breath or wheezing | Chest pain or heaviness | Heart racing or skipping beats | Feeling shaky or having tremors | Decreased bodily movement | Feeling nervous | Feeling downhearted, sad, and/or tearful | Mood swings | Dizziness and/or lightheadedness | Dizziness upon standing (from sitting or lying down) | Insomnia | Difficulty concentrating | Interrupted sleep | Tendency to take naps | TiredwheezingFeeling unusually tired | Falling asleep at inappropriate times | Ringing in the ears | Difficulty breathing | Sensation that I have to urinate much of the time | Discoloration of urine (ie, bloody) | Decreased libido | Unusually heavy menstrual flows (N/A if postmenopausal or male) | |
| Arm I (Carvedilol) | 0.0533 | 0.0933 | 0.1467 | 0.0667 | 0.0133 | 0.0667 | 0.0933 | 0.0533 | 0.0267 | 0 | 0.0933 | 0.0933 | 0.0933 | 0.08 | 0.08 | 0.0533 | 0.0133 | 0.1467 | 0.2 | 0.12 | 0.16 | 0.1467 | 0.1733 | 0.1067 | 0.2 | 0.12 | 0.2267 | 0.0267 | 0.0533 | 0.0267 | 0.0667 | 0 | 0.0667 | 0.2 |
| Arm II (Placebo) | 0.1316 | 0.0789 | 0.1447 | 0.1711 | 0.0921 | 0.0526 | 0.0526 | 0.0789 | 0.0395 | 0.0921 | 0.0789 | 0.1316 | 0.0395 | 0.0921 | 0.0395 | 0.0789 | 0.0395 | 0.1711 | 0.1184 | 0.0921 | 0.1316 | 0.1579 | 0.1711 | 0.1316 | 0.2105 | 0.1053 | 0.2237 | 0.0395 | 0.0921 | 0 | 0.0789 | 0.0395 | 0.0526 | 0.111 |
A liver function measurement (in U/L). Normal range is 8-48 IU/L. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | IU/L (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 29.122 | 28.014 | 30.148 | 27.196 | 29.86 |
| Arm II (Placebo) | 30.467 | 32.158 | 31.155 | 30.536 | 29.245 |
A liver function measurement (in U/L). Normal range is 14-20 for men, 10-36 for women. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | IU/L (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 26.608 | 24.068 | 25.426 | 24.375 | 24.561 |
| Arm II (Placebo) | 25.773 | 26.342 | 27.014 | 28.411 | 27.038 |
A liver function measurement (in mg/dL). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 0.5634 | 0.5973 | 0.563 | 0.593 | 0.5561 |
| Arm II (Placebo) | 0.4989 | 0.4942 | 0.4969 | 0.507 | 0.5449 |
N-terminal pro b-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | pg/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 85.6301 | 90.7536 | 87.7167 | 99.4912 | 101.8333 |
| Arm II (Placebo) | 115.7222 | 128.9565 | 115.6364 | 93.2105 | 107.849 |
Troponin I is a biomarker for myocardial cell injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 0.00446 | 0.00265 | 0.00467 | 0.00737 | 0.01111 |
| Arm II (Placebo) | 0.0011 | 0.00174 | 0.00742 | 0.00684 | 0.01132 |
The percentage of blood leaving the heart at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | Percent (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 57.6 | 58.16 | 58.07 | 57.35 | 58.16 |
| Arm II (Placebo) | 57.42 | 56.84 | 56.61 | 57.6 | 57.5 |
A measure to assess preload and afterload (in %). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | percent (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 28.5362 | 28.5409 | 29.6121 | 27.8219 | 28.0302 |
| Arm II (Placebo) | 28.4339 | 27.6866 | 28.1085 | 27.8891 | 28.5953 |
A protein produced by activated macrophages, and a member of a family of β-galactoside-binding lectings and promotes cardiac fibroblast proliferation and collagen synthesis following myocadial injury (in ng/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ng/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 4.4464 | 4.3252 | 3.7345 | 3.4548 | 3.8073 |
| Arm II (Placebo) | 5.2538 | 4.3735 | 4.3415 | 4.0214 | 4.0791 |
The amount of blood (in ml) in the heart's left ventricle just before the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 99.7507 | 99.3216 | 102.378 | 101.174 | 100.659 |
| Arm II (Placebo) | 93.3155 | 95.7434 | 96.5002 | 99.4656 | 98.9602 |
Thickness of cardiac muscle (in ml) of the left ventricle at the end of diastole. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24 | |
| Arm I (Carvedilol) | 4.5836 | 4.6035 | 4.636 | 4.6032 | 4.5147 |
| Arm II (Placebo) | 4.5269 | 4.565 | 0.0556 | 4.5462 | 4.5976 |
The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | centimeter (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 03.2765 | 3.2901 | 3.262 | 3.32 | 3.2441 |
| Arm II (Placebo) | 3.2396 | 3.3023 | 3.2964 | 3.2798 | 3.286 |
The amount of blood (in ml) in the heart's left ventricle just after the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ml (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 42.2193 | 41.6128 | 42.8437 | 43.1453 | 42.0086 |
| Arm II (Placebo) | 39.7354 | 41.3839 | 41.8113 | 1.605 | 42.442 |
Echocardiographic measure of left ventricular (LV) afterload based on LV pressure (P), volume (V), and wall thickness (T), calculated by the formula (P x V)/T, which equals the number referred to below in the Measure Type. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | g/cm^2 (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 93.2892 | 90.3088 | 88.984 | 93.9267 | 89.2513 |
| Arm II (Placebo) | 90.6135 | 96.8356 | 96.0616 | 91.6458 | 94.0647 |
The weight of the left ventricle adjusted for body surface area (in g/m2). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | g/m2 (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 57.4862 | 58.2839 | 60.2116 | 57.7053 | 58.3315 |
| Arm II (Placebo) | 57.9322 | 57.0924 | 59.4508 | 59.1793 | 59.1026 |
Z-score of the ratio of left ventricular (LV) posterior wall dimension of systole to internal LV dimension in diastole, calculated for each subject by subtracting the reference healthy population mean, then dividing by the standard deviation. The Z-score indicates the number of standard deviations away from the mean of the reference population. Negative Z- score indicates worse outcome. The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | z-score (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | -0.1372 | -0.2167 | -0.2416 | -0.2375 | 0.0213 |
| Arm II (Placebo) | -0.0893 | 0.3215 | -0.2367 | -0.1974 | 0.1834 |
B-type natriuretic peptide- a biomarker for heart failure (in pg/ml). The mean is reported by arm at each timepoint with corresponding standard errors. (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | pg/mL (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 27.3836 | 31.8406 | 26.8203 | 35.807 | 34.625 |
| Arm II (Placebo) | 31.4324 | 34.1857 | 33.2941 | 32.2807 | 33.3774 |
"Ratio of peak velocity blood flow from left ventricular relaxation in early diastole (E wave) to peak velocity flow in late diastole caused by atrial contraction (A wave). Number shown for Unit of Measure refers to this ratio. Normal: >1. Impaired: <1. The mean is reported by arm at each timepoint with corresponding standard errors." (NCT02717507)
Timeframe: Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation
| Intervention | ratio (Mean) | ||||
|---|---|---|---|---|---|
| BL | 6m | 12m | 18m | 24m | |
| Arm I (Carvedilol) | 1.728 | 1.642 | 1.723 | 1.732 | 1.603 |
| Arm II (Placebo) | 1.732 | 0.071 | 1.722 | 1.732 | 1.64 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | units per liter (U/L) (Mean) |
|---|---|
| CRV-IR | -10.2 |
| SK&F-105517-D | -0.1 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | beats per minute (Mean) |
|---|---|
| CRV-IR | -10.4 |
| SK&F-105517-D | -10.6 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | proportion of 1 (SI) (Mean) |
|---|---|
| CRV-IR | -0.0085 |
| SK&F-105517-D | -0.0095 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | picograms (pg) (Mean) |
|---|---|
| CRV-IR | 0.12 |
| SK&F-105517-D | -0.21 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | femtoliters (fL) (Mean) |
|---|---|
| CRV-IR | 0.1 |
| SK&F-105517-D | -0.1 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | tebi (2 to the power of 40)/liter (Ti/L) (Mean) |
|---|---|
| CRV-IR | -0.091 |
| SK&F-105517-D | -0.087 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | kilograms (kg) (Mean) |
|---|---|
| CRV-IR | 0.29 |
| SK&F-105517-D | -0.11 |
Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | millimeters of mercury (mmHg) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 24 h | Morning | Afternoon | Night | Waking | Sleeping | PDmax | PDmin | PDmax/PDmin | |
| CRV-IR | -7.10 | -7.68 | -5.32 | -9.01 | -5.11 | -12.68 | -10.45 | -1.34 | -0.24 |
| SK&F-105517-D | -4.89 | -8.24 | -10.25 | 0.73 | -8.56 | 5.38 | -17.91 | -0.24 | -0.36 |
Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | beats per minute (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 24 h | Morning | Afternoon | Night | Waking | Sleeping | PDmax | PDmin | PDmax/PDmin | |
| CRV-IR | -11.38 | -9.59 | -13.96 | -11.12 | -12.53 | -11.16 | -13.43 | -2.04 | -0.93 |
| SK&F-105517-D | -15.37 | -14.87 | -15.93 | -15.26 | -15.53 | -14.28 | -23.43 | -3.47 | -1.27 |
Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | millimeters of mercury (mmHg) (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 24 h | Morning | Afternoon | Night | Waking | Sleeping | PDmax | PDmin | PDmax/PDmin | |
| CRV-IR | -10.84 | -12.34 | -10.14 | -9.04 | -10.39 | -11.85 | -9.74 | -6.89 | 0.07 |
| SK&F-105517-D | -1.45 | -4.78 | -12.06 | 5.17 | -9.99 | 13.20 | -10.19 | 1.42 | -0.17 |
Area under the plasma concentration versus time curve from time zero to 24 hours (AUC0-24) of S-carvedilol, R-carvedilol, and M4 active metabolite (SB-203231) was measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK&F-105517-D group and Groups D, E, and F in the CRV-IR group. The analysis was performed on log-transformed data. Carvedilol is a racemic mixture. Non-selective β-blocking activity is shown by S-carvedilol, while α1-blocking activity is shown by both S-carvedilol and R-carvedilol. (NCT00742508)
Timeframe: Week 8
| Intervention | hours * nanograms per milliliter (ng/mL) (Geometric Mean) | ||
|---|---|---|---|
| S-carvedilol | R-carvedilol | SB-203231 | |
| CRV-IR | 60.040 | 170.728 | 28.113 |
| SK&F-105517-D | 155.109 | 284.313 | 64.687 |
Cardiothoracic ratio is a marker of the degree of heart enlargement and was measured by chest X-ray. It is shown as the ratio of the transverse diameter of the heart to the transverse diameter of the thorax, and is measured as a percentage. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline, n=22, 19 | Week 8, n=11, 8 | |
| CRV-IR | 53.70 | 50.91 |
| SK&F-105517-D | 53.58 | 52.35 |
Left ventricular ejection fraction (LVEF) is a marker of left ventricular systolic function and was measured by echocardiogram. It is shown as the ratio of left ventricular stroke volume (LVSV) to left ventricular end-diastolic volume (LVEDV), and is measured as a percentage. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline, n=20, 19 | Week 8, n=11, 8 | |
| CRV-IR | 34.0 | 42.0 |
| SK&F-105517-D | 32.2 | 37.6 |
Maximum Plasma Concentration (Cmax) and Trough Plasma Concentration (Cmin) of S-carvedilol, R-carvedilol, and M4 active Metabolite (SB-203231) were measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK&F-105517-D group and Groups D, E, and F in the CRV-IR group. The analysis was performed on log-transformed data. Carvedilol is a racemic mixture. Non-selective β-blocking activity is shown by S-carvedilol, while α1-blocking activity is shown by both S-carvedilol and R-carvedilol. (NCT00742508)
Timeframe: Week 8
| Intervention | nanograms per milliliter (ng/mL) (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| S-carvedilol, Cmax | S-carvedilol, Cmin | R-carvedilol, Cmax | R-carvedilol, Cmin | SB-203231, Cmax | SB-203231, Cmin | |
| CRV-IR | 6.7952 | 1.2072 | 19.1864 | 2.9445 | 3.1665 | 0.4843 |
| SK&F-105517-D | 12.8171 | 3.3796 | 27.1306 | 4.2565 | 6.3937 | 1.2386 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | grams per liter (g/L) (Mean) | |
|---|---|---|
| Albumin | Total Protein | |
| CRV-IR | 0.7 | 0.4 |
| SK&F-105517-D | -1.9 | -1.6 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | international units per liter (IU/L) (Mean) | ||||
|---|---|---|---|---|---|
| Alkaline Phosphatase | Alanine Aminotransferase | Aspartate Aminotransferase | Creatine Kinase | Gamma Glutamyl Transferase | |
| CRV-IR | -10.9 | -0.2 | 0.8 | 34.4 | -0.8 |
| SK&F-105517-D | -5.0 | 3.8 | 1.4 | -0.1 | 2.4 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | millimoles per liter (mmol/L) (Mean) | |||||
|---|---|---|---|---|---|---|
| Calcium | Chloride | Glucose | Potassium | Sodium | Urea/Blood Urea Nitrogen | |
| CRV-IR | -0.027218 | 0.2 | -0.136252 | -0.07 | 0.5 | 0.61339 |
| SK&F-105517-D | -0.056138 | 2.4 | -1.956728 | 0.07 | 1.6 | -0.58013 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (BB, brain-derived; MB=cardiac muscle-derived; MM=skeletal muscle-derived. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | percentage of Total Creatine Kinase (Mean) | ||
|---|---|---|---|
| Creatine Kinase BB percentage | Creatine Kinase MB percentage | Creatine Kinase MM percentage | |
| CRV-IR | -0.2 | -0.3 | 1.1 |
| SK&F-105517-D | 0.5 | -0.1 | 0.8 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | percentage of each WBC type in WBC count (Mean) | ||||
|---|---|---|---|---|---|
| Basophils | Eosinophils | Lymphocytes | Monocytes | Total Neutrophils | |
| CRV-IR | -0.06 | 0.15 | 0.05 | 0.19 | -0.41 |
| SK&F-105517-D | -0.06 | 0.76 | 2.21 | 1.28 | -4.31 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | grams per liter (g/L) (Mean) | |
|---|---|---|
| Hemoglobin | Mean Corpuscular Hemoglobin Concentration | |
| CRV-IR | -2.3 | 1.3 |
| SK&F-105517-D | -3.9 | -1.9 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | gibi (2 to the power of 30)/liter (Gi/L) (Mean) | |
|---|---|---|
| Platelet Count | White Blood Cell Count | |
| CRV-IR | -6.9 | 0.297 |
| SK&F-105517-D | -11.1 | -0.498 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | millimeters of mercury (mmHg) (Mean) | |
|---|---|---|
| Systolic blood pressure | Diastolic blood pressure | |
| CRV-IR | -5.7 | 0.6 |
| SK&F-105517-D | 10.0 | 2.8 |
Mean change from baseline was calculated as the Week 8 value minus the Baseline value (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | micromoles per liter (umol/L) (Mean) | ||
|---|---|---|---|
| Total Bilirubin | Creatinine | Uric Acid | |
| CRV-IR | 1.555 | 5.5451 | 30.8215 |
| SK&F-105517-D | -4.489 | -4.5305 | 14.1265 |
Brain natriuretic peptide is a surrogate marker of the severity of heart failure and was measured by a central laboratory. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | ng/L (nanogram per Liter) (Mean) | |
|---|---|---|
| Baseline, n=20, 19 | Week 8, n=11, 8 | |
| CRV-IR | 108.93 | 64.88 |
| SK&F-105517-D | 226.46 | 111.93 |
Drug-related adverse events (AEs) were defined as AEs that were judged to have a relationship with the investigational product by the investigator (or subinvestigator) with the use of clinical judgment and the Clinical Investigator Brochure to determine the relationship. Refer to adverse event information for type and frequency of adverse events. (NCT00742508)
Timeframe: Treatment Period from Week 0 (Baseline) to Week 8 and 1-week Follow-up Period (Week 9) for CRV-IR; Treatment Period from Week 0 (Baseline) to Week 14 and 1-week Follow-up Period (Week 15) for SK&F-105517-D
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Severe | Moderate | Mild | Severe (drug-related) | Moderate (drug-related) | Mild (drug-related) | |
| CRV-IR | 0 | 2 | 9 | 0 | 2 | 3 |
| SK&F-105517-D | 1 | 5 | 10 | 1 | 3 | 4 |
The NYHA classification assesses the severity of symptoms of heart failure as judged by the investigator and is comprised of. 4 classes: I, no resulting limitations on physical activity (PA); II, slight limitations on PA; III, marked limitations on PA; IV, inability to carry out any PA without discomfort. The number of participants with any change from Baseline in the NYHA Functional Class at Week 8 was calculated. Improved=class at the visit is decreased compared to baseline class, Unchanged=class at the visit is stable, Worsened=class at the visit is increased compared to baseline class. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worse | |
| CRV-IR | 0 | 11 | 0 |
| SK&F-105517-D | 1 | 7 | 0 |
There are 3 categories for electrocardiogram (ECG) findings: normal; abnormal, not clinically significant; and abnormal, clinically significant. Each of the findings was classified by the investigator according to whether it was normal. Abnormal ECGs were further classified according to whether they were felt to be clinically significant in the medical and scientific judgment of the investigator. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Normal, Baseline (BL), n=22, 19 | Abnormal-Not clinically significant, BL, n=22, 19 | Abnormal-Clinically significant, BL, n=22, 19 | Normal, Week (W) 8, n=11, 8 | Abnormal-Not clinically significant, W8, n=11, 8 | Abnormal-Clinically significant, W8, n=11, 8 | |
| CRV-IR | 2 | 12 | 8 | 2 | 5 | 4 |
| SK&F-105517-D | 1 | 9 | 9 | 1 | 1 | 6 |
Dipstick test values: Negative (-), Traces (+-), +1, +2, +3. +4. Normal ranges (qualitative): protein, - or +-; glucose, - or +-; occult blood, -; ketones, -. (NCT00742508)
Timeframe: Baseline and Week 8
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urine Glucose, Negative, Baseline, n=22, 19 | Urine Glucose, Traces, Baseline, n=22, 19 | Urine Glucose, 1+, Baseline, n=22, 19 | Urine Glucose, 2+, Baseline, n=22, 19 | Urine Glucose, 3+, Baseline, n=22, 19 | Urine Glucose, 4+, Baseline, n=22, 19 | Urine Ketones, Negative, Baseline, n=22, 19 | Urine Ketones, Traces, Baseline, n=22, 19 | Urine Ketones, 1+, Baseline, n=22, 19 | Urine Ketones, 2+, Baseline, n=22, 19 | Urine Ketones, 3+, Baseline, n=22, 19 | Urine Ketones, 4+, Baseline, n=22, 19 | Urine Occult Blood, Negative, Baseline, n=22, 19 | Urine Occult Blood, Traces, Baseline, n=22, 19 | Urine Occult Blood, 1+, Baseline, n=22, 19 | Urine Occult Blood, 2+, Baseline, n=22, 19 | Urine Occult Blood, 3+, Baseline, n=22, 19 | Urine Occult Blood, 4+, Baseline, n=22, 19 | Urine Protein, Negative, Baseline, n=22, 19 | Urine Protein, Traces, Baseline, n=22, 19 | Urine Protein, 1+, Baseline, n=22, 19 | Urine Protein, 2+, Baseline, n=22, 19 | Urine Protein, 3+, Baseline, n=22, 19 | Urine Protein, 4+, Baseline, n=22, 19 | Urine Glucose, Negative, Week 8, n=11, 8 | Urine Glucose, Traces, Week 8, n=11, 8 | Urine Glucose, 1+, Week 8, n=11, 8 | Urine Glucose, 2+, Week 8, n=11, 8 | Urine Glucose, 3+, Week 8, n=11, 8 | Urine Glucose, 4+, Week 8, n=11, 8 | Urine Ketones, Negative, Week 8, n=11, 8 | Urine Ketones, Traces, Week 8, n=11, 8 | Urine Ketones, 1+, Week 8, n=11, 8 | Urine Ketones, 2+, Week 8, n=11, 8 | Urine Ketones, 3+, Week 8, n=11, 8 | Urine Ketones, 4+, Week 8, n=11, 8 | Urine Occult Blood, Negative, Week 8, n=11, 8 | Urine Occult Blood, Traces, Week 8, n=11, 8 | Urine Occult Blood, 1+, Week 8, n=11, 8 | Urine Occult Blood, 2+, Week 8, n=11, 8 | Urine Occult Blood, 3+, Week 8, n=11, 8 | Urine Occult Blood, 4+, Week 8, n=11, 8 | Urine Protein, Negative, Week 8, n=11, 8 | Urine Protein, Traces, Week 8, n=11, 8 | Urine Protein 1+, Week 8, n=11, 8 | Urine Protein, 2+, Week 8, n=11, 8 | Urine Protein, 3+, Week 8, n=11, 8 | Urine Protein, 4+, Week 8, n=11, 8 | |
| CRV-IR | 20 | 1 | 0 | 0 | 1 | 0 | 22 | 0 | 0 | 0 | 0 | 0 | 18 | 1 | 2 | 1 | 0 | 0 | 21 | 0 | 0 | 1 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 10 | 1 | 0 | 0 | 0 | 0 |
| SK&F-105517-D | 19 | 0 | 0 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | 0 | 0 | 16 | 1 | 1 | 1 | 0 | 0 | 18 | 0 | 1 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 0 |
Time of maximal plasma concentration (tmax) of S-carvedilol, R-carvedilol, and M4 active metabolite (SB-203231) was measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK&F-105517-D group and Groups D, E, and F in the CRV-IR group. Carvedilol is a racemic mixture. Non-selective β-blocking activity is shown by S-carvedilol, while α1-blocking activity is shown by both S-carvedilol and R-carvedilol. (NCT00742508)
Timeframe: Week 8
| Intervention | hours (Median) | ||
|---|---|---|---|
| S-carvedilol | R-carvedilol | SB-203231 | |
| CRV-IR | 1.983 | 1.983 | 1.983 |
| SK&F-105517-D | 5.958 | 5.958 | 5.958 |
(NCT01502787)
Timeframe: 12 weeks after initiation of metoprolol
| Intervention | mmHg (Mean) |
|---|---|
| Metoprolol | 114 |
| Nebivolol | 113 |
(NCT01502787)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Initial Treatment With Metoprolol | 101 |
| Initial Treatment With Nebivolol | 103 |
(NCT01502787)
Timeframe: 12 weeks after each specified medication
| Intervention | ml/min (Mean) |
|---|---|
| First Intervention Metoprolol: 12 Weeks | 96 |
| Second Intervention Nebivolol: 24 Weeks | 105 |
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
"Difference in peak exercise minute ventilation between Time 1 and Time 3 (Time 3 - Time 1.~Minute ventilation = tidal volume (ml) multiplied by the respiratory rate (breaths/min)." (NCT00924833)
Timeframe: Time 1: sea level, baseline, no treatment. Time 3: within the first two days of high altitude exposure, under treatment.
| Intervention | L/min (Mean) |
|---|---|
| Placebo | 0.7 |
| Carvedilol | -9.3 |
| Nebivolol | 15.2 |
Difference in peak exercise oxygen consumption between Time 1 and Time 3 (Time 3 - Time 1) (NCT00924833)
Timeframe: Time 1: sea level, baseline, no treatment. Time 3: within the first two days of high altitude exposure, under treatment.
| Intervention | ml/Kg/min (Mean) |
|---|---|
| Placebo | -32.7 |
| Carvedilol | -37.6 |
| Nebivolol | -22.5 |
Minute ventilation at peak of exercise. Minute ventilation = tidal volume (ml) multiplied by the respiratory rate (breaths/min) (NCT00924833)
Timeframe: Time 1: sea level, baseline, no treatment. Time 2: sea level, after three weeks of allocated treatment. Time 3: within the first two days of high altitude exposure, under treatment.
| Intervention | L/min (Mean) | ||
|---|---|---|---|
| Time 1 | Time 2 | Time 3 | |
| Carvedilol | 90.3 | 89.6 | 84.5 |
| Nebivolol | 81.8 | 83.8 | 92.0 |
| Placebo | 93.9 | 95.6 | 90.3 |
Oxygen consumption at peak of exercise (NCT00924833)
Timeframe: Time 1: sea level, baseline, no treatment. Time 2: sea level, after three weeks of allocated treatment. Time 3: within the first two days of high altitude exposure, under treatment.
| Intervention | ml/Kg/min (Mean) | ||
|---|---|---|---|
| Time 1 | Time 2 | Time 3 | |
| Carvedilol | 37.6 | 36.2 | 24.0 |
| Nebivolol | 38.0 | 39.7 | 28.8 |
| Placebo | 33.9 | 33.9 | 22.9 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.88 |
| Carvedilol Controlled Release | -0.86 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 24.00 |
| Carvedilol Controlled Release | 53.37 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.20 |
| Carvedilol Controlled Release | -0.45 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.33 |
| Carvedilol Controlled Release | -0.36 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -0.76 |
| Carvedilol Controlled Release | -0.83 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .05 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .08 |
| Carvedilol Controlled Release | .08 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -42.22 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -18.29 |
| Carvedilol Controlled Release | -20.57 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | -36.61 |
| Carvedilol Controlled Release | -43.00 |
Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | mL/m^2 (Mean) |
|---|---|
| Coreg Immediate Release | -18.36 |
| Coreg Controlled Release | -20.81 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | 9.5 |
| Carvedilol Controlled Release | -9.29 |
(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period
| Intervention | percentage of change (Mean) |
|---|---|
| Carvedilol Immediate Release | .07 |
| Carvedilol Controlled Release | .05 |
SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)
| Intervention | number of SAEs (Number) |
|---|---|
| Carvedilol Immediate Release | 40 |
| Carvedilol Controlled Release | 35 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | subjects in each treatment group (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Entry (10mg Coreg CR, 3.125mg Coreg IR) | Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR) | End of Study (10mg Coreg CR, 3.125mg Coreg IR) | Study Entry (20mg Coreg CR, 6.25mg Coreg IR) | Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR) | End of Study (20mg Coreg CR, 6.25mg Coreg IR) | Study Entry (40mg Coreg CR, 12.5mg Coreg IR) | Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR) | End of Study (40mg Coreg CR, 12.5mg Coreg IR) | Study Entry (80mg Coreg CR, 25mg Coreg IR) | Maintenance Entry (80mg Coreg CR, 25mg Coreg IR) | End of Study (80mg Coreg CR, 25mg Coreg IR) | |
| Carvedilol Controlled Release | 83 | 0 | 4 | 39 | 9 | 16 | 27 | 16 | 22 | 4 | 114 | 111 |
| Carvedilol Immediate Release | 79 | 0 | 7 | 61 | 13 | 16 | 21 | 12 | 21 | 4 | 116 | 121 |
(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)
| Intervention | participants in each treatment group (Number) | ||
|---|---|---|---|
| Hospitalization for Heart Failure | Hospitalization Due to Any Cause | Hospitalization or Death | |
| Carvedilol Controlled Release | 6 | 29 | 29 |
| Carvedilol Immediate Release | 6 | 31 | 32 |
154 reviews available for carvedilol and Heart Failure
| Article | Year |
|---|---|
Covid-19 and development of heart failure: mystery and truth.
Topics: Adrenergic alpha-1 Receptor Antagonists; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Cardioton | 2021 |
Covid-19 and development of heart failure: mystery and truth.
Topics: Adrenergic alpha-1 Receptor Antagonists; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Cardioton | 2021 |
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Topics: Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Antibiotics, Antineoplastic; Breast Neopl | 2022 |
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Topics: Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Antibiotics, Antineoplastic; Breast Neopl | 2022 |
Beta-blockers for congestive heart failure in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Heart Fail | 2020 |
Beta-blockers for congestive heart failure in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Heart Fail | 2020 |
Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carvedilol; Cytochrome P-450 CYP2D6; Genetic Variation; Hea | 2020 |
Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carvedilol; Cytochrome P-450 CYP2D6; Genetic Variation; Hea | 2020 |
Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Heart Fail | 2014 |
Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Heart Fail | 2014 |
Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies.
Topics: Adrenergic beta-Antagonists; Age Factors; Bisoprolol; Carbazoles; Carvedilol; Child; Heart Defects, | 2015 |
Effects of beta-blockers for congestive heart failure in pediatric and congenital heart disease patients: a meta-analysis of published studies.
Topics: Adrenergic beta-Antagonists; Age Factors; Bisoprolol; Carbazoles; Carvedilol; Child; Heart Defects, | 2015 |
Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Global Health; Heart Failure; H | 2015 |
Meta-analysis of the effects of carvedilol versus metoprolol on all-cause mortality and hospitalizations in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Global Health; Heart Failure; H | 2015 |
Beta-blockers for congestive heart failure in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Heart Fail | 2016 |
Beta-blockers for congestive heart failure in children.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Heart Fail | 2016 |
[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Carbazoles; Cardi | 2016 |
[The benefits of carvedilol therapy in the treatment of patients with high cardiovascular risk].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Bisoprolol; Carbazoles; Cardi | 2016 |
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.
Topics: Adult; Carbazoles; Cardiotonic Agents; Carvedilol; Chagas Cardiomyopathy; Heart Failure; Humans; Mid | 2016 |
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.
Topics: Adult; Carbazoles; Cardiotonic Agents; Carvedilol; Chagas Cardiomyopathy; Heart Failure; Humans; Mid | 2016 |
Controlled-release carvedilol.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedi | 2008 |
Controlled-release carvedilol.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedi | 2008 |
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2008 |
Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2008 |
Role of carvedilol controlled-release in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carvedilol; Delayed-Action Prepara | 2009 |
Role of carvedilol controlled-release in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carvedilol; Delayed-Action Prepara | 2009 |
Realities of newer beta-blockers for the management of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolam | 2009 |
Realities of newer beta-blockers for the management of hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolam | 2009 |
Beta-blockers in heart failure: how far have we progressed?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Contraindi | 2002 |
Beta-blockers in heart failure: how far have we progressed?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Contraindi | 2002 |
Consistency of ss-blocker effect across various subgroups with heart failure: insights from the MERIT-HF trial.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Heart Failure; Humans; | 2002 |
Consistency of ss-blocker effect across various subgroups with heart failure: insights from the MERIT-HF trial.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Heart Failure; Humans; | 2002 |
Use of beta-blockers for heart failure in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Diabetes C | 2002 |
Use of beta-blockers for heart failure in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Diabetes C | 2002 |
β₂ AR agonists in treatment of chronic heart failure: long path to translation.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Apoptosis; Carbazoles; Cardiomyopathy, Dilated; Carved | 2011 |
β₂ AR agonists in treatment of chronic heart failure: long path to translation.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Apoptosis; Carbazoles; Cardiomyopathy, Dilated; Carved | 2011 |
The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Carbazoles; Cardiovascular Diseases; Carvedilol; | 2012 |
The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Carbazoles; Cardiovascular Diseases; Carvedilol; | 2012 |
β-blockers in stage B: a precursor of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; C | 2012 |
β-blockers in stage B: a precursor of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular System; C | 2012 |
β-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; China; Hea | 2012 |
β-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; China; Hea | 2012 |
Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy.
Topics: Adult; Carbazoles; Cardiotonic Agents; Carvedilol; Chagas Cardiomyopathy; Heart Failure; Humans; Pro | 2012 |
Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy.
Topics: Adult; Carbazoles; Cardiotonic Agents; Carvedilol; Chagas Cardiomyopathy; Heart Failure; Humans; Pro | 2012 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor | 2002 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor | 2002 |
Prevention of and medical therapy for atrial arrhythmias in heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2002 |
Prevention of and medical therapy for atrial arrhythmias in heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2002 |
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin | 2002 |
Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Chronic Di | 2002 |
Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Chronic Di | 2002 |
Beta-blocker therapy for heart failure: the standard of care.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2002 |
Beta-blocker therapy for heart failure: the standard of care.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2002 |
[Congestive heart failure and acute myocardial infarction: latest trials with beta-blocking agents].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2002 |
[Congestive heart failure and acute myocardial infarction: latest trials with beta-blocking agents].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2002 |
Current concepts in managing heart failure. Based on recent studies of beta-blocker therapy, treatment guidelines have been revised for patients who have mild, moderate, or severe HF.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Physical Examination; Pr | 2003 |
Current concepts in managing heart failure. Based on recent studies of beta-blocker therapy, treatment guidelines have been revised for patients who have mild, moderate, or severe HF.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Physical Examination; Pr | 2003 |
[Use of beta-blockers in heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Contraind | 2003 |
[Use of beta-blockers in heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Contraind | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Use of beta-blockers in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; F | 2003 |
Use of beta-blockers in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; F | 2003 |
Choosing metoprolol or carvedilol in heart failure (a pre-COMET commentary).
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Exercise; Heart Failu | 2003 |
Choosing metoprolol or carvedilol in heart failure (a pre-COMET commentary).
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Exercise; Heart Failu | 2003 |
Carvedilol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Drug Administration Schedule; | 2003 |
Carvedilol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Drug Administration Schedule; | 2003 |
Carvedilol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Drug Administration Schedule; | 2003 |
Carvedilol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Drug Administration Schedule; | 2003 |
Carvedilol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Drug Administration Schedule; | 2003 |
Carvedilol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Drug Administration Schedule; | 2003 |
Carvedilol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Drug Administration Schedule; | 2003 |
Carvedilol: a review of its use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Drug Administration Schedule; | 2003 |
Beta-blockers for chronic heart failure: surviving longer but feeling better?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Exercise Test; Exercise Tolerance; | 2003 |
Beta-blockers for chronic heart failure: surviving longer but feeling better?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Exercise Test; Exercise Tolerance; | 2003 |
Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.
Topics: Adrenergic beta-Antagonists; Aging; Carbazoles; Carvedilol; Down-Regulation; Heart Failure; Hemodyna | 2003 |
Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.
Topics: Adrenergic beta-Antagonists; Aging; Carbazoles; Carvedilol; Down-Regulation; Heart Failure; Hemodyna | 2003 |
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; E | 2003 |
Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; E | 2003 |
Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinical Trials as | 2003 |
Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinical Trials as | 2003 |
A clinical pharmacologist's response to Dr Milton Packer's perspective on the results of the COMET trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Mult | 2003 |
A clinical pharmacologist's response to Dr Milton Packer's perspective on the results of the COMET trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Mult | 2003 |
[The modern view on the role of inflammatory factors in chronic heart failure and possibilities of pharmacological modification].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory | 2003 |
[The modern view on the role of inflammatory factors in chronic heart failure and possibilities of pharmacological modification].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory | 2003 |
The update on the rationale, use and selection of beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
The update on the rationale, use and selection of beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Cardiac remodeling in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Echocardiography; Heart Failure; Humans; Myocar | 2004 |
Cardiac remodeling in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Echocardiography; Heart Failure; Humans; Myocar | 2004 |
Landmark studies: the Australia/New Zealand Heart Failure Collaborative Group (ANZ) Trial and the US Carvedilol Trials Program.
Topics: Adrenergic beta-Antagonists; Australia; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Fai | 2004 |
Landmark studies: the Australia/New Zealand Heart Failure Collaborative Group (ANZ) Trial and the US Carvedilol Trials Program.
Topics: Adrenergic beta-Antagonists; Australia; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Fai | 2004 |
Ventricular remodeling in heart failure and the effect of beta-blockade.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Ventricular remodeling in heart failure and the effect of beta-blockade.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Role of carvedilol in atrial fibrillation: insights from clinical trials.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Di | 2004 |
Role of carvedilol in atrial fibrillation: insights from clinical trials.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Carbazoles; Carvedilol; Di | 2004 |
Special considerations for carvedilol use in heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials a | 2004 |
Special considerations for carvedilol use in heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials a | 2004 |
Tolerability of carvedilol in heart failure: clinical trials experience.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2004 |
Tolerability of carvedilol in heart failure: clinical trials experience.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2004 |
Role of in-hospital initiation of carvedilol to improve treatment rates and clinical outcomes.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Hospit | 2004 |
Role of in-hospital initiation of carvedilol to improve treatment rates and clinical outcomes.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Hospit | 2004 |
Practical considerations for switching beta-blockers in heart failure patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 2004 |
Practical considerations for switching beta-blockers in heart failure patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 2004 |
Carvedilol: beta-blockade and beyond.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Clinical Trials as Topic; | 2004 |
Carvedilol: beta-blockade and beyond.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Clinical Trials as Topic; | 2004 |
Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Top | 2004 |
Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Top | 2004 |
Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Use of beta-blockers in older adults with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiovascu | 2004 |
Use of beta-blockers in older adults with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiovascu | 2004 |
Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Bronchoconstriction; Bronchodilator Agent | 2004 |
Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Bronchoconstriction; Bronchodilator Agent | 2004 |
The effects of beta blockers on morbidity and mortality in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2004 |
The effects of beta blockers on morbidity and mortality in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2004 |
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2004 |
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2004 |
Beta blockers as anti-arrhythmic agents.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbazoles; Carvedilol; H | 2004 |
Beta blockers as anti-arrhythmic agents.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbazoles; Carvedilol; H | 2004 |
Beta blocker therapy in African American patients with heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biological Transport; Black o | 2004 |
Beta blocker therapy in African American patients with heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biological Transport; Black o | 2004 |
Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2005 |
Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2005 |
[Carvedilol (dilatrend) treatment in cardiac failure].
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 2004 |
[Carvedilol (dilatrend) treatment in cardiac failure].
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 2004 |
Emerging trends in the management of heart failure: Beta blocker therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
Emerging trends in the management of heart failure: Beta blocker therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
[Beta blockers for therapy of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as | 2005 |
[Beta blockers for therapy of chronic heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as | 2005 |
[Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Cost-Benefit Analysis; Heart Failur | 2005 |
[Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Cost-Benefit Analysis; Heart Failur | 2005 |
[The value of BNP determination in general practice].
Topics: Acute Disease; Antihypertensive Agents; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Topic | 2004 |
[The value of BNP determination in general practice].
Topics: Acute Disease; Antihypertensive Agents; Biomarkers; Carbazoles; Carvedilol; Clinical Trials as Topic | 2004 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
Beta-blockers in heart failure: is more better?
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
Beta-blockers in heart failure: is more better?
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
Early initiation of beta blockade in heart failure: issues and evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol | 2005 |
Early initiation of beta blockade in heart failure: issues and evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol | 2005 |
Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Benzopyrans; Carbazoles; Carvedilol; Chronic Disease | 2006 |
Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Benzopyrans; Carbazoles; Carvedilol; Chronic Disease | 2006 |
[Beta-adrenolytics in heart failure--are they all really equal?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2005 |
[Beta-adrenolytics in heart failure--are they all really equal?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2005 |
[Future perspectives of beta-blockers in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Multicenter Studies as T | 2006 |
[Future perspectives of beta-blockers in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Multicenter Studies as T | 2006 |
The use of carvedilol in pediatric heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Child; Clinical Trials as Topic; Heart F | 2006 |
The use of carvedilol in pediatric heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Child; Clinical Trials as Topic; Heart F | 2006 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[Alpha beta-blockers for patients with hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2006 |
[Alpha beta-blockers for patients with hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carv | 2006 |
[The effectiveness of carvedilol in heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Double-Blind Method; Drug | 2006 |
[The effectiveness of carvedilol in heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Double-Blind Method; Drug | 2006 |
Carvedilol: use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
Carvedilol: use in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Diabe | 2007 |
The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Delayed-Action Preparations; D | 2006 |
The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Delayed-Action Preparations; D | 2006 |
Are there clinically important differences between beta-blockers in heart failure?
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Dosage Forms; Dose-Response Rel | 2005 |
Are there clinically important differences between beta-blockers in heart failure?
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Dosage Forms; Dose-Response Rel | 2005 |
Could beta-blockers precede or replace angiotensin-converting enzyme inhibitors in heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Drug | 2005 |
Could beta-blockers precede or replace angiotensin-converting enzyme inhibitors in heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Drug | 2005 |
[MUCHA(Multicenter Carvedilol Heart Failure Dose Assessment Trial)].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Clinical Trials as Top | 2007 |
[MUCHA(Multicenter Carvedilol Heart Failure Dose Assessment Trial)].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Clinical Trials as Top | 2007 |
[J-CHF Study].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2007 |
[J-CHF Study].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2007 |
[COMET: metoprolol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2007 |
[COMET: metoprolol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2007 |
[Beta blockers: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Contraind | 2007 |
[Beta blockers: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Contraind | 2007 |
[Application of beta-blockers for clinical practice].
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hum | 2007 |
[Application of beta-blockers for clinical practice].
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hum | 2007 |
Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Prop | 2007 |
Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Prop | 2007 |
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2007 |
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2007 |
Carvedilol in the treatment of elderly patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; C | 2008 |
Carvedilol in the treatment of elderly patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; C | 2008 |
Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Carbazoles; Carvedilol; Heart Failure; Hemody | 1993 |
Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Carbazoles; Carvedilol; Heart Failure; Hemody | 1993 |
Carvedilol in heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, D | 1993 |
Carvedilol in heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathy, D | 1993 |
Development of a multiaction beta blocker. Scientific challenges and regulatory needs.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 1993 |
Development of a multiaction beta blocker. Scientific challenges and regulatory needs.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 1993 |
Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Antioxidants; Carbazoles; Cardiovascu | 1996 |
Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Antioxidants; Carbazoles; Cardiovascu | 1996 |
Beta-blockers in heart failure. Future directions.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 1996 |
Beta-blockers in heart failure. Future directions.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 1996 |
[Therapy with beta blockers in heart failure. Recent studies of carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Hemody | 1996 |
[Therapy with beta blockers in heart failure. Recent studies of carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Hemody | 1996 |
Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Heart Failure; Hemodynamics; Hum | 1997 |
Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Heart Failure; Hemodynamics; Hum | 1997 |
[Beta-blockers and heart failure--a critical view].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Digit | 1996 |
[Beta-blockers and heart failure--a critical view].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Digit | 1996 |
Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Follow-Up Studies; Heart | 1997 |
Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Follow-Up Studies; Heart | 1997 |
Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Carbazoles; Cardiov | 1997 |
Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Carbazoles; Cardiov | 1997 |
Combination drug therapy in chronic heart failure: is treatment part of the problem in heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Carba | 1997 |
Combination drug therapy in chronic heart failure: is treatment part of the problem in heart failure?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Carba | 1997 |
Carvedilol [Coreg].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Controlled Clinical Trials as Topic; Double-Bli | 1997 |
Carvedilol [Coreg].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Controlled Clinical Trials as Topic; Double-Bli | 1997 |
Carvedilol for heart failure: renewed interest in beta blockers.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 1997 |
Carvedilol for heart failure: renewed interest in beta blockers.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 1997 |
Crosstalk of the heart and periphery: skeletal and cardiac muscle as therapeutic targets in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output; Cardiotonic Agents; Carvedilol; Exercise Th | 1997 |
Crosstalk of the heart and periphery: skeletal and cardiac muscle as therapeutic targets in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output; Cardiotonic Agents; Carvedilol; Exercise Th | 1997 |
Effects of beta-adrenergic blockade on survival of patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Clinical Trials as Topic; Disease Prog | 1997 |
Effects of beta-adrenergic blockade on survival of patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Clinical Trials as Topic; Disease Prog | 1997 |
[Beta blockers in heart failure. Experiences and recommendations for clinical use. ANMCO-Area Heart Failure].
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Controlled Clinical Trials as | 1998 |
[Beta blockers in heart failure. Experiences and recommendations for clinical use. ANMCO-Area Heart Failure].
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Controlled Clinical Trials as | 1998 |
Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure.
Topics: Adrenergic beta-Antagonists; Antioxidants; Carbazoles; Carvedilol; Heart; Heart Failure; Hemodynamic | 1998 |
Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure.
Topics: Adrenergic beta-Antagonists; Antioxidants; Carbazoles; Carvedilol; Heart; Heart Failure; Hemodynamic | 1998 |
Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Carbazoles; Carved | 1998 |
Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Carbazoles; Carved | 1998 |
Carvedilol use in heart failure.
Topics: Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans; Propanolamines; Treatment O | 1998 |
Carvedilol use in heart failure.
Topics: Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans; Propanolamines; Treatment O | 1998 |
Hypertension-induced congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 1998 |
Hypertension-induced congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 1998 |
Catecholamines and their blockade in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Norepinephrine; Propanol | 1998 |
Catecholamines and their blockade in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Norepinephrine; Propanol | 1998 |
Assuming the worst may not be bad at all. Carvedilol in heart failure treatment.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Middle Age | 1998 |
Assuming the worst may not be bad at all. Carvedilol in heart failure treatment.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Middle Age | 1998 |
Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Antioxidants; Apoptosis; Carbazoles; Carvedilol; Disease Progression; H | 1998 |
Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Antioxidants; Apoptosis; Carbazoles; Carvedilol; Disease Progression; H | 1998 |
Carvedilol: the new role of beta blockers in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Interactions; Heart Failure; Humans; Propa | 1998 |
Carvedilol: the new role of beta blockers in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Interactions; Heart Failure; Humans; Propa | 1998 |
Carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; | 1998 |
Carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; | 1998 |
The role of third-generation beta-blocking agents in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Vasodila | 1998 |
The role of third-generation beta-blocking agents in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Vasodila | 1998 |
Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Heart | 1998 |
Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Heart | 1998 |
Beta-blockade and amiodarone therapy: twin brothers from different parents.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Chronic Dis | 1998 |
Beta-blockade and amiodarone therapy: twin brothers from different parents.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Chronic Dis | 1998 |
Treatment of congestive heart failure. Has the time come for decreased complexity?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carbazoles; Carvedil | 1999 |
Treatment of congestive heart failure. Has the time come for decreased complexity?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carbazoles; Carvedil | 1999 |
Beta-blocker therapy in heart failure: pathophysiology and clinical results.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Exe | 1999 |
Beta-blocker therapy in heart failure: pathophysiology and clinical results.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Exe | 1999 |
Beta-blockers in heart failure. The 'new wave' of clinical trials.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 1999 |
Beta-blockers in heart failure. The 'new wave' of clinical trials.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 1999 |
[Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Bisoprolol; Carbazoles | 1999 |
[Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Bisoprolol; Carbazoles | 1999 |
Major beta blocker mortality trials in chronic heart failure: a critical review.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 1999 |
Major beta blocker mortality trials in chronic heart failure: a critical review.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 1999 |
Advanced practice nursing for congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Case Management; Cost | 1999 |
Advanced practice nursing for congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Case Management; Cost | 1999 |
Progression from hypertension to heart failure. Mechanisms and management.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Disease Progression; Heart Failure; Humans; Hyp | 1999 |
Progression from hypertension to heart failure. Mechanisms and management.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Disease Progression; Heart Failure; Humans; Hyp | 1999 |
Beta-adrenoceptor blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 1999 |
Beta-adrenoceptor blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 1999 |
beta-adrenergic receptor blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hea | 2000 |
beta-adrenergic receptor blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hea | 2000 |
Beta-blockers: the new standard of therapy for mild heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Diastole; Disease Progression; | 2000 |
Beta-blockers: the new standard of therapy for mild heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Diastole; Disease Progression; | 2000 |
The effect of beta-blockers on health-related quality of life in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Health St | 2000 |
The effect of beta-blockers on health-related quality of life in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Health St | 2000 |
Sympathetic activation and the role of beta-blockers in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Disease Progression; Heart Failure; Hemodynamic | 1999 |
Sympathetic activation and the role of beta-blockers in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Disease Progression; Heart Failure; Hemodynamic | 1999 |
The impact of beta-blockade on mortality rates in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Meta-Analysi | 2000 |
The impact of beta-blockade on mortality rates in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Meta-Analysi | 2000 |
Beta-adrenergic blockade in the treatment of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2000 |
Beta-adrenergic blockade in the treatment of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2000 |
Beta-blockers and spironolactone in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Mineralocort | 2000 |
Beta-blockers and spironolactone in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Mineralocort | 2000 |
Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2000 |
Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2000 |
Beta blockade in patients with congestive heart failure. Why, who, and how.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Heart Failure; H | 2000 |
Beta blockade in patients with congestive heart failure. Why, who, and how.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Heart Failure; H | 2000 |
Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Ethanolamines; Heart F | 2000 |
Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Ethanolamines; Heart F | 2000 |
Beta blockers and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Meta-Analysi | 2000 |
Beta blockers and congestive heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Meta-Analysi | 2000 |
The importance of beta blockers in the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Drug Administrat | 2000 |
The importance of beta blockers in the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Drug Administrat | 2000 |
Influence of beta-blockers on mortality in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hum | 2000 |
Influence of beta-blockers on mortality in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hum | 2000 |
Carvedilol versus other beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 2001 |
Carvedilol versus other beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 2001 |
Economic impact of beta blockade in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2001 |
Economic impact of beta blockade in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2001 |
Current role of beta-adrenergic blockers in the management of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chron | 2001 |
Current role of beta-adrenergic blockers in the management of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chron | 2001 |
Carvedilol in the treatment of chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2001 |
Carvedilol in the treatment of chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2001 |
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2001 |
Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2001 |
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol | 2001 |
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol | 2001 |
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans | 2001 |
Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans | 2001 |
[Adrenergic beta inhibitors in heart insufficiency: which and when?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
[Adrenergic beta inhibitors in heart insufficiency: which and when?].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Antioxi | 2001 |
Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Antioxi | 2001 |
[Clinical trials on heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme | 2001 |
[Clinical trials on heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme | 2001 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
[Role of beta-blockers in the treatment of chronic heart heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Controlled Clinica | 2001 |
Beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
Beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2001 |
Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channels, L-Type; Carbazoles; Cardiotoni | 2001 |
Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channels, L-Type; Carbazoles; Cardiotoni | 2001 |
Carvedilol in the failing heart.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans; Propanolam | 2001 |
Carvedilol in the failing heart.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans; Propanolam | 2001 |
Using carvedilol to treat heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Agents; Carvedilol; Diuretics; Drug Interact | 2002 |
Using carvedilol to treat heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Agents; Carvedilol; Diuretics; Drug Interact | 2002 |
[Progress in heart failure during the year 2001].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Turkey | 2001 |
[Progress in heart failure during the year 2001].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Turkey | 2001 |
Vasodilatory action of carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilo | 1992 |
Vasodilatory action of carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilo | 1992 |
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Fa | 1990 |
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Fa | 1990 |
251 trials available for carvedilol and Heart Failure
| Article | Year |
|---|---|
Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.
Topics: Biomarkers; Carvedilol; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Prospe | 2023 |
Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.
Topics: Biomarkers; Carvedilol; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Prospe | 2023 |
Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction.
Topics: Carvedilol; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; ST Ele | 2023 |
Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction.
Topics: Carvedilol; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; ST Ele | 2023 |
Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Inflammatory Agents; Bisoprolol; C-Reactive Protein; | 2020 |
Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Inflammatory Agents; Bisoprolol; C-Reactive Protein; | 2020 |
The curative effect of carvedilol combined with conventional therapy in treatment of chronic heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Carvedilol; Chronic Disease; Diuretics; Drug Therapy | 2019 |
The curative effect of carvedilol combined with conventional therapy in treatment of chronic heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Carvedilol; Chronic Disease; Diuretics; Drug Therapy | 2019 |
Carvedilol Does Not Improve Exercise Performance in Fontan Patients: Results of a Crossover Trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carvedilol; Child; Cross-Over Studies; Double-Blind | 2021 |
Carvedilol Does Not Improve Exercise Performance in Fontan Patients: Results of a Crossover Trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carvedilol; Child; Cross-Over Studies; Double-Blind | 2021 |
Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2017 |
Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2017 |
Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol - Insights From Japanese Chronic Heart Failure (J-CHF) Study.
Topics: Adrenergic beta-Antagonists; Aged; Anemia; Carvedilol; Chronic Disease; Female; Follow-Up Studies; H | 2018 |
Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol - Insights From Japanese Chronic Heart Failure (J-CHF) Study.
Topics: Adrenergic beta-Antagonists; Aged; Anemia; Carvedilol; Chronic Disease; Female; Follow-Up Studies; H | 2018 |
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Topics: Adrenergic beta-1 Receptor Agonists; Aged; Bisoprolol; Carvedilol; Cause of Death; Comorbidity; Denm | 2018 |
Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study.
Topics: Adrenergic beta-1 Receptor Agonists; Aged; Bisoprolol; Carvedilol; Cause of Death; Comorbidity; Denm | 2018 |
Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carvedilol; Clinical Trials, Phase IV as Topic; Delayed-Act | 2018 |
Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carvedilol; Clinical Trials, Phase IV as Topic; Delayed-Act | 2018 |
Anti-ß1-Adrenoreceptor auto-Antibodies in elderly heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Autoantibodies; Biomarkers; Bisoprolol; Carved | 2019 |
Anti-ß1-Adrenoreceptor auto-Antibodies in elderly heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Autoantibodies; Biomarkers; Bisoprolol; Carved | 2019 |
Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial.
Topics: Adult; Aged; Aged, 80 and over; Bisoprolol; Carvedilol; Heart Failure; Heart Rate; Humans; Japan; Mi | 2019 |
Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial.
Topics: Adult; Aged; Aged, 80 and over; Bisoprolol; Carvedilol; Heart Failure; Heart Rate; Humans; Japan; Mi | 2019 |
Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Carbazoles; Cardiac Resynchron | 2013 |
Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Carbazoles; Cardiac Resynchron | 2013 |
Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Benzopyrans; Bisoprolol; Ca | 2013 |
Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Benzopyrans; Bisoprolol; Ca | 2013 |
Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; C-Reactive Protein; Carbazoles; Carvedilol; Endotheli | 2013 |
Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; C-Reactive Protein; Carbazoles; Carvedilol; Endotheli | 2013 |
Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Disease-Free | 2014 |
Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) stud
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Disease-Free | 2014 |
Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Benzopyrans; Carbazoles; Carvedilol; Drug Therapy, Combinati | 2014 |
Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Benzopyrans; Carbazoles; Carvedilol; Drug Therapy, Combinati | 2014 |
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carb | 2013 |
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carb | 2013 |
Comparison of the effects of carvedilol and nebivolol on diastolic functions of the left ventricle in patients with non-ischemic heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Agonists; Carbazoles; Carvedilol | 2014 |
Comparison of the effects of carvedilol and nebivolol on diastolic functions of the left ventricle in patients with non-ischemic heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Agonists; Carbazoles; Carvedilol | 2014 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Differential effects of nonselective versus selective β-blockers on cardiac sympathetic activity and hemostasis in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Haplotypes | 2013 |
Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD).
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2014 |
Regional differences among female patients with heart failure from the Cardiac Insufficiency BIsoprolol Study in ELDerly (CIBIS-ELD).
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; C | 2014 |
Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; | 2013 |
Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with β-blockers: results of a multicentric observational APULIA study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; | 2013 |
Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chronic Di | 2014 |
Heart rate following short-term beta-blocker titration predicts all-cause mortality in elderly chronic heart failure patients: insights from the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chronic Di | 2014 |
Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Echocardiography; Female; Heart | 2015 |
Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Echocardiography; Female; Heart | 2015 |
Presence of autoantibody directed against β1-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol: Japanese Chronic Heart Failure (J-CHF) Study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Autoantibodies; Carbazoles; Carvedilol; Chronic Disease; D | 2015 |
Presence of autoantibody directed against β1-adrenergic receptors is associated with amelioration of cardiac function in response to carvedilol: Japanese Chronic Heart Failure (J-CHF) Study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Autoantibodies; Carbazoles; Carvedilol; Chronic Disease; D | 2015 |
Evaluation of synergistic effects of resynchronization therapy and a β-blocker up-titration strategy based on a predefined patient-management program: the RESTORE study.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Carbazoles; Cardiac Resynchronization Therapy; C | 2015 |
Evaluation of synergistic effects of resynchronization therapy and a β-blocker up-titration strategy based on a predefined patient-management program: the RESTORE study.
Topics: Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Carbazoles; Cardiac Resynchronization Therapy; C | 2015 |
The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Biomarkers; Carbazoles; Carvedilol; Case-Con | 2015 |
The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Biomarkers; Carbazoles; Carvedilol; Case-Con | 2015 |
Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Carbazoles; Carvedilol; Child; Child, Preschoo | 2015 |
Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Carbazoles; Carvedilol; Child; Child, Preschoo | 2015 |
Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; C | 2015 |
Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; C | 2015 |
Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Topics: Adrenergic Antagonists; Aged; Benzazepines; Carbazoles; Cardiovascular Agents; Carvedilol; Chronic D | 2016 |
Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Topics: Adrenergic Antagonists; Aged; Benzazepines; Carbazoles; Cardiovascular Agents; Carvedilol; Chronic D | 2016 |
Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk
Topics: Adrenergic beta-Antagonists; Age Factors; Anthracyclines; Antibiotics, Antineoplastic; Carbazoles; C | 2016 |
Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk
Topics: Adrenergic beta-Antagonists; Age Factors; Anthracyclines; Antibiotics, Antineoplastic; Carbazoles; C | 2016 |
Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Age Factors; Aged; Carbazoles; Cardiotonic Agents; Carvedil | 2016 |
Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Age Factors; Aged; Carbazoles; Cardiotonic Agents; Carvedil | 2016 |
Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Echocardiogra | 2017 |
Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Echocardiogra | 2017 |
Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Body Weight; Cachexia; Carbazoles; Carvedilol; | 2017 |
Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Body Weight; Cachexia; Carbazoles; Carvedilol; | 2017 |
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Bisoprolol; Carbazoles; Carvedilol; Double-Blin | 2008 |
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Bisoprolol; Carbazoles; Carvedilol; Double-Blin | 2008 |
The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Electrocardi | 2009 |
The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Electrocardi | 2009 |
Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Cardiotonic Agents; Carvedilol; Dobutamine; | 2008 |
Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Cardiotonic Agents; Carvedilol; Dobutamine; | 2008 |
Carvedilol reduces the severity of central sleep apnea in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationsh | 2009 |
Carvedilol reduces the severity of central sleep apnea in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationsh | 2009 |
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Confidence Intervals; Follow-Up Studies; Heart | 2009 |
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Confidence Intervals; Follow-Up Studies; Heart | 2009 |
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Autoantibodies; Carbazoles; Car | 2009 |
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Autoantibodies; Carbazoles; Car | 2009 |
Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic | 2009 |
Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic | 2009 |
Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Child; Child, Preschool; Fem | 2009 |
Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Child; Child, Preschool; Fem | 2009 |
Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart F
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Delayed-Action Prep | 2009 |
Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart F
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Delayed-Action Prep | 2009 |
Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agon | 2009 |
Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agon | 2009 |
Beta-blocker treatment of stable heart failure in primary care.
Topics: Adrenergic alpha-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Female; Heart Failure; Human | 2009 |
Beta-blocker treatment of stable heart failure in primary care.
Topics: Adrenergic alpha-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Female; Heart Failure; Human | 2009 |
Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Arteries; Blood Pressure; Carbazoles; Carvedilol; Echocardiograph | 2009 |
Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Arteries; Blood Pressure; Carbazoles; Carvedilol; Echocardiograph | 2009 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; | 2010 |
Enantioselective quantification of carvedilol in human plasma by HPLC in heavily medicated heart failure patients.
Topics: Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Heart Failure; Humans; Propanolamines; | 2010 |
Enantioselective quantification of carvedilol in human plasma by HPLC in heavily medicated heart failure patients.
Topics: Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Heart Failure; Humans; Propanolamines; | 2010 |
Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Blood Pressure; Carbazoles; Carvedilol; Female; Gen | 2010 |
Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Blood Pressure; Carbazoles; Carvedilol; Female; Gen | 2010 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chr | 2010 |
[Effect of beta-adrenoblockers on remodeling of myocardium and adhesive function of endothelium in patients with ischemic heart disease, complicated with chronic heart failure and atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Cell Adhesion Molecu | 2010 |
[Effect of beta-adrenoblockers on remodeling of myocardium and adhesive function of endothelium in patients with ischemic heart disease, complicated with chronic heart failure and atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Cell Adhesion Molecu | 2010 |
Carvedilol can prevent cardiac events in Duchenne muscular dystrophy.
Topics: Adolescent; Adult; Carbazoles; Carvedilol; Child; Chronic Disease; Heart Failure; Humans; Longitudin | 2010 |
Carvedilol can prevent cardiac events in Duchenne muscular dystrophy.
Topics: Adolescent; Adult; Carbazoles; Carvedilol; Child; Chronic Disease; Heart Failure; Humans; Longitudin | 2010 |
Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bayes Theorem; Ca | 2010 |
Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bayes Theorem; Ca | 2010 |
Effects of cAMP and β-adrenergic receptor antagonists on the function of peripheral T helper lymphocytes in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Cell Separation; Cyclic AMP; Femal | 2011 |
Effects of cAMP and β-adrenergic receptor antagonists on the function of peripheral T helper lymphocytes in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Cell Separation; Cyclic AMP; Femal | 2011 |
[Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia].
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Autoantibodies; Carbazoles; Carvedilol; Female; Heart | 2010 |
[Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia].
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Autoantibodies; Carbazoles; Carvedilol; Female; Heart | 2010 |
Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles | 2011 |
Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles | 2011 |
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, D | 2011 |
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, D | 2011 |
Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude.
Topics: Adrenergic Antagonists; Aged; Altitude; Carbazoles; Carvedilol; Chronic Disease; Exercise Test; Fema | 2012 |
Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude.
Topics: Adrenergic Antagonists; Aged; Altitude; Carbazoles; Carvedilol; Chronic Disease; Exercise Test; Fema | 2012 |
β-blockade restores muscle sympathetic rhythmicity in human heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Ca | 2011 |
β-blockade restores muscle sympathetic rhythmicity in human heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Ca | 2011 |
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Topics: Adult; Alleles; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Cytochrome P-450 CY | 2011 |
Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
Topics: Adult; Alleles; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Cytochrome P-450 CY | 2011 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvasta | 2011 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvasta | 2011 |
Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial).
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Carbazoles; Carvedilol; Cyclic Nucleotide-Gated Cat | 2011 |
Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial).
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Carbazoles; Carvedilol; Cyclic Nucleotide-Gated Cat | 2011 |
Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients.
Topics: Aged; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Female; Follow-Up | 2011 |
Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients.
Topics: Aged; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Female; Follow-Up | 2011 |
Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study.
Topics: Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Substitution; Endothelium, Vascular; Female; H | 2011 |
Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure--a randomized study.
Topics: Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Substitution; Endothelium, Vascular; Female; H | 2011 |
Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2011 |
Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2011 |
CArdiac resynchronization in combination with beta blocker treatment in advanced chronic heart failure (CARIBE-HF): the results of the CARIBE-HF study.
Topics: Adrenergic beta-Antagonists; Aged; Algorithms; Carbazoles; Cardiac Resynchronization Therapy; Carved | 2011 |
CArdiac resynchronization in combination with beta blocker treatment in advanced chronic heart failure (CARIBE-HF): the results of the CARIBE-HF study.
Topics: Adrenergic beta-Antagonists; Aged; Algorithms; Carbazoles; Cardiac Resynchronization Therapy; Carved | 2011 |
Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Blood Pressure; Carbazoles; Carved | 2012 |
Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Blood Pressure; Carbazoles; Carved | 2012 |
Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over | 2012 |
Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over | 2012 |
Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilo | 2012 |
Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Bisoprolol; Carbazoles; Carvedilo | 2012 |
Effect of β-blocker cessation on chronotropic incompetence and exercise tolerance in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Biomarkers; Bisoprolol; Carbazoles; Carved | 2012 |
Effect of β-blocker cessation on chronotropic incompetence and exercise tolerance in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Biomarkers; Bisoprolol; Carbazoles; Carved | 2012 |
The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: a prospective, randomized-controlled study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Cardiotonic Agents; Carvedilol; Ch | 2013 |
The effect of carvedilol treatment on chronic heart failure in pediatric patients with dilated cardiomyopathy: a prospective, randomized-controlled study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Cardiotonic Agents; Carvedilol; Ch | 2013 |
Beta blockers therapy is associated with improved left ventricular systolic function and sustained exercise capacity in elderly patients with heart failure. CIBIS-ELD sub-study.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Exerci | 2012 |
Beta blockers therapy is associated with improved left ventricular systolic function and sustained exercise capacity in elderly patients with heart failure. CIBIS-ELD sub-study.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Exerci | 2012 |
Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study.
Topics: Adrenergic beta-Antagonists; Aged; Asian People; Carbazoles; Carvedilol; Chronic Disease; Female; Fo | 2013 |
Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study.
Topics: Adrenergic beta-Antagonists; Aged; Asian People; Carbazoles; Carvedilol; Chronic Disease; Female; Fo | 2013 |
Trend of clinical outcome and surrogate markers during titration of β-blocker in heart failure patients with reduced ejection fraction: relevance of achieved heart rate and β-blocker dose.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Biomarkers; Carbazoles; Carvedilol; Dose-Response Rel | 2013 |
Trend of clinical outcome and surrogate markers during titration of β-blocker in heart failure patients with reduced ejection fraction: relevance of achieved heart rate and β-blocker dose.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Biomarkers; Carbazoles; Carvedilol; Dose-Response Rel | 2013 |
Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD).
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2013 |
Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD).
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2013 |
Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 2002 |
Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 2002 |
Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carved | 2002 |
Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carved | 2002 |
The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blo
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 2002 |
The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blo
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 2002 |
The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Age Factors; Carbazoles; Carv | 2002 |
The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Age Factors; Carbazoles; Carv | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedi | 2002 |
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Disease-Free Survival; Double- | 2002 |
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Disease-Free Survival; Double- | 2002 |
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Disease-Free Survival; Double- | 2002 |
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Disease-Free Survival; Double- | 2002 |
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Disease-Free Survival; Double- | 2002 |
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Disease-Free Survival; Double- | 2002 |
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Disease-Free Survival; Double- | 2002 |
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Disease-Free Survival; Double- | 2002 |
Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Female; Heart Failure; Hu | 2002 |
Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Female; Heart Failure; Hu | 2002 |
The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Continuity of Patient Care; Heart Failure; Hosp | 2002 |
The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Continuity of Patient Care; Heart Failure; Hosp | 2002 |
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Carbazoles; | 2002 |
Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Carbazoles; | 2002 |
Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Blood Pressure; | 2002 |
Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Blood Pressure; | 2002 |
Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Exercise; Heart Failure; H | 2002 |
Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Exercise; Heart Failure; H | 2002 |
[Long term use of a non-selective beta-blocker with vasodilating properties carvedilol in patients with severe heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazole | 2002 |
[Long term use of a non-selective beta-blocker with vasodilating properties carvedilol in patients with severe heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazole | 2002 |
Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedilol; Double-Blind Method; | 2003 |
Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedilol; Double-Blind Method; | 2003 |
Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Aged; Basal Metabolism; Bisoprolol; Blood Pressure; Bod | 2002 |
Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Aged; Basal Metabolism; Bisoprolol; Blood Pressure; Bod | 2002 |
Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting En | 2003 |
Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting En | 2003 |
[Tolerance and efficacy of carvedilol prescription in patients with mild to moderated chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Chronic Disease | 2000 |
[Tolerance and efficacy of carvedilol prescription in patients with mild to moderated chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Chronic Disease | 2000 |
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Heart Failure; Humans; Pro | 2003 |
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Heart Failure; Humans; Pro | 2003 |
Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Chronic Disease; Cross-Over | 2003 |
Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Chronic Disease; Cross-Over | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Beta-blocker benefit according to severity of heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Hos | 2003 |
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Double-Blind Method; Female; Fo | 2003 |
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Double-Blind Method; Female; Fo | 2003 |
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Female; Heart Failure; Hum | 2003 |
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Female; Heart Failure; Hum | 2003 |
Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Factor; Carbazo | 2003 |
Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Factor; Carbazo | 2003 |
[Contribution of antioxidant properties of carvedilol in its effect on cardiac remodeling in patients with ischemic heart disease with incipient heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Antioxida | 2003 |
[Contribution of antioxidant properties of carvedilol in its effect on cardiac remodeling in patients with ischemic heart disease with incipient heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Antioxida | 2003 |
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuret | 2003 |
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuret | 2003 |
[Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Therapy, | 2003 |
[Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Therapy, | 2003 |
Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol).
Topics: Adrenergic beta-Antagonists; Aged; Blood Gas Analysis; Carbazoles; Carvedilol; Case-Control Studies; | 2003 |
Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol).
Topics: Adrenergic beta-Antagonists; Aged; Blood Gas Analysis; Carbazoles; Carvedilol; Case-Control Studies; | 2003 |
Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly?
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Carbazoles; Carvedilol; Electrocardiography; | 2003 |
Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly?
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Carbazoles; Carvedilol; Electrocardiography; | 2003 |
Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; | 2003 |
Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; | 2003 |
Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double- | 2004 |
Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double- | 2004 |
Heart failure in a district general hospital: are target doses of beta-blockers realistic?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; Carvedilol; | 2004 |
Heart failure in a district general hospital: are target doses of beta-blockers realistic?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; Carvedilol; | 2004 |
NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.
Topics: Aged; Biomarkers; Carbazoles; Cardiovascular Agents; Carvedilol; Double-Blind Method; Female; Heart | 2004 |
NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy.
Topics: Aged; Biomarkers; Carbazoles; Cardiovascular Agents; Carvedilol; Double-Blind Method; Female; Heart | 2004 |
[Severe heart failure: treatment optimisation and monitoring using plasma NT-proBNP levels--an useful tool in clinical practice].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 2004 |
[Severe heart failure: treatment optimisation and monitoring using plasma NT-proBNP levels--an useful tool in clinical practice].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol | 2004 |
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Female; | 2004 |
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Female; | 2004 |
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2004 |
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2004 |
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 2004 |
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 2004 |
Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Heart Failure; Humans; Pro | 2004 |
Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Heart Failure; Humans; Pro | 2004 |
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chi-Square Distribution; Continuity of Pa | 2004 |
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chi-Square Distribution; Continuity of Pa | 2004 |
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Body Mass Index; Carbazoles; Carvedilol; Comorbidity | 2004 |
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Body Mass Index; Carbazoles; Carvedilol; Comorbidity | 2004 |
Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Flow Velocity; Blood Pressure; Carbazole | 2004 |
Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Flow Velocity; Blood Pressure; Carbazole | 2004 |
Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Diastole; Do | 2004 |
Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Diastole; Do | 2004 |
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2004 |
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2004 |
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Dizziness; Fatig | 2004 |
Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibit | 2004 |
Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibit | 2004 |
Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Drug Administration Schedule; | 2004 |
Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Drug Administration Schedule; | 2004 |
[A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Female; Follow-Up St | 2004 |
[A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Female; Follow-Up St | 2004 |
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Blood Pressure; Carbazoles; Cardiovascular Agents; Ca | 2004 |
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Blood Pressure; Carbazoles; Cardiovascular Agents; Ca | 2004 |
Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2004 |
Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Bloo | 2004 |
[Effects of carvedilol on functional capacity, left ventricular function, catecholamines and oxidative stress in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Catecholamines; Female; Heart Failure; He | 2004 |
[Effects of carvedilol on functional capacity, left ventricular function, catecholamines and oxidative stress in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Catecholamines; Female; Heart Failure; He | 2004 |
Predictors of stable outcome in treating chronic heart failure patients with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Cohort Studies; Drug Admi | 2004 |
Predictors of stable outcome in treating chronic heart failure patients with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Cohort Studies; Drug Admi | 2004 |
Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relatio | 2004 |
Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relatio | 2004 |
Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relationship, Dru | 2004 |
Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relationship, Dru | 2004 |
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Double-Blind Method; | 2005 |
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Double-Blind Method; | 2005 |
[Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
[Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Echocardiography; Fema | 2005 |
Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Echocardiography; Fema | 2005 |
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Double-Blind Method; Fe | 2005 |
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Double-Blind Method; Fe | 2005 |
Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Atrial Natriuretic Factor; Biomarkers; Carbazoles; Car | 2005 |
Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Atrial Natriuretic Factor; Biomarkers; Carbazoles; Car | 2005 |
Symptoms in patients with heart failure are prognostic predictors: insights from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Disease Progression; Dou | 2005 |
Symptoms in patients with heart failure are prognostic predictors: insights from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Disease Progression; Dou | 2005 |
Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure.
Topics: Aged; Analysis of Variance; Carbazoles; Carvedilol; Diastole; Double-Blind Method; Female; Follow-Up | 2005 |
Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure.
Topics: Aged; Analysis of Variance; Carbazoles; Carvedilol; Diastole; Double-Blind Method; Female; Follow-Up | 2005 |
Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
Effects of carvedilol upon intra- and interventricular synchrony in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationship, Dr | 2005 |
Effects of carvedilol upon intra- and interventricular synchrony in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationship, Dr | 2005 |
How should COMET influence heart failure practice?
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Meth | 2004 |
How should COMET influence heart failure practice?
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Meth | 2004 |
Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Morbidity; M | 2004 |
Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Morbidity; M | 2004 |
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Dose-Response | 2005 |
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Dose-Response | 2005 |
[The effect of carvedilol on cardiac function and autoantibodies against the cardiac receptors].
Topics: Adult; Aged; Autoantibodies; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; Human | 2005 |
[The effect of carvedilol on cardiac function and autoantibodies against the cardiac receptors].
Topics: Adult; Aged; Autoantibodies; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; Human | 2005 |
[Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Car | 2005 |
[Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Car | 2005 |
Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial).
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Double-Blin | 2006 |
Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial).
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Double-Blin | 2006 |
Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Diastole; Disease Progression; Double-Bli | 2005 |
Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Diastole; Disease Progression; Double-Bli | 2005 |
Early initiation of beta blockade in heart failure: issues and evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol | 2005 |
Early initiation of beta blockade in heart failure: issues and evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol | 2005 |
Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Heart Failure | 2005 |
Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Heart Failure | 2005 |
The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carv | 2006 |
The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carv | 2006 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 2005 |
Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Female; Heart Failure; Heart Fun | 2005 |
Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Female; Heart Failure; Heart Fun | 2005 |
Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Chromatogra | 2005 |
Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Chromatogra | 2005 |
Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Echoca | 2006 |
Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cross-Over Studies; Double-Blind Method; Echoca | 2006 |
[Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Carbazoles; Carvedilol; Femal | 2005 |
[Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Carbazoles; Carvedilol; Femal | 2005 |
Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits.
Topics: Adrenergic beta-Antagonists; Adult; Ambulatory Care; Carbazoles; Carvedilol; Drug Monitoring; Female | 2006 |
Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits.
Topics: Adrenergic beta-Antagonists; Adult; Ambulatory Care; Carbazoles; Carvedilol; Drug Monitoring; Female | 2006 |
Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304).
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carv | 2006 |
Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304).
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carv | 2006 |
The effect of carvedilol therapy on myocardial functional reserve in patients with advanced heart failure caused by nonischemic dilated cardiomyopathy.
Topics: Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Heart; Heart Failure; Humans; Male; | 2006 |
The effect of carvedilol therapy on myocardial functional reserve in patients with advanced heart failure caused by nonischemic dilated cardiomyopathy.
Topics: Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Heart; Heart Failure; Humans; Male; | 2006 |
Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?
Topics: Aged; Antihypertensive Agents; Area Under Curve; Carbazoles; Cardiotonic Agents; Carvedilol; Digoxin | 2006 |
Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?
Topics: Aged; Antihypertensive Agents; Area Under Curve; Carbazoles; Cardiotonic Agents; Carvedilol; Digoxin | 2006 |
Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzopyrans; Carbazoles; Carvedilol; Electrocardiography; | 2006 |
Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzopyrans; Carbazoles; Carvedilol; Electrocardiography; | 2006 |
Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Carbazoles; Carve | 2006 |
Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Carbazoles; Carve | 2006 |
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Area Under Curve; Canada; C | 2006 |
Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Area Under Curve; Canada; C | 2006 |
On the antioxidant activity of carvedilol in human polymorphonuclear leukocytes in vitro and ex vivo.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Antioxidants; Carbazoles; Carvedilol; Di | 2006 |
On the antioxidant activity of carvedilol in human polymorphonuclear leukocytes in vitro and ex vivo.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Antioxidants; Carbazoles; Carvedilol; Di | 2006 |
Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Function, Left; Carbazoles; Carvedilol; Echocardiography, | 2007 |
Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Function, Left; Carbazoles; Carvedilol; Echocardiography, | 2007 |
The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA (Carvedilol Open Label Assessment) II Study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Blood Pressure; Carbazoles; Carvedilol; Female; Hear | 2006 |
The impact of baseline HR and BP on the tolerability of carvedilol in the elderly: the COLA (Carvedilol Open Label Assessment) II Study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Blood Pressure; Carbazoles; Carvedilol; Female; Hear | 2006 |
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Carbazoles; Carvedilol; Chi-Square Distribution; D | 2007 |
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Carbazoles; Carvedilol; Chi-Square Distribution; D | 2007 |
Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Algorithms; Area Under Curve; Asian Peo | 2007 |
Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Algorithms; Area Under Curve; Asian Peo | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Blood Flow Velocity; Blood Pressure; C-Reactiv | 2007 |
Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Blood Flow Velocity; Blood Pressure; C-Reactiv | 2007 |
The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hu | 2007 |
The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hu | 2007 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Cross-Over S | 2007 |
Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant?
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Cross-Over S | 2007 |
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; H | 2007 |
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; H | 2007 |
Carvedilol therapy is associated with an improvement in left atrial appendage function in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Atrial Appendage; Blood Pressure; Carbazoles; Carvedilol; Echocardiogra | 2007 |
Carvedilol therapy is associated with an improvement in left atrial appendage function in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Atrial Appendage; Blood Pressure; Carbazoles; Carvedilol; Echocardiogra | 2007 |
The safety of amiodarone in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2007 |
The safety of amiodarone in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2007 |
Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; C-Reactive Protein; Carbazo | 2007 |
Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; C-Reactive Protein; Carbazo | 2007 |
[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin].
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; | 2007 |
[The effects of beta-adrenoblocker therapy on the physical working capacity of patients with chronic heart failure of various origin].
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; | 2007 |
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; H | 2007 |
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; H | 2007 |
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Body Weight; Carbazoles; Carvedilol; C | 2008 |
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Body Weight; Carbazoles; Carvedilol; C | 2008 |
Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2007 |
Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2007 |
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cause of Death; Chi-Square Distribution; | 2007 |
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cause of Death; Chi-Square Distribution; | 2007 |
The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Fail | 2007 |
The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Fail | 2007 |
Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
Topics: Adrenergic beta-Antagonists; Biomarkers; Bisoprolol; Carbazoles; Carvedilol; Female; Heart Failure; | 2007 |
Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
Topics: Adrenergic beta-Antagonists; Biomarkers; Bisoprolol; Carbazoles; Carvedilol; Female; Heart Failure; | 2007 |
[Serum autoantibodies against the cardiac beta(1)-adrenergic receptor in patients with chronic heart failure: clinical characteristics and response to carvedilol].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Autoantibodies; Carbazoles; Carvedilol; Female; Follow-Up | 2007 |
[Serum autoantibodies against the cardiac beta(1)-adrenergic receptor in patients with chronic heart failure: clinical characteristics and response to carvedilol].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Autoantibodies; Carbazoles; Carvedilol; Female; Follow-Up | 2007 |
Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Body Weight; Carbazoles; Carvedilol; Child; Child, | 2008 |
Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Body Weight; Carbazoles; Carvedilol; Child; Child, | 2008 |
[Treating heart failure with carvedilol in private practice (initiating treatment and follow-up at one year. The KEOPS study].
Topics: Aged; Carbazoles; Carvedilol; Female; France; Heart Failure; Humans; Male; Middle Aged; Private Prac | 2007 |
[Treating heart failure with carvedilol in private practice (initiating treatment and follow-up at one year. The KEOPS study].
Topics: Aged; Carbazoles; Carvedilol; Female; France; Heart Failure; Humans; Male; Middle Aged; Private Prac | 2007 |
Sudden cardiac death risk factors in patients with heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Female; He | 2007 |
Sudden cardiac death risk factors in patients with heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Female; He | 2007 |
Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationship, Dr | 2008 |
Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Dose-Response Relationship, Dr | 2008 |
Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carbon Dioxide; Carvedilol; Dose-Resp | 2008 |
Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carbon Dioxide; Carvedilol; Dose-Resp | 2008 |
Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Endothelin-1; Exercise; Exercise T | 2008 |
Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Endothelin-1; Exercise; Exercise T | 2008 |
Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Colorado; Disease Management; Female; Health St | 2008 |
Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Colorado; Disease Management; Female; Health St | 2008 |
Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; Ex | 1995 |
Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; Ex | 1995 |
Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Meth | 1995 |
Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Meth | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Electrocardio | 1995 |
Vasodilating beta-blockers in heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Dose-Res | 1995 |
Vasodilating beta-blockers in heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angina Pectoris; Carbazoles; Carvedilol; Dose-Res | 1995 |
Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Carbazoles; Carvedilol; Double-Blind Method; Endothelins; | 1996 |
Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Carbazoles; Carvedilol; Double-Blind Method; Endothelins; | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Cardiovascular Diseases; Carv | 1996 |
[Beta receptor blockade in heart failure: a new look at an old topic].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contraindications; Female; Heart Failure; Hemod | 1996 |
[Beta receptor blockade in heart failure: a new look at an old topic].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contraindications; Female; Heart Failure; Hemod | 1996 |
The preventative effects of vasodilating beta-blockers in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Chronic Disease; Female; | 1996 |
The preventative effects of vasodilating beta-blockers in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Carbazoles; Carvedilol; Chronic Disease; Female; | 1996 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Australia; Carbazoles; Carvedilol; Double-Blind Method; Exercise | 1997 |
Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure.
Topics: Adaptation, Physiological; Adrenergic beta-Antagonists; Aerobiosis; Aged; Angiotensin-Converting Enz | 1997 |
Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure.
Topics: Adaptation, Physiological; Adrenergic beta-Antagonists; Aerobiosis; Aged; Angiotensin-Converting Enz | 1997 |
Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; Fe | 1997 |
Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; Fe | 1997 |
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 1997 |
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Double-Blind Me | 1997 |
[A failed improvement in pulmonary function and exercise capacity with carvedilol in congestive heart failure despite an excellent effect on left ventricular function].
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Chronic Disease; Exercise Tolerance; Fem | 1998 |
[A failed improvement in pulmonary function and exercise capacity with carvedilol in congestive heart failure despite an excellent effect on left ventricular function].
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Chronic Disease; Exercise Tolerance; Fem | 1998 |
Effects of carvedilol on right ventricular function in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Follow-Up Stu | 1998 |
Effects of carvedilol on right ventricular function in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Double-Blind Method; Follow-Up Stu | 1998 |
Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure.
Topics: Adrenergic Antagonists; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazoles; Carv | 1998 |
Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure.
Topics: Adrenergic Antagonists; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazoles; Carv | 1998 |
[Place of beta blockaders in the treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 1998 |
[Place of beta blockaders in the treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 1998 |
Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Carbazoles; Carvedilol; Double-Blind Method; Drug Int | 1998 |
Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy. Australia/New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Carbazoles; Carvedilol; Double-Blind Method; Drug Int | 1998 |
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Arginine Vasopressin; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Double-Blind Method; Heart | 1999 |
Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Arginine Vasopressin; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Double-Blind Method; Heart | 1999 |
Randomized trial of carvedilol in treatment of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Middle Age | 1997 |
Randomized trial of carvedilol in treatment of congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Middle Age | 1997 |
Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 1999 |
Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Dou | 1999 |
Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Chronic Disease; Double | 1999 |
Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Carbazoles; Carvedilol; Chronic Disease; Double | 1999 |
Carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Evaluation Studies as Topi | 1999 |
Carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Evaluation Studies as Topi | 1999 |
Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Exercise Tolerance; Female; Heart Failur | 1999 |
Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Exercise Tolerance; Female; Heart Failur | 1999 |
Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; Carvedilol; | 1999 |
Beta-blockade in heart failure: a comparison of carvedilol with metoprolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; Carvedilol; | 1999 |
The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography, Doppler; | 2000 |
The carvedilol hibernation reversible ischaemia trial, marker of success (CHRISTMAS) study. Methodology of a randomised, placebo controlled, multicentre study of carvedilol in hibernation and heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography, Doppler; | 2000 |
beta-blocker improvement in diastolic performance: the yin and yang of ventricular function changes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Diastole; Female; Heart Failure; H | 2000 |
beta-blocker improvement in diastolic performance: the yin and yang of ventricular function changes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Diastole; Female; Heart Failure; H | 2000 |
Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Diastole; Echocardiography; Female | 2000 |
Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Diastole; Echocardiography; Female | 2000 |
Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2000 |
Effects of carvedilol on left ventricular regional wall motion in patients with heart failure caused by ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2000 |
Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Drug Therapy, Combination; | 2000 |
Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Drug Therapy, Combination; | 2000 |
Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female | 2000 |
Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female | 2000 |
The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; E | 1999 |
The carvedilol hibernation reversible ischaemia trial; marker of success (CHRISTMAS). The CHRISTMAS Study Steering Committee and Investigators.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Double-Blind Method; Echocardiography; E | 1999 |
Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.
Topics: Adrenergic beta-Antagonists; Baroreflex; Carbazoles; Carvedilol; Case-Control Studies; Chronic Disea | 2000 |
Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.
Topics: Adrenergic beta-Antagonists; Baroreflex; Carbazoles; Carvedilol; Case-Control Studies; Chronic Disea | 2000 |
Beta blocker benefits patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Human | 2000 |
Beta blocker benefits patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Human | 2000 |
Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Antioxidants; Carbazoles; Carvedilol | 2001 |
Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Antioxidants; Carbazoles; Carvedilol | 2001 |
Different impact of carvedilol and transdermal scopolamine on cardiovascular performance of mild-moderate chronic heart failure patients: evidence of useful effects of scopolamine on tolerance to work load.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Diseas | 2000 |
Different impact of carvedilol and transdermal scopolamine on cardiovascular performance of mild-moderate chronic heart failure patients: evidence of useful effects of scopolamine on tolerance to work load.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Diseas | 2000 |
Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.
Topics: Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Double-Blind Method; Echocardiography; | 2001 |
Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial.
Topics: Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Double-Blind Method; Echocardiography; | 2001 |
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antidepressive Agents, Second-Generation; Autonomic Nervou | 2001 |
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antidepressive Agents, Second-Generation; Autonomic Nervou | 2001 |
[Clinical efficacy of carvedilol in patients with severe cardiac insufficiency].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Middle Age | 2001 |
[Clinical efficacy of carvedilol in patients with severe cardiac insufficiency].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Middle Age | 2001 |
Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Follow-Up Studies; Gated | 2001 |
Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Follow-Up Studies; Gated | 2001 |
[Economic study of carvedilol in heart failure. A cost effectiveness study in France].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cost-Benefit Analysis; Digitalis; Economics, Ho | 2001 |
[Economic study of carvedilol in heart failure. A cost effectiveness study in France].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cost-Benefit Analysis; Digitalis; Economics, Ho | 2001 |
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
Topics: Adrenergic Antagonists; Black People; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization | 2001 |
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
Topics: Adrenergic Antagonists; Black People; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization | 2001 |
Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Carbazoles; Carvedilol; Echocardiography; Epinephr | 2001 |
Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Carbazoles; Carvedilol; Echocardiography; Epinephr | 2001 |
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Atrial Natriuretic Factor; Blood Pressure; Carbazoles; Carvedilol; Chro | 2001 |
Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Atrial Natriuretic Factor; Blood Pressure; Carbazoles; Carvedilol; Chro | 2001 |
Differing beta-blocking effects of carvedilol and metoprolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Cr | 2001 |
Differing beta-blocking effects of carvedilol and metoprolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Cr | 2001 |
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol | 2001 |
Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cachexia; Carbazoles; Carboxylic Acids; Carvedilol | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Effect of carvedilol on survival in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Double-Blind Method; Fem | 2001 |
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Adrenergic beta-Antagonists; Adrenomedullin; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; He | 2001 |
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Topics: Adrenergic beta-Antagonists; Adrenomedullin; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; He | 2001 |
Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Atrial Fibrillation; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Digitalis Glycosi | 2001 |
Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Atrial Fibrillation; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Digitalis Glycosi | 2001 |
Carvedilol titration in patients with congestive heart failure receiving inotropic therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedilol; Dose-Response Relatio | 2001 |
Carvedilol titration in patients with congestive heart failure receiving inotropic therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiotonic Agents; Carvedilol; Dose-Response Relatio | 2001 |
Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Carbazoles; | 2001 |
Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Carbazoles; | 2001 |
Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Cross-Over Studies; Female; He | 2001 |
Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Cross-Over Studies; Female; He | 2001 |
Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; | 2001 |
Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; | 2001 |
Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2001 |
Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; | 2001 |
Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double-Blind | 2001 |
Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double-Blind | 2001 |
Impact of pharmacotherapy on lymphocyte volumes and activity of the Na+/H+ exchanger in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Cell Size | 2001 |
Impact of pharmacotherapy on lymphocyte volumes and activity of the Na+/H+ exchanger in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Cell Size | 2001 |
[Tolerability and clinical effects of carvedilol in patients over 70 years of age with chronic heart failure due to left ventricular dysfunction].
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Carbazoles; Carvedilol; Data Interpretat | 2001 |
[Tolerability and clinical effects of carvedilol in patients over 70 years of age with chronic heart failure due to left ventricular dysfunction].
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Carbazoles; Carvedilol; Data Interpretat | 2001 |
Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; Heart | 2002 |
Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; Heart | 2002 |
Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibi | 2002 |
Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibi | 2002 |
Dual chamber pacing in patients with severe heart failure on beta blocker and amiodarone treatment: preliminary results of a randomised study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiac Pacing, Artific | 2002 |
Dual chamber pacing in patients with severe heart failure on beta blocker and amiodarone treatment: preliminary results of a randomised study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiac Pacing, Artific | 2002 |
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Europe; Female; Heart Fail | 2002 |
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Europe; Female; Heart Fail | 2002 |
Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy.
Topics: Aged; Analysis of Variance; Blood Glucose; Carbazoles; Carvedilol; Catecholamines; Coronary Vessels; | 2002 |
Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy.
Topics: Aged; Analysis of Variance; Blood Glucose; Carbazoles; Carvedilol; Catecholamines; Coronary Vessels; | 2002 |
Effects of carvedilol on ventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Carv | 1992 |
Effects of carvedilol on ventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Carbazoles; Carv | 1992 |
Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; | 1992 |
Can intravenous beta-blockade predict long-term hemodynamic benefit in chronic congestive heart failure secondary to ischemic heart disease? A comparison of intravenous with oral carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; | 1992 |
The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Coronary Disease; Female; Heart Failure; | 1991 |
The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Coronary Disease; Female; Heart Failure; | 1991 |
[Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Coronary Disease; Doub | 1990 |
[Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Coronary Disease; Doub | 1990 |
422 other studies available for carvedilol and Heart Failure
| Article | Year |
|---|---|
Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study.
Topics: Aged; Carvedilol; Denmark; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Metoprolo | 2021 |
Long-Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study.
Topics: Aged; Carvedilol; Denmark; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Metoprolo | 2021 |
The double anaerobic threshold in heart failure.
Topics: Adrenergic beta-Antagonists; Anaerobic Threshold; Bisoprolol; Carvedilol; Exercise Test; Heart Failu | 2022 |
The double anaerobic threshold in heart failure.
Topics: Adrenergic beta-Antagonists; Anaerobic Threshold; Bisoprolol; Carvedilol; Exercise Test; Heart Failu | 2022 |
[Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report].
Topics: Aged; Bisoprolol; Carvedilol; Chylothorax; Dyspnea; Female; Heart Failure; Humans; Hypertension, Por | 2022 |
[Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report].
Topics: Aged; Bisoprolol; Carvedilol; Chylothorax; Dyspnea; Female; Heart Failure; Humans; Hypertension, Por | 2022 |
Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2022 |
Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2022 |
Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Cross-Sectional Studies; Heart Failure; Humans; Neuro | 2023 |
Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Cross-Sectional Studies; Heart Failure; Humans; Neuro | 2023 |
Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carvedilol; Defibrillators, Implantable; Heart Fai | 2023 |
Effect of Carvedilol vs Metoprolol on Atrial and Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carvedilol; Defibrillators, Implantable; Heart Fai | 2023 |
Tip loaded cyclodextrin-carvedilol complexes microarray patches.
Topics: Administration, Oral; Animals; Biological Availability; Carvedilol; Cyclodextrins; Heart Failure; Ra | 2023 |
Tip loaded cyclodextrin-carvedilol complexes microarray patches.
Topics: Administration, Oral; Animals; Biological Availability; Carvedilol; Cyclodextrins; Heart Failure; Ra | 2023 |
Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac K
Topics: Bisoprolol; Carvedilol; Heart; Heart Failure; Humans; Metoprolol; Protein Isoforms | 2023 |
Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac K
Topics: Bisoprolol; Carvedilol; Heart; Heart Failure; Humans; Metoprolol; Protein Isoforms | 2023 |
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrioventricular Block; Bisoprolol; Carvedilol | 2019 |
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrioventricular Block; Bisoprolol; Carvedilol | 2019 |
Cocaine, Heart Failure, and Carvedilol: Triangulating the Safety of β-Blocker Therapy.
Topics: Adrenergic beta-Antagonists; Carvedilol; Cocaine; Heart Failure; Humans; Propanolamines | 2019 |
Cocaine, Heart Failure, and Carvedilol: Triangulating the Safety of β-Blocker Therapy.
Topics: Adrenergic beta-Antagonists; Carvedilol; Cocaine; Heart Failure; Humans; Propanolamines | 2019 |
Carvedilol Among Patients With Heart Failure With a Cocaine-Use Disorder.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Cocaine-Related Disorders; Female; Heart Failure; Hos | 2019 |
Carvedilol Among Patients With Heart Failure With a Cocaine-Use Disorder.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Cocaine-Related Disorders; Female; Heart Failure; Hos | 2019 |
Effect of Cardioprotective Drugs on Chemotherapy-Induced Heart Failure and New Risk Stratification.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Heart Failure; Humans; Lisinopr | 2019 |
Effect of Cardioprotective Drugs on Chemotherapy-Induced Heart Failure and New Risk Stratification.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Heart Failure; Humans; Lisinopr | 2019 |
Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Jap | 2020 |
Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Jap | 2020 |
Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged | 2020 |
Metoprolol Versus Carvedilol in Patients With Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus, and Renal Failure.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Aged | 2020 |
A rare case of biventricular non-compaction.
Topics: Cardiomyopathies; Carvedilol; Coronary Artery Disease; Dyspnea; Furosemide; Heart Failure; Heart Ven | 2020 |
A rare case of biventricular non-compaction.
Topics: Cardiomyopathies; Carvedilol; Coronary Artery Disease; Dyspnea; Furosemide; Heart Failure; Heart Ven | 2020 |
Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
Topics: Antihypertensive Agents; Carvedilol; Cost-Benefit Analysis; Decision Trees; Health Expenditures; Hea | 2021 |
Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.
Topics: Antihypertensive Agents; Carvedilol; Cost-Benefit Analysis; Decision Trees; Health Expenditures; Hea | 2021 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2020 |
MitraClip or Ventricular Assist Device?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2020 |
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Adrenergic beta-Antagonists; Betaxolol; Bisoprolol; Carbazoles; Carvedilol; Czech Republic; Heart Fa | 2021 |
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Adrenergic beta-Antagonists; Betaxolol; Bisoprolol; Carbazoles; Carvedilol; Czech Republic; Heart Fa | 2021 |
Effects of carvedilol and metoprolol on the myocardium during mechanical unloading in a rat heterotopic heart transplantation model.
Topics: Adrenergic beta-Antagonists; Animals; Carvedilol; Heart Failure; Heart Transplantation; Metoprolol; | 2021 |
Effects of carvedilol and metoprolol on the myocardium during mechanical unloading in a rat heterotopic heart transplantation model.
Topics: Adrenergic beta-Antagonists; Animals; Carvedilol; Heart Failure; Heart Transplantation; Metoprolol; | 2021 |
Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Biomarkers; Bisoprolol; Carvedilol; Cluster Analysis; | 2021 |
Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Biomarkers; Bisoprolol; Carvedilol; Cluster Analysis; | 2021 |
Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes.
Topics: Aged; Carvedilol; Diabetes Mellitus; Heart Failure; Humans; Hyperglycemia; Male; Medicare; Metoprolo | 2021 |
Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes.
Topics: Aged; Carvedilol; Diabetes Mellitus; Heart Failure; Humans; Hyperglycemia; Male; Medicare; Metoprolo | 2021 |
Contraindications Differ Widely Among Beta Blockers and Ought to be Cited for an Individual Drug, Not for the Entire Class.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carvedilol; Contraindications; Heart Failure; Humans; Nebiv | 2021 |
Contraindications Differ Widely Among Beta Blockers and Ought to be Cited for an Individual Drug, Not for the Entire Class.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carvedilol; Contraindications; Heart Failure; Humans; Nebiv | 2021 |
Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline-rich protein 1A.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Carvedilol; Cornified Envelope Proline-Rich Protein | 2021 |
Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline-rich protein 1A.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Carvedilol; Cornified Envelope Proline-Rich Protein | 2021 |
Preventive role of carvedilol in adriamycin-induced cardiomyopathy.
Topics: Aged; Carbazoles; Cardiomyopathies; Carvedilol; Doxorubicin; Echocardiography; Female; Heart Failure | 2016 |
Preventive role of carvedilol in adriamycin-induced cardiomyopathy.
Topics: Aged; Carbazoles; Cardiomyopathies; Carvedilol; Doxorubicin; Echocardiography; Female; Heart Failure | 2016 |
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2017 |
Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; | 2017 |
Digoxin Toxicity in a Neonate Caused by the Interaction with Carvedilol.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Carvedilol; Digoxin; Disease Progression; Heart | 2017 |
Digoxin Toxicity in a Neonate Caused by the Interaction with Carvedilol.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Carvedilol; Digoxin; Disease Progression; Heart | 2017 |
Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Forced Expiratory | 2017 |
Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Forced Expiratory | 2017 |
The neuropeptide galanin promotes an anti-thrombotic phenotype on endocardial endothelial cells from heart failure patients.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Antithrombins; Carbazoles; Carve | 2017 |
The neuropeptide galanin promotes an anti-thrombotic phenotype on endocardial endothelial cells from heart failure patients.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Antithrombins; Carbazoles; Carve | 2017 |
THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2017 |
THE SAFETY AND EFFICACY OF AMIODARONE AND CARVEDILOL COMBINATION IN TREATMENT OF PATIENTS WITH SEVERE CARDIAC RHYTHM DISORDERS.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2017 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
The evaluation of β-adrenoceptor blocking agents in patients with COPD and congestive heart failure: a nationwide study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2017 |
Impact of Anemia on Left Ventricular Reverse Remodeling in Response to Carvedilol.
Topics: Adrenergic beta-Antagonists; Anemia; Carvedilol; Heart Failure; Humans; Ventricular Remodeling | 2018 |
Impact of Anemia on Left Ventricular Reverse Remodeling in Response to Carvedilol.
Topics: Adrenergic beta-Antagonists; Anemia; Carvedilol; Heart Failure; Humans; Ventricular Remodeling | 2018 |
β-Blockers in Myocardial Infarction: Issues With Standard Admission Order Sets.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contraindications, Drug; Electrocardiography; H | 2018 |
β-Blockers in Myocardial Infarction: Issues With Standard Admission Order Sets.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contraindications, Drug; Electrocardiography; H | 2018 |
Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carvedilol; Comorbidity; Croatia; Diabetes Mel | 2019 |
Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carvedilol; Comorbidity; Croatia; Diabetes Mel | 2019 |
Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; | 2018 |
Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; | 2018 |
Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Dose-Response Relationship, Drug; Female; Follow-Up S | 2018 |
Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Dose-Response Relationship, Drug; Female; Follow-Up S | 2018 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Risk of renal dysfunction in an elderly patient with chronic heart failure.
Topics: Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; Diclofenac; Digoxin; Drug Interactio | 2016 |
Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Male; Meto | 2018 |
Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Male; Meto | 2018 |
The CARVIVA HF trial- Is the devil in the detail?
Topics: Carvedilol; Exercise; Heart Failure; Humans; Ivabradine | 2019 |
The CARVIVA HF trial- Is the devil in the detail?
Topics: Carvedilol; Exercise; Heart Failure; Humans; Ivabradine | 2019 |
Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle.
Topics: Adrenergic beta-Antagonists; Carvedilol; Female; Heart Failure; Humans; Male; Myocardium; Pharmacoge | 2018 |
Clinical pharmacogenomics of carvedilol: the stereo-selective metabolism angle.
Topics: Adrenergic beta-Antagonists; Carvedilol; Female; Heart Failure; Humans; Male; Myocardium; Pharmacoge | 2018 |
Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Heart Failure, Systolic; Humans; | 2018 |
Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Heart Failure, Systolic; Humans; | 2018 |
The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carvedilol; Female; Hea | 2019 |
The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carvedilol; Female; Hea | 2019 |
Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Carvedilol; Cohort Studies; Drug Prescript | 2019 |
Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Bisoprolol; Carvedilol; Cohort Studies; Drug Prescript | 2019 |
Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amino Acid Substit | 2018 |
Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amino Acid Substit | 2018 |
A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arkansas; Carvedilol; Cause of Death; Death, Su | 2019 |
A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arkansas; Carvedilol; Cause of Death; Death, Su | 2019 |
Effect of carvedilol on heart rate response to cardiopulmonary exercise up to the anaerobic threshold in patients with subacute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Anaerobic Threshold; Carvedilol; Cross-Sectional Studies; Exercis | 2019 |
Effect of carvedilol on heart rate response to cardiopulmonary exercise up to the anaerobic threshold in patients with subacute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Anaerobic Threshold; Carvedilol; Cross-Sectional Studies; Exercis | 2019 |
β-Blockers and 1-Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2019 |
β-Blockers and 1-Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2019 |
Acute effects of intravenous carvedilol versus metoprolol on baroreflex-mediated sympathetic circulatory regulation in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Animals; Baroreflex | 2019 |
Acute effects of intravenous carvedilol versus metoprolol on baroreflex-mediated sympathetic circulatory regulation in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Animals; Baroreflex | 2019 |
Improvement of the outcome in patients with infantile dilated cardiomyopathy over three decades - The usefulness of long-term gradually medical supportive care.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2019 |
Improvement of the outcome in patients with infantile dilated cardiomyopathy over three decades - The usefulness of long-term gradually medical supportive care.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization The | 2019 |
Response letter to Dr. William's letter to the editor entitled "The CARVIVA HF trial - Is the devil in the detail?" published August 2018.
Topics: Carvedilol; Exercise; Exercise Tolerance; Heart Failure; Humans; Ivabradine | 2019 |
Response letter to Dr. William's letter to the editor entitled "The CARVIVA HF trial - Is the devil in the detail?" published August 2018.
Topics: Carvedilol; Exercise; Exercise Tolerance; Heart Failure; Humans; Ivabradine | 2019 |
Photobiomodulation therapy combined with carvedilol attenuates post-infarction heart failure by suppressing excessive inflammation and oxidative stress in rats.
Topics: Animals; Carvedilol; Catalase; Disease Models, Animal; Echocardiography; Female; Heart Failure; Hemo | 2019 |
Photobiomodulation therapy combined with carvedilol attenuates post-infarction heart failure by suppressing excessive inflammation and oxidative stress in rats.
Topics: Animals; Carvedilol; Catalase; Disease Models, Animal; Echocardiography; Female; Heart Failure; Hemo | 2019 |
Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol.
Topics: Adult; Aged; Carbazoles; Cardiomyopathies; Carvedilol; Female; Gadolinium; Heart Failure; Humans; Ma | 2013 |
Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol.
Topics: Adult; Aged; Carbazoles; Cardiomyopathies; Carvedilol; Female; Gadolinium; Heart Failure; Humans; Ma | 2013 |
Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Moni | 2013 |
Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Drug Moni | 2013 |
Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Dizziness; Dose-Response Rela | 2013 |
Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Dizziness; Dose-Response Rela | 2013 |
Update on pharmacological advances.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea | 2004 |
Update on pharmacological advances.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Disea | 2004 |
Questions and answers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbazoles; Cardiac Resynchronization Therapy; Carvedilol; | 2004 |
Questions and answers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbazoles; Cardiac Resynchronization Therapy; Carvedilol; | 2004 |
[Economic analysis of the treatment of heart failure with beta-blockers].
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Top | 2013 |
[Economic analysis of the treatment of heart failure with beta-blockers].
Topics: Adrenergic beta-Antagonists; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Top | 2013 |
Integrative effect of carvedilol and aerobic exercise training therapies on improving cardiac contractility and remodeling in heart failure mice.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Calcium Signaling; Carbazoles; Carvedilol; Cel | 2013 |
Integrative effect of carvedilol and aerobic exercise training therapies on improving cardiac contractility and remodeling in heart failure mice.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Calcium Signaling; Carbazoles; Carvedilol; Cel | 2013 |
Beta blocker treatment of heart failure patients with ongoing cocaine use.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cocaine-Related Disorders; Female; Follow-Up St | 2013 |
Beta blocker treatment of heart failure patients with ongoing cocaine use.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cocaine-Related Disorders; Female; Follow-Up St | 2013 |
Chronotropic incompetence: real life observations of a theoretical concept.
Topics: Adrenergic beta-1 Receptor Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; | 2013 |
Chronotropic incompetence: real life observations of a theoretical concept.
Topics: Adrenergic beta-1 Receptor Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; | 2013 |
β-Blockers in heart failure--are all created equal?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2013 |
β-Blockers in heart failure--are all created equal?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2013 |
Population pharmacokinetics of carvedilol in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cytochrome P-450 CYP2D6; Female; Heart Fa | 2013 |
Population pharmacokinetics of carvedilol in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cytochrome P-450 CYP2D6; Female; Heart Fa | 2013 |
Inappropriate implantable defibrillator shocks: an adverse outcome that can be prevented.
Topics: Carbazoles; Cardiac Resynchronization Therapy; Carvedilol; Defibrillators, Implantable; Female; Hear | 2013 |
Inappropriate implantable defibrillator shocks: an adverse outcome that can be prevented.
Topics: Carbazoles; Cardiac Resynchronization Therapy; Carvedilol; Defibrillators, Implantable; Female; Hear | 2013 |
Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort St | 2013 |
Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort St | 2013 |
Successful treatment of cocaine-induced cardiotoxicity with carvedilol therapy.
Topics: Adult; Carbazoles; Carvedilol; Cocaine; Female; Heart Failure; Humans; Propanolamines; Treatment Out | 2015 |
Successful treatment of cocaine-induced cardiotoxicity with carvedilol therapy.
Topics: Adult; Carbazoles; Carvedilol; Cocaine; Female; Heart Failure; Humans; Propanolamines; Treatment Out | 2015 |
Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Carbazoles; Cardiotonic Agents; Carvedilol; Dobutami | 2014 |
Weaning from inotropic support and concomitant beta-blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Carbazoles; Cardiotonic Agents; Carvedilol; Dobutami | 2014 |
Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cyclic Nucleotide Phosphodiesterases, Ty | 2014 |
Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cyclic Nucleotide Phosphodiesterases, Ty | 2014 |
Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; | 2014 |
Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; | 2014 |
Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Denmark; Female; Follow-Up Studies | 2014 |
Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Denmark; Female; Follow-Up Studies | 2014 |
The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Antioxidants; Carbazoles; Carvedilol; Echocardiography; Female; H | 2015 |
The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Antioxidants; Carbazoles; Carvedilol; Echocardiography; Female; H | 2015 |
Heart failure patients with B1-adrenoreceptor polymorphisms have augmented carvedilol response as detected by cardiac I123-MIBG scintigraphy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; H | 2014 |
Heart failure patients with B1-adrenoreceptor polymorphisms have augmented carvedilol response as detected by cardiac I123-MIBG scintigraphy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; H | 2014 |
[Association of T190C polymorphism of β3 adrenergic receptor gene with response to carvedilol in patients with chronic heart failure].
Topics: Adult; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Po | 2015 |
[Association of T190C polymorphism of β3 adrenergic receptor gene with response to carvedilol in patients with chronic heart failure].
Topics: Adult; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Po | 2015 |
Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response Relation | 2016 |
Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response Relation | 2016 |
Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Case-Control Stud | 2015 |
Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Case-Control Stud | 2015 |
A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
Topics: Adolescent; Adult; Age Factors; Carbazoles; Carvedilol; Child; Child, Preschool; Comorbidity; Cytoch | 2015 |
A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
Topics: Adolescent; Adult; Age Factors; Carbazoles; Carvedilol; Child; Child, Preschool; Comorbidity; Cytoch | 2015 |
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol | 2015 |
Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol | 2015 |
Should pharmacotherapy of digoxin be reviewed in male patients with heart failure in the case of association with carvedilol?
Topics: Adrenergic beta-Antagonists; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; B | 2015 |
Should pharmacotherapy of digoxin be reviewed in male patients with heart failure in the case of association with carvedilol?
Topics: Adrenergic beta-Antagonists; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; B | 2015 |
Reverse Remodeling Achieved by Combination Therapy With High-Dose Beta Blocker and Cardiac Resynchronization.
Topics: Adrenergic beta-Antagonists; Bundle-Branch Block; Carbazoles; Cardiac Resynchronization Therapy; Car | 2015 |
Reverse Remodeling Achieved by Combination Therapy With High-Dose Beta Blocker and Cardiac Resynchronization.
Topics: Adrenergic beta-Antagonists; Bundle-Branch Block; Carbazoles; Cardiac Resynchronization Therapy; Car | 2015 |
Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Bradycardia; Carbazoles; Cardiac Resynchronizatio | 2016 |
Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Bradycardia; Carbazoles; Cardiac Resynchronizatio | 2016 |
Left ventricular reverse remodeling with infantile dilated cardiomyopathy and pitfalls of carvedilol therapy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response Relation | 2016 |
Left ventricular reverse remodeling with infantile dilated cardiomyopathy and pitfalls of carvedilol therapy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response Relation | 2016 |
Comparison of metoprolol succinate versus carvedilol in time to cardiovascular admission in a Veterans Affairs healthcare system: An observational study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; He | 2015 |
Comparison of metoprolol succinate versus carvedilol in time to cardiovascular admission in a Veterans Affairs healthcare system: An observational study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; He | 2015 |
Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2016 |
Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2016 |
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Con | 2016 |
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Con | 2016 |
Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Biological Availability; Biotransformation; Ca | 2016 |
Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Biological Availability; Biotransformation; Ca | 2016 |
β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.
Topics: Adrenergic beta-Antagonists; Animals; beta-Arrestins; Carbazoles; Carvedilol; Cell Line, Tumor; Drug | 2016 |
β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.
Topics: Adrenergic beta-Antagonists; Animals; beta-Arrestins; Carbazoles; Carvedilol; Cell Line, Tumor; Drug | 2016 |
BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2016 |
BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Chi-Square | 2016 |
Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Aged, 80 and over; Angiotens | 2016 |
Clinical and echocardiographic characteristics and outcomes in congestive heart failure at the Hospital of The State University of Haiti.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Distribution; Aged; Aged, 80 and over; Angiotens | 2016 |
Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.
Topics: Animals; beta-Arrestin 2; Carbazoles; Carvedilol; Cells, Cultured; Cyclic Nucleotide Phosphodiestera | 2017 |
Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.
Topics: Animals; beta-Arrestin 2; Carbazoles; Carvedilol; Cells, Cultured; Cyclic Nucleotide Phosphodiestera | 2017 |
Vidarabine, an Anti-Herpes Virus Agent, Protects Against the Development of Heart Failure With Relatively Mild Side-Effects on Cardiac Function in a Canine Model of Pacing-Induced Dilated Cardiomyopathy.
Topics: Animals; Antiviral Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Models, Animal; | 2016 |
Vidarabine, an Anti-Herpes Virus Agent, Protects Against the Development of Heart Failure With Relatively Mild Side-Effects on Cardiac Function in a Canine Model of Pacing-Induced Dilated Cardiomyopathy.
Topics: Animals; Antiviral Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Disease Models, Animal; | 2016 |
Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Databases, Fa | 2017 |
Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Databases, Fa | 2017 |
Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 2017 |
Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Bisoprolol; Carbazoles; Carvedilol; Female; He | 2017 |
CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cytochrome P-45 | 2017 |
CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cytochrome P-45 | 2017 |
Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressur | 2008 |
Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressur | 2008 |
Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Arginine; Carbazoles; Carvedilol; C | 2008 |
Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Arginine; Carbazoles; Carvedilol; C | 2008 |
Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Heart Failure; | 2008 |
Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Heart Failure; | 2008 |
Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.
Topics: Adrenergic alpha-Agonists; Adrenergic Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; C | 2008 |
Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.
Topics: Adrenergic alpha-Agonists; Adrenergic Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; C | 2008 |
Beta-blockade as first-line therapy in the elderly heart failure patient--the proper approach or asking for trouble?
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2008 |
Beta-blockade as first-line therapy in the elderly heart failure patient--the proper approach or asking for trouble?
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Chro | 2008 |
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Disease Progression; Female; Genotype; Ha | 2008 |
Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Disease Progression; Female; Genotype; Ha | 2008 |
Heart rate dynamics during a treadmill cardiopulmonary exercise test in optimized beta-blocked heart failure patients.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Case-Control Studies; Exercise Test; Exe | 2008 |
Heart rate dynamics during a treadmill cardiopulmonary exercise test in optimized beta-blocked heart failure patients.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Case-Control Studies; Exercise Test; Exe | 2008 |
Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Heart Failure; | 2008 |
Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Heart Failure; | 2008 |
Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Diastole; Drug Administration Schedule; F | 2008 |
Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Diastole; Drug Administration Schedule; F | 2008 |
The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; | 2008 |
The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; | 2008 |
The relationship between heart rate reserve and oxygen uptake reserve in heart failure patients on optimized and non-optimized beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
The relationship between heart rate reserve and oxygen uptake reserve in heart failure patients on optimized and non-optimized beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort Studies; Dose-R | 2009 |
Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort Studies; Dose-R | 2009 |
Heart rate dynamic during an exercise test in heart failure patients with different sensibilities of the carvedilol therapy: heart rate dynamic during exercise test.
Topics: Adult; Carbazoles; Carvedilol; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Male; Middl | 2010 |
Heart rate dynamic during an exercise test in heart failure patients with different sensibilities of the carvedilol therapy: heart rate dynamic during exercise test.
Topics: Adult; Carbazoles; Carvedilol; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Male; Middl | 2010 |
Acutely decompensated systolic heart failure: effects of frequent doses of furosemide vs a single dose plus carvedilol on clinical status, neurohormonal activation and ventricular arrhythmias.
Topics: Acute Disease; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diuretics; Drug Administration S | 2010 |
Acutely decompensated systolic heart failure: effects of frequent doses of furosemide vs a single dose plus carvedilol on clinical status, neurohormonal activation and ventricular arrhythmias.
Topics: Acute Disease; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diuretics; Drug Administration S | 2010 |
Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
Topics: Adiponectin; Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Femal | 2009 |
Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
Topics: Adiponectin; Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Femal | 2009 |
Exercise haemodynamic variables rather than ventilatory efficiency indexes contribute to risk assessment in chronic heart failure patients treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Exercise; Female; Heart Failur | 2009 |
Exercise haemodynamic variables rather than ventilatory efficiency indexes contribute to risk assessment in chronic heart failure patients treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Exercise; Female; Heart Failur | 2009 |
Heart rate dynamics in heart transplantation patients during a treadmill cardiopulmonary exercise test: a pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Carbazoles; Carvedilol; Exercise Test; Female; Hear | 2009 |
Heart rate dynamics in heart transplantation patients during a treadmill cardiopulmonary exercise test: a pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Carbazoles; Carvedilol; Exercise Test; Female; Hear | 2009 |
Acute myocardial infarction after Kawasaki disease in an infant: treatment with coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Coronary Aneurysm; Coronary Angiography; Corona | 2009 |
Acute myocardial infarction after Kawasaki disease in an infant: treatment with coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Coronary Aneurysm; Coronary Angiography; Corona | 2009 |
Eligibility criteria for beta-blockade might have to be taken into account.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Patient Selection; Propa | 2009 |
Eligibility criteria for beta-blockade might have to be taken into account.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Patient Selection; Propa | 2009 |
[Carvedilol therapy in pediatric patients with Takayasu's arteritis complicated with congestive heart failure: a case report].
Topics: Carbazoles; Carvedilol; Child, Preschool; Heart Failure; Humans; Male; Propanolamines; Takayasu Arte | 2009 |
[Carvedilol therapy in pediatric patients with Takayasu's arteritis complicated with congestive heart failure: a case report].
Topics: Carbazoles; Carvedilol; Child, Preschool; Heart Failure; Humans; Male; Propanolamines; Takayasu Arte | 2009 |
Peak exercise responses in heart failure: back to basics.
Topics: Carbazoles; Carvedilol; Exercise; Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Oxygen Co | 2009 |
Peak exercise responses in heart failure: back to basics.
Topics: Carbazoles; Carvedilol; Exercise; Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Oxygen Co | 2009 |
[Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction].
Topics: Animals; Calcium; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Male; Myocardial | 2009 |
[Effect of carvedilol and perindopril on Ca(2+) pump activity and Ca(2+)-release channel density in myocardial sarcoplasmic reticulum in rats with chronic heart failure following myocardial infarction].
Topics: Animals; Calcium; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Male; Myocardial | 2009 |
[B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Failure; Natriuretic Peptide, Br | 2009 |
[B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Failure; Natriuretic Peptide, Br | 2009 |
The effect of beta-blockers on the adaptive immune system in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; | 2009 |
The effect of beta-blockers on the adaptive immune system in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; | 2009 |
Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Meto | 2010 |
Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Meto | 2010 |
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H | 2009 |
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H | 2009 |
The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Australia; Bisoprolol; Carbazoles; Carvedilol; | 2009 |
The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Australia; Bisoprolol; Carbazoles; Carvedilol; | 2009 |
Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Biomarkers; Carbazoles; Carvedilol; Chi-Square | 2009 |
Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure--special reference to transcardiac [corrected] gradient of norepinephrine.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Biomarkers; Carbazoles; Carvedilol; Chi-Square | 2009 |
Re: Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
Topics: Adiponectin; Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Heart | 2009 |
Re: Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
Topics: Adiponectin; Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Chronic Disease; Heart | 2009 |
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2013 |
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2013 |
Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; American Heart Association; Antihypertensive Agents; Carbazoles; | 2010 |
Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; American Heart Association; Antihypertensive Agents; Carbazoles; | 2010 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Combined amiodarone and low-dose carvedilol treatment for severe heart failure in childhood.
Topics: Adolescent; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dos | 2010 |
Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Bisoprolol; Carbazoles; C | 2010 |
Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Bisoprolol; Carbazoles; C | 2010 |
High-dose carvedilol therapy for mechanical circulatory assisted patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Heart-Assis | 2010 |
High-dose carvedilol therapy for mechanical circulatory assisted patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Heart-Assis | 2010 |
The carvedilol's beta-blockade in heart failure and exercise training's sympathetic blockade in healthy athletes during the rest and peak effort.
Topics: Adaptation, Physiological; Adrenergic beta-Antagonists; Adult; Age Factors; Carbazoles; Carvedilol; | 2010 |
The carvedilol's beta-blockade in heart failure and exercise training's sympathetic blockade in healthy athletes during the rest and peak effort.
Topics: Adaptation, Physiological; Adrenergic beta-Antagonists; Adult; Age Factors; Carbazoles; Carvedilol; | 2010 |
Chronotropic incompentence and functional capacity in chronic heart failure: no role of β-blockers and β-blocker dose.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Dose-Respons | 2012 |
Chronotropic incompentence and functional capacity in chronic heart failure: no role of β-blockers and β-blocker dose.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Chronic Disease; Dose-Respons | 2012 |
Differential effects of carvedilol and metoprolol on renal function in patients with heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; Carvedilol; Drug Evaluation; Female; Glome | 2010 |
Differential effects of carvedilol and metoprolol on renal function in patients with heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Carbazoles; Carvedilol; Drug Evaluation; Female; Glome | 2010 |
Replacement of carvedilol for propranolol in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Drug Substitution; Echocardiography; Fol | 2010 |
Replacement of carvedilol for propranolol in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Drug Substitution; Echocardiography; Fol | 2010 |
Effects of beta-blockers on ventilation efficiency in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Echocardiography; Exercise Test; Fe | 2010 |
Effects of beta-blockers on ventilation efficiency in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Echocardiography; Exercise Test; Fe | 2010 |
BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Carbazoles; Cardiomyopathies; Carvedilol; Chi- | 2010 |
BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Carbazoles; Cardiomyopathies; Carvedilol; Chi- | 2010 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Alleles; Carbazoles; Carvedilol; Chronic Disease; Comorbidity; Cy | 2010 |
Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Alleles; Carbazoles; Carvedilol; Chronic Disease; Comorbidity; Cy | 2010 |
Association of physical training with beta-blockers in heart failure in mice.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Carbazoles; Carvedilol; Collagen; Combin | 2010 |
Association of physical training with beta-blockers in heart failure in mice.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Carbazoles; Carvedilol; Collagen; Combin | 2010 |
A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Catheterization; Cardiac Pacing, Artificia | 2010 |
A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Cardiac Catheterization; Cardiac Pacing, Artificia | 2010 |
Letter by Lowenthal et al regarding article, "BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial".
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Clinical Trials as Top | 2010 |
Letter by Lowenthal et al regarding article, "BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial".
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child, Preschool; Clinical Trials as Top | 2010 |
Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.
Topics: Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Genotype; Heart Failure; Humans; Male; Meto | 2011 |
Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.
Topics: Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Genotype; Heart Failure; Humans; Male; Meto | 2011 |
Effect of carvedilol on heart failure in patients with a functionally univentricular heart.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors | 2011 |
Effect of carvedilol on heart failure in patients with a functionally univentricular heart.
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors | 2011 |
[Effects of carvedilol and proxodolol on nitric oxide (NO) metabolism in various organs in a congestive heart failure model].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Failure; Male; Nitric Oxide; Org | 2011 |
[Effects of carvedilol and proxodolol on nitric oxide (NO) metabolism in various organs in a congestive heart failure model].
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Failure; Male; Nitric Oxide; Org | 2011 |
[Impact of Gly389Arg beta1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Alleles; Carbazoles; Carvedilol; DNA; Dose-Response R | 2010 |
[Impact of Gly389Arg beta1-adrenoceptor polymorphism on the risk of chronic heart failure, the nature of its course, and on the efficiency of its treatment with carvedilol].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Alleles; Carbazoles; Carvedilol; DNA; Dose-Response R | 2010 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
Novel design and synthesis of modified structure of carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Delayed-Action Preparations; Half-Life | 2011 |
Novel design and synthesis of modified structure of carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Delayed-Action Preparations; Half-Life | 2011 |
A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Electrocardiography; Exercis | 2007 |
A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Electrocardiography; Exercis | 2007 |
[Effect of carvedilol and Radix astragali on ryanodine receptor in heart failure in mice].
Topics: Adrenergic beta-Antagonists; Animals; Astragalus Plant; Astragalus propinquus; Carbazoles; Carvedilo | 2011 |
[Effect of carvedilol and Radix astragali on ryanodine receptor in heart failure in mice].
Topics: Adrenergic beta-Antagonists; Animals; Astragalus Plant; Astragalus propinquus; Carbazoles; Carvedilo | 2011 |
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure?
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Male; | 2011 |
Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure?
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Male; | 2011 |
Critical evaluation of the optimal medical therapy in the cardiac resynchronization therapy candidates--single centre experience.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2011 |
Critical evaluation of the optimal medical therapy in the cardiac resynchronization therapy candidates--single centre experience.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2011 |
Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure.
Topics: Adenosine Triphosphate; Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Echoc | 2013 |
Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure.
Topics: Adenosine Triphosphate; Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Echoc | 2013 |
New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility.
Topics: Aged; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Myo | 2012 |
New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility.
Topics: Aged; Carbazoles; Carvedilol; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Aged; Myo | 2012 |
In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Carbazoles; Carv | 2012 |
In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Carbazoles; Carv | 2012 |
[COPD patients with heart failure: no concern about the beta blocker!].
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Comorbidity; Con | 2012 |
[COPD patients with heart failure: no concern about the beta blocker!].
Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Comorbidity; Con | 2012 |
When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiotonic Agent | 2012 |
When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiotonic Agent | 2012 |
Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Angiotensinogen; Carbazoles | 2012 |
Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Angiotensinogen; Carbazoles | 2012 |
Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function.
Topics: Adrenergic beta-Antagonists; Amides; Carbazoles; Carvedilol; Fumarates; Heart Failure; Humans; Propa | 2012 |
Combined use of direct renin inhibitor and carvedilol in heart failure with preserved systolic function.
Topics: Adrenergic beta-Antagonists; Amides; Carbazoles; Carvedilol; Fumarates; Heart Failure; Humans; Propa | 2012 |
The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cohort Studies; Defibrillators, Implanta | 2012 |
The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: implications for timing of implantable cardioverter-defibrillator implantation.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cohort Studies; Defibrillators, Implanta | 2012 |
Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathies; Carvedilol; Cohort Studies; Delayed-Actio | 2012 |
Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effectiveness analysis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathies; Carvedilol; Cohort Studies; Delayed-Actio | 2012 |
[Effect of the third generation beta-blockers on ion-regulating renal function in rats with heart failure model].
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Carbazoles; Carvedilol; Disease Models, Animal; D | 2012 |
[Effect of the third generation beta-blockers on ion-regulating renal function in rats with heart failure model].
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Carbazoles; Carvedilol; Disease Models, Animal; D | 2012 |
Titration of β-blockers for patients with heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Heart Rate; | 2013 |
Titration of β-blockers for patients with heart failure.
Topics: Adrenergic alpha-1 Receptor Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Heart Rate; | 2013 |
Current research on carvedilol in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2002 |
Current research on carvedilol in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2002 |
Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Cost-Benefit Analysis; Costs a | 2002 |
Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Cost-Benefit Analysis; Costs a | 2002 |
Carvedilol-induced changes in cardiac diastolic performance in a patient with isolated noncompaction of the myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathies; Carvedilol; Diastole; Echocardiogr | 2002 |
Carvedilol-induced changes in cardiac diastolic performance in a patient with isolated noncompaction of the myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathies; Carvedilol; Diastole; Echocardiogr | 2002 |
[Beta blockers in post-infarction state].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Human | 2002 |
[Beta blockers in post-infarction state].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Therapy, Combination; Heart Failure; Human | 2002 |
[Beta blockers in heart failure therapy with special reference to the COPERNICUS Study].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Drug | 2002 |
[Beta blockers in heart failure therapy with special reference to the COPERNICUS Study].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Drug | 2002 |
[Hormonal hyperactivity in heart failure. Differences in beta blockers].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Drug Therapy, Combina | 2002 |
[Hormonal hyperactivity in heart failure. Differences in beta blockers].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Drug Therapy, Combina | 2002 |
Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hospitalization; Humans; Propano | 2002 |
Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hospitalization; Humans; Propano | 2002 |
Haemorheological and endothelial-dependent alterations in heart failure after ACE inhibitor, calcium antagonist and beta blocker.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Arginine; B | 2002 |
Haemorheological and endothelial-dependent alterations in heart failure after ACE inhibitor, calcium antagonist and beta blocker.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Arginine; B | 2002 |
Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Asthma; Carbazoles; Carvedilol; Chi-Square Distribution; C | 2002 |
Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Asthma; Carbazoles; Carvedilol; Chi-Square Distribution; C | 2002 |
Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status.
Topics: Carbazoles; Cardiomyopathies; Cardiovascular Agents; Carvedilol; Heart Failure; Humans; Male; Middle | 2002 |
Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status.
Topics: Carbazoles; Cardiomyopathies; Cardiovascular Agents; Carvedilol; Heart Failure; Humans; Male; Middle | 2002 |
beta-blockers in heart failure--much more than heart rate reduction.
Topics: Adrenergic beta-Antagonists; Basal Metabolism; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; He | 2002 |
beta-blockers in heart failure--much more than heart rate reduction.
Topics: Adrenergic beta-Antagonists; Basal Metabolism; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; He | 2002 |
[Beta blockers and ACE inhibitors In heart failure to be combined at the beginning!].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Doubl | 2002 |
[Beta blockers and ACE inhibitors In heart failure to be combined at the beginning!].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Doubl | 2002 |
[Use of carvedilol in daily practice].
Topics: Adrenergic beta-Antagonists; Bradycardia; Carbazoles; Cardiology; Carvedilol; Coronary Disease; Drug | 1999 |
[Use of carvedilol in daily practice].
Topics: Adrenergic beta-Antagonists; Bradycardia; Carbazoles; Cardiology; Carvedilol; Coronary Disease; Drug | 1999 |
Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Follow-Up Stud | 2003 |
Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Female; Follow-Up Stud | 2003 |
Beta-blocker treatment before high-risk cardiac surgery.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Surgical Procedures; Carvedilol; Heart Failure; Hum | 2003 |
Beta-blocker treatment before high-risk cardiac surgery.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Surgical Procedures; Carvedilol; Heart Failure; Hum | 2003 |
Improving care of chronic heart failure: advances from drugs to devices.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiac Pacing, A | 2003 |
Improving care of chronic heart failure: advances from drugs to devices.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiac Pacing, A | 2003 |
Major heart failure news from 2001.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cohort Studies; Electrocardiography; Follow-Up | 2002 |
Major heart failure news from 2001.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cohort Studies; Electrocardiography; Follow-Up | 2002 |
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2003 |
Bedside B-type natriuretic peptide and functional capacity in chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzy | 2003 |
Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; | 2003 |
Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; | 2003 |
[Carvedilol in ischemic heart failure. Hibernating myocardium resuscitated].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Myocardial Stunning; Pla | 2003 |
[Carvedilol in ischemic heart failure. Hibernating myocardium resuscitated].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Myocardial Stunning; Pla | 2003 |
Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern.
Topics: Analysis of Variance; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dose-Response | 2003 |
Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern.
Topics: Analysis of Variance; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dose-Response | 2003 |
QT dispersion after beta-blocker therapy (carvedilol or metoprolol) in children with heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child Welfare; Child, Presch | 2003 |
QT dispersion after beta-blocker therapy (carvedilol or metoprolol) in children with heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Child Welfare; Child, Presch | 2003 |
Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Female; Gene Frequency; Genotype; | 2003 |
Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Female; Gene Frequency; Genotype; | 2003 |
Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; Bisoprolol; Carbazoles; Car | 2003 |
Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chronic heart failure oxidant stress: implications for beta-blocker selection.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; Bisoprolol; Carbazoles; Car | 2003 |
Beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2003 |
Beta blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2003 |
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2003 |
Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Apoptosis; Carbazo | 2003 |
[The changes of plasma levels of brain natriuretic peptides in evaluation of treatment responses in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Female; | 2003 |
[The changes of plasma levels of brain natriuretic peptides in evaluation of treatment responses in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Natriuretic Factor; Carbazoles; Carvedilol; Female; | 2003 |
[Heart failure symptoms despite normal pump function. Beta blockers also improve diastole].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Diastole; Echocardiog | 2003 |
[Heart failure symptoms despite normal pump function. Beta blockers also improve diastole].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Diastole; Echocardiog | 2003 |
Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Defibrillators, Imp | 2003 |
Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Defibrillators, Imp | 2003 |
Decreased heart rate recovery after exercise in patients with congestive heart failure: effect of beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Diastole; Exercise | 2003 |
Decreased heart rate recovery after exercise in patients with congestive heart failure: effect of beta-blocker therapy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Carvedilol; Diastole; Exercise | 2003 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adenosine Triphosphatases; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol | 2003 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adenosine Triphosphatases; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol | 2003 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carve | 2003 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carve | 2003 |
[Comet or snoop?].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Mult | 2003 |
[Comet or snoop?].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Europe; Heart Failure; Humans; Metoprolol; Mult | 2003 |
[The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Humans; Metopro | 2003 |
[The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Humans; Metopro | 2003 |
Top heart failure drugs compared.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Heart Failure; Humans; Met | 2003 |
Top heart failure drugs compared.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Heart Failure; Humans; Met | 2003 |
Myocardial dysfunction: hibernation and remodelling.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Coronary Circulation; Heart; Heart Failure; Hum | 2003 |
Myocardial dysfunction: hibernation and remodelling.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Coronary Circulation; Heart; Heart Failure; Hum | 2003 |
[For the first time beta blockers are in direct comparison With carvedilol weak hearts beat longer].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Doubl | 2003 |
[For the first time beta blockers are in direct comparison With carvedilol weak hearts beat longer].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Doubl | 2003 |
[Comparative study in heart failure. Which beta blocker saves more life time?].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2003 |
[Comparative study in heart failure. Which beta blocker saves more life time?].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2003 |
AVID and COMET.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Heart Conduction System; | 2003 |
AVID and COMET.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Heart Conduction System; | 2003 |
[A fairer comparison between carvedilol and metoprolol is still to be done].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2003 |
[A fairer comparison between carvedilol and metoprolol is still to be done].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Heart Failure | 2003 |
A COMET lost.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Controlled Clinical Trials as Topic; Dose-Respo | 2003 |
A COMET lost.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Controlled Clinical Trials as Topic; Dose-Respo | 2003 |
A case of severe diabetes mellitus occurred during management of heart failure with carvedilol and furosemide.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Diabetes Mellitus; Diuretics; Drug Thera | 2003 |
A case of severe diabetes mellitus occurred during management of heart failure with carvedilol and furosemide.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Diabetes Mellitus; Diuretics; Drug Thera | 2003 |
Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Catheterization; Carvedilol; Chronic Disease; | 2003 |
Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Catheterization; Carvedilol; Chronic Disease; | 2003 |
Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Male | 2004 |
Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Heart Rate; Humans; Male | 2004 |
In heart failure, all beta-blockers are not necessarily equal.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2003 |
In heart failure, all beta-blockers are not necessarily equal.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Clinical Trials as Topic; Cost-Bene | 2003 |
Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Ambulatory Care Facilities; Carbazoles; Carvedilol; | 2004 |
Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Ambulatory Care Facilities; Carbazoles; Carvedilol; | 2004 |
Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Child; Child, P | 2003 |
Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Child; Child, P | 2003 |
Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carv | 2004 |
Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carv | 2004 |
[Beta-blocking drugs indicated in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Diseases; Heart Failure; | 2003 |
[Beta-blocking drugs indicated in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Diseases; Heart Failure; | 2003 |
Case studies in heart failure.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Catheteriz | 2003 |
Case studies in heart failure.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiac Catheteriz | 2003 |
[Beta blocker in heart failure. Dosage too low].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Dose-Response Relatio | 2003 |
[Beta blocker in heart failure. Dosage too low].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Dose-Response Relatio | 2003 |
Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Heart Failure; Humans; Pro | 2003 |
Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U.S. carvedilol study.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Heart Failure; Humans; Pro | 2003 |
Clinical trials in Japan and the United States.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Dose-Response Relatio | 2004 |
Clinical trials in Japan and the United States.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Dose-Response Relatio | 2004 |
Which beta-blocker for heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Coronary Disease | 2004 |
Which beta-blocker for heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Contraindications; Coronary Disease | 2004 |
A comment on COMET: how to interpret a positive trial?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Europe; Heart | 2003 |
A comment on COMET: how to interpret a positive trial?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Europe; Heart | 2003 |
Beta-blockers for heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2003 |
Beta-blockers for heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2003 |
Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Biomarkers; Blood Pressure; Body Weight; Cachexia; Carbazoles; Carvedil | 2003 |
Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Biomarkers; Blood Pressure; Body Weight; Cachexia; Carbazoles; Carvedil | 2003 |
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003.
Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metop | 2003 |
The European Society of Cardiology working group on heart failure: Heart Failure Update 2003.
Topics: Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Eplerenone; Europe; Heart Failure; Humans; Metop | 2003 |
Limited predictive value of cardiopulmonary exercise indices in patients with moderate chronic heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Female; Heart Failure; Humans; M | 2004 |
Limited predictive value of cardiopulmonary exercise indices in patients with moderate chronic heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Female; Heart Failure; Humans; M | 2004 |
[Therapy of chronic heart failure--carvedilol vs. metoprolol. COMET Study].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Chronic Disease; Double-Blind M | 2004 |
[Therapy of chronic heart failure--carvedilol vs. metoprolol. COMET Study].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Chronic Disease; Double-Blind M | 2004 |
Blood pressure and the therapy of advanced heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Vasodila | 2004 |
Blood pressure and the therapy of advanced heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Vasodila | 2004 |
I have been diagnosed with heart failure, and my cardiologist has prescribed a medication called Coreg. What will it do for me?
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Heart Failure; Humans; Pro | 2003 |
I have been diagnosed with heart failure, and my cardiologist has prescribed a medication called Coreg. What will it do for me?
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Output, Low; Carvedilol; Heart Failure; Humans; Pro | 2003 |
Commentary on the Carvedilol or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Commentary on the Carvedilol or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2004 |
Assessing the impact of heart failure specialist services on patient populations.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Combined Modality Therapy; Decision Support Tec | 2004 |
Assessing the impact of heart failure specialist services on patient populations.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Combined Modality Therapy; Decision Support Tec | 2004 |
Long-term oral carvedilol in chronic heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical | 2004 |
Long-term oral carvedilol in chronic heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical | 2004 |
Remote titration of carvedilol for heart failure patients by advanced practice nurses.
Topics: Adrenergic beta-Antagonists; Aged; Bradycardia; Carbazoles; Carvedilol; Clinical Protocols; Cohort S | 2004 |
Remote titration of carvedilol for heart failure patients by advanced practice nurses.
Topics: Adrenergic beta-Antagonists; Aged; Bradycardia; Carbazoles; Carvedilol; Clinical Protocols; Cohort S | 2004 |
Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2004 |
Chronic left ventricular failure in the community: Prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2004 |
Carvedilol and metoprolol European trial: do the results merit challenge?
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Heart Failure; Human | 2004 |
Carvedilol and metoprolol European trial: do the results merit challenge?
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Double-Blind Method; Heart Failure; Human | 2004 |
Bob Ruffolo discusses the rhythm of drug development.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chemistry, Pharmaceutical; Drug Industry; Heart | 2004 |
Bob Ruffolo discusses the rhythm of drug development.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chemistry, Pharmaceutical; Drug Industry; Heart | 2004 |
Do pharmacological differences among beta-blockers affect their clinical efficacy in heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2004 |
Do pharmacological differences among beta-blockers affect their clinical efficacy in heart failure?
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2004 |
Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Clinical | 2004 |
Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy.
Topics: Adrenergic beta-Antagonists; Betaxolol; Carbazoles; Cardiac Pacing, Artificial; Carvedilol; Clinical | 2004 |
Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Carbazoles; | 2004 |
Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Pressure; Carbazoles; | 2004 |
Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chi-Square Distribution; Feasibility Stud | 2004 |
Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chi-Square Distribution; Feasibility Stud | 2004 |
[Incomplete and delayed parallel publication].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Conflict of Interest; Denmark; Drug Industry; H | 2004 |
[Incomplete and delayed parallel publication].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Conflict of Interest; Denmark; Drug Industry; H | 2004 |
Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiology; | 2004 |
Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiology; | 2004 |
Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Cohort Studies; Dose-Response Rela | 2004 |
Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Cohort Studies; Dose-Response Rela | 2004 |
Dismantling mandates in the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carbazoles; C | 2004 |
Dismantling mandates in the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carbazoles; C | 2004 |
Estimating mortality reduction by comparing survival curves.
Topics: Carbazoles; Cardiovascular Agents; Carvedilol; Computer Simulation; Evidence-Based Medicine; Heart F | 2004 |
Estimating mortality reduction by comparing survival curves.
Topics: Carbazoles; Cardiovascular Agents; Carvedilol; Computer Simulation; Evidence-Based Medicine; Heart F | 2004 |
Hemodynamic effects of carvedilol infusion and the contribution of the sympathetic nervous system in rats with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Algorithms; Animals; Blood Pressure; Carb | 2004 |
Hemodynamic effects of carvedilol infusion and the contribution of the sympathetic nervous system in rats with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Algorithms; Animals; Blood Pressure; Carb | 2004 |
[Prediction of intolerance to beta blocker therapy in chronic heart failure patients using BNP].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Natr | 2004 |
[Prediction of intolerance to beta blocker therapy in chronic heart failure patients using BNP].
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Natr | 2004 |
Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Anthracyclines; Carbazoles; Cardiomyopathies; Carvedilol; Echoca | 2004 |
Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Anthracyclines; Carbazoles; Cardiomyopathies; Carvedilol; Echoca | 2004 |
The role of growth hormone replacement in a growth hormone deficient patient with underlying cardiomyopathy and severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles | 2005 |
The role of growth hormone replacement in a growth hormone deficient patient with underlying cardiomyopathy and severe congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles | 2005 |
Observational cohort study to monitor the use and safety of carvedilol in the treatment of heart failure in clinical practice in England--1st interim report.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cohort Studies; England; Female; Health S | 2005 |
Observational cohort study to monitor the use and safety of carvedilol in the treatment of heart failure in clinical practice in England--1st interim report.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cohort Studies; England; Female; Health S | 2005 |
Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; H | 2005 |
Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; H | 2005 |
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Western; Carbazoles; Carvedilol; Echocardiography; H | 2005 |
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blotting, Western; Carbazoles; Carvedilol; Echocardiography; H | 2005 |
Influence of pretreatment systolic blood pressure on benefit from carvedilol in severe chronic heart failure patients.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Heart | 2005 |
Influence of pretreatment systolic blood pressure on benefit from carvedilol in severe chronic heart failure patients.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Heart | 2005 |
Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cost of Illness; Cost Savings; Female; He | 2005 |
Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cost of Illness; Cost Savings; Female; He | 2005 |
Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Bisoprolol; Carbazoles; Carvedilol; Heart Failur | 2005 |
Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of Carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Bisoprolol; Carbazoles; Carvedilol; Heart Failur | 2005 |
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Alleles; Angiography; Bisoprolol; Carbazoles; Carvedilol; Codon; | 2005 |
Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Alleles; Angiography; Bisoprolol; Carbazoles; Carvedilol; Codon; | 2005 |
Hemodynamic effects of orally administered carvedilol in healthy conscious dogs.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonis | 2005 |
Hemodynamic effects of orally administered carvedilol in healthy conscious dogs.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonis | 2005 |
Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Atrial Fibr | 2005 |
Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Atrial Fibr | 2005 |
Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Carbaz | 2005 |
Carvedilol blockade of alpha1- and beta-adrenoceptor induced inotropic responses in rats with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Carbaz | 2005 |
The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Exercise Test; Heart Failure; | 2005 |
The effects of long-term beta-blockade on the ventilatory responses to exercise in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Exercise Test; Heart Failure; | 2005 |
Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Female; Heart Failure; He | 2005 |
Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Female; Heart Failure; He | 2005 |
[The effect of carvedilol on apoptosis gene PDCD5 expression in chronic heart failure patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Apoptosis; Apoptosis Regulat | 2005 |
[The effect of carvedilol on apoptosis gene PDCD5 expression in chronic heart failure patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Apoptosis; Apoptosis Regulat | 2005 |
[Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy].
Topics: Adrenergic Agents; Adult; Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Catalase; Female; F | 2005 |
[Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy].
Topics: Adrenergic Agents; Adult; Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Catalase; Female; F | 2005 |
Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Exercise Tolerance; Female; Foll | 2005 |
Effects of beta-blocker therapy on ventilatory responses to exercise in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Test; Exercise Tolerance; Female; Foll | 2005 |
Impact of carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Dose- | 2005 |
Impact of carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Dose- | 2005 |
Beta-blocker treatment before angiotensin-converting enzyme inhibitor therapy in newly diagnosed heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
Beta-blocker treatment before angiotensin-converting enzyme inhibitor therapy in newly diagnosed heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Carve | 2005 |
Do standardized beta-blocker titration protocols in heart failure improve compliance? The GESICA registry experience.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Huma | 2005 |
Do standardized beta-blocker titration protocols in heart failure improve compliance? The GESICA registry experience.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Huma | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arg | 2005 |
Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Blotting, Western; Calcium-Binding Proteins; C | 2005 |
Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium-handling proteins in rat failing heart.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Blotting, Western; Calcium-Binding Proteins; C | 2005 |
Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Electrocardiography, Ambulatory; Heart Failure; | 2005 |
Do metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Electrocardiography, Ambulatory; Heart Failure; | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2005 |
Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover.
Topics: Adrenergic beta-Antagonists; Baroreflex; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Humans; | 2005 |
Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover.
Topics: Adrenergic beta-Antagonists; Baroreflex; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Humans; | 2005 |
Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Varian | 2006 |
Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Varian | 2006 |
Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats.
Topics: Adrenergic beta-Antagonists; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Carbaz | 2005 |
Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats.
Topics: Adrenergic beta-Antagonists; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Carbaz | 2005 |
[Effect of carvedilol on ryanodine receptor in heart failure].
Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Calcium; Calcium Signaling; Calcium-Transpor | 2005 |
[Effect of carvedilol on ryanodine receptor in heart failure].
Topics: Adrenergic beta-Antagonists; Animals; Animals, Newborn; Calcium; Calcium Signaling; Calcium-Transpor | 2005 |
Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; Carvedilol; Female | 2006 |
Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; Carvedilol; Female | 2006 |
Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart.
Topics: Adrenergic beta-Antagonists; Calcium Channels, L-Type; Carbazoles; Carvedilol; Dose-Response Relatio | 2006 |
Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart.
Topics: Adrenergic beta-Antagonists; Calcium Channels, L-Type; Carbazoles; Carvedilol; Dose-Response Relatio | 2006 |
Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Ad | 2005 |
Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Drug Ad | 2005 |
Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Blood Glucose; Carbazoles; Carvedilol; Dose-Response | 2005 |
Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Blood Glucose; Carbazoles; Carvedilol; Dose-Response | 2005 |
Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dobutamine; Feasibili | 2005 |
Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dobutamine; Feasibili | 2005 |
How FDA currently makes decisions on clinical studies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Ch | 2005 |
How FDA currently makes decisions on clinical studies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Ch | 2005 |
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as Topic; Drug | 2006 |
Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as Topic; Drug | 2006 |
Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; C | 2006 |
Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Carbazoles; Carvedilol; C | 2006 |
Significance of combined angiotensin II receptor blocker and carvedilol therapy in patients with congestive heart failure and arginine variant.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Carbazoles; Carvedilol; | 2006 |
Significance of combined angiotensin II receptor blocker and carvedilol therapy in patients with congestive heart failure and arginine variant.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Carbazoles; Carvedilol; | 2006 |
Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria.
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Carbazoles; Carvedilol; Dose-Response Relationship, D | 2006 |
Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria.
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Carbazoles; Carvedilol; Dose-Response Relationship, D | 2006 |
[Use of betablockers in elderly patients with congestive heart failure].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprol | 2006 |
[Use of betablockers in elderly patients with congestive heart failure].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Antihypertensive Agents; Bisoprol | 2006 |
Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia.
Topics: Adrenergic beta-Antagonists; Bradycardia; Carbazoles; Carvedilol; Comorbidity; Cost-Benefit Analysis | 2006 |
Prophylactic pacemaker use to allow beta-blocker therapy in patients with chronic heart failure with bradycardia.
Topics: Adrenergic beta-Antagonists; Bradycardia; Carbazoles; Carvedilol; Comorbidity; Cost-Benefit Analysis | 2006 |
Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: when differences may matter.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Delayed-Action Preparations; Heart Failure; Hum | 2006 |
Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: when differences may matter.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Delayed-Action Preparations; Heart Failure; Hum | 2006 |
Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND.
Topics: Carbazoles; Carvedilol; Child; Cholesterol, LDL; Clinical Trials as Topic; Darbepoetin alfa; Diureti | 2006 |
Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND.
Topics: Carbazoles; Carvedilol; Child; Cholesterol, LDL; Clinical Trials as Topic; Darbepoetin alfa; Diureti | 2006 |
[Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Asian People; Carbazoles; Carvedilol; Drug Tolerance; Female; Follow-Up | 2006 |
[Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Asian People; Carbazoles; Carvedilol; Drug Tolerance; Female; Follow-Up | 2006 |
Enantioselective and highly sensitive determination of carvedilol in human plasma and whole blood after administration of the racemate using normal-phase high-performance liquid chromatography.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calibration; Carbazoles; Carvedilol; Chro | 2006 |
Enantioselective and highly sensitive determination of carvedilol in human plasma and whole blood after administration of the racemate using normal-phase high-performance liquid chromatography.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calibration; Carbazoles; Carvedilol; Chro | 2006 |
Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cholines | 2006 |
Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cholines | 2006 |
Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atenolol | 2006 |
Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atenolol | 2006 |
Carvedilol reduces aldosterone release in systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Biomarkers; Carbazoles; Carvedilol; Female; Follow-Up Stud | 2006 |
Carvedilol reduces aldosterone release in systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Biomarkers; Carbazoles; Carvedilol; Female; Follow-Up Stud | 2006 |
Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Heart; | 2006 |
Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure.
Topics: Animals; Antihypertensive Agents; Aorta; Blood Pressure; Body Weight; Carbazoles; Carvedilol; Heart; | 2006 |
Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Area Under Curve; Carbazoles; Carvedilol; Clinica | 2006 |
Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Area Under Curve; Carbazoles; Carvedilol; Clinica | 2006 |
COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chemistry, Pharmaceutical | 2006 |
COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chemistry, Pharmaceutical | 2006 |
Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chemistry, Pharmaceutical; Delayed-Action Prepa | 2006 |
Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chemistry, Pharmaceutical; Delayed-Action Prepa | 2006 |
Fosinopril and carvedilol reverse hypertrophy and change the levels of protein kinase C epsilon and components of its signaling complex.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2006 |
Fosinopril and carvedilol reverse hypertrophy and change the levels of protein kinase C epsilon and components of its signaling complex.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2006 |
Effect of adrenergic blockade on plasma adrenomedullin concentration during static handgrip in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adrenomedullin; Aged; Analysis of Variance; Biomarkers; Blood Pressure; | 2006 |
Effect of adrenergic blockade on plasma adrenomedullin concentration during static handgrip in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adrenomedullin; Aged; Analysis of Variance; Biomarkers; Blood Pressure; | 2006 |
Clinical trials of newly developed anti-cancer agents in children with acute leukemia.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Carbazoles; Ca | 2006 |
Clinical trials of newly developed anti-cancer agents in children with acute leukemia.
Topics: Acute Disease; Adolescent; Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Carbazoles; Ca | 2006 |
Predictors of clinical outcomes in patients given carvedilol for heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Clinical Competence; Female; Heart Failur | 2006 |
Predictors of clinical outcomes in patients given carvedilol for heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Clinical Competence; Female; Heart Failur | 2006 |
Carvedilol can restore the multifractal properties of heart beat dynamics in patients with advanced congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Complexes, Premature; Carvedilol; Electrocardiograp | 2007 |
Carvedilol can restore the multifractal properties of heart beat dynamics in patients with advanced congestive heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiac Complexes, Premature; Carvedilol; Electrocardiograp | 2007 |
Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Heart Failure; | 2007 |
Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Heart Failure; | 2007 |
Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug The | 2006 |
Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug The | 2006 |
Relationship between beta-blocker treatment and the severity of central sleep apnea in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chi-Square Distribution; Echocardiography | 2007 |
Relationship between beta-blocker treatment and the severity of central sleep apnea in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chi-Square Distribution; Echocardiography | 2007 |
The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Carbazoles; Carvedilol; Drug Therapy, Combination; Ec | 2007 |
The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Carbazoles; Carvedilol; Drug Therapy, Combination; Ec | 2007 |
Chronic treatment with carvedilol improves Ca(2+)-dependent ATP consumption in triton X-skinned fiber preparations of human myocardium.
Topics: Adrenergic beta-Antagonists; Calcium; Carbazoles; Carvedilol; Heart; Heart Failure; Humans; Metoprol | 2007 |
Chronic treatment with carvedilol improves Ca(2+)-dependent ATP consumption in triton X-skinned fiber preparations of human myocardium.
Topics: Adrenergic beta-Antagonists; Calcium; Carbazoles; Carvedilol; Heart; Heart Failure; Humans; Metoprol | 2007 |
Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Gene | 2007 |
Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Gene | 2007 |
Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2007 |
Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Follow-Up Studies; Heart Failure; | 2007 |
[The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Clini | 2007 |
[The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Clini | 2007 |
Beta-blocker dosing in community-based treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Community Networks; Drug Administration S | 2007 |
Beta-blocker dosing in community-based treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Community Networks; Drug Administration S | 2007 |
Heart failure treatment profile at the beta blockers era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Carbazoles; Carved | 2007 |
Heart failure treatment profile at the beta blockers era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Carbazoles; Carved | 2007 |
Images in cardiovascular medicine. Mitochondrial cardiomyopathy evaluated with cardiac magnetic resonance.
Topics: Aged; Biopsy; Carbazoles; Cardiomyopathies; Carvedilol; Coenzymes; Coronary Angiography; Enalapril; | 2007 |
Images in cardiovascular medicine. Mitochondrial cardiomyopathy evaluated with cardiac magnetic resonance.
Topics: Aged; Biopsy; Carbazoles; Cardiomyopathies; Carvedilol; Coenzymes; Coronary Angiography; Enalapril; | 2007 |
Low-dose carvedilol reduces transmural heterogeneity of ventricular repolarization in congestive heart failure.
Topics: Action Potentials; Animals; Blood Pressure; Carbazoles; Carvedilol; Female; Heart Failure; Male; Pro | 2007 |
Low-dose carvedilol reduces transmural heterogeneity of ventricular repolarization in congestive heart failure.
Topics: Action Potentials; Animals; Blood Pressure; Carbazoles; Carvedilol; Female; Heart Failure; Male; Pro | 2007 |
Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aluminum; Atenolol; California; Carbazo | 2007 |
Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aluminum; Atenolol; California; Carbazo | 2007 |
[The optimal treatment of chronic heart failure with beta-blockers may be dependent upon the genetic background of the patient].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Genomics; Genotype; Heart Failure; Humans; Phar | 2007 |
[The optimal treatment of chronic heart failure with beta-blockers may be dependent upon the genetic background of the patient].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Genomics; Genotype; Heart Failure; Humans; Phar | 2007 |
Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cause of Death; Dose-Response Relationshi | 2008 |
Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cause of Death; Dose-Response Relationshi | 2008 |
Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort Studies; Delaye | 2008 |
Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cohort Studies; Delaye | 2008 |
Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Cardiotonic Agents; Carvedi | 2008 |
Hemodynamic effects of dobutamine in patients with an exacerbation of chronic systolic heart failure treated with low doses of carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Cardiotonic Agents; Carvedi | 2008 |
Recovery of heart function in children with acute severe heart failure.
Topics: Acute Disease; Captopril; Carbazoles; Cardiotonic Agents; Carvedilol; Child; Child, Preschool; Datab | 2008 |
Recovery of heart function in children with acute severe heart failure.
Topics: Acute Disease; Captopril; Carbazoles; Cardiotonic Agents; Carvedilol; Child; Child, Preschool; Datab | 2008 |
Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cytochrome P-450 CYP2D | 2008 |
Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Cytochrome P-450 CYP2D | 2008 |
Changing beta-blockers in heart failure: when is a class not a class?
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Heart; Heart Failure; Hum | 2008 |
Changing beta-blockers in heart failure: when is a class not a class?
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Heart; Heart Failure; Hum | 2008 |
Carvedilol therapy in heart failure--I.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Survival | 1995 |
Carvedilol therapy in heart failure--I.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Survival | 1995 |
Carvedilol therapy in heart failure--II.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 1995 |
Carvedilol therapy in heart failure--II.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 1995 |
Carvedilol therapy in heart failure--III.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Propanolamines | 1995 |
Carvedilol therapy in heart failure--III.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Propanolamines | 1995 |
Carvedilol--a wide therapeutic potential in cardiovascular syndromes. Introduction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Free Radical Scavengers; | 1993 |
Carvedilol--a wide therapeutic potential in cardiovascular syndromes. Introduction.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Free Radical Scavengers; | 1993 |
Beta-adrenergic blockers and survival in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 1996 |
Beta-adrenergic blockers and survival in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines | 1996 |
Carvedilol for heart failure, with care.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Heart Failure; Humans; Middle Aged; Propa | 1996 |
Carvedilol for heart failure, with care.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Heart Failure; Humans; Middle Aged; Propa | 1996 |
[Carvedilol in cardiac decompensation].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans; Propanolam | 1996 |
[Carvedilol in cardiac decompensation].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans; Propanolam | 1996 |
Effect of carvedilol on mortality and morbidity in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hospitalization; Humans; Morbidi | 1996 |
Effect of carvedilol on mortality and morbidity in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Hospitalization; Humans; Morbidi | 1996 |
[Beta blockers in heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contraindications; Dose-Response Relationship, | 1996 |
[Beta blockers in heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Contraindications; Dose-Response Relationship, | 1996 |
Slowing the progression of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Contr | 1996 |
Slowing the progression of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Contr | 1996 |
[Carvedilol and heart failure: new findings].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 1996 |
[Carvedilol and heart failure: new findings].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 1996 |
Carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bias; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Re | 1996 |
Carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Bias; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Re | 1996 |
Carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Research | 1996 |
Carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Research | 1996 |
Beta-blockade in heart failure: a potential role.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Propanolam | 1997 |
Beta-blockade in heart failure: a potential role.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Male; Propanolam | 1997 |
[Beta blocker for therapy of heart failure. Decreased mortality and fewer clinic admissions].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Patient Admission; Propa | 1997 |
[Beta blocker for therapy of heart failure. Decreased mortality and fewer clinic admissions].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Patient Admission; Propa | 1997 |
[Carvedilol].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Heart Failure; Humans; | 1997 |
[Carvedilol].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Heart Failure; Humans; | 1997 |
Carvedilol for heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials a | 1997 |
Carvedilol for heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials a | 1997 |
Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 1998 |
Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 1998 |
Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carv | 1997 |
Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carv | 1997 |
Effects of beta blockers on symptoms and functional capacity in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Tolerance; Heart Failure; Hospitalizat | 1997 |
Effects of beta blockers on symptoms and functional capacity in heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Exercise Tolerance; Heart Failure; Hospitalizat | 1997 |
Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Decerebrate State; Drug Evaluation, Pr | 1998 |
Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Decerebrate State; Drug Evaluation, Pr | 1998 |
Beta blockers for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Pregnancy; | 1998 |
Beta blockers for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Pregnancy; | 1998 |
Measurement of clinical efficacy in studies of heart failure.
Topics: Adrenergic Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Dizziness; Heart Failure; | 1998 |
Measurement of clinical efficacy in studies of heart failure.
Topics: Adrenergic Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Dizziness; Heart Failure; | 1998 |
Pharmacist-managed carvedilol heart failure clinic.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; Carbazoles; Carvedilol; Heart Failure; Humans; Patient | 1998 |
Pharmacist-managed carvedilol heart failure clinic.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; Carbazoles; Carvedilol; Heart Failure; Humans; Patient | 1998 |
Doxorubicin-induced cardiomyopathy treated with carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Carbazoles; | 1998 |
Doxorubicin-induced cardiomyopathy treated with carvedilol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Carbazoles; | 1998 |
[Effects of carvedilol (beta 1, beta 2, alpha 1 bloker) on refractory congestive heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Tolerance; Female; Heart Failure; Humans; | 1998 |
[Effects of carvedilol (beta 1, beta 2, alpha 1 bloker) on refractory congestive heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Tolerance; Female; Heart Failure; Humans; | 1998 |
Possible adverse skin reaction to carvedilol.
Topics: Adrenergic beta-Antagonists; Antipruritics; Carbazoles; Carvedilol; Diphenhydramine; Drug Eruptions; | 1998 |
Possible adverse skin reaction to carvedilol.
Topics: Adrenergic beta-Antagonists; Antipruritics; Carbazoles; Carvedilol; Diphenhydramine; Drug Eruptions; | 1998 |
[Drugs prescribed for chronic heart failure. Current data on their effectiveness].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biso | 1998 |
[Drugs prescribed for chronic heart failure. Current data on their effectiveness].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biso | 1998 |
Carvedilol and the Food and Drug Administration approval process: an introduction.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; He | 1999 |
Carvedilol and the Food and Drug Administration approval process: an introduction.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; He | 1999 |
Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; He | 1999 |
Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; He | 1999 |
End-point interpretation in clinical trials: the case for discipline.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; He | 1999 |
End-point interpretation in clinical trials: the case for discipline.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; He | 1999 |
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Bisoprolol; Carbaz | 1999 |
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Bisoprolol; Carbaz | 1999 |
Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Adverse Drug Reaction Reporting Systems; Age | 1999 |
Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Adverse Drug Reaction Reporting Systems; Age | 1999 |
Now there are four: Carvedilol takes its place in therapeutical line-up for heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Multicenter Studies as T | 1997 |
Now there are four: Carvedilol takes its place in therapeutical line-up for heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Multicenter Studies as T | 1997 |
Cost effectiveness of carvedilol for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiotonic Agent | 1999 |
Cost effectiveness of carvedilol for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiotonic Agent | 1999 |
Beta blockers: are they difficult to use in heart failure patients?
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Clinical Trials as Topic; Dose-Response R | 1999 |
Beta blockers: are they difficult to use in heart failure patients?
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Clinical Trials as Topic; Dose-Response R | 1999 |
Carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Heart Failure; Hemodyn | 1999 |
Carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Heart Failure; Hemodyn | 1999 |
To trust or not to trust.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coron | 1999 |
To trust or not to trust.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coron | 1999 |
Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Hear | 1999 |
Carvedilol improves functional class in patients with severe left ventricular dysfunction referred for heart transplantation.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Hear | 1999 |
Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Chi-Square | 1999 |
Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Chi-Square | 1999 |
[Prospective evaluation of effect of carvedilol therapy on heart rate variability in patients with dilated cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response R | 1999 |
[Prospective evaluation of effect of carvedilol therapy on heart rate variability in patients with dilated cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Dose-Response R | 1999 |
Carvedilol in class IV heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Survival | 1999 |
Carvedilol in class IV heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Survival | 1999 |
[The role of beta-adrenergic blocking agents in treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 1999 |
[The role of beta-adrenergic blocking agents in treatment of heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Cardiac Ou | 1999 |
Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Cardiac Ou | 1999 |
Combination therapy with carvedilol and amiodarone in patients with severe heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Drug Therap | 2000 |
Combination therapy with carvedilol and amiodarone in patients with severe heart failure.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Drug Therap | 2000 |
[New milestones in the therapy of chronic heart failure with beta blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Cardi | 2000 |
[New milestones in the therapy of chronic heart failure with beta blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Carbazoles; Cardi | 2000 |
[Ergometric test and level of daily physical activity in chronic heart failure].
Topics: Adult; Carbazoles; Carvedilol; Child; Double-Blind Method; Dyspnea; Electrocardiography; Exercise; E | 2000 |
[Ergometric test and level of daily physical activity in chronic heart failure].
Topics: Adult; Carbazoles; Carvedilol; Child; Double-Blind Method; Dyspnea; Electrocardiography; Exercise; E | 2000 |
Beta-blockers for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Heart Failure; Humans; | 2000 |
Beta-blockers for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Bradycardia; Carbazoles; Carvedilol; Heart Failure; Humans; | 2000 |
Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Catecholamines; Female; Guanylyl I | 2000 |
Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Catecholamines; Female; Guanylyl I | 2000 |
Are there differences between vasodilating and nonvasodilating beta-blockers in patients with heart failure? Do patients with ischemic heart disease benefit to the same degree?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; Humans; | 2000 |
Are there differences between vasodilating and nonvasodilating beta-blockers in patients with heart failure? Do patients with ischemic heart disease benefit to the same degree?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Female; Heart Failure; Hospitalization; Humans; | 2000 |
Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Carbazoles; Carvedilol; Heart Failure; Humans; Mal | 2000 |
Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Carbazoles; Carvedilol; Heart Failure; Humans; Mal | 2000 |
Experience of commencing Carvedilol in elderly patients with heart failure in a routine outpatient clinic.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Ambulatory Care Faciliti | 2000 |
Experience of commencing Carvedilol in elderly patients with heart failure in a routine outpatient clinic.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Ambulatory Care Faciliti | 2000 |
Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans; M | 2000 |
Selective or nonselective beta-adrenergic blockade in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Heart Failure; Hemodynamics; Humans; M | 2000 |
Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Clinical Trials as Top | 2000 |
Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Clinical Trials as Top | 2000 |
The COHERE Registry: hype or hope?
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Clinical Trials as Topic; Female; Heart F | 2000 |
The COHERE Registry: hype or hope?
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Clinical Trials as Topic; Female; Heart F | 2000 |
[Patient with heart failure. Beta blockage becomes mandatory].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Randomiz | 2000 |
[Patient with heart failure. Beta blockage becomes mandatory].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolamines; Randomiz | 2000 |
[Is myocardial impairment in idiopathic dilated hypertrophic cardiomyopathy reversible by carvedilol?: a case report].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Fatty Acids; Female; H | 2000 |
[Is myocardial impairment in idiopathic dilated hypertrophic cardiomyopathy reversible by carvedilol?: a case report].
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Fatty Acids; Female; H | 2000 |
[Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2000 |
[Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; | 2000 |
Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Confidence Intervals; Di | 2000 |
Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Confidence Intervals; Di | 2000 |
Experience with beta-blocker therapy in patients with advanced heart failure evaluated for HTx.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 2000 |
Experience with beta-blocker therapy in patients with advanced heart failure evaluated for HTx.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 2000 |
Baseline predictors of tolerability to carvedilol in patients with chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carba | 2000 |
Baseline predictors of tolerability to carvedilol in patients with chronic heart failure.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carba | 2000 |
Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Algorithms; Analysis of Variance; Baroreflex; Blood Pressure; Carbazole | 2000 |
Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Algorithms; Analysis of Variance; Baroreflex; Blood Pressure; Carbazole | 2000 |
Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Carbazoles; Cardiomyopathies; Carvedilol; Clinical Tria | 2000 |
Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Carbazoles; Cardiomyopathies; Carvedilol; Clinical Tria | 2000 |
Beta-blockers in heart failure. 1. Clinical evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Prescriptions; Heart Failure; Humans; Prog | 2000 |
Beta-blockers in heart failure. 1. Clinical evidence.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Prescriptions; Heart Failure; Humans; Prog | 2000 |
Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Antioxidants; Apoptosis; Carbazoles; Carvedilol; Cells, Cultured; | 2000 |
Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol.
Topics: Adrenergic beta-Antagonists; Aged; Antioxidants; Apoptosis; Carbazoles; Carvedilol; Cells, Cultured; | 2000 |
[Info-congress. COPERNICUS and Val-HEFT studies].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coron | 2000 |
[Info-congress. COPERNICUS and Val-HEFT studies].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coron | 2000 |
[Cardiac insufficiency and B-blockers].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Heart F | 1998 |
[Cardiac insufficiency and B-blockers].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Heart F | 1998 |
[Comprehensive anti-adrenergic therapy. It can save the weak heart].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Administration Schedule; Heart Failure; Hu | 2001 |
[Comprehensive anti-adrenergic therapy. It can save the weak heart].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Administration Schedule; Heart Failure; Hu | 2001 |
Impressive amelioration of clinical (NYHA class) and echocardiographic parameters in heart failure patients treated with amiodarone and carvedilol.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Cytokines; | 2001 |
Impressive amelioration of clinical (NYHA class) and echocardiographic parameters in heart failure patients treated with amiodarone and carvedilol.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Cytokines; | 2001 |
[Severe heart failure. Carvedilol lowers mortality].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Humans; Propano | 2001 |
[Severe heart failure. Carvedilol lowers mortality].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Heart Failure; Humans; Propano | 2001 |
[New indications for beta blockers. Cave hypertension focus/heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; D | 2000 |
[New indications for beta blockers. Cave hypertension focus/heart failure].
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; D | 2000 |
Carvedilol--a new dimension in pediatric heart failure therapy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Heart Failure; Humans; Propanolamines | 2001 |
Carvedilol--a new dimension in pediatric heart failure therapy.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Child; Heart Failure; Humans; Propanolamines | 2001 |
Carvedilol as therapy in pediatric heart failure: an initial multicenter experience.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol | 2001 |
Carvedilol as therapy in pediatric heart failure: an initial multicenter experience.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol | 2001 |
Racial differences in the response to drugs--pointers to genetic differences.
Topics: Adrenergic Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Cytochrome | 2001 |
Racial differences in the response to drugs--pointers to genetic differences.
Topics: Adrenergic Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Cytochrome | 2001 |
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chron | 2001 |
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chron | 2001 |
Mechanisms of carvedilol action in human congestive heart failure.
Topics: Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Heart Ve | 2001 |
Mechanisms of carvedilol action in human congestive heart failure.
Topics: Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Heart Failure; Heart Rate; Heart Ve | 2001 |
Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carb | 2001 |
Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carb | 2001 |
A cost-effectiveness analysis of bisoprolol for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Cost-Benefit Analysis; Follow-Up St | 2001 |
A cost-effectiveness analysis of bisoprolol for heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Cost-Benefit Analysis; Follow-Up St | 2001 |
Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial.
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Female; Heart Failure; Hemodynamics; Humans; | 2001 |
Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial.
Topics: Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Female; Heart Failure; Hemodynamics; Humans; | 2001 |
Expanding indications for beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Black People; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolam | 2001 |
Expanding indications for beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Black People; Carbazoles; Carvedilol; Heart Failure; Humans; Propanolam | 2001 |
Beta-blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Oxygen Consu | 2001 |
Beta-blockade in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Oxygen Consu | 2001 |
Beta-blocker trials seem to be in conflict.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Contraindications; Heart Failu | 2001 |
Beta-blocker trials seem to be in conflict.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Contraindications; Heart Failu | 2001 |
[Options in drug combinations].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2001 |
[Options in drug combinations].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2001 |
The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)--rationale and design.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Clini | 2001 |
The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)--rationale and design.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Clini | 2001 |
Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cana | 2001 |
Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cana | 2001 |
Effects of beta-blocker therapy in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diuretics; Drug Therapy, Combination; Heart Fai | 2001 |
Effects of beta-blocker therapy in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Diuretics; Drug Therapy, Combination; Heart Fai | 2001 |
Effects of beta-blocker therapy in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Drug | 2001 |
Effects of beta-blocker therapy in severe chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Drug | 2001 |
[Effect of carvedilol on survival in severe chronic heart failure. A trial of the beta-blocker bucindolol in patient with advanced heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as Topic; Hear | 2001 |
[Effect of carvedilol on survival in severe chronic heart failure. A trial of the beta-blocker bucindolol in patient with advanced heart failure].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Chronic Disease; Clinical Trials as Topic; Hear | 2001 |
Echo-Doppler mitral flow monitoring: an operative tool to evaluate day-to-day tolerance to and effectiveness of beta-adrenergic blocking agent therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Blood Flow Velocity; Carbazoles; Carvedilol; Chro | 2001 |
Echo-Doppler mitral flow monitoring: an operative tool to evaluate day-to-day tolerance to and effectiveness of beta-adrenergic blocking agent therapy in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Blood Flow Velocity; Carbazoles; Carvedilol; Chro | 2001 |
The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathies; Carvedilol; Dose-Response Re | 2001 |
The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathies; Carvedilol; Dose-Response Re | 2001 |
Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Card | 2001 |
Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; Card | 2001 |
Beta-blockers in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2002 |
Beta-blockers in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin | 2002 |
Apoptosis--new opportunities for novel therapeutics for heart diseases.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Apoptosis; Carbazoles; Carvedilol; DN | 2001 |
Apoptosis--new opportunities for novel therapeutics for heart diseases.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Apoptosis; Carbazoles; Carvedilol; DN | 2001 |
Coreg. New indication for heart failure drug.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; Heart Failure; Humans; Propanola | 2002 |
Coreg. New indication for heart failure drug.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Drug Approval; Heart Failure; Humans; Propanola | 2002 |
Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Carbazoles; Cardiomyopat | 2002 |
Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Carbazoles; Cardiomyopat | 2002 |
Unique effects of carvedilol on noradrenaline release in the human heart.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; H | 2002 |
Unique effects of carvedilol on noradrenaline release in the human heart.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; H | 2002 |
[Severe heart failure--effects of carvedilol therapy. The Copernicus Study].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double-Blind | 2002 |
[Severe heart failure--effects of carvedilol therapy. The Copernicus Study].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double-Blind | 2002 |
[Beta blockers in severe heart failure. Prognosis improves already after a short time].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2002 |
[Beta blockers in severe heart failure. Prognosis improves already after a short time].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Clinical Trials as Topic; Heart Failure; Humans | 2002 |
Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Drug Therapy, Combination; | 2002 |
Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure.
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Drug Therapy, Combination; | 2002 |
Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Echocardiography; Echocardiography, | 2002 |
Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; Echocardiography; Echocardiography, | 2002 |
Left ventricular systolic dysfunction in a cardiac transplant recipient treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Heart Transplantation; Humans; M | 2002 |
Left ventricular systolic dysfunction in a cardiac transplant recipient treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Heart Transplantation; Humans; M | 2002 |
Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Child; | 2002 |
Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Child; | 2002 |
Effects of carvedilol on heart rate dynamics in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Female; Heart Failure; He | 2002 |
Effects of carvedilol on heart rate dynamics in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Carvedilol; Female; Heart Failure; He | 2002 |
Effect of beta blockers on new congestive heart failure in older persons with healed myocardial infarcts.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Heart Failure; Humans; Myocardial Infarct | 2002 |
Effect of beta blockers on new congestive heart failure in older persons with healed myocardial infarcts.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Heart Failure; Humans; Myocardial Infarct | 2002 |
Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Binding, Competitive; Carbazoles; Cardiomyopat | 1992 |
Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Binding, Competitive; Carbazoles; Cardiomyopat | 1992 |
Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Carbazoles; Carved | 1992 |
Can intravenous beta blockade predict long-term haemodynamic benefit in chronic congestive heart failure secondary to ischaemic heart disease? A comparison between intravenous and oral carvedilol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Carbazoles; Carved | 1992 |
Value of carvedilol in congestive heart failure secondary to coronary artery disease.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Catheterization; Carved | 1990 |
Value of carvedilol in congestive heart failure secondary to coronary artery disease.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Catheterization; Carved | 1990 |